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ABSTRACI' 
Surgical excision has been the method of choice for initial treatment of operable breast 
cancer, but is limited in its potential to produce cure. Postoperative systemic therapy 
prolongs survival, but kinetics theory and experimental data suggest it may be more 
effective if given preoperatively, with the added advantage of leaving the tumour as a 
marker of treatment progress. Important questions regarding the efficacy of primary 
systemic treatment (PST), its effects on known prognostic indicators, and its influence on 
surgical and psychological morbidity remain to be answered. These were addressed in this 
thesis. 
171 women aged 27 -69 with operable (T2_31\10.1 M0) breast cancers 31 -85 mm in diameter 
were randomised over 68 months, 86 to conventional treatment (CONV) and 85 to PST. In 
CONY, surgery was followed by tamoxifen, except for node -positive premenopausal women 
who received 6 cycles of cyclophosphamide, methotrexate and 5- fluorouracil. PST was 
started after tumour oestrogen receptor (ER) measurement. Patients with ERA 9 fmol /mg 
were treated by goserelin if premenopausal or with tamoxifen if postmenopausal. Response 
was assessed by weekly examination. Sequential mammography and ultrasound, and 
serum CA 15 -3 and HMFG2 measurements were studied as alternative means of 
monitoring response. Non responding patients and all patients with ER<20 fmol /mg were 
treated with 6 cycles of cyclophosphamide, doxorubicin and prednisolone (CAP). Surgery 
followed 12 -16 weeks of PST. The first part of the trial included 79 patients with tumours 
>40 mm, all of whom underwent mastectomy. The second part allowed tumours >30 mm, 
and breast conservation was an option. 
The first 79 patients were studied for morbidity. All toxicity was recorded. Psychological 
morbidity was assessed by means of the Hospital Anxiety and Depression, and the Mental 
Adjustment to Cancer questionnaires, completed before, during and after treatment. 
Surgical morbidity was recorded prospectively according to a pre- defined protocol. 
170 evaluable patients have been followed up for a median of 37 months and have 
sustained 53 events. No survival difference has emerged. Axillary lymph nodes, ER and 
tumour response have emerged as independent indicators of prognosis. Systemic therapy 
produced significant changes in tumour characteristics but post treatment prognostic data 
was qualitatively similar to conventionally gathered information. 
Patients experienced increased anxiety during PST, but psychological adjustment was 
similar after completion of all treatment. Despite longer treatment for PST, quality adjusted 
survival was identical to that found for CONY. Surgical morbidity was similar for both 
groups. 
Ultrasound proved a highly effective method for measuring tumour size and response to 
primary systemic therapy. Tumour marker levels were generally low and did not reflect 
response. 
The present package of primary systemic treatment is a safe and effective method for 
treating operable breast cancer, does not lead to excess morbidity, and offers the 
advantages of a response based approach to therapy. 
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THE OVERALL PLAN OF THE THESIS 
The treatment of breast cancer remains a complex and rapidly evolving arca of medicine. 
Developments in molecular biology and pharmacology promise to open new avenues of 
treatment for future investigation, but much remains to be done with drugs and techniques 
already available. 
Selective primary systemic therapy is an attempt to optimise the way in which existing 
treatments arc administered. Previous experience with this treatment has been greatly 
encouraging, but questions regarding efficacy, morbidity and the optimum method of 
administration remain to be answered. This thesis aims to explore answers to some of these 
questions. 
This thesis is arranged in three parts. The rationale, and the theoretical background to the use 
of primary systemic treatment are described in the first part (chapters 1 & 2). In the second 
part (chapters 3 -8) the protocol and results of a randomised clinical trial addressing the 
questions of efficacy and morbidity are described and discussed. An important objection to 
primary systemic treatment - loss of prognostic indicators - is addressed through analyses 
specific to the primary systemic treatment group of patients. The question of the optimisation 
of tumour monitoring during primary systemic therapy is addressed in the final part (chapters 
9 -11). 
The rationale 
The use of systemic therapy as the initial treatment for breast cancer represents a significant 
departure from the norms of breast cancer treatment. 
The first chapter describes the theoretical principles which support the use of systemic therapy 
as initial treatment in breast cancer. The second chapter describes the clinical applications of 
primary systemic therapy and summarises the results reported by others in relation to its use. 
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Plan of the trial 
The results from a sequential series of patients treated by selective primary systemic therapy 
hinted at substantial potential benefits. Its actual efficacy can only be established by testing 
the new treatment against conventional therapy in a randomised trial. 
A new mode of therapy, particularly if it proves to be of marginal survival benefit, cannot be 
evaluated simply on the basis of its effects on survival. The true value of a treatment must be 
decided by weighing potential benefits against the relative costs of treatment in terms of the 
patient's quality of life and other associated morbidity. 
Randomised studies 
The study uses a randomised design to ask four questions about primary systemic treatment. 
This part of the thesis spans over chapters 3 to 8, and is the largest part of the thesis. 
Is primary systemic treatment better at treating cancer? 
The protocol for a randomised trial of selective primary systemic treatment versus 
conventional treatment is described in chapter 3. Treatment outcomes are compared in chapter 
4, and the value of prognostic indicators with particular reference to the effects of primary 
systemic therapy arc described in chapter 5. Results are summarised and discussed in 
chapter 6. 
Is quality of life adversely affected? 
The psychological well -being of patients in the two arms of the trial is compared in chapter 7. 
Results are presented. The survival results are re analysed, taking into consideration quality of 
life issues. 
Does primary systemic therapy affect surgical outcome? 
In chapter 8 the patients in the main trial are studied to assess whether primary systemic 
treatment increases surgical complication rates following mastectomy. Results are presented 
and discussed. 
Optimising the method 
Even if primary systemic treatment proves to be no better than conventional therapy, provided 
that it is no worse, the practical advantages it offers particularly in terms of allowing response 
assessment may still make it the treatment of choice in certain patients. It is therefore 
important that tumour response could be measured accurately. 
In the chapters 9 -11, the use of ultrasound and serological tumour markers as methods of 
improving the efficacy of tumour monitoring during primary systemic treatment arc 
investigated and ways of optimising the monitoring regime are explored. 
Concluding remarks 
The main findings of the thesis are summarised, and whole thesis issues are discussed in the 





1. Treatment of Breast Cancer 
and 
Failure of Treatment 
1.1 THE IMPACT OF BREAST CANCER 
1.1.1 Breast cancer incidence 
In 1993, breast cancer resulted in the deaths of 1280 Scottish women. This represents 5% of 
all female deaths and 26% of female cancer related deaths in Scotland (Registrar General for 
Scotland: 1994). The incidence of breast cancer in Scotland rose by 18% between 1982 and 
1991, giving Scottish women a 7.3% life time risk of developing breast cancer (Scottish health 
statistics: 1993), Figure 1-1]. The age adjusted breast cancer mortality rate of 47.4 per 
100,000 of the female Scottish population is amongst the highest in the world, being surpassed 
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Figure 1 -1: Changes in incidence and mortality from breast cancer in 
Scotland between 1975 and 1991 
Impact of breast cancer 
1 -3 
1.1.2 Breast cancer mortality 
Despite increasingly radical operations and the more recent use of systemic therapy, there has 
been little change in breast cancer mortality over the past 40 years, with crude mortality 
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Figure 1 -2: Trends in breast cancer mortality (all ages) for United Kingdom, 
Scotland and U.S.A. 
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1.2 LOCOREGIONAL TREATMENT OF BREAST CANCER 
Surgery has an important place in the treatment of breast cancer, and other treatment 
modalities such as radiotherapy and systemic therapy have traditionally been regarded as aids 
to the main treatment. The role of locoregional treatment of breast cancer in achieving a cure 
will be explored in this section. 
1.2.1 The evolution of surgery for breast cancer 
The pioneering surgeons who perfected the techniques of radical surgery for breast cancer had 
very clear aims in mind when they offered treatment to breast cancer sufferers. Surgeons such 
as Halsted were faced with a disease which resulted in extensive local tissue destruction, and 
eventually killed the patient from metastases. Their aim was to control local disease in order to 
palliate the symptoms of their patients. As early as 1863 Sir James Paget wrote: "I am not 
aware of a single clear instance of recovery, that is, as that the patient should live for more 
than 10 years free from the disease. In deciding for or against removal of a cancerous breast in 
any single case, we may, I think, dismiss all hope that the operation will be the final remedy 
for the disease." 'quoted in (liaagensen: 1971)]. Surgery was the only technique available to 
the early cancer clinicians. By adapting the principles of lymphatic spread expounded by his 
contemporaries such as Sir William Banks (Banks: 1887), William Halsted of Baltimore had 
already been able to develop the surgical techniques such that local recurrence rates fell from 
the 60 -80% reported by the surgical authorities of his time such as Volkmann and Billroth, to 
a mere 6% (I- Ialsted: 1894). But even Halsted was under no illusions about the potential for 
cure which his operation of radical mastectomy offered the patient: "unfortunately the tumour 
must first be recognised by the patient, and a scirrhous cancer large enough to attract her 
attention has quite surely already gone afield" (Halsted: 1907). 
There were only two avenues open to Halsted and his contemporaries in search of an 
improvement in cure rates. One was earlier surgery and the other, more radical surgery 
(Halsted: 1913; Halsted: 1907). The first was out of the hands of the surgeon. The second 
dominated the treatment of breast cancer for the first seven decades of the twentieth century. 
Local eradication to prevent local progression and stop the formation of metastases was 
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regarded as the most important aspect of treatment, and expediency of surgical removal was 
emphasised. 
The increasing use of systemic therapy in the latter half of the century has provided an 
alternative approach to breast cancer treatment. Nevertheless, systemic treatment has largely 
been seen as an aid to surgery which is still regarded as the main treatment, hence the term 
"adjuvant ". 
1.2.2 Curability by locoregional therapy alone 
Halsted stressed the importance of accurate staging and the systematic collection of data; 
however a direct comparison between untreated and locoregionally treated groups of patients 
is unethical. The contribution of locoregional treatment to survival can therefore only be 
extrapolated from indirect studies. 
The impact of locoregional therapy on survival may be assessed in four principal ways as 
fol lows: 
1. The course of untreated breast cancer 
2. 'The long term follow -up of patients treated by locoregional therapy only 
3. The results of less radical locoregional measures 
4. The results of earlier detection and treatment by screening 
1.2.2.1 Untreated breast cancer 
Survival from untreated breast cancer has been studied using retrospective analysis of data on 
patients presenting before surgery was widely available. These series estimate survival from 
the time the tumour had been first noticed by the patient (Bloom et al: 1962; Wade: 1946; 
Daland: 1927; Greenwood: 1926; Wyard: 1925; Lazarus- Barlow and Leeming: 1924). The 
median survival without treatment has been estimated at 2.3 -2.7 years, but survival can range 
from a few months to over 15 years (Bloom et al: 1962). In the studies by Daland and Wade, 
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the survival curves for untreated patients are plotted alongside those of the patients treated by 
radical mastectomy, calculated from the time of diagnosis. The curves are parallel, although 
separated in favour of the treated group, suggesting that surgery acts as a debulking procedure 
without provoking a biological cure (Wade: 1946; Daland: 1927). 
1.2.2.2 Survival following locoregional treatment 
By the middle part of this century, long term follow -up data on women treated for breast 
cancer were becoming available. Initial studies of large number of breast cancer sufferers 
suggested that despite extensive local measures, the majority of patients eventually died of 
metastatic disease (Brinkley and Haybittle; 1968), an observation which was confirmed as the 
total duration of follow -up became longer (Brinkley and Haybittle: 1984; Brinkley and 
Haybittle: 1975). 
It is now clear that even 35 years following locoregional therapy, women who have survived 
breast cancer will have an age adjusted all cause mortality risk which is between 1.5 to 2.5 
times, and a risk of death from breast cancer which is 15 to 25 times greater than that 
expected for the general population (Haybittle: 1991). 
Data such as these provide strong evidence that locoregional therapy alone is not enough to 
provide a biological cure for breast cancer. 
The ratio of the number of deaths from breast cancer to the number of cases registered four 
years earlier is about 0.65 (Haybittle: 1991). This suggests that as many as 1/3 of all patients 
treated by local measures will not experience any recurrence from breast cancer within their 
life time (Haybittle: 1991). Even if this group have subclinical breast cancer at the time of 
death from another cause, they must be considered as having achieved a personal "cure ". 
1.2.2.3 The extent of local therapy 
1.2.2.3.1 Extended radical mastectomy 
Extended radical mastectomy, to include removal of the internal nodes was devised because of 
dissatisfaction with the results of ilalsted's operation (Valagussa et al: 1978; Haagenscn and 
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Stout: 1942). A large randomised clinical trial has clearly shown that more radical surgery 
does not result in longer disease free or overall survival (Lacour et al: 1983). 
1.2.2.3.2 Modified radical mastectomy 
The removal of the pectoralis major is a highly mutilating component of Halsted's operation, 
resulting in marked cosmetic deformity and significant impairment of arm function (Budd et 
al: 1978; Pollard et al: 1976). The observation by Gray that the deep fascia is poor in 
lymphatics led Patcy to argue that the removal of the pectoralis major was not necessary for 
adequate local clearance of the tumour (Patey and Dyson: 1948). Handley reviewed the 
outcome of over 200 Patey's modified radical mastectomies and demonstrated that the results 
were no different to those achieved in historical controls following Halsted's operation 
(Langlands et al: 1980; Handley: 1964). Patey's operation has the advantage of having 
significantly less associated morbidity compared with the radical mastectomy ( Feigenberg et 
al: 1977). 
The efficacy of modified radical mastectomy has been clearly demonstrated in controlled 
series (Baker et al: 1979) and in two randomised clinical trials which have shown identical 
disease free and overall survival rates for the two operations (Maddox et al: 1987; Turner et 
al: 1981). 
1.2.2.3.3 Breast conservation 
Removal of the tumour, without removal of the breast, followed by radiotherapy to treat 
remaining breast and axillary disease has been tested in a number of large clinical trials. This 
much less radical approach results in a greater proportion of local recurrences but the disease 
free and overall survival times for the patients remain unaffected (Veronesi et al: 1981; Fisher 
et al: 1989; Stewart et al: 1989; Osteen and Smith: 1990). 
1.2.2.3.4 The effects of incomplete local treatment 
1.2.2.3.4.1 Inadequate radiotherapy 
Mastectomy, without axillary dissection can potentially leave tumour tissue in the axilla. 
Locoregional treatment 
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Two trials of simple mastectomy and radiotherapy versus radical mastectomy have found 
superior survival results for the radical mastectomy group, particularly in groups of patients 
with early stage tumours (Bcrstock et al: 1985; Hayward and Caleffi: 1987; Langlands et a!: 
1980). The dose of radiotherapy used in these trials is considered inadequate by today's 
standards. When the axilla is adequately treated by radiotherapy or by surgical clearance on 
recurrence, the distant disease free and overall survival rates arc the same as those expected 
for radical mastectomy (Cuzick et a!: 1987; Fisher and Wolmark: 1985). 
In another trial of 960 patients undergoing modified radical mastectomy with or without 
radiotherapy, the risk of developing distant metastases was smaller in node -positive patients 
who had received radiotherapy. On multivariate analysis the increased risk of distant 
metastases appeared to be completely explained by the 5 fold increase in the risk of local 
recurrence experienced by the no- radiotherapy group. The model therefore indicated that local 
recurrence does increase the risk of distant metastases (Arriagada et al: 1995). 
Overall, early adequate axillary treatment, and in particular adequate radiotherapy (Levitt: 
1994), may prevent future relapse in 5 -10% of patients (Harris and Osteen: 1985). 
1.2.2.3.4.2 Breast conservation trials 
Following treatment for breast conservation, patients who developed local recurrence 
appeared to be at significantly increased risk of systemic relapse (Fisher el al: 1991). Other 
breast conservation trials however, despite showing a much greater incidence of local 
recurrence in non -irradiated breasts, have failed to show a disadvantage in terms of distant 
disease free or overall survival (Osborne et a!: 1992; Abner et al: 1993; Kurtz et al: 1988). 
The number of patients are however relatively small, and many received systemic therapy 
following local recurrence which may have altered the course of systemic disease. 
1.2.2.3.5 The benefits of screening 
In the trials of more versus less radical surgery it is often the subgroups of patients with the 
earliest stages of the disease who derive maximum benefit from the more radical operations 
(Osborne and Borgen: 1990; Hayward and Caleffi: 1987; Langlands et a!: 1980). 
Locoregional treatment 
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Early detection and surgical ablation of cancer may potentially eliminate all malignant cells 
before they have acquired metastatic potential. Detection methods are more likely to diagnose 
indolent tumours (length bias) and apparent improvements in results following early detection 
may simply reflect the time it would have taken a tumour to become clinically apparent (lead 
time bias). These problems have been addressed in the seven randomised trials of population 
screening for breast cancer (Buzdar: 1990; Frisch et a!: 1991; Miller et a!: 1992; Miller et al: 
1992; Nystrom et al: 1993; Shapiro: 1994; Andersson et al: 1988; Tabar et al: 1992; Roberts 
et al: 1990). Taken together, these trials have clearly shown that early detection of breast 
cancer using mammographie screening can result in a reduction in the odds of breast cancer 
mortality of the order of 25 -40% at 12 years of follow -up (Shapiro: 1994). The majority of 
tumours detected in these programmes were treated by locoregional measures alone, and these 
screening trials provide the strongest body of evidence in support of the notion that timely and 
adequate locoregional therapy can alter the natural history of breast cancer (Tabar et al: 
1992a). 
1.2.3 The place of locoregional therapy 
1.2.3.1 Locoregional control 
The main aim of local treatment should be adequate locoregional control. Modified radical 
mastectomy can be regarded as the standard against which other treatments must be 
compared. Many tumours may be treated by modern breast conservation techniques with 
acceptable results. 
1.2.3.2 Systemic control 
Locoregional therapy is most likely to achieve total cancer control in the earliest stages of the 
disease. Inadequate eradication of cancer cells in the breast and the axilla has a detrimental 
effect not only on locoregional outcome, but also on survival. Ever more radical locoregional 
measures however do not produce improved survival. 
Locoregional treatment 
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1.3 THE ROLE OF SYSTEMIC THERAPY 
Most clinically palpable breast cancers will not be cured by locoregional treatment alone. The 
role of systemic therapy in the treatment of breast cancer will be considered in this section. 
1.3.1 The evolution of systemic treatment 
1.3.1.1 Systemic treatment for systemic disease 
It is intuitive to use systemic treatment to treat widespread cancer. Beaston's use of ovarian 
ablation to produce remission in a patient with disseminated breast cancer is one of the earliest 
attempts at the systemic treatment of breast cancer (Beaston: 1896). Various forms of surgical 
and medical hormonal manipulations have been used in the treatment of metastatic breast 
cancer, and can induce remission in more than a third of unselected cases, and in up to half of 
the patients with oestrogen receptor positive disease (Buzdar: 1990). 
The majority of patients however do not respond to endocrine manipulation, and many of 
those who initially respond would eventually become hormone resistant (Wong and 
Henderson: 1994). Breast cancer can be sensitive to a large number of single agents but these 
can produce clinically significant remission in only 20 to 30% of cases (Hortobagyi: 1994). 
Standard regimes of multi -agent chemotherapy with combinations of cyclophosphamide, 5- 
Iluorouracil, and either methotrexate or doxorubicin can produce response rates of 35 to 80/0 
in previously untreated patients (Hayes el al: 1995), and are now widely used in treatment of 
metastatic breast cancer (Wong and Henderson: 1994). Further progress in the treatment of 
metastatic cancer is being made with the use of new cytotoxic agents such as taxoids (Piccart: 
1995), and dose intensive treatment regimes (Steward: 1995). 
1.3.1.2 Adjuvant systemic treatment 
The high remission rates achieved with endocrine therapies and chemotherapeutic agents in 
advanced breast cancer (Hortobagyi: 1995), combined with the evolving knowledge of tumour 
kinetics (see below), paved the way for the use of systemic treatment in early breast cancer for 
the treatment of micro metastasis. 
Hormonal ablation, single agent cytotoxic chemotherapy and multi -agent chemotherapy have 
all been tested as adjuvants to the locoregional treatment of early breast cancer and a large 
body of controlled data is available to quantify their benefits. The data have been summarised 
by the Early Breast Cancer Trialists' Collaborative Group (1992) and their main findings are 
presented below. 
1.3.2 The results of systemic therapy in early breast cancer 
1.3.2.1 The meta -analysis of clinical trials 
In January 1992, the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) 
published the results of a meta -analysis of 133 randomised clinical trials starting before 1985 
and investigating many aspects of the systemic treatment of early breast cancer . Detailed data 
from 74652 women included in these trials were collated and collectively analysed on the basis 
of intention to treat (Early Breast Cancer Trialists' Collaborative Group. 1990). Their 
conclusions are based on 23956 deaths and 31299 recurrences in this group of patients. 11íc 
main points relevant to the present study are summarised below. 
1.3.2.2 Results of tamoxifen 
Forty two sets of results from 40 randomised trials of tamoxifen versus no tamoxifen, 
including 30081 patients were analysed with a minimum ten year period of follow -up. 
1.3.2.2.1 Recurrence free survival 
Tamoxifen produces an overall reduction of 25% in the annual odds of recurrence. This is an 
average for the entire ten years. The size of the benefit is greatest during the first five years, 
with survival curves tending to become parallel thereafter. 
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1.3.2.2.2 Overall survival 
Tamoxifen produces a reduction of 17% in the annual odds of death. Unlike the benefits seen 
for recurrence, the survival benefit is sustained for the entire follow -up period with the 
survival curves continuing to diverge at ten years. 
1.3.2.2.3 Duration of tamoxifen treatment 
Tamoxifen was given for less than 2 years in 12 trials, average of two years in 23 trials, and 
for longer than two years in 7 trials. The recurrence and survival benefits were heterogeneous 
between the three groups with longer duration of tamoxifen producing the maximum benefit. 
Thus the subgroup of women who received tamoxifen for longer than two years experienced 
an annual reduction in the odds of recurrence estimated at 38% and in the odds of death 
estimated at 24 %. 
1.3.2.2.4 Age at randomisation 
"there were significant differences in the size of the overall benefits from tamoxifen between 
different age groups. In this respect age, rather than menopausal status appeared to be the 
critical factor. For women aged less than 50 the reduction in the annual odds of recurrence and 
death were 12 and 6% respectively. The survival benefit in this age group was not statistically 
significant. In women over the age of 50 the magnitude of the recurrence benefit was in the 
order of 30% and survival benefit of 20 %. 
1.3.2.2.5 The effect of axillary nodal involvement 
The overall magnitude of the reduction in the odds of death was the same for node -negative 
and node -positive patients. 
1.3.2.2.6 Oestrogen receptor status 
The influence of oestrogen receptor (ER) levels on response to tamoxifen has been reported in 
individual studies of metastatic (Bezwoda et al: 1991; Rosner et al: 1989) and primary 
breast cancer (The International Breast Cancer Study Group. 1990; Singh et al: 1988; 
Rutqvist et al: 1989; Rose et al: 1985). These observations were confirmed in the EBCTCG 
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meta- analysis. Oestrogen receptor positive (ER 10 U) and ER negative (<10 U) women 
benefited from tamoxifen although the size of the benefit in the ER positive women was 
approximately twice that seen in ER negative patients. 
1.3.2.2.7 Summary of tamoxifen results 
All breast cancer patients benefit from the use of tamoxifen. The maximum benefit accrues 
from the use of tamoxifen for over two years, and ER positive patients older than 50 arc likely 
to experience the largest benefit. 
1.3.2.3 Results of ovarian ablation 
Results were available from ]0 of 12 trials identified and comprised data from 3072 women, 
and were analysed separately for women aged under 50 (1746 patients) and those aged over 
50 (1326 patients). At a follow -up of 15 years there was no benefit in terms of recurrence free 
or overall survival to the women older than 50 who received ovarian ablation. The results for 
younger women are presented below. 
1.3.2.3.1 Recurrence free survival 
There was a 261, reduction in the annual odds of recurrence over the 15 year follow -up 
period, with the main divergence occurring in the first ten years. 
1.3.2.3.2 Overall survival 
The reduction in the annual odds of death was 25% following ovarian ablation, and the effect 
was sustained throughout the 15 year follow -up period 
1.3.2.3.3 The effect of axillary nodal involvement 
The number of events in the node- negative group were too small for reliable analysis. 
Nevertheless it did appear that the reduction in the annual odds of recurrence and death was 
greatest among node -negative women, although the absolute benefits were still greater 
amongst node- positive women who had the highest risk of recurrence and death. 
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1.3.2.3.4 The effect of cytotoxic chemotherapy 
The magnitude of the reduction in the odds of recurrence and death attributable to ovarian 
ablation was slightly reduced when patients received concurrent chemotherapy, but this 
reduction did not reach significance. In these younger women, ovarian ablation and cytotoxic 
chemotherapy had effects on survival which were largely independent of each other. 
1.3.2.3.5 Summary of ovarian ablation results 
Ovarian ablation has no measurable benefit in women aged 50 or older. In the younger age 
groups ovarian ablation produces a sustained reduction in the odds of recurrence and survival. 
Its effects arc independent of cytotoxic chemotherapy, and may be most substantial in node - 
negative women. 
1.3.2.4 Cytotoxic chemotherapy 
Results were available on 18403 women treated in 47 randomised trials of some form of 
chemotherapy versus no chemotherapy. Because of the wide variation in the regimes used, the 
trials were grouped according to treatment to calculate the true magnitude of the 
chemotherapy effect. Multi -agent chemotherapy, given for more than one month had the 
largest survival benefit when compared with single agent regimes or regimes of shorter 
duration. The analysis therefore concentrated on the results of ten years of follow -up in 11041 
women treated in 31 trials of prolonged multi -agent chemotherapy comprising 32 separate 
comparisons. 
1.3.2.4.1 Recurrence free survival 
At ten years of follow -up multi -agent chemotherapy resulted in a 28% reduction in the annual 
odds of recurrence. Most of this reduction was achieved in the first five years, with survival 
curves being parallel thereafter. 
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1.3.2.4.2 Overall survival 
Chemotherapy produced a 16% reduction in the annual odds of death. The effect was 
sustained throughout the ten years of follow -up and the survival curves may be continuing to 
diverge after ten years. 
1.3.2.4.3 The effects of the chemotherapy regime 
The CMF' regime was used in 11 comparisons on its own and in a further 7 comparisons in 
conjunction with other drugs. A variety of other multi -agent chemotherapy regimes were used 
in the remaining studies. There was no significant difference in the magnitude of the benefit 
observed using different multi -agent chemotherapy regimes. 
1.3.2.4.4 Duration of treatment 
Multi -agent chemotherapy continued for more than a month produces a greater reduction in 
the annual Odds of recurrence and death compared with treatments of less than one month's 
duration. The magnitude of the benefit for chemotherapy given for about 6 months however is 
the same as the benefit derived with more prolonged treatment. 
1.3.2.4.5 Age at randomisation 
Information could be reliably analysed up to the age of 70. All age groups derive benefit from 
chemotherapy. Women aged less than 50 appear to experience the largest reduction in odds of 
recurrence (36 %) and death (25 %). Women aged between 60 and 70 however still experience 
a substantial reduction in the odds of recurrence of the order of 20% and in odds of death of 
about 10%. 
I CMF: Cyclophosphamide, Methotrexate and 5-Fluorouracil 
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1.3.2.4.6 The effect of axillary nodal involvement 
The magnitude of the reduction in the annual odds of recurrence or death is essentially the 
same for node- positive and node- negative women, although clearly both the absolute risks, and 
therefore the absolute benefits are much higher in node- positive patients. 
1.3.2.4.7 Summary of trials of prolonged multi -agent chemotherapy 
All patients can potentially derive benefit from chemotherapy although patients younger than 
50 derive greater benefit. More benefit can be accrued by giving chemotherapy for more than 
one month, but prolongation beyond about six months is of no further advantage. 
1.3.3 Improving the results 
The EBCTCG overview leaves no doubt that systemic therapy can prolong survival from 
breast cancer. Nevertheless substantial proportions of patients continue to suffer recurrence 
and die from breast cancer despite full locoregional and systemic therapy. 
There are important theoretical reasons which indicate that available treatments can be used in 
such a way as to kill more cancer cells. This subject will be considered in the next section. 
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1.4 FAILURE OF SYSTEMIC TREATMENT 
Systemic treatment has been able to alter the natural history of breast cancer, but available 
techniques leave a substantial proportion of patients with residual disease which eventually 
causes systemic recurrence and death. 
The failure of systemic therapy can be attributed to three general reasons: 
1. Failure of systemic agents to reach target cells 
2. Unfavourable tumour kinetics: failure to attack target cells at their most vulnerable 
3. Biochemical resistance of individual cells to the systemic agents 
Often all three of these mechanisms can act together to result in the eventual recurrence of 
cancer. The contribution of each resistance mechanism to eventual treatment failure will be 
considered below. 
1.4.1 Reaching Target Cells 
1.4.1.1 Possible mechanisms of failure 
1.4.1.1.1 Pharmacological sanctuaries 
The systemic administration of drugs aims to achieve therapeutic drug concentrations in all 
arcas of the body where tumour cells may be present. Under some circumstances the 
antineoplastic agents may be physically unable to reach all their target cells. One such 
situation is the presence of malignant cells in pharmacological sanctuaries such as the central 
nervous system, where they are protected from the actions of some drugs by the blood/brain 
barrier (Whitehouse and Kay: 1979). 
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1.4.1.1.2 Poor blood supply 
Another example of relatively protected cells are those at the centre of large tumour masses 
with a relatively poor blood supply, where the drug may have to diffuse through several cell 
layers (Hanna, Jr. el al: 1983). In vitro experiments using the multicellular spheroid model 
have shown that most of the drug is concentrated in the outer layers, leaving the central cells 
relatively protected (Sutherland el a!: 1971) . 
1.4.1.2 Relevance to breast cancer 
In practice these factors are likely to have little influence on the final outcome of systemic 
treatment. Most recurrences of breast cancer happen in tissues with a good drug distribution 
such as bone marrow, lung and liver (Gompel and van Kirkem: 1983). Drug diffusion is only 
likely to be a significant problem in tumours of great bulk, in which there will be other much 
more compelling reasons for incurability (Goldie and Coldman: 1984). 
1.4.2 The Influence of tumour kinetics 
One of the defining characteristics of a neoplasm is that its growth rate exceeds that of normal 
tissues (Willis: 1952). Early experiments using in vivo labelling of solid tumours with tritiated 
thymidine demonstrated that there is little difference in the cycle times of normal and 
malignant cells. The faster growth rate of cancers compared with normal tissue is entirely 
explained by the presence of a greater proportion of proliferating cells (Young and DeVita: 
1970). Cancers, however, by no means consist entirely of dividing cells as demonstrated by 
experiments involving prolonged continuous infusions of tritiated thymidine which 
demonstrated that certain subpopulations of malignant cells never take up the 
label (Mendelsohn: 1962). 
Many treatment schedules are designed around assumptions about the growth characteristics 
of cancers. Exponential and Gompertzian functions are able to explain the growth behaviour 
of most human cancers, but have very different implications for treatment scheduling. The fine 
detail is also important, as not all drugs are able to kill all cancer cells at all times. These 
points arc considered below. 
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1.4.2.1 Exponential growth kinetics 
1.4.2.1.1 The fractional cell kill model 
In 1964 Skipper and colleagues put forward a mathematical model to explain the behaviour of 
cancer cells in response to chemotherapy. This still forms the basis for much of the thinking 
behind the design of cancer therapeutic protocols. The model is based on data from the study 
of the murine leukaemia L1210 cells (Skipper el al: 1964). Three sets of observations form 
the basis for Skipper's "fractional cell kill" or "log- kill" model for the action of antineoplastic 
agents. 
1.4.2.1.1.1 Exponential growth 
The growth pattern of this leukaemia closely approximates an exponential curve, thus the 
tumour burden increases by a constant fraction over time, and death occurs when a relatively 
constant lethal number of cells is reached (DeVita ci al: 1969). 
1.4.2.1.1.2 Dose response relationship 
Skipper observed that when a specified tumour burden was given a fixed dose of 
chemotherapy, a fixed prolongation in survival was obtained. Furthermore, cells surviving 
following treatment followed a re- growth curve which was identical to that of the untreated 
cells. Given these observations Skipper was able to estimate the number of cells killed from 
the length of prolongation in survival. 
1.4.2.1.1.3 Fractional Kill 
The third, rather surprising, observation was that the prolongation of survival obtained by a 
fixed dose of drug was not influenced by the size of the initial tumour burden. This clearly 
indicated that a fixed dose of chemotherapy does not, as might have been expected, kill a fixed 
number of cells, but that it kills a fixed fraction of cells. 
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1.4.2.1.2 Implications for treatment 
Skipper's fractional cell kill model has a number of important treatment implications. Based 
on principles derived from his theoretical model Skipper was able to design treatment 
protocols which could produce cure even in advanced tumours (Skipper et al: 1964). 
1.4.2.1.2.1 Dose is important 
Because of the observed dose response relationship, it is clear that dose is important in 
producing the maximum cell kill. Skipper proposed the use of multi -agent chemotherapy as a 
way of achieving greater total dose of drug within the limits of toxicity for each individual 
agent. 
1.4.2.1.2.2 The inverse rule 
The probability of cure is inversely related to the initial tumour burden. Thus chemotherapy 
given in the setting of early disease for a tumour such as breast cancer, which was observed to 
respond in the advanced case (Cooper: 1969), is predicted to produce a high probability of 
cure. 
Reducing the initial tumour bulk by removing the primary would be a way of reducing initial 
tumour burden and hence increasing the probability of cure. This model therefore supports the 
concept that systemic therapy should follow local tumour eradication. 
1.4.2.2 Gompertzian growth kinetics 
Many of the modern chemotherapeutic treatment regimes have been formulated based on 
Skipper's fractional cell kill model. This model is based on observations on systems with 
exponential growth characteristics, and does not take into consideration the consequences of 
the natural death of tumour cells. In many cancers, including breast cancer, the growth rate is 
not constant but varies in proportion to the tumour bulk. Exponential kinetics do not 
adequately explain the growth of these tumours. 
In 1825 Gompertz described an equation for actuarial analysis in human populations (1825). 
His equation was later proposed by Winsor as a growth curve (1932). The Gompertzian 
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function describes a mode of growth in which exponential growth is accompanied by an 
exponential retardation in the rate of growth (Figure 1 -3). This Gompertzian function 
describes the growth of many solid tumours much more accurately than the exponential 
function (Laird: 1969; Laird: 1964). 
Figure 1 -3: The Gompertzian growth function. 
The Gompertzian plot is represented by the equation: y= exp[A /a(l- e'")] where A is the 
growth constant and a represents the retardation constant and x and y are the plot axis. In this 
representation a= 0.1A.. In the case where a tends to zero, the equation simplifies to the 
exponential curve represented by the equation: y= exp(Ax) 
1.4.2.2.1 Gompertzian growth of breast cancer 
Norton, using data from three separate sources, has put forward a compelling argument for 
the Gompertzian growth of human breast cancer (Norton: 1988). 
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1.4.2.2.1.1 Untreated breast cancer 
In the nineteenth century non- intervention was regarded as acceptable treatment for breast 
cancer. Detailed follow -up data on 250 women with histologically proven breast cancer 
managed in this way at the Central Middlesex hospital were published by Bloom & colleagues 
in 1962 . Norton used these data to construct a survival curve for untreated breast cancer, and 
showed that Gompertzian function describes this curve with a very high degree of accuracy. 
1.4.2.2.1.2 Survival following mastectomy 
Using parameters calculated from the Gompertzian fit to the Bloom data, Norton was able to 
construct highly realistic survival curves for patients treated by radical mastectomy in the 
NSABP* adjuvant chemotherapy trial (Fisher et al: 1975). 
1.4.2.2.1.3 Growth of "missed" breast cancers 
Additional support for Gompertzian growth was provided from analysis of data published by 
Hanser on cancers detected on the second round of a mammographie screening programme, 
which had, on retrospective review, also been present on mammograms done during the first 
round (Hcuser et al: 1979). Twenty three patients had measurable tumour growth on 
mammography. The change in tumour volume was used to calculate the Gompertzian growth 
constant for each cancer. The probability distribution for actual Gompertzian growth 
constants was calculated using parameters obtained using the Bloom data. The calculated 
constants perfectly fitted the probability distribution curve, confirming that the 
mammographie tumours had indeed increased in size in a Gompertzian fashion. 
While the growth of these tumours can be explained by more complex mathematics such as 
the stochastic growth model proposed by Speer and colleagues (1984), the relative simplicity 
of the Gompertzian model has allowed it to be used as a basis for models for predicting cell 
kill and drug resistance. 
* NSABI': National Surgical Adjuvant Breast and Bowel Project 
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1.4.2.2.2 The behaviour of tumours showing Gompertzian growth 
Skipper's original equation does not accurately predict the behaviour of Gompertzian growing 
tumours. Norton and Simon (1986) have proposed a modification of Skipper's equation, thus 
generalising it to systems with changing growth fractions. Cell kill as predicted by this 
modificatio n is proportional to the instantaneous growth fraction, as well as the dose of drug 
administered. When the growth fraction is constant, as in exponential growth, the Norton - 
Simon model simplifies back to the Skipper model (Norton and Simon: 1986). 
1.4.2.2.3 Implications of Gompertzian growth for treatment 
This kind of modelling would predict that the rate of tumour regression would decrease with 
shrinking tumour volume. The prolongation in.survival produced by a given dose of drug will 
no longer be constant, but will depend on the position of the initial tumour on its Gompertzian 
growth curve. This has important implications for adjuvant therapy. Thus in direct 
contradiction to Skipper's inverse rule, a regime producing even complete clinical regression 
in an advanced tumour, may not be able to eradicate the saine tumour in the adjuvant setting. 
Treatment will tail to produce cure in the absence of any form of cellular resistance (Norton 
and Simon: 1986; Norton: 1990). 
1.4.2.3 The importance of the cell cycle 
The differential sensitivity of proliferating and non -proliferating cells forms a fundamental 
assumption underlying the construction of mathematical models to predict the effects of 
anticancer agents. 
The position of cancer cells within the cell cycle is an important factor in determining 
sensitivity to chemotherapy. In general, proliferating cells are much more sensitive to the 
actions of anticancer agents than non -proliferating cells (Lamerton: 1972; Valeriote and van 
Pulten: 1975). Bruce and his colleagues (1966) studied the action of a wide variety of 
antincoplastic agents on the proliferative capacity of normal haematopoietic stem cells and 
transplanted lymphoma cells. They showed that antineoplastic agents can be divided into two 
broad categories of "cycle specific" and "phase specific ". Both classes of drugs killed many 
more neoplastic cells than they did normal cells (Bruce et al: 1966). This was shown to be 
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because significantly larger fractions of the normal cells were outside the cell cycle in the Go 
resting state (Bruce and Meeker: 1967; Bruce et ak 1969). 
1.4.2.3.1 Cycle specific agents 
Cycle specific agents are drugs such as cyclophosphamide which produce exponential dose - 
response curves. This indicates that once cells have left the resting phase, they would become 
susceptible to the action of these drugs in all the phases of the cell cycle. 
1.4.2.3.2 Phase specific agents 
The second group of agents includes drugs such as 5- fluorouracil. The dose -response curve 
for this group of drugs reaches a plateau, indicating that dividing cells which are outside 
specific phases of the cell cycle arc no longer susceptible to the action of these drugs. 
1.4.2.4 The clinical relevance of kinetic resistance 
That kinetic resistance is important in the clinical setting is borne out by the fact that the 
remission rate in tumours recurring for the first time is often very similar to the rate observed 
in cancers treated de nova by the same drugs (Kardinal et al: 1988; Fisher et al: 1979). 
Nevertheless, subsequent recurrences eventually do become resistant to treatment, and it is the 
uncontrolled growth of such biochemically resistant cells which will bring about the demise of 
the patient. Treatment strategies designed to minimise the probability of overgrowth with 
resistant cells will therefore have the greatest likelihood of affecting a cure. 
1.4.3 Biological cellular drug resistance 
Tumours are sensitive to the effects of chemotherapeutic agents to varying degrees. Malignant 
melanoma represents an example of a tumour which may be regarded as intrinsically resistant 
to chemotherapy. Breast cancer, on the other hand often responds to initial treatment. but will, 
with subsequent recurrence acquire drug resistance. 
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1.4.3.1 The origins of drug resistance 
The question of whether resistance is truly acquired (i.e., it develops as a consequence of 
exposure to drug), or it is pre -existent and is simply selected out by chemotherapy was first 
addressed in bacteria by Luria and Delbrück's (1943) classic fluctuation analysis experiment. 
This is now regarded as the main tool for dealing with a heritable property that is acquired by 
a stochastic mechanism. 
Luria and Delbrück exposed subcultures obtained from a number of sublines of the same 
bacterium to a bacteriophage, and after a specified period, determined the number of resistant 
bacteria in each subculture. If resistance had developed as a result of exposure to the 
bacteriophage the variance in the number of resistant bacteria should have been the same 
between sublines and subcultures. In fact the variance in the number of resistant colonies 
between the sublines was much greater than that seen between the subcultures, indicating that 
resistance had developed at a variable time before exposure to the bacteriophage (Figure 1 -4). 
XPOSURE TO PHAGE EXPOSURE TO PHAGE 
Figure 1 -4: Illustration of Luria and Delbrück's fluctuation analysis 
experiment. 
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Nine years later Law applied the same fluctuation analysis method to study anti -folate 
resistance in L1210 murine leukaemia cells, with identical results (Law: 1952). Similar results 
have been found in other experimental neoplastic systems (Ling: 1975; Poche el al: 1975). It 
is now accepted that resistance develops as a result of random spontaneous mutations during 
the developmental lifetime of the tumour before, and not as a result of, exposure to treatment. 
1.4.3.2 Probability of developing the resistant phenotype 
1.4.3.2.1 Exponentially growing tumours 
In 1979 Goldie and Coldman proposed a mathematical model to predict the probability of a 
resistant phenotype emerging at a given time point in the life of the tumour by a process of 
random spontaneous mutation. The model assumes that all cells and their progeny are capable 
of dividing and that any mutant resistant cells will survive. According to this model emergence 
of resistance is dependent only on the underlying mutation rate, and the total number of cells 
present at any given time, regardless of the growth function of the tumour. The model also 
predicts that the change from a low probability of resistance to a high probability of resistance 
takes over a relatively short critical period in the life of the tumour. The fractional 
growth required for this transformation is constant regardless of mutation rate or starting 
tumour size. Faster mutation rates simply result in the process starting at smaller tumour 
sizes. 
The probability function is defined by the Goldie -Coldman equation y= exp(- a(x -1)], Where 
y= probability of no resistance, x = number of cells and a = mutation rate. The shape of the 
probability plot remains constant. It can be calculated that a tumour will need to undergo a 60 
fold increase in size (log growth = 1.77) in order for the probability of the presence of a 
resistant cell to rise from 0.05 to 0.95. This degree of growth represents less than six tumour 
doublings (Figure 1 -5). 
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Figure 1 -5: The probability of curability (no resistant cells) at different 
mutation rates for growth with no cell loss 
1.4.3.2.2 Modification for Gompertzian growth 
The assumption that all mutations are stable and that no loss of cells takes place is unrealistic. 
In 1983 Goalie and Coldman published a generalisation of their earlier model to account for 
the probability of cell death . When cell death is zero the modified model simplifies back to the 
original. For deal!' rates greater than zero the change from low to high probability of 
resistance takes place at progressively smaller volumes. In practical terms the model predicts 
that in real tumours where cells can die as well as be born, the probability of resistance does 
not relate to the tumour size per se, but rather to the number of doublings it has undergone in 
order to reach a given size. A tumour with high death rate reaches a given size after many 
more doublings than a tumour with a smaller death rate, and will have a greater probability of 
resistance at that size. 
1.4.3.2.2.1 Implications for single resistance 
In the case of a single resistant phenotype, death rate has only a small influence on probability 
of resistance, since the increased probability of resistance at higher death rates is to some 
extent balanced by the correspondingly increased chance of the emergent resistant cells 
becoming extinct. 
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1.4.3.2.2.2 Implications for multiple resistance 
Where death rate influences the probability of phenotypic change markedly is in the emergence 
of cells with more than one aberrant phenotypic characteristic. In contrast to single resistance, 
doubly resistant cells have two potential progenitors. The birth of such cells is no longer 
balanced by death. And since births are no longer balanced by deaths, multiple resistant cells 
will accumulate, forming an increasingly greater fraction of the total tumour burden. This 
effect happens purely on random statistical grounds, and will be even more marked when three 
or more randomly acquired phenotypic alterations are considered. Although the probability of 
multiple resistance will always be smaller than that for any single character, the shape of the 
probability curve will remain similar to that found for the most simple case. The critical mass 
for the change from low to high probability of multiple resistance however will be much more 
sensitive to death rates. The final consequence is that tumours with high rates of cell loss will 
display a much greater degree of heterogeneity at a given size than the more rapidly growing 
tumours with smaller death rates. 
This hypothesis provides a stochastic explanation for the very high level of heterogeneity 
observed in most solid tumours (Fidler el al: 1978; Nowcl: 1976; Chow and Greenberg: 
1980). 
1.4.3.3 Implications of cellular resistance 
1.4.3.3.1 The incurable tumour 
The shape of the probability curve, notwithstanding any resistance mechanisms the tumour 
may have inherited from its normal ancestors, indicates that no matter how refractory a 
tumour may eventually become, there is a period in its life during which time the probability 
of resistance is low and the tumour potentially curable. The change from the curable to the 
incurable state can take place over a relatively short period of time, perhaps 
a few weeks. 
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1.4.4 Success with systemic therapy 
1.4.4.1 Cellular resistance is the key 
In this section three reasons for failure of systemic treatment have been examined. Hidden 
cancer cells, and kinetic failures could in theory be overcome by more treatment when they 
eventually manifest themselves. The theory does not work because of cellular resistance. Thus 
large tumour masses may be less curable because they may have already reached the critical 
size for incurability. A tumour recurrence after a "kinetic" failure may be refractory to 
chemotherapy because by the time it becomes clinically apparent it has acquired multiple 
levels of biochemical drug resistance. 
1.4.4.1.1 Curing micro metastases 
The reason systemic treatment is necessary at all is that tumours metastasise. 
The rapid change from the curable to the incurable stage has important implications for the 
treatment of micro metastases in the adjuvant setting. Micro metastases may have a size 
distribution which is below the level at which probability of cure is lost, and may be 
particularly susceptible to the actions of antineoplastic agents (Goldie: 1987). Here timing of 
treatment will be of crucial importance to outcome. Treatment should be started as early as 
possible since even short delays are likely to result in loss of curability. 
Any protocol design must take account of the mechanisms for metastasis and the behaviour of 
metastatic deposits. This subject will be considered next. 
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1.5 THE PROCESS OF METASTASES 
1.5.1 The nature of metastases 
Metastasis, the growth of a tumour arising from a primary but at a site distant from the 
primary is the unequivocal hallmark of malignant neoplasia. Metastatic deposits appear to 
arise from single cells which have randomly expressed a pre- existent metastatic phenotype. 
The evidence is reviewed below. 
1.5.1.1 Single cell origin 
Experiments using radiation induced chromosomal markers in a murine model have 
demonstrated that metastatic deposits arise from the growth of a single metastatic cell and that 
each deposit has a different progenitor cell. This holds true even after the direct intravascular 
injection of multicellular cell clumps (Talmadge el al: 1982). 
1.5.1.2 Stochastic nature of the metastatic process 
Metastatic deposits are established at the culmination of a series of sequential steps, the 
failure of any of which can result in the failure of the entire process (Fidler: 1990; Poste and 
Fidler: 1980). 
The question whether the metastatic steps are completed by random chance, or ability to 
metastasise is a genetically acquired phenotype has been addressed by Fidler and his 
colleagues. They showed that metastatic ability can be selected and enhanced by passaging 
metastatic lung nodules through syngenic mice (Fidler: 1973). Mice were injected with 
cultured melanoma cells in a step analogous to the "phage exposure" step of the classical 
fluctuation analysis experiment of Luria and Delbrück (1943). Analysis of variance of the 
number of metastatic deposits established that the ability to form metastases was not a 
consequence of random release into the blood stream, but was a genetically acquired pre- 
existent phenotype (Fidler and Kripke: 1977). These results were confirmed by other 
experimenters, using different cell lines (Fidler and Hart: 1982; Chambers el al: 1981) and in 
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vivo using spontaneously metastasising experimental tumours (Neri el al: 1982). Attempts are 
now being made to identify some of the genetic events underlying the metastatic phenotype 
(Poste et al: 1982). 
1.5.1.3 Critical mass for metastasis 
The application of the Goldie -Coldman model (Goldie and Coldman: 1979; Goldman and 
Goldie: 1983) to the metastatic process predicts that there will be a critical size below which 
the presence of metastases is improbable, and that the likelihood of metastasis will 
dramatically increase once this size is reached. This prediction has proved correct in 
experimental systems (Hill et al: 1984) and is borne out clinically by the observation that 
some cancers appear clinically cured by locoregional therapy alone. 
1.5.1.4 Metastasis and drug resistance 
Harris and colleagues have calculated mutation rates for the acquisition of the metastatic 
phenotype in murinc tumours. The rates appear much greater than those estimated for 
development of drug resistance (Harris et al: 1982; Hill et al: 1984). This has been suggested 
as an indication of the genetic instability of the metastatic phenotype, resulting in the rapid 
development of other abnormal phenotypic features such as drug resistance ( Cilio et al: 1987; 
Nowel: 1976). However experimental systems designed to estimate the rate of development of 
resistance in cells which acquire the metastatic phenotype, suggest that metastatic ability and 
drug resistance evolve independently of each other at different rates (fang and Hill: 1991; 
Damen et al: 1989). It is therefore theoretically possible for the expression of metastatic 
potential to predate the expression of drug resistance. Thus a metastatic deposit could still 
retain a low probability of drug resistance. Since the main bulk of early tumours is formed by 
the primary, it is likely to be the number of cells in this which determines the probability of 
resistance for its micro metastases. 
Metastasis 
1 -32 
1.5.2 Interactions between primary tumour and its metastases 
1.5.2.1 Shared regulatory mechanisms 
The Gompertzian growth pattern suggests that the growth of cancer while abnormal, is 
nevertheless subject to some form of control. The idea that any growth inhibition is simply the 
result of the failure of supply of oxygen and nutrients to an otherwise exponentially growing 
collection of cells (Burton: 1966), is unlikely to be correct since such failure would be 
expected to result in sudden and rapid growth retardation. The progressive slow -down which 
characterises Gompertzian growth of solid tumours (Laird: 1969) is similar to the pattern of 
growth seen in many normal tissues (Laird and Howard: 1966; Laird et al: 1965), suggesting 
that specific regulatory mechanisms are involved. Although metastatic deposits rapidly 
acquire marked heterogeneity both with individual deposits and between different deposits 
(Poste el al: 1982), it is still likely that they continue to share at least some regulatory 
mechanisms with each other and with their parent tumour. If this is the case metastatic 
deposits will not act as independently growing new tumours. Rather the cells making up the 
tumour and its metastases will behave like a single growing population. 
1.5.2.2 Effects of removing the primary on the growth of metastases 
1.5.2.2.1 Tumour excision accelerates metastatic growth 
Partial or complete removal of an experimental tumour results in the accelerated growth of 
metastatic deposits. This was first observed during the early part of this century (Tadenuma 
and Okonogi: 1924; Tyzzer: 1913), and later experiments repeated the observation (Schatten: 
19.58b). Increase in the rate of metastatic growth was shown to be independent of the effects 
of anaesthesia or surgical trauma (Schatten: 1958a). Numerous investigators have since 
confirmed that non -curative excision results in increased growth of residual tumour or any 
metastatic deposits (Gunduz el al: 1979; Ketcham et (/l: 1961; Ketcham et al: 1959; 
Simpson -Herren el al: 1976). 
That this is not merely an epi- phenomenon observed as a result of longer survival following 
tumour debulking has been shown using kinetic studies with tritiated thymidine labelling. 
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These have established that following partial excision there is an increase in the size of the 
tumour growth fraction (Gunduz et al: 1979; Simpson -Herren et al: 1976), produced by 
recruitment of resting cells into the cell cycle (Fisher et al: 1983b). 
1.5.2.2.2 Inhibition of post excisional growth spurt 
The accelerated growth following excision of the primary can be inhibited by the 
re- implantation of the tumour (Gorelik et al: 1978; DeWys: 1972). The inhibition is tumour 
specific: re- implantation of an unrelated tumour fails to influence metastatic growth (Gorelik 
et al: 1978). That actual growth stimulatory substances are also involved is suggested by the 
observation that in some models, serum from a mouse which has had its tumour removed, is 
able to stimulate tumour growth in a second mouse, or in cultured cancer cells. No such effect 
is seen following sham surgery (Fisher et al: 1989a). The post excisional growth spurt can be 
abolished in experimental animals by preoperative chemotherapy (Fisher et al: 1989d; Fisher 
et al: 1983d), and to a lesser extent by preoperative radiotherapy (Fisher et a!: 1986). 
1.5.2.2.3 Rapid tumour growth after ablation of related non -malignant tissue 
Substances have been characterised which regulate the growth and regeneration of normal 
tissues, including hepatocytes, renal cells and colonic mucosal cells (Iversen: 1991). Similar 
molecules have been implicated in the regulation of growth in tumours Merlyn and 
Malkowicz: 1991). 
The essential similarity between the regeneration response of normal tissue and the post 
excisional growth spurt seen in cancer is emphasised by the observation that growth of 
experimental tumours can be stimulated in a tissue specific manner by ablation of related 
normal tissue (Fidler: 1991). Thus cancers from a gastro -intestinal origin undergo growth 
stimulation in animals with regenerating livers following hepatectomy. Hepatectomy has no 
effect on the growth of renal cancers, which are however stimulated following removal of a 
normal kidney (Fidler: 1991). 
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1.5.2.2.4 Application to breast cancer 
Breast cancer represents a prime example of a tumour in which growth is regulated by 
complex interactions between systemic hormones (Brunner: 1990) and tumour derived growth 
stimulatory and growth inhibitory peptides. Many of these have been characterised. Growth 
promoters include insulin -like growth factors IGF -I and II (Yee et al: 1989; Yee el a!: 1988); 
transforming growth factor alpha (TGF -a) (Bates et al: 1988) and epidermal growth factor 
(EGF) (Osborne el al: 1980). Growth inhibitory substances such as the transforming growth 
factor beta (TGF -ß 1 and 2) (Zugmaier et al: 1989; Knabbe el a!: 1987) and the mammary 
derived growth inhibitor (Grosse et a!: 1991; Grosse and Langen: 1990) also play an 
important role in the regulation of breast cancer growth. 
Although the precise nature of the interactions between these mechanisms is not known, it is 
very likely that accelerated metastatic growth may be a consequence of primary tumour 
excision in at least some breast cancers. 
1.5.3 Implications for treatment of breast cancer 
Expedient removal of the primary tumour early in its life can potentially result in cure as the 
cancer may not as yet have acquired metastatic potential. This is borne out by the success of 
the breast screening trials (see section 1.2.2.3.5), and is undoubtedly the correct treatment for 
very early cancers. 
The situation for larger tumours which have already formed micro metastatic deposits is 
entirely different. Here early removal may in certain circumstances be actually detrimental, 
and a strong argument may be made for the use of systemic therapy before local excision. 
This argument will be put forward in the next section 
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1.6 PRIMARY SYSTEMIC TREATMENT OF BREAST CANCER 
Operable breast cancer has conventionally been treated by some form of surgical excision 
followed, in appropriate cases, by systemic therapy given as an adjuvant to surgery. In the 
light of the foregoing discussion it may be more appropriate to view breast cancer as a 
complex systemic disease, which should in the first instance be treated by systemic means. 
Reversing the conventional sequence of treatment offers several potential advantages which 
may render breast cancer more curable. 
1.6.1 Potential advantages of primary systemic treatment 
1.6.1.1 Theoretical advantages 
1.6.1.1.1 Favourable Kinetics 
Most patients with operable breast cancer at the time of diagnosis have tumours which are on 
the steepest part of the Gompertzian growth curve (Brown el al: 1984). Locoregional 
treatment will significantly reduce the total body burden of cancer cells. Residual cells, in the 
form of micro metastatic deposits will return to the initial slow growth phase of the 
Gompertzian curve and will be difficult to eradicate purely for kinetic reasons. 
Systemic therapy before tumour excision will treat micro metastatic disease when it is 
kinetically most vulnerable. With response, the tumour will eventually reach a kinetically 
refractory size, but residual cells are most likely to be located in the part of the tumour with 
greatest initial number of cells, i.e., the primary tumour, and will be eliminated by "adjuvant 
surgery ". 
1.6.1.1.2 Avoidance of delay 
A tumour, and in particular its metastases can progress from a curable to an incurable state 
over a short critical period of time. This critical time period may be made even shorter by the 
"tumour regeneration" response caused by surgical excision of the primary tumour. Primary 
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systemic treatment eliminates any delay which may otherwise be introduced by the time 
required to complete locoregional therapy. Furthermore it may abolish the tumour 
regeneration response in any residual cancer cells. 
1.6.1.2 Practical advantages 
1.6.1.2.1 Assessment of response 
Micro metastatic deposits are by definition clinically undetectable. Surgical excision removes 
the only means by which the response of the tumour to systemic treatment may be assessed. 
Primary systemic treatment will allow optimisation of treatment regimes based on observed 
tumour response (Goldie: 1987; Fisher et al: 1990; DeVita, Jr. 1983). In addition, the final 
degree of response may be used to evaluate the patient's final prognosis (Hortobagyi et al: 
1988; Jacquillat et al: 1991; Jacquillat et al: 1990). Application of response based treatment 
regime is one of the most important practical advantages offered by primary systemic 
treatment, and accurate measurement of tumour response must be regarded as critical to its 
success. 
1.6.1.2.2 Easier locoregional control 
The regression of the primary breast tumour in response to systemic therapy has been 
regarded by some as a way of increasing breast conservation rates (Singletary et al: 1992; 
Schwartz et al: 1994; Bonadonna et al: 1990). 
1.6.2 Potential disadvantages of primary systemic treatment 
The potential advantages of primary systemic treatment should be balanced against the 
possible disadvantages of delaying surgical excision. 
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1.6.2.1 Theoretical disadvantages 
1.6.2.1.1 Risk of further metastases 
Stochastic theory predicts that metastases develop over a short critical time period. A delay in 
surgical excision runs the risk of allowing localised disease to establish micro metastases. 
In practice, since metastatic potential develops very early in the history of the tumour, this is 
likely to be a significant consideration only in very early cancers such as those detected on 
screening. 
1.6.2.1.2 Kinetic considerations 
Very large cancers may have reached the plateau part of the Gompertzian growth curve and 
be refractory to treatment without initial debulking. In practice this situation is only likely to 
arise in very advanced disease and is not likely to apply to operable breast cancer (Brown el 
al: 1984). 
1.6.2.2 Practical disadvantages 
1.6.2.2.1 Loss of full pathological information 
Histological and biochemical information normally available from examination of the surgical 
specimen will only become available after completion of systemic therapy, and may not 
represent the true nature of the tumour. Pre -treatment tumour biopsy and axillary sampling 
can to some extent overcome this problem, although it may also reduce some of the expected 
benefits of primary systemic therapy. 
1.6.2.2.2 Surgical considerations 
A period of what is often toxic treatment can result in compromised immune defences and 
wound healing. This may have serious consequences for the morbidity experienced by the 
patient following surgery. 
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1.6.2.2.3 Psychological considerations s 
The diagnosis of breast cancer represents a major life event for the patient, and facing the 
potential of loss of life can be associated with major adverse psychological reactions. Primary 
systemic therapy requires that the patient should live with the tangible component of her 
cancer for an extended period of time. It may be speculated that this, combined with the added 
anxiety of not knowing whether the tumour is going to respond to treatment could have further 
adverse effects on her psychological well- being. 
1.6.3 Weighing up the options 
Primary systemic therapy can potentially make a contribution to the successful treatment of 
women wish breast cancer. The remainder of this document describes a study carried out to 
assess the extent of this contribution. 
Role of primary systemic treatment 
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CHAPTER 2 
2. Clinical Applications 
of 
Primary Systemic Treatment 
2.1 APPLICATIONS IN TUMOURS OTHER THAN BREAST CANCER 
In a limited number of tumours primary systemic treatment has proven of value both in 
preserving function and in improving survival, and is regarded as standard treatment. 
2.1.1 Sarcomas 
In Ewing's sarcoma and osteogenic sarcoma, primary treatment has resulted in greatly 
improved rates of limb salvage, and considerable gains in disease free survival in the 70 -80% 
of patients who show complete response to initial treatment (Picci et al: 1994; Eilber and 
Rosen: 1989; Smith et al: 1991; Jurgens et a!: 1988). In these tumours primary systemic 
therapy is now considered standard treatment. Similarly in soft tissue sarcomas primary 
systemic treatment, although of no proven value in increasing survival, can ease surgical 
resection, particularly when the tumour is in the vicinity of neurovascular bundles (Eilber et 
a!: 1990). 
2.1.2 Carcinomas 
2.1.2.1 Head and neck tumours 
In the treatment of head and neck tumours primary systemic therapy, although not yielding 
any definite survival advantage, has proved of great value in allowing preservation of 
anatomical function, and in simplifying locoregional therapy (Urba and Wolf: 1991). This has 
resulted in functional laryngeal and pharyngeal preservation in up to two third of patients 
treated in this way (Dimery and Hong: 1993). 
2.1.2.2 Anal squamous cell carcinoma 
In the treatment of squamous carcinoma of the anal canal, a combination of chemotherapy and 
radiotherapy can produce over 90% response rates (Nigro et a!: 1989; Cummings el al: 
1991), resulting in preservation of fugction. 
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2.1.2.3 Other epithelial cancers 
Unfortunately the role of primary systemic treatment is least clear in the treatment of the 
common epithelial cancers. The use of combinations of radiotherapy and chemotherapy have 
been reported to produce clinical response without any obvious advantage in overall outcome 
in lung (Ginsberg: 1993; Murren and Buzaid: 1993), bladder (Scher: 1993; Walther: 1993), 
cervical (Joncs: 1993; Potish and Twiggs: 1993), oesophageal (Kelsen et al: 1990; Fink et al: 
1994), gastric (Ajani et al: 1991; Alexander el al: 1993) and pancreatic cancer (Douglass: 
1993). 
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2.2 LOCALLY ADVANCED BREAST CANCER 
Local eradication has traditionally been regarded as the main method of treatment for tumours 
apparently confined to the breast (Bonadonna: 1989). For early breast cancers good local 
control can generally be achieved by well established techniques of surgery and radiotherapy, 
the main debate focusing on ways of minimising the extent of local therapy (Mansfield el al: 
1991; Hayward and Caleffi: 1987; Fisher et al: 1985; Atkins et al: 1972). There are 
nevertheless a significant number of breast cancers which although not metastatic at 
presentation, will be regarded as "locally advanced ", a term referring to a heterogeneous 
group of patients including those with tumours classified under the TNM classification 
(UICC: 1987) as T3, T4, or N2. Eleven to 29% of breast cancers have been reported to 
present in a locally advanced state (McWhirter: 1955; Haagensen: 1971). 
2.2.1 Local treatment 
Although resection of locally advanced tumours is technically possible, surgery is associated 
with a high rate of relapse and short survival (Ackland el al: 1985; Haagensen: 1971; 
1- Iaagensen and Stout: 1943). Radiotherapy can achieve better local control (Baillet et al: 
1993; Fletcher: 1971), but survival remains short, most patients relapsing with distant 
metastases (Zucali et al: 1976; Rubens el al: 1977). The overall survival of a group of 9055 
such patients treated with a combination of surgery and radiotherapy was 33% at five years 
and 22% at ten years. The results in the special subgroup of inflammatory cancers were even 
poorer, 97% being dead at five years (Hortobagyi: 1990). 
2.2.2 The influence of systemic treatment 
With the publication of 1992 overview of adjuvant breast cancer trials (Early Breast Cancer 
Trialists' Collaborative Group: 1992) the case for systemic therapy in early breast cancer can 
now be regarded as proven. By extrapolation the need for some form of systemic treatment in 
locally advanced breast cancer is assumed (Ragaz el al: 1991). 
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In the case of the special subgroup of patients with inflammatory breast cancer, systemic 
treatment has produced five year survival rates of 30 -50 %. Compared with survival rates of 
2 -3% reported with locoregional therapy alone this is such a pronounced improvement that the 
need for direct comparisons between systemic therapy and no- systemic therapy groups has 
been eliminated (Jaiycsimi el al: 1992). 
This is not the case with the more common forms of non -inflammatory locally advanced breast 
cancer. Systemic therapy for this disease produces five year disease free survival rates of 30- 
60%, being only slightly better than those reported with local therapy alone (Hortobagyi: 
1990). Nevertheless in view of the observed improvements, and the findings of adjuvant trials 
in early breast cancer, studies which do not include some form of systemic treatment are now 
regarded as ethically unjustified (Swain and Lippman: 1991). 
2.2.2.1 Sequential series of systemic therapy 
The success of multi -agent chemotherapy regimes in producing remissions in significant 
numbers of patients with metastatic breast cancer (Greenspan: 1966; Carter: 1972), led in the 
early 1970's to the development of the concept of "combined modality approach" for the 
treatment of breast cancer (Carter and Soper: 1974). A large number of studies have been 
used to test different forms of systemic treatment for locally advanced breast cancer. Since the 
disease is by definition "inoperable" many studies have used systemic therapy as the primary 
treatment, with better locoregional control and reduced treatment related morbidity as a 
desirable by- product. The main treatment objective however remains to prolong survival. A 
representative sample of these studies are summarised in Table 2 -1. 
Most patients had truly inoperable cancers although a few patients with large but operable 
tumours (T3 by the current TNM classification) were also included. The initial reports from 
these series concentrated on the objective response rates, and the adequacy of local control 
following a combination of chemotherapy, radiotherapy and surgery, including breast 
conservation. Survival has frequently been longer than that seen with historical controls, but 
better data are provided by the few comparative studies available. 
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Treatment No. Resp MS Sury 
(De Lena et al: 1978) ST +RT 72 64% 30 20% 
(De Lena et al :: 1981) ST +RT +ST 126 75% 42 36% 
(Valagussa et al: 1983) ST +S +ST 79 82% 68 51% 
(Hortobagyi et al: 1983) ST +RT ±S +ST 52 94% 64 55% 
(Hortobagyi et al: 1988) ST +RT +S +ST 174 96% 66 55% 
(Pierce et al: 1992) ST +RT +S +ST 107 92% 39 43% 
(Jacquillat et al: 1989b) ST +RT +ST 98 91% NR 64% 
(Schaake -Koning et al: 1985) ±ST +RT +ST 73 71% 46 37% 
(Schwartz et al: 1994) ST +S +RT +ST 189 84% NR 69% 
(Campbell et al: 1988) ST +S +RT 37 61% 24 50 %(2yrs) 
(Conte et al.' 1987) ST +S +ST 39 72% NR 60 %(3yrs) 
(Perloff et al: 1988) ST ±S ±R +ST 113 81% 39 NA 
( Jacquillat et al: 19890) ST +RT +ST 75 75% NR 58% 
(Cocconi et 0l: 1990) ST +S +ST +RT 49 67% 60 49% 
(Rubens et al: 1980) ST +RT +ST 12 67% 36 50 %(3yrs) 
(Lopez et al: 1990) ST +S +ST 17 76% 56 41% 
(Lynch et al: 1989) ST +S +RT +ST 26 46% NR 77 %(2yrs) 
(Rainer: 1993) ST +S +ST ±RT 
(Shanta and Krishnamurthi: 1991) ST +RT +S 211 61% 
(Frank et al: 1992) S +RT +ST 113 54% 
(Luboinski et al: 1991) ST +S +ST 160 38% 
(Heys et al: 1993) ST +RT ±S ±ST 42 76% NR 65% 
(Balawajder et al: 1983) ST +RT ±S 53 NA NA 42% 
" ± ": allocation to study arms, ST: Systemic therapy; RT: radiotherapy; S: Surgery; NR: Not Reached, 
NA: Not available. Resp: proportion of responders, MS: Median survival in months, Surv: 
Proportion alive. Follow -up 5 years unless indicated in brackets 
Table 2 -1: Summary of studies using primary systemic therapy for locally 
advanced breast cancer. Only the relevant part of the study is quoted. 
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2.2.2.2 Comparisons with matched historical controls 
In a comparative study 164 patients treated with radiotherapy and surgery alone were 
compared with 211 cases, treated during a later period with chemotherapy prior to 
radiotherapy and surgery. The five and ten year survival was better for the chemotherapy 
group, with 47 %, versus 61% at five years and 36% versus 44% at ten years (Shanta and 
Krishnamurthi: 1991). 
2.2.2.3 Non -randomised matched controls 
Two non -randomised studies with matched controls have also reported increased survival for 
patients receiving adjuvant therapy. In one study 47 patients having radiotherapy with or 
without mastectomy were compared with 53 patients who had been given induction 
chemotherapy. Mastectomy improved local control without changing the odds of survival, 
whereas chemotherapy resulted in an increased probability of survival at ten years 
(Balawajder et al: 1983). In another study 75 patients receiving different forms of 
radiotherapy alone were compared with 41 who had chemotherapy or hormonal manipulation 
following radiotherapy. More than half of the adjuvant group were disease free at four years, 
compared with less than one third of those who had received radiotherapy alone (Bruckman et 
al: 1979). 
2.2.2.4 Randomised Trials 
Three of five small randomised clinical trials comparing conventional or primary adjuvant 
systemic therapy against locoregional treatment alone have found a survival advantage for the 
systemically treated group. One trial of radiotherapy versus radiotherapy followed by adjuvant 
chemo/ or hormonal therapy containing a total of 87 patients, suggested significantly superior 
survival for patients receiving adjuvant treatment at a median follow -up of three years 
(Caceres et al: 1980). In another, 120 patients with large operable cancers (T3 NO -2 MO) 
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were randomised to post- mastectomy radiotherapy alone versus post -mastectomy 
chemotherapy, with and without radiotherapy (Grohn et al: 1984). At five year follow -up 
significantly greater numbers of patients receiving chemotherapy were still alive, with the best 
results obtained with combination of postoperative chemotherapy and radiotherapy (Klefstrom 
et al: 1987). A third randomised study allocated 209 patients to either receive mastectomy and 
radiotherapy (pre and postoperatively) alone, or to have pre and postoperative chemotherapy. 
Five year overall survival figures were significantly better for the chemotherapy group 
(Rainer: 1993). 
Two randomised studies, both confined to patients with T4 cancers, however have failed to 
show any advantage for systemic therapy. In a study of 118 patients randomised to receive 
radiotherapy alone, or radiotherapy with preoperative, or postoperative cherno- hormonal 
adjuvant therapy, overall survival at a median follow -up of 66 months was identical for all 
groups at 37% (Schaake -Koning et al: 1985). The second study with 52 patients compared 
primary multi -agent chemotherapy followed by radiotherapy with radiotherapy alone. 
Actuarial survival at three years was identical for both groups, although patients given 
chemotherapy achieved a greater rate of full local control (Leonard et al: 1991). 
In interpreting these studies it is important to note that the EBCTCG meta -analysis found that 
most randomised trials in early breast cancer were too small to be able to detect the advantage 
for systemic therapy with sufficient confidence, and that it was often those studies which 
detected an unusually high level of benefit which attained statistical significance (Early Breast 
Cancer Trialists' Collaborative Group. 1992). A similar situation is likely to exist with locally 
advanced breast cancer. 
2.2.3 Studies designed to examine timing of systemic therapy 
The timing of systemic treatment in relation to local therapy has been addressed in a number 
of small trials (Table 2 -2). None have found primary systemic treatment to be inferior to 
treatment given after local therapy, and some have shown trends in favour of primary systemic 
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therapy. This coupled with the improvements in local control (Buzdar et a/: 1993; Leonard el 
a/: 1991) have made primary systemic therapy the treatment of choice for locally advanced 
breast cancer. 
Treatment No. Res M S jury 
(Olsen et al: 1986) RT+ST 99 24 32%(4yrs) 
ST+RT+ST 76% 34 33% 
(Schaake-Koning et at: 1985) RT+ST 39 50 37% 
ST+RT+ST 34 71% 45 37% 
(Rubens et a!: 1980) RT+ST 12 36 50%(3yrs) 
ST+RT+ST 12 50% 36 50% 
(Lopez et al: 1990) RT+ST 17 76% 15 6% 
not randomised ST+RT+ST 17 76% 56 41% 
ST: Systemic therapy; R'l': radiotherapy; S: Surgery; NR: Not Reached, NA: Not available. Resp: 
proportion of responders, MS: Median survival in months, Surv: Proportion alive. Follow -up 5 years 
unless indicated in brackets 
Table 2 -2: Randomised trials of primary locoregional therapy versus 
primary systemic treatment in locally advanced breast cancer 
2.2.3.1.1 Main findings of primary systemic treatment studies 
Three important points have emerged from treating locally advanced breast cancer with 
primary systemic therapy: 
1. Tumour response to initial treatment correlates strongly with subsequent survival 
( Jacquillat el al: 1989b; Jacquillat et a/: 1988b). 
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2. The best response rates arc obtained with the least bulky tumours (Hortobagyi: 1990; 
Swain and Lippman: 1991). 
3. Best survival figures are seen for patients with "operable" cancers (Pierce el al: 1992; 
Valagussa el al: 1990; Hortobagyi: 1994). 
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2.3 OPERABLE BREAST CANCER 
The experience of using primary systemic treatment in locally advanced breast cancer 
provided strong evidence for the safety of the technique, both in terms of local control and 
survival (Singletary et al: 1992; Schwartz et al: 1994; Valagussa et al: 1990). This, 
combined with the observation that it is often the least bulky tumours which respond best to 
systemic therapy (Pierce et al: 1992; Hortobagyi: 1994; Valagussa et al: 1990) has been the 
starting point for attempts to extend the scope of this treatment to include women with earlier 
stages of the disease. With the proven efficacy of breast conservation (Fisher et al: 1989b; 
Veronesi el al: 1981b; Fisher et al: 1985b; Osteen and Smith: 1990b) patients with operable 
breast cancer can be surgically subdivided into those treatable by breast conservation and 
those requiring mastectomy. The latter group often have larger tumours with poor prognosis. 
Primary systemic treatment offers these women a chance to avoid mastectomy, and may 
improve their survival. These women have often been targeted in the studies of primary 
systemic treatment for breast cancer. Only studies which address the specific question of the 
efficacy of primary versus conventional systemic therapy are reviewed. 
2.3.1 Sequential series 
Primary systemic therapy has been used by the Milan group in patients with tumours over 3 
cm in diameter (median 4.5 cm) since 1988 (Bonadonna et al: 1995; Bonadonna el al: 1993; 
Bonadonna et al: 1990; Bonadonna and Veronesi: 1991; Bonadonna el al: 1991). A total of 
227 patients have been treated with cytotoxic chemotherapy using the CMF1, FAC2 and FEC3 
regimes. Tumour response was observed in 78% of patients. Complete pathological remission 
was seen in 3.5 %, and disease progression in 2% of patients. The main objective of this study, 
which was to avoid mastectomy, was achieved in 201/227 patients with a local relapse rate at 
three years of 3.5 %. Degree of response was found to be a predictor of relapse free survival, 
1CMF: Cyclophosphamide, Methotrexate and 5- Fluorouracil 
2FAC: 5- Fluorouracil, Adriamycin (doxorubicin) and Cyclophosphamide 
3FEC: 5- Fluorouracil, Epirubicin and Cyclophosphamide 
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with 52% of poor responders having relapsed at three years as compared with only 27% of 
responders (Bonadonna et al: 1993). 
The French group, led by the late Claude Jacquillat, have reported the results of their 
programme of primary systemic treatment which has been miming since 1980 (Jacquillat et 
al: 1991a; Jacquillat et al: 1990a; Jacquillat et al: 1989a; Jacquillat et al: 1989a; Baillet et 
al: 1989a; Jacquillat et al: 1988a). Their treatment programme includes patients with all 
stages of localised breast cancer, and is aimed at avoiding surgery altogether. Of the 250 
patients whose treatment has been reported, 192 had operable breast cancer, and of these, 21 
patients had small (T1) tumours. Patients were treated with cytotoxic chemotherapy with 
VTMF ±At. In addition 195 patients received tamoxifen. An overall pre -radiotherapy response 
rate of 75% was achieved with the best response (94 %) in the smallest tumours. Response 
rates were significantly better in the subgroup given tamoxifen. Although the local recurrence 
rates were relatively high (13 -19% according to stage), the overall survival figures were -better 
than expected, with 80% of patients with node -positive operable disease alive at 5 years 
(Jacquillat et al: 1990). In a multivariate analysis of risk factors, initial tumour regression 
again emerged as an important predictor of final prognosis (Jacquillat el al: 1991b). 
Calais and colleagues (1994) have reported the results of a series of 158 patients with large 
(mean tumour diameter: 5.6 cm) operable breast cancers treated with preoperative N /EVCF2 
regime. Clinical regression was achieved in over 60 %, and was complete in 20 %. Five year 
overall survival was 73.2% with responding patients surviving significantly longer than non - 
responding patients (Calais et al: 1994). 
A series of 126 patients with all stages of operable breast cancer (94 were T2), treated by 
primary chemotherapy has been reported by Belembaogo and colleagues (1991). A response 
rate of 83% and a breast conservation rate of 85% was achieved. At a median follow -up of 30 
months 7 patients (6 %) had died ( Belembaogo et al: 1992). 
Ragaz and colleagues have reported a series of 43 patients with operable breast cancer treated 
with CMF ( Ragaz et al: 1985). Survival at 2 years was 97 %. 
t VTMF±A: Vinblastinc. Thiotepa, Methotrexate and 5-Fluorouracil ± Adriamyein (doxorubicin) 
2N/EVCF: Mitoxantrone or Epirubicin, Vindesin, Cyclophosphamide, and 5-Fluorouracil 
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Other studies in progress where no survival data has been reported include those by Sinn and 
colleagues (1994) who have observed clinical regression in 2/3 of 51 patients they treated with 
primary chemotherapy, and the sequential series of 40 patients with operable tumours over 3 
cm reported by Lemaire and colleagues (1992) in whom half of the patients had a clinical 
response to chemotherapy. 
2.3.2 Randomised Trials 
The question of whether primary treatment can actually influence survival is currently being 
addressed by the NSABP1 trial B -18 (Fisher and Wickerham: 1991). This is of a simple 
design, testing surgery followed by chemotherapy with doxorubicin and cyclophosphamide, 
against chemotherapy followed by surgery. All women aged over 50 will also receive 
tamoxifen. The results of this trial are awaited. The same question is being asked by the 
EORTC2 10902 trial of preoperative versus postoperative chemotherapy (van de Velde: 
1993). 
The Royal Marsden group have also been running a trial of pre and postoperative 
chemotherapy versus postoperative chemotherapy only. The trial includes 212 patients with 
tumours over 2 cm in diameter, 105 whom were randomised to receive primary systemic 
treatment. At 28 months follow -up the number of events have been too small for any 
conclusions about survival (Powles et al: 1995). 
Two trials with published survival results, have indicated a benefit in favour of primary 
systemic treatment, although part of the advantage may be attributable to the more aggressive 
schedules used for primary therapy. 
The trial by Scholl and colleagues included 390 evaluable patients 191 of whom had received 
primary FAC3 chemotherapy (Scholl et al: 1994; Scholl et al: 1991; Scholl et al: 1991). 
Response rate was found to be significantly related to the actual drug dose given, and survival 
was better for responders compared with non -responders. At a median follow -up of 54 months 
1NSABP: National Surgical Adjuvant Breast Project 
2EORTC: European Organisation for Research and Treatment of Cancer 
3FAC: 5- Fluorouracil, Adriamycin (doxorubicin) and Cyclophosphamide 
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there was a survival advantage in favour of the primary systemic treatment group (Scholl et 
al: 1994). 
In a second trial by Mauriac and colleagues (1991) 272 women with operable tumours of over 
3 cm in maximum diameter were randomised to receive either 6 cycles of primary 
chemotherapy with EVM -MTV', or post- mastectomy chemotherapy to node- positive patients 
only. Node -negative patients were not given systemic treatment in the adjuvant arm of the 
study. One third of the 134 patients given primary treatment had complete tumour regression 
following chemotherapy, and a further third had partial responses. Oestrogen and progesterone 
receptor positive tumours were less likely to respond to cytotoxic chemotherapy. At a median 
follow -up of 34 months patients treated by primary systemic treatment had significantly better 
overall survival, although recurrence free survival was identical for both groups (Mauriac et 
al: 1991). 
2.3.3 Application of Selective Primary Systemic Treatment 
One of the important advantages offered by primary systemic treatment is the ability to use the 
observed tumour response to plan and modify treatment. 
The Royal Marsden Group have used induction chemotherapy primarily as a method of 
treating a series of patients, the majority of whom had large tumours over 4 cm in diameter, 
with primary chenu) and endocrine therapy (Smith et al: 1995; Smith et al: 1993; Mansi et al: 
1989). Although their primary aim was to avoid mastectomy, the group has utilised the 
observed tumour response as a method of evaluating the effectiveness of different 
chemotherapy regimes. Thus an overall response rate of 69 %, including 17% complete 
remission was improved to 98% (66% complete) with a regime including continuous infusion 
5- fluorouracil (Smith et al: 1995). 
'EVM -MTV: Epiruhicin, Vincristine, Methotrexate: 3 cycles followed by Mitomycin, 'I'hiotep a and 
Vindesine: 3 cycles 
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2.3.4 Selective chemo- endocrine primary systemic treatment 
2.3.4.1 Primary endocrine therapy 
Systemic endocrine therapy has been generally neglected in trials of primary systemic 
treatment, where its use has usually been in conjunction with cytotoxics (Jacquillat et al: 
1990), or following the completion of cytotoxic chemotherapy (Smith et al: 1993). Gazet and 
colleagues have used endocrine therapy for the treatment of locally advanced (Gazet et al: 
1991) and early (Gazet et al: 1996) breast cancer. Response rates to endocrine therapy were 
found to be low for unsclected patients (Gazet et al: 1991). When only patients with oestrogen 
receptor -rich tumours were given endocrine therapy over 40% responded, although the rate 
was still lower than the 60% achieved with cytotoxic chemotherapy ( Gazet et al: 1996). 
Primary endocrine therapy has also been used for the treatment of postmenopausal patients by 
the Marsden group (Powles et al: 1995; Mansi et al: 1989). 
2.3.5 The Edinburgh programme of selective chemo- endocrine therapy 
2.3.5.1 Selection by response 
The Edinburgh programme for primary systemic treatment was started in 1985. It is different 
from other series in that the main rationale was to use tumour response as a method of 
assessing the effectiveness of primary endocrine therapy and to base further treatment on the 
observed response (Kjellgren el al: 1989). In the initial stages of the programme endocrine 
therapy was used in all patients, with chemotherapy reserved for those whose tumours failed 
to respond. In the Scottish breast conservation trials, an upper limit of 4 cm was set for breast 
conservation (Stewart et al: 1989), and historically the programme was confined to patients 
with operable cancers over 4 cm in maximum diameter who were not suitable for the 
conservation trials. Endocrine therapy consisted of medical oophorectomy with goserelin for 
premenopausal patients and 4- hydroxy -androstenedione or tamoxifen for postmenopausal 
patients. Cytotoxic chemotherapy was given with cyclophosphamide, doxorubicin and 
vincristinc, with prcdnisolone to protect the marrow (CHOP regime). Since the study of 
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response to treatment was one of the main aims of this study, tumour size was measured on a 
weekly basis after the start of the treatment, and response was defined as a consistent decrease 
in tumour size. No attempt at breast conservation was made following primary systemic 
therapy, the main outcome measure being survival. 
2.3.5.2 Selection by oestrogen receptor levels 
Of the first 43 unselected patients treated with endocrine therapy, 18 patients showed a 
response. The tumour progressed in 11 and was static in 14. Ten of the 11 progressing 
tumours lead an oestrogen receptor (ER) level of less than 20 fmol/mg cytosol protein. All 
responding tumours had a level greater than this (Anderson et al: 1989). The protocol was 
therefore modified so as to give the low ER patients chemotherapy from the start. 
2.3.5.3 Results of the initial series 
In a sequential series, 88 patients were treated with the above protocol, including the 43 who 
were treated before the introduction of selection by oestrogen receptor status. Twenty four 
were given endocrine treatment only, 27 cytotoxics only and the remainder received endocrine 
treatment followed by chemotherapy. At the end of primary chemo- endocrine therapy 66 of 
the 88 patients achieved clinical response which was complete in 14 (16 %) cases (Forrest and 
Anderson: 1991; Forrest et al: 1991; Anderson et al: 1991). At a median follow -ui, of 24 
months 86% of the patients were alive (Anderson et al: 1991). 
2.3.6 A randomised trial 
The Edinburgh series has shown that the most appropriate adjuvant treatment for individual 
patients can be selected, by careful assessment and monitoring of tumours during primary 
systemic therapy. The approach offers an integrated treatment package for high risk operable 
breast cancer. The next section describes a randomised trial, started in 1990, and designed to 
compare this treatment package with what was considered to be best conventional therapy for 
breast cancer. 




3. Protocol for 
a 
Randomised Clinical Trial 
3.1 AIMS AND OVERALL DESIGN 
3.1.1 Aims 
3.1.1.1 Primary aim 
To assess the value of selected preoperative systemic therapy by comparing the local 
recurrence rate, distant disease free interval and survival of patients with large but operable 
breast cancers, randomised to treatment by either primary selected systemic therapy followed 
by mastectomy, or mastectomy and unselected adjuvant systemic therapy. 
3.1.1.2 Subsidiary aims 
To compare the impact of primary systemic treatment on psychological and surgical morbidity 
with that seen with conventional therapy 
3.1.2 Design of trial 
A randomised design without stratification was used. The overall scheme of the trial is 
represented in Figure 3 -1. 
3.1.2.1 Registration, stratification and randomisation 
All eligible patients were registered and the reason why those not randomised for therapy 
within the trial recorded. 
3.1.2.1.1 Randomisation procedure 
J 
Randomisation was performed at the Scottish Cancer Trials Office from a list of random 
numbers. Eligibility for the trial was rechecked by the office and the patient allocated to an 
3 -58 
arm of the trial. Copies of registration details, investigations, follow -up details and pathology 
reports were collected by the trials office. 
3.1.2.2 Modification of the protocol 
On 30 April 1992, a modified protocol was implemented to allow patients with smaller 
tumours to be included in the study. The details of the original protocol were for the most part 
unchanged. In the account that follows the original protocol is described. Where relevant, 
details of the modified protocol are provided under separate headings in boxed paragraphs. 
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Figure 3 -1: Scheme of the protocol for the randomised trial of conventional 
versus selective primary systemic treatment 
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3.2 PATIENT RECRUITMENT 
3.2.1 Entrance criteria 
The following criteria were used to define suitability for recruitment into the trial. 
3.2.1.1 Personal history 
1. Female patients only 
2. Age over 25 and under 70 
3. No previous history of malignant disease other than adequately treated basal- or squamous- 
ccll carcinoma of the skin or carcinoma in situ of the cervix. 
4. No previous history of significant cardiac or respiratory disease or of any other condition 
which may preclude adequate surgery, adjuvant therapy or follow -up. 
3.2.1.2 Tumour details 
1. Proven breast malignancy 
2. Tumour over 40 mm in at least one diameter 
Modification 
2. Tumour over 30 mm in at least one diameter 
3. Locally operable: T4 or N2 (TNM classification) tumours excluded 
a. No evidence of skin invasion by either tumour or lymph nodes 
b. No fixation to chest wall by tumour or nodes 
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c. No involvement of overlying skin by tumour or lymph nodes (Paget's disease of the 
nipple or tethering to the skin acceptable) 
d. No peu d' orange (small area directly over the tumour acceptable) 
c. No inflammatory carcinomas 
4. Tumour freely mobile within the breast with no clinically detectable fixation to pectoral 
muscle or fascia 
5. No evidence of distant metastases 
3.2.2 Exclusion criteria 
1. Bilateral primary breast cancer 
2. In -situ carcinoma only 
3. Pregnancy, lactation or expressed intent for future pregnancy 
4. High probability of inadequate follow -up (e.g.: overseas residents) 
3.2.3 Pre -recruitment investigations 
,/ 
The following investigations were carried out in all potentially eligible patients to establish the 
diagnosis of invasive breast carcinoma and to exclude the presence of distant metastases prior 
to recruitment into the trial. 
3.2.3.1 Diagnostic investigations 
1. Fine needle aspiration cytology 
2. Bilateral 2 -view mammography 
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3.2.3.2 Investigations to exclude metastatic disease 
3.2.3.2.1 Haematological investigations 
Haematological investigations were carried out as part of routine clinical work up at the 
Department of Haematology, The Royal Infirmary, Edinburgh, EH3 9YW. 
All patients had a full blood count and a measurement of erythrocyte sedimentation 
rate. Patients with abnormal results had bone marrow aspiration and trephine to 
exclude metastatic disease. 
3.2.3.2.2 Biochemical investigations 
Biochemical investigations were carried out as part of routine clinical work up at the 
Department of Clinical Chemistry, The Royal Infirmary, Edinburgh, EH3 9YW. 
All patients had the following parameters measured: serum electrolytes, urea and crcatinine, 
serum calcium and liver function tests. Abnormal results were appropriately investigated. 
3.2.3.2.3 Radiological investigations 
Radiological investigations were carried out under the care of Dr. J. S. Walsh, Consultant 
Radiologist, The Edinburgh Breast Unit, Western General Hospital, Edinburgh, EH4 2X U. 
All patients underwent chest radiography, and a radio -isotope bone scan with radiographs of 
suspicious arcas. Patients with abnormal liver function tests or other clinical indications of 
liver disease also had ultrasound scan or computerised tomography of the liver. 
3.2.3.3 Determination of menopausal status 
The menopausal status in patients who had previously had a hysterectomy without bilateral 
oophorectomy or whose last menstrual period was more than 3 months but less than 12 
months earlier, was determined by the measurement of plasma oestradiol, oestrone, FSH and 
LH at the Regional Immunoassay Laboratories, The Royal Infirmary, Edinburgh, E113 9YW. 
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Patients were classified as premenopausal or postmenopausal, according to the following 
definition: 
3.2.3.3.1 Postmenopausal 
Patients whose last menstrual period was at least 12 months previously or who had formerly 
had an unrelated bilateral oophorectomy or whose serum hormone levels indicated cessation of 
ovulation. 
3.2.3.3.2 Premenopausal 
Patients with a menstrual period within the preceding 3 months, or with hormone levels 
indicative of continuing ovulation. 
3.2.3.4 Other investigations 
3.2.3.4.1 Histological examinations 
All examination and reporting of cytological and histological samples was carried out under 
the care of Dr. T. J. Anderson, Consultant Pathologist, The Edinburgh Breast Unit, 
Western General Hospital, Edinburgh, EH4 2XU. 
3.2.3.4.2 Determination of oestrogen receptor levels 
Oestrogen receptor determination was carried out by Dr. R. A. Hawkins at the Lister 
Research Laboratories, The Royal Infirmary, Edinburgh, EH3 9YW. Homogenised tissue was 
examined using a monoclonal antibody based enzyme immunoassay technique. The assay was 
obtained in a commercial kit (Abbot ER -EIA kit, Abbot diagnostics division, Abbot House, 
Norden Road, Maidenhead, Berkshire, SL6 4XF). The performance of the assay has been 
described previously both in this laboratory (Hawkins el al: 1987), and by other investigators 
(Jordan et al: 1986; Lecicrcq el al: 1986). l 
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3.3 TRIAL OPTIONS 
Patients were randomised to one of the following two options: 
1. Primary systemic therapy followed by mastectomy 
2. Conventional treatment with mastectomy followed by adjuvant systemic therapy 
3.3.1 Primary systemic treatment 
An incisional biopsy was performed to obtain tissue for measurement of oestrogen receptor 
(ER) levels. Systemic treatment was started depending on the tumour ER. Tumour regression 
was monitored and patients whose tumours failed to respond or progressed on endocrine 
therapy were given cytotoxic chemotherapy. Tumour progression on chemotherapy was 
managed by termination of systemic treatment and immediate mastectomy. Treatment details 
were as follows: 
3.3.1.1 Initial biopsy 
Local anaesthesia was used unless the patient requested general anaesthesia. A transverse 
incision placed directly over the tumour was deepened down to the surface of the tumour. A 
wedge of tumour was removed and sent fresh for histology and ER. The minimum acceptable 
quantity of tumour was removed, not exceeding 0.6 grams in total. The four quadrants of the 
tumour were marked using metal haemostatic clips before closure. Any excess tissue left over 
from ER or histological examination was stored in liquid nitrogen. 
Patients who presented with obviously clinically malignant axillary lymph nodes, had a lymph 
node biopsy in preference to an incisional biopsy. A single enlarged node was removed 
through a "lazy S" incision. 
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3.3.1.2 Systemic therapy 
This was started as soon as the invasive nature of the tumour had been established and ER 
values were available. Patients with ER equal or greater than 20 fmol/mg cytosol protein were 
initially treated by endocrine therapy. 
All patients with ER less than 20 fmol/mg cytosol protein, and those patients whose tumours 
did not respond or progressed on endocrine treatment were given cytotoxic chemotherapy. 
3.3.1.2.1 Endocrine therapy 
Premenopausal patients were given a subcutaneous implant of goserelin, 3.6 mg, repeated 
once every 4 weeks for a total of 12 weeks. Those who responded were treated with bilateral 
oophorectomy at the time of mastectomy. 
Postmenopausal patients were given tamoxifen 20 mg daily for 12 weeks, and those who 
responded were asked to continue tamoxifen after their mastectomy for five years or until 
recurrence, whichever was sooner. 
3.3.1.2.2 Cytotoxic chemotherapy 
Four cycles of treatment were given once every three weeks before mastectomy. Two further 
cycles were administered postoperatively, starting as soon as practicable after the mastectomy. 
Chemotherapy cycles were delayed by one week if the patients' white blood cell count 
remained less than 3 x 109/l when they were due for chemotherapy. 
The following drugs were used for each cycle: 
Cyclophosphamide 1g/m2 single intravenous dose 
Doxorubicin 50 mg/m2 single intravenous dose 
Prednisolone 40 mg orally daily for five days 
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3.3.1.3 Measurement of response 
3.3.1.3.1 Examination and tumour measurement 
Patients were examined once a week for signs of disease progression in the breast or the 
axilla, and the tumour size was measured by callipers. Eight measurements were taken at 
22.5° axes, and mean tumour diameter and tumour volume calculated. Initial tumour 
measurements were obtained at the time of entry into the study. Measurements were resumed 
four weeks after the initial tumour biopsy to avoid errors due to post -surgical swelling and 
continued for the duration of primary systemic treatment. 
Patients also underwent weekly breast ultrasound examination and four weekly mammography 
during primary systemic treatment. 
3.3.1.3.2 Response assessment 
A probit plot was used to assess the distribution of values for "tumour volume ". This was 
shown to be positively skewed and a logarithmic transformation of volume was used in 
assessment of response (section 10.3). 
For each patient linear regression was used to assess the relationship between duration of 
primary systemic treatment as the independent variable against the natural logarithm of 
tumour volume as the dependent variable. Using the method of least squares, the slope and the 
intercept for the regression line were calculated, and the correlation coefficient determined. If 
the slope was negative and correlation significant at the 95% level, the tumour was classed as 
one which had responded to treatment. 
3.3.1.4 Grading of tumour response 
The degree of tumour response was assessed by calculating the proportional reduction in the 
product of two maximum tumour diameters, as defined by the criteria set out by the 
International Union Against Cancer (Hayward el al: 1977). Pre -treatment tumour diameter 
was estimated from a combination of clinical and radiological measurements, and post 
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treatment diameter was measured on the cut surface of resected tumour specimens as 
described in section 10.2.1.2.4. 
3.3.1.4.1 Response categories 
Six tumour response categories were defined as follows: 
1. Complete pathological remission: no evidence of residual cancer on histological 
examination of the post treatment specimen 
2. Complete clinical remission: no clinical or radiological evidence of residual tumour, but 
residual cancer cells identified in the tumour resection specimen 
3. Clinical response: a reduction of 75% or more in the product of two maximum tumour 
diameters 
4. Partial response: a reduction of 50% to 74% in the product of two maximum tumour 
diameters 
5. Minimal response: a reduction of 25% to 49% in the product of two maximum tumour 
diameters 
6. No response: a reduction of less than 25% in the product of two maximum tumour 
diameters 
3.3.1.4.2 Tumour half life 
A more detailed assessment of the way each tumour responded to treatment was obtained 
using the regression line fitted to the sequential tumour measurements. Time taken for the 
tumour to regress to half its original volume (tumour half life: ti ) was calculated from the 
slope of the regression line (nr) using this equation: In 2 
ti = 
-m 
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3.3.1.5 Locoregional Therapy 
Modification 
Suitable patients were allowed breast conservation as an option. The appropriate form of 
surgery and radiotherapy was decided before randomisation. The patients weressessed jointly 
by the responsible surgeon and radiation oncologist. A decision was made to treat the breast 
by mastectomy or by wide local excision of the tumour, depending on the clinical and 
mammographie appearance of the tumour, and taking into consideration patient preference. 
Following primary systemic treatment, if the tumour had regressed or was static, this original 
decision was adhered to regardless of the extent of tumour regression. If the tumour has 
progressed, the decision was revised according to the immediate preoperative findings. 
3.3.1.5.1 Timing of locoregional therapy 
Patients responding to primary endocrine treatment received locoregional therapy no later than 
16 weeks after starting tamoxifen or goserelin. 
Locoregional treatment followed the fourth cycle of cytotoxic chemotherapy, or an earlier 
cycle if it become clear that the tumour was failing to respond. Patients were allowed a 
recovery period of 3 weeks or until the white blood cell count was equal to, or greater than 
3 x 109/1, whichever was later. Locoregional treatment took place within one week following 
this recovery period. 
3.3.1.5.2 Surgical treatment 
The breast was treated by total mastectomy in all patients. Skin margins were marked from 
the centre of any residual tumour mass. When a tumour was smaller than at presentation a 
margin equivalent to the original tumour radius plus 3 cm was required. If the tumour size had 
not changed or had increased, a 3 cm margin was allowed around the palpable tumour. Where 
achieving an adequate skin clearance precluded primary closure of the wound, a latissimus 
dorsi myocutancous flap (LD flap) was used. 
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Modification 
The breast was treated by wide local excision where appropriate. The breast was reassessed in 
the immediate preoperative period to confirm that breast conservation remained possible. The 
tumour was excised down to pectoral fascia, with a margin of normal breast tissue. When a 
tumour was smaller than at presentation the margin was planned according to the original size 
of the tumour. If the tumour size had not changed or had increased, the margin was planned 
around the palpable tumour. 
The axilla was treated by a full level III axillary clearance. 
All patients were offered primary breast reconstruction following mastectomy. A LD flap was 
used where this was needed to achieve skin closure, otherwise the patients were offered a 
subpectoral tissue expander. 
The details of the mastectomy procedure are presented in section 8.2.3. 
3.3.1.5.3 Radiotherapy 
Patients with tumours which were clinically tethered to pectoral fascia or muscle were 
excluded from the trial. I Iowever if a tumour clinically judged to be free was found at surgery 
to be tethered to the pectoral fascia or muscle, breast reconstruction was not pertòrmed and 
radiotherapy was given to the skin flaps. Radiotherapy was also given if indicated from 
tumour histology. 
Modification 
Patients treated by wide local excision received postoperative radiotherapy to the breast. 
In patients on endocrine treatment, radiotherapy was started as soon as practicable after 
surgery. In other patients, radiotherapy was delayed until after the completion of cytotoxic 
chemotherapy. 
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3.3.2 Conventional therapy 
Conventional treatment consisted of primary locoregional treatment followed by adjuvant 
systemic therapy determined by the patient's menopausal status and axillary lymph node 
status. 
3.3.2.1 Locoregional therapy 
3.3.2.1.1 Confirmation of diagnosis 
Prior to surgery, patients under the age of 50 received a core biopsy in addition to other 
diagnostic tests in order to confirm the presence of invasive malignancy. For patients over the 
age of 50 an unequivocal malignant report on the fine needle aspirate and on mammography 
were deemed adequate proof of malignancy. 
Modification 
Prior to surgery, patients under the age of 50 who required a mastectomy underwent a core 
biopsy in addition to other diagnostic tests in order to confirm the presence of invasive 
malignancy. For patients over the age of 50 or any patients being treated by breast 
conservation an unequivocal malignant report on the fine needle aspirate and on 
mammography were deemed adequate proof of malignancy. 
3.3.2.1.2 Surgical treatment 
A mastectomy and full level III axillary clearance was carried out as the initial treatment. The 
details of the operation and breast reconstruction were identical to that described for patients 
undergoing primary systemic treatment. 
Modification 
A mastectomy or a wide local excision was carried out along with a full level III axillary 
clearance as the initial treatment. The details of the operation and breast reconstruction were 
identical to that described for patients undergoing primary systemic treatment. 
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3.3.2.1.3 Radiotherapy 
Indications for radiotherapy were as described for primary systemic treatment. 
In endocrine treated patients radiotherapy was started as soon as practicable after surgery. 
Patients who required postoperative chemotherapy were started on radiotherapy after two 
cycles of chemotherapy had been administered. Chemotherapy was resumed 3 weeks after 
radiotherapy had been completed. 
3.3.2.2 Adjuvant systemic treatment 
3.3.2.2.1 Cytotoxic chemotherapy 
Premenopausal patients who had one or more involved axillary lymph nodes were treated with 
cytotoxic chemotherapy. Six cycles of treatment were given once every three weeks. 
Chemotherapy cycles were delayed by one week if the patients' white blood cell count 
remained less than 3 x 109/1 when they were due for chemotherapy. 
The following drugs were used: 
Cyclophosphamide 600 mg/m2 Single intravenous dose 
Methotrcxate 50 mg/m2 Single intravenous dose 
5-fluorouracil 600 mg/m2 Single intravenous dose 
3.3.2.2.2 Endocrine therapy 
Premenopausal patients with no axillary lymph node involvement and all postmenopausal 
patients regardless of axillary nodal status were treated with adjuvant tamoxifen 20 mg daily 
for 5 years or until first recurrence, whichever was sooner. 
Trial options 3 -71 
3.4 TREATMENT RELATED TOXICITY 
3.4.1 Endocrine treatment 
Any side effects reported by patients on endocrine treatment were recorded. Complications 
directly relating to surgical oophorectomy were also recorded. 
3.4.2 Cytotoxic chemotherapy 
Toxicity relating to cytotoxic chemotherapy was divided into four main categories as follows: 
1. Gastrointestinal (GI) disturbances in the form of nausea and diarrhoea 
2. Inflammation of mucous membranes (mucositis) including conjunctivitis 
3. Alopecia 
4. Myclosuppression 
3.4.2.1 Grading of toxicity 
Toxicity was recorded at the time of administering each cycle of chemotherapy on a scale of O 
to 3, defined as follows: 
t): No manifestation, or very minor lasting less than 12 hours 
1: Mild, lasting less than 48 hours 
2: Severe side effects lasting up to 12 hours, moderate severity lasting up to 48 hours, or 
mild side effects lasting over 48 hours 
3: Severe side effects lasting over 12 hours 
3 -72 
3.4.2.2 Analysis of results 
On completion of treatment, the mean score over the course of 6 cycles was calculated to 
obtain an average side effects score for the individual patient. 
3.4.2.2.1 Dose intensity 
Prolonged neutropenia was dealt with by reduction in the dose of cyclophosphamide and 
lengthening of the interval between chemotherapy cycles, resulting in an overall reduction in 
dose intensity. Actual dose intensity as a percentage of planned dose intensity was calculated 
and compared. 
Treatment related toxicity 3 -73 
3.5 FOLLOW -UP AND ANALYSIS 
3.5.1 Follow -up 
Patients were seen at regular intervals during their breast cancer treatment as dictated by the 
requirements of specific treatment regimes. 
3.5.1.1 Discharge to follow -up 
Patients were discharged to follow -up once all cancer related treatment had been completed. 
For patients receiving cytotoxic chemotherapy this was when the patient had fully recovered 
from any immediate side effects of their final cycle of chemotherapy. For patients on 
endocrine treatment this was regarded as the time when the patient was first started on long 
terni tamoxifen, or when the patient had fully recovered from any complications of surgery, 
whichever was later. If radiotherapy was the final adjuvant treatment, time of discharge was 
regarded as the time of full recovery from the effects of radiotherapy. Hospital visits for breast 
reconstruction were not regarded as cancer treatment. 
3.5.1.2 Long term follow -up 
Patients were reviewed once every three months for the first 2 years, once every four months 
in the third year, once every six months for the fourth and the fifth years and annually 
thereafter. All patients received annual two view mammograms of the untreated breast. 
3.5.1.3 Treatment of recurrence 
The choice of further treatment once a recurrence was detected was left entirely open to the 
discretion of the surgeons and oncologists involved in treatment at the time of recurrence. 
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3.5.2 Projected trial statistics 
Projected trial statistics were determined in conjunction with Dr. R. J. Prescott, Department of 
Medical Statistics, University of Edinburgh Medical School, Teviot Place, Edinburgh, EH8 
9AG. 
3.5.2.1 Trial power 
Based on previous studies (section 2.3), it was deemed reasonable to expect an overall 
survival of 50% at 5 years for conventionally treated patients. An absolute improvement in 
survival of the order of 15% was assumed to be the minimum desirable improvement for 
patients treated by primary systemic therapy. 
At this level of risk reduction, it was calculated that 163 patients were needed in each arm of 
the trial in order to provide 75% power to detect the difference at the 5% level of statistical 
significance. Based on previous experience of the Edinburgh Breast Unit, it was estimated that 
this number could have been recruited within 5 years. 
3.5.2.2 Interim analysis 
Distant disease free survival and overall survival were analysed at six monthly intervals. A 
statistically significant survival difference at the 1% level was regarded as the threshold for 
the termination of the trial. 
3.5.3 Ethical considerations 
The details of the protocol and the ramifications of all possible treatments were explained to 
eligible patients at two separate interviews conducted jointly by a nurse counsellor and a 
doctor. Patients were required to give written consent before being randomised to an arm of 
the trial. 
The protocol was approved by the "Medicine/ clinical oncology ethics of medical research 
sub -committee" of the Lothian Health Board. 
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Modification 
The modified protocol was independently approved by the "Medicine/ clinical oncology ethics 
of medical research sub -committee" of the Lothian Health Board. 
3.5.4 Analysis of results 
All analyses were performed using the statistical software package Stata 4.0 for Windows, 
Stata Corporation, 702 University Drive East, College Station, Texas 77840 USA. 
3.5.4.1 The first part of the trial 
Data for the trial are presented on the basis of intention to treat and actual treatments received. 
Details of statistical methods are specified within the text of the results section. 
3.5.4.1.1 Survival analysis 
Life tables were used to plot Kaplan -Meier survival curves. The hazard ratio, and its 
significance were calculated using univariate Cox's regression (Cox: 1972). The results were 
analysed on the basis of intention to treat and separately on the basis of actual treatments 
given. Survival outcome was death from all causes. 
3.5.4.2 Results including patients treated in the modified protocol 
The results of the entire trial, including all patients recruited after the protocol was modified 
are reported separately. Patient and tumour characteristics are described in so far as is 
relevant to the interpretation of the survival results. Detailed toxicity data, and response data 
for patients in the primary systemic treatment arm are not reported. 
3.5.4.3 Assessment of prognostic indicators 
Prognostic factors were analysed on all trial patients including those treated after the 
modification of the trial protocol. 
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Cox's proportional hazard model (Cox: 1972) was used to assess the importance of tumour 
and patient characteristics in predicting overall survival. For the purpose of analysing 
prognostic indicators, only deaths from breast cancer were considered. Data from patients 
dying of other conditions were treated as censored observations. The following factors were 
considered in the analysis: 
1. Age at randomisation 
2. Clinical tumour diameter at the time of diagnosis 
3. Actual number of involved axillary lymph nodes 
4. Initial tumour oestrogen receptor levels, normalised by log transformation 
5. initial tuillollr differentiation, classed as poor, moderate or well 
6. Actual treatment received classed as Primary systemic or Conventional 
Factors which proved significant with p <0.15 on univariate analysis were included in the 
multivariate model. 
Significant prognostic factors were further analysed by dividing them into categorical 
variables, and plotting Kaplan -Meier survival curves for each category. Details are described 
in the results section. 
3.5.4.3.1 The significance of the ERICA assay 
3.5.4.3.1.1 Methods 
As part of an ongoing investigation, a portion of cells from the initial diagnostic fine needle 
aspirate were assayed for oestrogen receptors using an 91,Estrogen 
Receptor Immuno- 
Cytochemical Assay (ERICA). Assays were performed by 
Kathryn Sangster and Dr R. A. 
Hawkins at the Lister Research Laboratories, The Royal Infirmary, 
Edinburgh, EH3 9YW. A 
commercial kit was used for the assays (Abbot ER -ICA kit, Abbot 
diagnostics division, Abbot 
House, Norden Road, Maidenhead, Berkshire, SL6 4XF). 
The details of the assay and its 
characteristics have previously been reported by Dr Hawkins' 
group (Hawkins el al: 1988; 
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Hawkins et al: 1987), and by other investigators (Flowers et a!: 1986; Cavailles el al: 1987; 
Weintraub el a!: 1987; McClelland et a!: 1987). 
3.5.4.3.1.2 Analysis 
The results were reported as the proportion of cells staining for ER. Patients had been classed 
as ER positive or ER negative according to the initial oestrogen receptor content of their 
tumour as determined by the enzyme immuno -assay. This was set as the standard against 
which ERICA measurements were compared. 
To determine the relationship between ERICA values and patient oestrogen receptor status, 
the patients were categorised to ERICA negative and ERICA positive using a series of cut off 
values. The number of ER negative and ER positive patients correctly identified by the 
ERICA negative and ERICA positive categories were determined and the "positive predictive 
value'" for each cut off level calculated. In addition the relative overall survival for the two 
ERICA categories was calculated for each cut off level using Cox's regression. 
The following cut off values were investigated: 0 /1, 1/2, 2/3, 3/4, 4/5, 7/8, 10/11, 14/15, 
19/20, 29/30, 39/40, 49/50. 
3.5.5 Results specific to the primary systemic treatment group 
3.5.5.1 Post treatment prognostic indicators 
Cox's proportional hazard model (Cox: 1972) was used to assess the importance of post 
treatment tumour characteristics in predicting overall survival. Only deaths from breast cancer 
were considered. The following tumour factors, assessed on specimens obtained after the 
completion of primary systemic therapy, were studied: 
1. Actual number of involved axillary lymph nodes without consideration of any pre- 
treatment information on lymph nodes 
t Positive Predictive value = ((Number identified as POSITIVE by both ER and ERICA) +( Number 
identified as NEGATIVE by both ER and ERICA)]/ (total number of patients) 
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2. Post treatment tumour oestrogen receptor levels, normalised by log transformation 
3. Post treatment tumour differentiation, classed as poor, moderate or well 
Factors which proved significant with a probability of <0.15 on univariate analysis were 
included in the multivariate model. 
Significant prognostic factors were further analysed by dividing them into categorical 
variables, and plotting Kaplan -Meier survival curves for each category. Details are described 
in the results section. 
3.5.5.2 Tumour response and survival 
The patients were divided into "fast responders" and "slow responders" by comparing 
individual tumour half lives with the median value for tumour half life. Patterns of response 
were found to be different for endocrine and cytotoxic treatments. The fast and the slow 
responders for the two treatment categories were therefore determined separately. 
3.5.5.2.1 Categorisation of non -responders 
Patients who failed to respond to endocrine treatment and subsequently received cytotoxic 
chemotherapy were considered along with chemotherapy only patients. Tumour behaviour 
during the endocrine phase of treatment was discounted for this group of patients and tumour 
half life based on regression during the cytotoxic therapy phase. 
Patients who failed to respond to cytotoxic chemotherapy, (i.e.: had a regression slope which 
was not significantly different from zero) by definition had a tumour half life of "infinity ". 
3.5.5.2.2 Allocation to response categories 
The median half life for each treatment category was determined. Patients with tumour half 
lives shorter than or equal to the median half life for their treatment category were classed as 
"fast responders" while those with longer half lives were classed "slow responders ". 
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3.5.5.2.3 Analysis of survival in relation to response 
Cox's proportional hazard model was used to assess the influence of tumour response in 
relation to distant disease free and overall survival. The following patient characteristics were 
considered: 
1. Menopausal status, classed as pre or postmenopausal 
2. Mean tumour diameter at the time of diagnosis 
3. Axillary nodal involvement, classed as node- positive or node -negative 
4. Oestrogen receptor status, classed as ER <20 and ER >19 
5. Tumour differentiation, classed as poor, moderate or well differentiated 
6. Tumour response categorised as "slow" or "fast" 
Factors which on univariate analysis where significant with p <0.1.5 were included in the 
multivariate model. 
3.5.5.3 Relationship between tumour characteristics and the rate of response 
The distribution of tumour half lives was examined using a probit plot and was found to be 
near normal. A model was constructed using multiple regression analysis to assess the 
contribution of patient and tumour characteristics to the speed of response as measured by 
tumour half life. The following characteristics were examined: 
1. Menopausal status, classed as pre or postmenopausal 
2. Tumour diameter at the time of diagnosis 
3. The natural logarithm of the actual oestrogen receptor levels 
4. Tumour differentiation, classes as poor, moderate or well differentiated 
Follow -up and analysis 3 -80 
Since axillary nodal status was determined following the completion of primary systemic 
treatment, it could potentially have been affected by regression and it was not entered into the 
model. 
Follow -up and analysis 3 -81 
CHAPTER 4 
4. Results of the Main Trial 
4.1 RESULTS RELATING TO THE FIRST PART OF THE TRIAL 
4.1.1 Recruitment and compliance 
4.1.1.1 Recruitment 
The first patient was recruited into the pilot study on 31 January 1990. The pilot was closed 
on 29 April 1992. In the 27 month period of the study 559 breast cancer patients were treated 
at the Edinburgh Breast Unit, 86 of whom fulfilled the criteria for entry into the trial. One 
patient with mental disability was deemed unable to provide informed consent and was not 
approached. 
Eighty five patients were counselled regarding the trial. Six patients refused to enter the trial 
and were treated in a conventional manner. A total of 79 patients were recruited into the study 
and randomised in accordance with trial protocol. 
4.1.1.2 Treatment allocation and compliance 
Thirty nine patients were allocated to the conventional arm of the trial and 40 women were 
randomised to receive primary systemic treatment (PST). 
4.1.1.2.1 Major protocol violations 
There were 5 major protocol violations with the trial as follows. 
4.1.1 .2.1.1 Primary systemic treatment 
There were 3 protocol violations in this arm of the trial. Two patients who were initially 
allocated to receive PST later requested conventional therapy. One of these patients had made 
her request after undergoing a wedge biopsy, and was given 3 weeks of tamoxifen before 
mastectomy. In a third patient initial wedge biopsy failed to confirm the presence of invasive 
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carcinoma, and a complete tumour excision was carried out to establish the diagnosis. This 
patient was subsequently treated conventionally. 
4.1.1.2.1.2 Conventional treatment 
There were two major protocol violations in this arm. One patient requested and after 
discussion with the local ethics committee, she was treated according to the primary systemic 
therapy protocol by initial chemotherapy. This patient was put on long term tamoxifen 
following mastectomy. 
The second patient was a 64 year old postmenopausal woman who was treated by initial 
mastectomy. Her mastectomy specimen contained ductal carcinoma in situ only with no 
evidence of invasive disease. This patient has not been given any form of systemic treatment 
and has been excluded from further analysis. She remains alive and well after 56 months of 
follow -up. 
4.1.1.2.2 Minor protocol violations 
There were 4 minor protocol violations two of which occurred in patients who already had 
major protocol violations as explained above. 
The third patient was recruited into the PST arm of the study having been started on goserclin 
3 weeks earlier for a gynaecological condition. Goserelin was subsequently continued when it 
was shown to have been the appropriate treatment for the patient's breast cancer. The final 
patient was premenopausal and was treated by chemotherapy in the PST arm but failed to 
respond to treatment. She was put on long term tamoxifen postoperatively. 
4.1.1.3 Reporting of results 
Seventy eight patients were eligible for analysis. Forty were allocated to PST and 38 to 
conventional treatment. 40 were treated conventionally and 38 by PST. 
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4.1.2 Patient and tumour characteristics 
4.1.2.1 Patient characteristics 
4.1.2.1.1 Age 
The cohort of 78 patients had a mean age of 51 years (range 31 -69). The age distribution 
between the two arms by intention to treat and by actual treatments are shown in Table 4 -1. 
There was no significant difference in age distribution between the two arms of the trial. 
Conventional PST t= P= 
By intention to treat 
By actual treatments given 
50.9 (31 -69) 
51.4 (31 -69) 
51.1 (33 -69) 





Mean age and age range. Student's t -test with 76 degrees of freedom 
Table 4 -1: Age distribution of patients in the first part of the trial 
4.1.2.1.2 Menopausal status 
Menopausal status was clear on the basis of history alone in 75 patients, and was determined 
from scrum hormone estimates in a further 3. There were 41 premenopausal patients and 37 
postmenopausal patients in the entire cohort. The numbers of pre and postmenopausal patients 
in each arm of the study are shown in Table 4 -2. The distribution of pre and postmenopausal 
patients between the two treatment groups was not significantly different. 
Conventional PST 
Pre Post Pre Post p= 
By intention to treat 19 19 22 18 0.821 
By actual treatments given 19 21 22 16 0.375 
Proportions compared using Fisher's exact test 
Table 4 -2: Menopausal status for patients in the first part of the trial 
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4.1.2.2 Tumour characteristics 
4.1.2.2.1 Tumour diameter 
The distribution of tumour size by intention to treat is shown in Figure 4 -1. The median 










Tumour diameter (mm) 
Figure 4 -1: Tumour size distribution for patients in the first part of the trial 
The median and range of tumour sizes for patients in each arm of the trial are presented in 
Table 4 -3. There were no significant differences. 
Conventional PST zr p= 
By intention to treat 
By actual treatments given 
46 (41 -85) 
47 (41 -85) 
46 (41 -83) 





Median and range of tumour sizes. Mann -Whitney U test 
Table 4 -3: Tumour size for patients in the first part of the trial 
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4.1.2.2.2 Axillary lymph node involvement 
Following primary axillary clearance a median of 17 (range 3 -33) nodes were recovered. This 
was not significantly different from the median of 14 (range 4 -29) nodes recovered when 
axillary clearance followed primary systemic treatment (z= -0.84, p= 0.40, Mann -Whitney U 
test). Five patients treated by PST had histological evidence of axillary nodal metastases prior 
to start of treatment. On subsequent axillary clearance, two of these patients had no residual 
axillary involvement. These two patients were nevertheless classed as "node- positive ". 
In total, 46 patients had evidence of axillary metastases. The proportion of patients with any 
axillary nodal involvement are presented in Table 4 -4. There were no significant differences 
between the two groups. 
Conventional PST 
Involved Free Involved Free p= 
By intention to treat 











using Fisher's exact lest 
Table 4 -4: Number of patients with axillary metastases 
The median and range of the number of involved axillary nodes for patients with involved 
axillac are presented in Table 4 -5. Patients treated conventionally had a significantly greater 
number of involved axillary nodes compared with patients treated with PST. 
Conventional PST z= p= 
By intention to treat 
By actual treatments given 
8 (1 -23) 
7 (1 -23) 
3 (1 -13) 





Median and range of the numbers of involved nodes. Mann -Whitney U test 
Table 4 -5: Number of involved nodes amongst node -positive patients 
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4.1.2.2.3 Oestrogen receptors 
Initial oestrogen receptor (ER) estimates were available on tumour samples from all 78 
patients, obtained at mastectomy or by incisional biopsy. The median and range of ER values 
arc presented in Table 4 -6. There was no significant difference in initial ER values between 
the two arms of the trial. 
Conventional PST z= p= 
By intention to treat 
By actual treatments given 
22 (2 -233) 









Median and range of initial ER values in fmol /mg cytosol protein. Mann -Whitney U test 
Table 4 -6: Initial oestrogen receptor values 





Figure 4 -2: Distribution of tumour ER values. 
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4.1.2.2.4 Tumour histological type and grade 
The number of patients with ductal and lobular cancers, and with special types arc 
summarised in Table 4 -7. The proportions of different type of cancer were similar for the two 
groups. 
Conventional PST P= 
Ductal carcinoma, no special type 31 33 
Ductal carcinoma, special types 1 3 0.604 
Lobular carcinoma 6 4 
Proportions compared using Fisher's exact test 
Table 4 -7: Tumour histological types in the first part of the trial 
Tumour differentiation was recorded as "poor ", "moderate" or "well ". The number of patients 
in each category are summarised in Table 4 -8. There were no significant differences in tumour 
differentiation between the two arms of the trial. 
Conventional PST 
well mod poor well mod poor p= 
By intention to treat 6 26 6 5 29 6 0.938 
By actual treatment given 6 28 6 5 27 6 1.000 
Number of patients in each differentiation category. proportions compared using Fisher's exact test 
Table 4 -8: Distribution of tumour differentiation categories 
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4.1.3 Treatments and toxicity 
4.1.3.1 Delay to start of treatment 
For patients treated conventionally, treatment was regarded to have been started on the date 
the patient underwent a mastectomy. In the primary systemic treatment group start of 
treatment was recorded as the date the first dose of appropriate drug was administered. The 
requirement for initial incisional biopsy in the primary systemic treatment group did not 
significantly delay start of treatment compared with conventionally treated patients. The 
biopsy was performed a median of one day (range: 0 -11) after randomisation. Treatment was 
started a median of 13 days following randomisation to conventional treatment (range 1 -35), 
compared with a median of 14 days (range: 7 -34) following randomisation to primary 
systemic treatment (x2 =1.23, p =0.27 Log rank test). 
4.1.3.2 Delay to the start of systemic treatment 
Delay in starting systemic treatment can in theory have a deleterious effect on survival. An 
important objective in using primary systemic treatment is to minimise this delay. Every effort 
was made to start systemic therapy in conventionally treated patients as soon as possible 
following mastectomy. 
The median time to the start of systemic treatment was 14 days (range: 7 -34) for the patients 
treated by primary systemic therapy, significantly shorter than the median of 35 days (range: 
14 -85) for conventional treatment x2 =37, p <0.0001, Log rank test). 
4.1.3.3 Overall duration of hospital cancer treatment 
Patients were discharged to long term follow -up when all cancer treatment was completed, and 
any associated complications dealt with. Additional hospital attendance for breast 
reconstruction was not included in the overall duration of hospital cancer treatment. 
Duration of treatment for each group is shown in Table 4 -9. Overall, primary systemic 
treatment was significantly more protracted than conventional therapy. This was particularly 
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noticeable in patients receiving primary endocrine treatment. When cytotoxic chemotherapy 
was the treatment given, overall duration of treatment for conventional and primary systemic 
treatment was similar. 
Conventional PST z x = P= 
All patients (n =78) 41 (21 -262) 168 (96 -271) 8.7 0.003 
Cytotoxic treatment only (n =34) 184 (91 -262) 176 (96 -227) 0.67 0.41 
Endocrine treatment only (n =44) 35 (21 -89) 140 (112 -271) 32.3 0.0001 
Treatment duration in days: median (range), compared using log -rank test 
Table 4 -9: Duration of cancer treatment 
4.1.3.4 Actual treatments received 
4.1.3.4.1 Conventional treatment group 
Of the 39 patients randomised to this arm of the trial 37 received postoperative adjuvant 
systemic treatment. Treatment details appear in Table 4 -10. One patient with ductal 
carcinoma in situ only, was not systemically treated, and a second patient was treated using 
primary chemotherapy with the CAP regime, followed by postoperative adjuvant tamoxifen. 
Premenopausal Postmenopausal Total 
Tamoxifen 3 19 22 
CMF chemotherapy 15 0 15 
None I o 1 
Primary CAP chemo 1 0 1 
Total number of patients 20 19 39 
Number of patients given each treatment. Italics indicate protocol violations. 
Table 4 -10: Details of adjuvant systemic treatment received by patients in 
the conventional arm of the study 
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4.1.3.4.2 Primary systemic treatment 
Thirty seven of the 40 patients randomised to this arm received preoperative systemic therapy. 
Treatment details are listed in Table 4 -11. Three patients who were treated by conventional 
adjuvant systemic treatment received postoperative tamoxifen. 
Premenopausal Postmenopausal Total 
Primary tamoxifen alone 0 7 7 
Primary goserelin alone 7 () 7 
Primary CAP alone 12 6 18 
Failed tamoxifen followed by CAP 0 3 3 
Failed goserelin followed by CAP (2 0 2 
conventional tamoxifen 1 2 3 
Total number of patients 22 18 40 
Number of patients given each treatment. Italics indicate protocol violations. 
Table 4 -11: Details of primary systemic treatment 
4.1.3.4.3 Treatment differences 
Overall, systemic treatment was administered to 40 patients according to the conventional 
treatment protocol and to 38 patients according to the protocol for primary systemic 
treatment. Patients treated according to the primary systemic treatment protocol were 
significantly more likely to receive cytotoxic chemotherapy compared with conventionally 
treated patients: 15 of the conventionally treated patients and 24 patients given primary 
systemic treatment received cytotoxic chemotherapy (p= 0.025, Fisher's exact test). This 
difference was accounted for by the provision of cytotoxic chemotherapy for some 
postmenopausal patients in the primary systemic treatment protocol. None of the 21 
conventionally treated postmenopausal patients received cytotoxic chemotherapy compared 
with 9 of the 16 postmenopausal patients completing primary systemic treatment (p= 0.000, 
Fisher's exact test). 
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4.1.3.5 Treatment related toxicity 
4.1.3.5.1 Endocrine treatment 
Endocrine treatment was well tolerated with minimal associated morbidity. 
4.1.3.5.1.1 Tamoxifen 
Thirty five patients received tamoxifen. Two of 3 premenopausal patients and one 
postmenopausal patient experienced menopausal symptoms with tamoxifen. Treatment was 
temporarily discontinued in one postmenopausal patient because of a transient rash. None of 
the patients experienced serious side effects. 
4.1.3.5.1.2 Goserelin and oophorectomy 
Nine patients received goscrclin. All experienced significant menopausal symptoms, and 1 
complained of problems with the implantation site. Seven patients subsequently had an 
oophorectomy. None experienced significant morbidity in relation to the oophorectomy which 
was performed at the same time as the mastectomy. 
4.1.3.5.2 Cytotoxic chemotherapy 
All patients receiving cytotoxic chemotherapy experienced significant toxicity. In particular all 
patients developed myclosuppression following each cycle of chemotherapy. This was 
generally mild and always resolved but was the main reason for dose reduction or delay in 
treatment resulting in reduced dose intensity of chemotherapy. 
4.1.3.5.2.1 Comparison between toxicity of CAP and CMF regimes 
Fifteen patients were treated with CMF as compared with 24 who received CAP. Patients 
treated with CAP had a median age of 49.5 (range: 33 -69), significantly older than the median 
age of 44 (range: 31 -50) for those patients given CMF (p= 0.025, Mann -Whitney U test). 
Median toxicity scores and the proportion of planned dose intensity are summarised in Table 
4 -12. Prolonged neutropenia was less frequent with the CAP regime, and 18 (75%) of 24 
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patients received 90% or more of the full planned dose of CAP in the allotted time compared 
with 5 (33 %) of 15 patients who were given CMF. However nausea and mucositis were more 
common with CAP. Total alopecia was universal in patients given CAP, whereas only one 
patient in the CMF group lost all hair and four others experienced minor degrees of hair loss. 
CAP (n =24) CMF (n =15) z= p= 
GI symptoms 1.55 (0 -3) 1.0 (0 -3) 2.23 0.02 
Mucositis 0.5 (0 -2) 0 (0 -1.6) 1.19 0.23 
Alopecia 3.0 (3) 0 (0 -3) 5.70 0.0001 
% Planned dose intensity 100 (83- 100) 83 (68 -100) 2.58 0.01 
Median (range) of toxicity grades. Values compared using Mann Whitney U test 
Table 4 -12: Severity of side effects produced by the CAP and CMF regimes 
4.1.4 Follow -up and survival 
The main outcome measure for this trial was overall survival. The survival results are 
presented in this section. Kaplan -Meier survival curves are presented along with the text. Life 
tables relating to each survival curve are provided in the appendix. The reference to the 
relevant life table is given in the text. 
4.1.4.1 Entire cohort of patients 
The cohort of 78 patients have been followed up for a median of 65 months from the time of 
entry until the time of analysis (range: 51 to 77 months). The median follow -up until death or 
censoring has been 57 months (range: 6 -77). All patients have been seen according to 
protocol, and there have been no loses to follow -up. 
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4.1.4.1.1 Local recurrence 
Four patients have been treated for locoregional recurrence. All patients had been treated in a 
conventional manner by initial surgery. One had been randomised to primary systemic 
treatment, but received an initial mastectomy, because of difficulty in establishing diagnosis. 
4.1.4.1.2 Systemic recurrence 
There have been 36 systemic recurrences of breast cancer amongst the 78 patients treated 
within the trial. The Kaplan -Meier curve for distant disease free survival for the entire cohort 
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Figure 4 -3: Distant disease free survival for patients in the first part of the 
trial 
4.1.4.1.3 Deaths 
There have been 33 deaths in the entire cohort of 78 patients. Thirty one patients died from 
metastatic breast cancer. 
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Two patients were free of breast cancer at the time of death. One died as a result of acute 
myocardial infarction. The second patient died as a result of a mixed mesodermal tumour of 
myometrial origin, disseminated to the peritoneal cavity. 
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Figure 4 -4: Overall survival (all causes) for patients in the first part of the 
trial 
4.1.4.2 Survival by treatment category 
4.1.4.2.1 Systemic recurrence 
The number of patients suffering systemic recurrence in each arm of the trial are presented in 
Table 4 -13. The difference in the proportion of patients with recurrence is not significant. 
First part of the trial 4 -96 
Conventional PST 
well recurred well recurred P= 
By intention to treat 18 20 
By actual treatments given 20 20 
24 16 0.364 
22 0.505 
Proportions compared using Fisher's exact test 
Table 4 -13: Number of patients with systemic recurrence in the first part of 
the trial 
4.1.4.2.1.1 Recurrence free survival by intention to treat 
The Kaplan -Meier curves for distant disease free survival by intention to treat is presented in 
Figure 4 -5 (Table 14 -3). The median recurrence free survival for patients treated 
conventionally was 53 months by intention to treat. Median recurrence free survival for 
patients treated by l'ST has not been reached yet. The difference in survival curves is not 
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Figure 4 -5: Kaplan -Meier distant disease free survival curves by intention to 
treat 
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4.1.4.2.1.2 Recurrence free survival by actual treatments given 
The distant disease free survival according to actual treatments given is presented in Figure 4- 
6 (Table 14 -4). The median recurrence free survival for patients treated conventionally was 69 
months by actual treatments received. Median recurrence free survival for patients treated by 
PST has not been reached yet. There is no significant difference between the curves (hazard 
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Figure 4 -6: Kaplan -Meier distant disease free survival curves by actual 
treatments given 
4.1.4.2.2 Deaths 
The number of patients dying form breast cancer or other causes in each arm of the trial is 
presented in Table 4 -14. The difference in the proportion of patients who have died in each 
arm of the trial is not significant. Survival is analysed on the basis of mortality from any 
cause. 
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Conventional PST 
Alive Dead D (df) Alive Dead D (df) p= 
By intention to treat 20 17 1 25 14 1 0.739 
By actual treatment given 22 17 1 23 14 1 0.821 
D (df): died free of breast cancer. Proportions compared using Fisher's exact test 
Table 4 -14: Number of patients who have died in the first part of the trial 
4.1.4.2.2.1 Overall survival by intention to treat 
The Kaplan -Meier curves for overall survival by intention to treat is presented in Figure 4 -7 
(Table 14 -5). The median overall survival has not been reached for either arm of the trial. The 
difference in survival curves is not significant (hazard ratio: 0.69, 95% C.1.: 0.35 -1.37, 
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Figure 4 -7: Kaplan -Meier overall survival curves by intention to treat for 
patients in the first part of the trial 
First part of the trial 4 .99 
4.1.4.2.2.2 Overall survival by actual treatments given 
The overall survival according to actual treatments given is presented in Figure 4 -8 (Table 14- 
6). The median survival for either for of treatment has not been reached yet. There is no 
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Figure 4 -8: Kaplan -Meier overall survival curves by actual treatments given 
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4.2 RESULTS INCLUDING THE SECOND PART OF THE TRIAL 
4.2.1 Recruitment and compliance 
4.2.1.1 Recruitment 
The modified trial protocol was implemented on 30 April 1992, and the first patient was 
recruited on 13 May 1992. The trial was closed on 19 September 1995. During the period of 
the second part of the study 1508 breast cancer patients presented to the Edinburgh Breast 
Unit, 257 of whom were potentially eligible for the study. Of these 92 patients were recruited 
into the trial, providing a total of 171 patients. One patient with in situ cancer only was 
excluded from further analysis, leaving a total of 170 evaluable patients. 
J 
4.2.1.2 Treatment allocation and compliance 
Eighty six patients were allocated to the conventional arm of the trial, one of whom was 
excluded from further analysis (see above). Eighty five women were randomised to receive 
primary systemic treatment (PST). 
4.2.1.2.1 Major protocol violations 
There were 19 significant protocol violations. Five occurred in the first part of the trial and 
have been described above (4.1.1.2). The protocol violations were as follows: 
4.2.1.2.1.1 Primary systemic treatment 
Nine protocol violations occurred in this arm of the study six of which occurred in the second 
part of the trial. 
Two patients requested conventional treatment after being randomised to PST. One was 
treated according to the conventional treatment protocol. The second patient was a 
postmenopausal patient who was given postoperative CMF chemotherapy. 
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Oophorectomy was omitted in three premenopausal patient whose tumour had responded to 
goserelin. Two were given postoperative chemotherapy and a third patient was given 
tamoxifen. 
One premenopausal patient became pregnant following successful chemotherapy. She had a 
normal delivery and remains disease free. 
4.2.1.2.1.2 Conventional treatment 
Ten protocol violations occurred in this arm of the trial, 8 of which were in the second part. 
One premenopausal, node- negative patient underwent oophorectomy instead of tamoxifen. 
Five patients with 4 or more involved axillary lymph nodes were treated by postoperative 
sequential doxorubicin followed by CMF, as described by Bonadonna's group (Buzzoni el al: 
1991). Three were postmenopausal patients who would have received tamoxifen according to 
the protocol. Two premenopausal patients were given this regime in place of CMF. 
Two patients were given CMF in place of tamoxifen. One was postmenopausal, the second 
was a premenopausal women with a high grade tumour, but no involved axillary lymph nodes. 
4.2.1.2.2 Minor protocol violations 
Four patients in the primary systemic treatment arm who should have undergone mastectomy, 
were treated by breast conservation following tumour regression with PST. 
4.2.1.3 Reporting of results 
The results for all 170 evaluable patients are reported by intention to treat. 
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4.2.2 Patient and tumour characteristics 
4.2.2.1 Patient characteristics 
The two arms of the trial were balanced with regard to age and menopausal status as shown in 
Table 4 -15. 
Conventional PST P= 




52 (27 -69) 
39 
46 





Age: Student's t -test. Proportions compared using Fisher's exact test. 
Table 4 -15: Age and menopausal status distribution of patients in the entire 
trial 
4.2.2.2 Tumour characteristics 
4.2.2.2.1 Tumour diameter 
The distribution of tumour sizes by intention to treat is shown in Figure 4 -9. The median 
tumour diamctcr for the entire cohort of patients was 43 mm, with a range of 31 to 85 mm. 
Of the 92 patients recruited into the second part of the trial, 54 had tumours between 31 -40 
mm in diameter. Median tumour diameters for patients treated conventionally , and for those 
treated by PST were 43 mm (range 31 -85). There was no significant difference in tumour 
diameters (z= -0.51, p =0.61, Mann -Whitney U test). 
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Figure 4 -9: Tumour size distribution for the entire trial 
4.2.2.2.2 Axillary lymph node Involvement 
Information about axillary nodes was available in all conventionally treated patients and 83 
patients randomised to PST. The number of nodes recovered and the number of involved 
axillary lymph nodes are summarised in Table 4 -16. 
Conventional PST z= p= 
Median number of nodes recovered 17 (3 -33) 16 (4 -34) -0.88 0.38 
Median number of nodes involved 5 (1 -23) 3 (1 -14) -2.83 0.0047 
Patients with involved nodes Total 85 83 
None 76 36 40 
1 -3 43 19 24 Exact 0.234 
4 -9 29 16 13 
10 20 14 6 
Medians: Mann Whitney U test. Proportions: Fisher's exact test 
Table 4 -16: Axillary lymph node involvement by trial option 
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On average fewer involved nodes were recovered when the axilla was cleared following 
primary systemic treatment. The proportions of patients in each nodal category were however 
similar. 
4.2.22.3 Oestrogen receptors 
Initial oestrogen receptor (ER) estimates were available on tumour samples from all 168 
patients The median and range of ER values and the proportion of patients who were ER 
negative or ER positive arc shown in Table 4 -17. There was no significant difference in initial 
ER values between the two arms of the trial. 
Conventional PST z= p= 
Median ER values 
Patients in each ER category 
ER<20 
ER>19 
37 (1 -592) 
37 
48 







Medians: Mann Whitney U test. Proportions: Fisher's exact test 
Table 4 -17: Initial oestrogen receptor values 
4.2.2.2.4 Tumour histological type and grade 
The numbers of patients with different histological tumour types and grades are summarised 
in Table 4 -18. Where were no significant differences. 
Conventional PST P= 
Histological types 
Ductal, no special type 71 73 
Ductal, special types 2 4 0.509 
Lobular carcinoma 12 8 
Tumour differentiation 
Well 10 10 
Moderate 52 51 1.000 
Poor 23 23 
Proportions compared using Fisher's exact test 
Table 4 -18: Tumour histological types and grades for the entire trial 
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4.2.3 Treatments and toxicity 
4.2.3.1 Overall duration of hospital cancer treatment 
Duration of cancer treatment is defined in section 3.5.1. At the time of analysis two patients, 
one in each arm of the trial were continuing to receive treatment. 
Duration of treatment for each group is show in Table 4 -19, according to actual treatments 
received. Overall, primary systemic treatment was significantly more protracted than 
conventional therapy. This was entirely attributable to the more prolonged treatment in 
patients treated by endocrine therapy. 
Conventional PST x2= P= 
All patients (n =170) 115 (21 -394) 195 (80 -507) 14.55 0.0001 
Cytotoxic treatment only (n =81) 223 (91 -394) 222.5 (80 -507) 0.00 0.962 
Endocrine treatment only (n =89) 42 (21 -223) 147.5 (92 -328) 37.16 (.000(1 
Treatment duration in days: median (range), compared using Log -rank test 
Table 4 -19: Duration of cancer treatment for all trial patients 
Overall duration of cancer treatment was significantly longer for patients in the second part of 
the trial compared with those in the first part. Much of the difference was due to the more 
frequent use of radiotherapy during the second part, as well as the use of prolonged 
chemotherapy out with the trial protocol. When patients treated by non -trial protocols, and 
those given radiotherapy were excluded, duration of treatment for the remaining patients was 
similar (Table 4 -20). 
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Trial part 
First second 2 x = P= 
n time n time 
All patients 78 140 (21- 271) 92 199.5 (21 -507) 26.00 0.000 
Violations and XRT excluded 69 150 (21 -271) 36 133 (21 -358) 0.51 0.477 
Violations and XRT only 9 39 (21 -242) 56 244 (80 -507) 35.03 0.000 
Treatment duration in days: median (range), compared using Log -rank test. XRT: Radiotherapy 
Table 4 -20: Duration of cancer treatment in the first and second parts of the 
trial 
4.2.3.2 Actual treatments received 
4.2.3.2.1 Conventional treatment group 
Treatment details for patients treated in the conventional arm of the study are summarised in 
Table 4 -21. One patient with ductal carcinoma in situ only, was not systemically treated. 
Premenopausal Postmenopausal Total 
Tamoxifen 11 42 53 
CMF chemotherapy 24 1 25 
A -CMF chemotherapy 2 3 5 
Oophorectomy I O 1 
Primary CAP chemotherapy I 0 1 
None 1 0 1 
Total number of patients 40 46 86 
Number of patients given each treatment. Italics indicate protocol violations. 
Table 4 -21: Details of adjuvant systemic treatment received by patients in 
the conventional arm of the study. 
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4.2.3.2.2 Primary systemic treatment 
Details of primary systemic treatment are provided in Table 4 -22. The table includes 
information on 6 patients who were treated by primary surgery. 
Premenopausal Postmenopausal Total 
Primary tamoxifen alone 0 25 25 
Primary goserelin alone 9 0 9 
Primary CAP alone 22 13 35 
Failed tamoxifen followed by CAP O 4 4 
Failed goserelin followed by CAP 4 0 4 
Primary LHRH, postop tamoxifen I O I 
Primary LHRH, conventional CMF I o 1 
Conventional A -CMF 1 1 2 
Conventional tamoxifen 2 2 4 
Total number of patients 40 45 85 
Number of patients given each treatment. Italics indicate protocol violations. 
Table 4 -22: Details of primary systemic treatment for the entire trial 
4.2.3.2.3 Treatment differences 
Postmenopausal patients treated in the PST arm were significantly more likely to receive 
cytotoxic chemotherapy compared with those treated conventionally. There was no difference 
in the proportion of patients treated by endocrine or cytotoxic chemotherapy amongst 
premenopausal patients (Table 4 -23). 
Conventional PST 
Endo Chemo Endo Chemo p= 
All patients 54 31 35 50 0.006 
Premenopausal patients 12 27 11 29 0.808 
Postmenopausal patients 42 4 24 21 0.000 
Number of patients in each category. Proportions compared using Fisher's exact test 
Table 4 -23: The proportion of patients treated by cytotoxic chemotherapy 
and by endocrine therapy 
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4.2.3.3 Locoregional treatment 
A total of 168 patients received definitive locoregional therapy in the forni of surgery. In the 
first part of the trial all patients received a mastectomy. In the second part breast conservation 
was allowed as an option. Two patients who developed evidence of metastatic disease during 
initial cancer treatment were treated by radiotherapy only and did not undo surgery. The 
number of patients treated by different forms of locoregional therapy are summarised in Table 
4 -24. There were no significant differences in the proportions of patients treated by different 
forms of locoregional treatment. 
Conventional PST Total p= 
Patey mastectomy alone 54 60 114 
Patey mastectomy and XRT 11 6 17 0.280 
Breast conservation (includes XRT) 20 17 37 
XRT alone 0 2 2 
Number of patients given different forms of locoregional treatment. XRT: radiotherapy. Proportions 
compared using Fisher's exact test. 
Table 4 -24: Locoregional treatment for patients in different arms of the trial 
4.2.4 Follow -up and survival 
4.2.4.1 Entire cohort of patients 
The cohort of 170 patients have been followed up for a median of 48 months from the date of 
entry to the time of analysis (range: 10 to 77 months). The median follow -up until death or 
censoring for the entire trial has been 37 months (range 6 -77 months). All patients have been 
seen according to protocol, and there have been no loses to follow -up. 
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4.2.4.1.1 Local recurrence 
Four patients from the first part of the trial have been treated for locoregional recurrence 
(4.1.4.1.1). A fifth patient, treated by PST in the second part of the trial has been treated for 
local recurrence following a mastectomy. 
4.2.4.1.2 Systemic recurrence 
There have been 51 systemic recurrences of breast cancer amongst the 170 patients treated 
within the trial. The Kaplan -Meier curve for distant disease free survival for all patients is 
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Figure 4 -10: Distant disease free survival for all patients 
4.2.4.1.3 Deaths 
There have been 44 deaths amongst 170 patients. Forty one patients died from metastatic 
breast cancer. Two non- breast cancer related deaths are discussed in section 4.1.4.1.3. A third 
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patient died from histologically proven metastatic gastric carcinoma. She was free of breast 
cancer recurrence at the time of death. 
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Figure 4 -11 : Overall survival (all causes) for all patients 
4.2.4.2 Survival by treatment category 
The number of patients suffering systemic recurrence and death in each arm of the trial are 
presented in Table 4 -25. The difference in the proportion of patients is not significant. 
Conventional PST 
well recurred well recurred P= 












Proportions compared using Fisher's exact test 
Table 4 -25: Number of patients with systemic recurrence and death 
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4.2.4.2.1 Recurrence free survival 
The Kaplan -Meier curves for distant disease free survival by intention to treat are presented in 
Figure 4 -12 (Table 14 -9). Median recurrence free survival for either group has not been 
reached yet. The difference in survival curves is not significant (hazard ratio: 0.80, 95% C.I.: 
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Figure 4 -12: Kaplan -Meier distant disease free survival curves by intention 
to treat 
4.2.4.2.2 Overall survival 
The Kaplan -Meier curves for overall survival by intention to treat are presented in Figure 4- 
13 (Table 14 -10). The median overall survival has not been reached for either arm of the trial. 
The difference in survival curves is not significant (hazard ratio: 0.73, 95% C.I.: 0.40 -1.32, 
p= 0.299, Cox's regression). 
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PST: 1 
CONV:0 
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Figure 4 -13: Kaplan -Meier overall survival curves by intention to treat for all 
patients 
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CHAPTER 5 
5. Prognostic Indicators 
and 
Primary Systemic Treatment 
5.1 PROGNOSTIC INDICATORS 
The contribution of patient and tumour factors to distant disease free and overall survival was 
studied in patients in both parts of the trial using Cox's proportional hazard model. The 
factors entered into the model are summarised in section 3.5.4.3. 
5.1.1 Univariate analysis 
The individual contributions of each possible prognostic indicator to disease free survival are 
presented in Table 5 -1. 
Results of univariate analysis 
n= Hazard ratio 95% C.I. z= p= 
Age 170 1.00 0.97 -1.03 -0.09 0.927 
Tumour diameter 170 1.16 0.92 -1.50 1.92 0.198 
In of initial ER 168 0.74 0.62 -0.89 -3.22 0.001 
Number of involved axillary nodes 168 1.12 1.07 -1.16 5.45 0.000 
Tumour grade 168 1.33 0.84 -2.12 1.20 0.229 
Mode of treatment 170 0.83 0.48 -1.45 -0.65 0.514 
Results calculated using Cox's proportional hazard model 
Table 5 -1: Univariate analysis of the contribution of various risk factors, 
including "actual mode of treatment" to disease free survival. 
Axillary lymph node involvement and initial oestrogen receptor levels were the only significant 
predictors of distant disease free survival. Similar results were obtained for overall survival, 
as presented in Table 5 -2. 
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Results of univariate analysis 
Hazard ratio 95% C.I. z= p= 
Age 0.99 0.97 -1.02 -0.35 0.725 
Tumour diameter 1.19 0.91 -1.55 1.30 0.195 
In of initial ER 0.71 0.58 -0.88 -3.18 0.001 
Number of involved axillary nodes 1.12 1.07- 1.16 5.08 0.000 
Tumour grade 1.18 0.70 -1.98 0.63 0.529 
Mode of treatment 0.77 0.41 -1.43 -0.83 0.404 
Results calculated using Cox's proportional hazard model 
Table 5 -2: Univariate analysis of the contribution of various risk factors, 
including "actual mode of treatment" to overall survival. 
5.1.2 Multivariate models 
Number of axillary lymph nodes and In of initial ER were entered into a multivariate model. 
The results for disease free survival are presented in Table 5-3, and for overall survival in 
Table 5 -4. 
Results of multivariate analysis 
Hazard ratio 95% C.I. z= p= 
In of initial ER 0.68 0.56 -0.82 -3.95 0.000 
Number of involved axillary nodes 1.13 1.08 -1.17 5.74 0.000 
Log Likelihood = -199.78 n =166 x2 =39.30 0.0000 
Results calculated using Cox's proportional hazard model 
Table 5 -3: Cox's proportional hazard model to study the contribution of 
axillary nodes and initial ER to distant disease free survival 
Results of multivariate analysis 
Hazard ratio 95% C.I. z= p= 
In of initial ER 0.63 0.50 -0.79 -4.01 0.000 
Number of involved axillary nodes 1.13 1.08 -1.18 5.53 0.000 
Log Likelihood = -155.43 n =166 x2 =37.95 0.0000 
Results calculated using Cox's proportional hazard model 
Table 5 -4: Cox's proportional hazard model to study the contribution of 
axillary nodes and initial ER to overall survival 
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In multivariate analysis, the number of axillary lymph nodes and initial tumour oestrogen 
receptor levels remain highly significant independent predictors of distant disease free and 
overall survival. 
5.1.3 Analysis of significant risk factors 
5.1.3.1 Oestrogen receptor status 
Patients were categorised into oestrogen receptor positive (ER >19) and oestrogen receptor 
negative (ER <20) according to initial ER levels. The overall survival for ER positive and ER 
negative patients is presented in Figure 5 -1 (Table 14 -11). Oestrogen receptor status is a 
highly significant predictor of overall survival (hazard ratio: 0.26, 95% C.I.: 0.13 -0.52, 
p= 0.000, Cox's regression). 
En positive: 1 
En negative: 0 
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Figure 5 -1: Overall survival by oestrogen receptor status 
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5.1.3.1.1 The significance of the ERICA assay 
Information on initial oestrogen receptor values was available by the immuno -cytochemical 
assay in 96 patients, 47 from the first part and 49 from the second part of the trial. There was 
no significant difference in patient and tumour factors between those patients from whom an 
ERICA measurement was available and those in whom no ERICA had been performed (Table 
5 -5). 
ERICA done No ERICA Stat. p= 
Mean age (range) 52.3 (27-69) 51.5 (31-69) 1=-053 0.595 
Median initial tumour diameter 44 (31-85) 43 (31-80) z=-0.78 0.434 
Median initial ER (range) 34 (2-712) 28.5 (0-623) z=-0.11 0.915 
Number of involved axillary nodes 1(0-21) 1 (0-23) z=-0.10 0.917 
Tumour grade (well 'moderate 'poor) 14 59 22 6 44 24 Exact 0.232 
Mode of treatment (Cony PST) 50 46 40 34 Exact 0.877 
Age compared using student's 1-test. Z values by Mann -Whitney U test. Proportions compared using 
Fisher's exact lest 
Table 5 -5: Patient and tumour characteristics for patients with and without 
ERICA values 
Oestrogen receptor values obtained by the cytochemical assay correlated with values obtained 
on tissue samples (p= 0.686, p= 0.000, Spearman's rank correlation). 
The details of the assessment for a "cut off' value for ERICA are provided in Table 5 -6, 
along with comparison of overall survival between the two categories derived with each cut- 
off. There is a significant survival difference between "ERICA positive" and "ERICA 
negative" patients over a wide range of cut off values, with little change in the hazard ratio for 
different cut off levels. 
The cut off level of 1 -2% classifies 85% of ER positive and ER negative (see 3.5.4.3.1.2) 
patients correctly. At that level the difference in overall survival for "ERICA positive" 
(greater than 1 %, of tumour cells staining) and "ERICA negative" (0 -1% of tumour cells 
staining) is highly significant (hazard ratio: 0.32, 95% C.I.: 0.14 -0.83, p= 0.006). 
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Cut off level 





PPV H.R. 95% C.I. p= 
0 vs. 1%+ 31 50 0.86 0.37 0.17 -0.83 0.016 
0-1% vs. 2 %+ 31 49 0.85 0.32 0.14 -0.72 0.006 
0 -2% vs. 3 %+ 31 47 0.83 0.36 0.16 -0.81 0.014 
0 -3% vs. 4 %+ 31 47 0.83 0.36 0.16 -0.81 0.014 
0 -4% vs. 5 %+ 32 47 0.84 0.30 0.13 -0.69 0.005 
0 -7% vs. 8 %+ 33 45 0.83 0.37 0.16 -0.84 0.018 
0 -10% vs. 11%+ 33 42 0.80 0.42 0.19 -0.98 0.045 
0 -14% vs. 15 %+ 33 37 0.74 0.45 0.19 -1.07 0.070 
0 -19% vs. 20 %+ 35 34 0.73 0.29 0.11 -0.77 0.014 
0 -29% vs. 30 %+ 35 30 0.69 0.37 0.14 -0.99 0.047 
0 -39% vs. 40 %+ 37 21 0.62 0.36 0.11 -1.21 0.098 
0 -49% vs. 50 %+ 38 11 0.52 1.000 
ER positive by the EREIA was defined as >19. PPV: positive predictive value. Hazard ratios 
calculated using Cox's regression. 
Table 5 -6: The effects of using different cut off values for oestrogen 
receptor 
The Kaplan -Meier survival curves for patients categorised as ER negative and ER positive at 
this cut off level are shown in Figure 5 -2 (Table 14 -12). The pattern of survival by ERICA 
category is similar to that found for ER determined by the EREIA assay, with survival curves 
converging towards the end of the follow -up period. 
ERICA ER positive: 1 
ERICA Ert negative: 0 








lo 00 o no to 
0 12 24 
I I 
36 48 
Months of follow -up 
60 72 78 
Figure 5 -2: Overall survival by oestrogen receptor levels as determined by 
the ERICA assay 
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5.1.3.2 Axillary nodal involvement 
The number of involved axillary lymph nodes significantly correlates with survival. The 
overall survival for patients with no axillary nodal involvement and those with one or more 
involved nodes is shown in Figure 5 -3 (Table 14 -13). The difference in survival is significant 
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Figure 5 -3: Overall survival by axillary nodal status 
The influence of axillary lymph node was further studies by allocating patients to one of four 
nodal categories as follows: 
1. No nodes involved 
2. Between 1 and 3 nodes involved 
3. Between 4 and 9 nodes involved 
4. Ten or more nodes involved 
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The numbers of patients in each category are summarised in Table 4 -16. The survival curves 
according to each of four nodal categories are presented in Figure 5 -4 (Table 14 -14). The 
relationship between nodal category and survival is highly significant (hazard ratio: 2.00, 95% 
C.I.: 1.51 -2.65, p= 0.000). 
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Figure 5 -4: Overall survival by nodal category for all patients in the trial 
Each nodal category was compared individually with other nodal categories. The results are 
summarised in Table 5 -7. 
Number of nodes None 1 -3 4 -9 


















0.001 2.09 0.9 -4.9 0.088 
Table 5 -7: Comparisons between different nodal categories 
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5.2 RESULTS SPECIFIC TO PRIMARY SYSTEMIC TREATMENT 
Data are described mainly for patients in the first part of the trial. Additional data on post 
treatment oestrogen receptor values and tumour grade were available from patients in the 
second part of the trial and were used for pre- and post -treatment comparisons, and for 
assessment of the significance of post treatment prognostic indicators. 
5.2.1 Tumour characteristics after primary systemic treatment 
Following completion of primary systemic treatment tumour tissue was available in 35 of the 
38 patients in the first part of the trial. The characteristics are described below. 
5.2.1.1 Tumour size 
The distribution of post treatment tumour diameters is shown in Figure 5 -5. The median 







0 -10 11 -20 21 -30 31 -40 41 -50 51 -60 
Tumour size (mm) 
Figure 5 -5: Distribution of tumour sizes following completion of primary 
systemic treatment 
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5.2.1.2 Axillary lymph node involvement 
Twenty one of the 38 patients had residual axillary nodal involvement following PST. The 
distribution of the number of involved nodes is shown in Figure 5 -6. Significantly fewer nodes 
were recovered following primary systemic treatment compared with conventional therapy 
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Figure 5 -6: Distribution of the number of involved axillary nodes 
5.2.1.3 Oestrogen receptors 
Enough tumour to allow assessment of post- treatment oestrogen receptor levels was recovered 
in 28 patients in the first part of the trial. There was insufficient material available for 
postoperative oestrogen receptor assay in 9 patients with complete clinical or pathological 
tumour remission. Seven had been treated with chemotherapy, or had received cytotoxic 
chemotherapy following failed endocrine treatment. Post treatment tissue submitted for ER 
contained no tumour in a tenth patient who had been treated with tamoxifen alone. 
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The median initial ER values in the group of patients with sufficient material for a second ER 
assay was 40.5 fmol/mg (range: 0 -522), significantly greater than the initial ER levels for the 
ten patients from whom insufficient tumour was recovered for a second assay (median 4, 
range: 0 -108, z= -2.87, p= 0.004, Mann- Whitney U test). - 
.. 
5.2.1.3.1 Changes in oestrogen receptor content 
Data were available from 28 patients treated in the first part of the trial and from a further 20 
patients treated in the second part of the trial. The results from the two parts are reported 
together. The median and range of pre- and post- treatment ER values for all patients, and for 
patients treated by Chemotherapy (including chemotherapy after failed endocrine treatment), 
goserclin and tamoxifen arc presented in Table 5 -8. 
Number Initial ER Final ER z= p= 
All patients 48 40.5 (0 -623) 30.5 (2 -292) 2.75 0.006 
Chemotherapy 21 10 (0 -156) 9 (2 -292) -1.37 0.170 
Goserelin 10 69.5 (23 -394) 52 (15 -173) 1.27 0.203 
Tamoxifen 17 234 (25 -623) 57 (4- 151) 3.22 0.001 
Wilcoxon signed -rank 
Table 5 -8: Changes in ER following primary systemic treatment 
Overall, post treatment values were lower than initial values, largely due to the drop in 
oestrogen receptor levels following primary systemic treatment with tamoxifen. (Figure 5 -7). 
Tam ox ifen LHRH Chemotherapy 
Figure 5 -7: Changes in ER content following primary systemic treatment 
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Of the 48 patients in whom pre and post treatment ER values were available, 31 had ER >19 
(ER positive) and 17 had ER <20 (ER negative). Following primary systemic treatment 5 ER 
positive patients became ER negative, and 4 ER negative patient became ER positive. 
5.2.1.4 Tumour histological type and grade 
These characteristics wcrctssessable in 35 of the 38 patients who had completed primary 
systemic therapy in the first part of the trial. The histological types were identical to that 
found with the initial biopsy (Table 4 -18). There were 11 well differentiated, 19 moderately 
differentiated and 5 poorly differentiated tumours following completion of primary systemic 
treatment. 
5.2.1.4.1 changes in tumour histology 
Data were available for 35 patients in the first part of the trial, and an additional 29 patients 
treated in the second part: The number of patients in each differentiation category before and 
after primary systemic treatment are shown in Table 5 -9. A significantly larger proportion of 
tumours were classed as well differentiated following the completion of all treatment. 
Initial tumour 
grade 
Final tumour grade 






















Proportions compared using Fisher's exact test 
Table 5 -9: Number of tumours in each differentiation category before and 
after primary systemic treatment 
5.2.2 Prognostic significance of post treatment tumour characteristics 
The relationship between tumour factors as assessed on specimens obtained after the 
completion of jnimary systemic treatment and overall survival was studied in patients treated 
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by primary systemic therapy in the entire trial. Results of univariate analysis are presented in 
Table 5 -10. Post treatment information was incomplete, and the number of cases are included 
in the table. 
Results of univariate analysis 
n= Hazard ratio 95% C.I. z= p= 
In of post treatment ER 49 0.42 0.24 -0.74 -3.00 0.003 
Number of involved axillary nodes 78 1.22 1.09 -1.37 3.43 0.001 
Post treatment tumour grade 66 1.80 0.86 -3.80 1.55 0.120 
Results calculated using Cox's proportional hazard model 
Table 5 -10: Contribution of post treatment tumour factors to overall survival 
following primary systemic treatment 
Information on all three factors was available in 49 patients. The multivariate model including 
all three tumour factors is presented in Table 5 -11. 
Results of multivariate analysis 
Hazard ratio 95% C.I. z= p= 
In of post treatment ER 0.36 0.19 -0.67 -3.22 0.001 
Number of involved axillary nodes 1.24 1.06 -1.44 2.73 0.006 
Post treatment tumour grade 0.89 0.29 -2.66 -0.22 0.829 
Log Likelihood = -29.26 n =49 x2= 15.57 0.0014 
Results calculated using Cox's proportional hazard model 
Table 5 -11: The contribution of post treatment tumour factors to overall 
survival 
Oestrogen receptor levels and number of involved lymph nodes again emerged as significant 
independent indicators of prognosis. 
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5.2.2.1 Post treatment oestrogen receptor levels 
Post treatment oestrogen receptor levels were available in 49 patients. Patients were 
categorised into oestrogen receptor positive (ER >19) and oestrogen receptor negative (ER<20) 
according to post treatment ER levels. The overall survival for ER positive and ER negative 
patients is presented in Figure 5 -8 (Table 14 -15). The difference in survival is highly 
significant (hazard ratio: 0.17, 95% C.I.: 0.05 -0.58, p= 0.005). 
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Figure 5 -8: Overall survival by post treatment oestrogen receptor levels 
5.2.2.2 Axillary lymph nodes 
Post treatment information on axillary lymph nodes was available in 78 patients treated by 
PST. The overall survival for patients with no axillary nodal involvement and those with one 
or more involved nodes is shown in Figure 5 -9 (Table 14 -16). Forty one patients were node - 
negative and 37 patients node -positive. The difference in survival was significantly (hazard 
ratio 3.19, 95% C.I.: 1.01-10.02, p= 0.047). 
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Figure 5 -9: Overall survival by axillary nodal involvement following PST 
The influence of axillary nodal involvement on survival was further investigated by allocating 
patients to four categories of nodal involvement as described in section 5.1.3.2. There were 41 
patients with no axillary nodal involvement, 21 with 1 -3 involved nodes, 11 with 4 -9 involved 
nodes, and 5 with 10 or more involved nodes. The survival by each nodal category is 
presented in Figure 5 -10 (Table 14 -17). The difference between the 4 categories is significant 
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Figure 5 -10: Overall survival by the number of axillary nodes involved 
following PST 
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Each nodal category was compared individually with other nodal categories. The results are 
summarised in Table 5 -12. 
Number of nodes None 1 -3 4 -9 


















0.007 12.59 1.3 -124 0.030 
Table 5 -12: Comparisons between different nodal categories following 
primary systemic treatment 
'Ihe pattern of differences is similar to that found for all patients (Table 5 -7), although less 
confidence can be placed on the results because the analysis was performed in fewer patients. 
5.2.3 The significance of tumour response 
Data from patients in the first part of the trial is described. 
5.2.3.1 Tumour response and treatment 
Nineteen patients with oestrogen receptor poor tumours (ER <20 units) were given cytotoxic 
chemotherapy from the start. Four tumours failed to show a response to treatment. 
Nineteen patients had oestrogen receptor rich tumours. Ten were postmenopausal and were 
treated with tamoxifen; 3 of these patients failed to respond. The remaining 9 premenopausal 
patients were treated with goserelin and two failed to respond. In accordance with the primary 
systemic treatment protocol, 5 patients not responding to endocrine therapy were treated by 
cytotoxic chemotherapy. All five responded to the latter treatment. The breakdown of patients 
according to the six response categories defined previously (section 3.3.1.4.1) are summarised 
in Table 5 -13. 
Results specific to PST 5 -129 
Total CAP TCAP GCAP TAM GOS 
Total Number 38 19 2 11) 9 
Complete Pathological remission 3 
Complete Clinical remission 6 4 - 2 
Clinical response ( >75% reduction) 3 2 1 
Partial Response (50 -74% reduction) 17 5 2 5 5 
Minimal Response (25 -49% reduction) 5 1 1 2 1 
No response ( <25% reduction) 4 4 3 2 
Number of patients in each category of response. CAP: Cyclophosphamide, Adriamycin and 
Prednisolone. TCAP: CAP following failed tamoxifen. GCAP: CAP following failed goserelin. 
TAM: Tamoxifen. GOS: Goscrelin 
Table 5 -13: Response to primary systemic treatment 
5.2.3.2 Treatment and speed of response 
To assess differences in pattern of response, the half lives of tumours treated with any form of 
chemotherapy were compared with those treated with endocrine therapies alone, using the 
Mann Whitney U test. Four non -responding tumours had no measurable "half life" and were 
excluded from analysis. The median half life in response to cytotoxic chemotherapy was 25 
days (range: 7 -63 days), significantly shorter than the half life of 55.5 days (range: 28 -116 
days) achieved with endocrine therapies (z =3.20, p= 0.001, Mann Whitney U test). 
For a more detailed assessment of patterns of response, tumour half lives achieved with 
chemotherapy (CAP), tamoxifen (TAM) and goserelin (LHRH) were compared using 
Kruskal -Wallis one way analysis of variance. Five patients who had received chemotherapy 
following failed endocrine treatment (E -CAP) formed a fourth comparison group. There was a 
significant difference in half lives between the four treatment groups (x2 =15.03, p= 0.002). 
There was however no significant difference when the goserelin, tamoxifen and E -CAP groups 
alone were compared (x2 =3.48, p= 0.176). Median half life in response to CAP (25 days with 
non -responders excluded) was compared with that for each of the other treatment groups using 
the Maim-Whitney U test. Median half life following CAP was significantly shorter compared 
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with goserclin (43 days, p= 0.008), tamoxifen (63 days, p= 0.002) and E -CAP (53 days, 
















CAP LHRH TAM E -CAP 
Treatment options 
Figure 5 -1 1: Tumour half lives in response to different regimes of treatment 
5.2.3.3 Tumour characteristics and response 
A multiple regression model was used to assess the contribution of patient and tumour factors 
to the rate of response (section 3.5.5.3). The model was tested for the entire group of patients, 
and separately for patients on cytotoxic and endocrine treatments. 
5.2.3.3.1 All patients 
The results for the entire group of 38 patients are summarised in Table 5 -14. Menopausal 
status, tumour differentiation and tumour ER were able to explain over half of the variability 
seen in tumour half life (R2= 0.511, p =0. 0003). Being premenopausal, having a poorly 
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differentiated tumour or having a low ER value were associated with faster tumour regression. 
Initial tumour diameter did not contribute to the model. 
Coefficient Standardised 
Coefficient 
t -value Probability 
Menopausal status -12.85 -0.26 1.76 0.089 
Tumour diameter 0.64 0.024 0.18 0.860 
ER status 5.16 0.374 2.42 0.022 
Tumour differentiation -15.87 -0.36 2.59 0.017 
Intercept = 74.58 R= 0.715, R2= 0.511 p = 0.0003 
Table 5 -14: Relationship between tumour and patient characteristics and 
tumour regression with primary systemic treatment 
5.2.3.3.2 Cytotoxic chemotherapy 
The results for patients given cytotoxic chemotherapy are presented in Table 5 -15. 
Menopausal status was not a significant predictor of response rate, and did not contribute to 
the overall model. Poor tumour differentiation continued to predict fast response, while high 
initial tumour ER became a highly significant predictor of a slow response rate (Table 5 -15). 
Coefficient Standardised 
Coefficient 
t -value Probability 
Menopausal status -6.74 -0.15 0.79 0.439 
Tumour diameter 
v kb to c\ 
0.96 0.05 0.23 0.823 
ER stage-- 1 9.19 0.61 3.16 0.007 
Tumour differentiation -13.12 -0.33 1.89 0.078 
Intercept = 47.24 R= 0.749, R2 =0.561 p = 0.0108 
Table 5 -15: Relationship between tumour and patient characteristics and 
tumour regression following primary cytotoxic therapy in 24 patients 
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5.2.3.3.3 Endocrine treatment 
The results for patients given endocrine therapy are presented in Table 5 -16. Premenopausal 
status and poor tumour differentiation continued to indicate a faster response rate in patients 
given endocrine treatment, while ER no longer contributed to the overall model. 
Coefficient Standardised 
Coefficient 
t -value Probability 
Menopausal status -31.60 -0.71 2.69 0.025 
Tumour diameter -5.99 -0.21 0.93 0.379 
ER status -10.57 -0.47 1.74 0.116 
Tumour differentiation -28.00 -0.57 2.47 0.036 
Intercept = 230.97 R= 0.752, R2= 0.566 p = 0.0831 
Table 5 -16: Relationship between tumour and patient characteristics and 
tumour regression following primary endocrine therapy in 14 patients 
5.2.3.3.4 ER content and speed of response 
The relationship between initial tumour ER content and tumour half life in response to 
treatment was examined for each treatment group using Spearman's rank correlation. There 
was no relationship between tumour half life and tumour ER content for 14 patients who had 
responded to endocrine treatment only (p =0.22, p= 0.43). Fifteen patients with relatively ER 
poor tumours who had responded to cytotoxic chemotherapy showed a significant direct 
correlation between actual ER content and tumour half life (p =0.75, p= 0.0048). 
The median ER content for ER poor tumours was 4 finol/mg. Responding tumours with ER 
content less or equal to this value had significantly shorter half lives in response to CAP 
compared with those tumours with ER values of 5 to 19 units (p= 0.0056, Mann Whitney U 
test, Figure 5 -12). Response to chemotherapy was significantly faster in patients with very 
low ER values (ER: 0 -4) compared with those with moderate ER levels (ER: 5 -19). 
(p= 0.0056, Mann Whitney U test). Of the four non -responding tumours, 3 had ER values 
greater than 4 units. 
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Figure 5 -12: Half lives of ER negative tumours according to ER 
5.2.3.4 Tumour response and survival 
Patients were allocated to fast and slow response categories as described in section 3.5.5.2.2. 
There were 19 fast and 19 slow responding patients in each response category. Cox's 
proportional hazard model was used to assess the contribution of the speed of response to 
survival in the context of other prognostic indicators (section 3.5.4.3). Breast cancer mortality 
was used as the end point. 
5.2.3.4.1 Recurrence free survival 
On univariate analysis, response emerged as a highly significant predictor of distant disease 
free survival. At the time of analysis sixteen of the 19 fast responders remain recurrence free, 
whereas 13 of the low responders have experienced breast cancer recurrence (hazard ratio: 
6.98, 95% C.I. 1.97- 24.67, p= 0.003, Cox's regression). The recurrence free survival is 
presented in Figure 5-13 (Table 14 -18). 
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Figure 5 -13: Recurrence free survival by the rate of response to primary 
systemic treatment 
The results of multivariate analysis are presented in Table 5 -17. Rate of response continues to 
predict disease free survival, although its influence is markedly reduced when other factors are 
taken into consideration. 
Hazard ratio 95% C.I. z= p= 
=- Tumour response? 3.83 1.00 -14.65 1.96 0.050 
age 1.03 0.98 -1.11 1.19 0.232 
Tumour diameter 1.11 0.50 -2.48 0.25 0.800 
Axillary nodes 7.12 1.59 -31.88 2.57 0.010 
ER status 0.08 0.01 -0.47 -2.78 .005 
Tumour differentiation 0.75 0.21 -2.64 -0.45 0.651 
Log Likelihood =-41.25 2 x= 25.89 p = 0.0002 
Table 5 -17: Cox's proportional hazard model to assess the contribution of 
tumour response to distant disease free survival 
Kaplan -Meier survival curves, adjusted for other prognostic indicators are presented in Figure 
5 -14 (Table 14 -19). 
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Figure 5 -14: Distant disease free survival by speed of tumour response, 
adjusted as indicated in Table 5 -17 
5.2.3.4.2 Overall survival 
Results for overall survival were similar to those obtained for recurrence free survival. On 
univariate analysis, response emerged as a highly significant predictor of overall survival. At 
the time of analysis 17 of the 19 fast responders remain alive, whereas 12 of the slow 
responders have died (hazard ratio: 9.48, 95% C.I. 2.10 -42.73, p= 0.003, Cox's regression). 
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Figure 5 -15: Overall survival by the rate of response to primary systemic 
treatment 
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On multivariate analysis, tumour response remained a significant independent predictor of 
overall survival. The results are presented in Table 5 -18, and the adjusted Kaplan -Meier 
survival curve is shown in Figure 5 -16 (Table 14 -21). 
Hazard ratio 95% C.I. Z. P. 
Tumour response 5.56 1.12 -27.57 2.10 0.036 
age 1.05 0.97 -1.12 1.25 0.212 
Tumour diameter 1.58 0.67 -3.72 1.05 0.293 
Axillary nodes 6.43 1.21 -34.07 2.19 0.029 
ER status 0.04 0.004 -0.33 -2.97 0.003 
Tumour differentiation 0.37 0.08 -1.63 -1.31 0.189 
Log Likelihood = -33.03 x2= 26.65 p = 0.0002 
Table 5 -18: Cox's proportional hazard model for the importance of speed of 
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Figure 5 -16: Overall survival by speed of tumour response, adjusted as 
indicated in Table 5 -18 
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CHAPTER 6 
6. Discussion 
6.1 DETAILS OF TRIAL PROTOCOL 
6.1.1 Tumour size as the main selection criterion 
Tumour diameter was used as the primary entrance criterion for this study. Recruitment was 
confined to those patients with breast cancers greater than 4 cm in maximum diameter. The 
rationale for this is discussed below. 
6.1.1.1 Selection of high risk patients 
Patients at highest risk of recurrence are likely to derive the largest absolute reductions in the 
odds of recurrence and death from improvements in treatment. Confining the trial to the 
highest risk patients maximises the statistical power of the trial, and minimises the total 
number of patients who are exposed to "experimental" therapy (Pocock: 1983b). Since 
primary systemic therapy for operable breast cancer is experimental, it is ethically justified to 
confine it to those patients at the greatest risk of recurrence. 
6.1.1.2 Assessment of risk 
Although numerous prognostic indicators have been suggested for breast cancer (Sunderland 
and McGuire: 1990) the traditional measures of axillary nodal involvement and tumour size 
remain the most useful indicators of risk. 
6.1.1.2.1 Axillary nodes 
The presence of axillary lymph node involvement is the most discriminating prognostic 
indicator in breast cancer (Carter et al: 1989; Nemoto et al: 1980; Fisher et al: 1980; 
Valagussa et al: 1978; Adair et al: 1974). Furthermore the actual number of involved nodes 
has an inverse correlation with the length of recurrence free survival ( Nemoto et al: 1980; 
Fisher et al: 1980; Fisher and Slack: 1970; Adair et al: 1974). 
6 -139 
Axillary clearance is the only reliable method for obtaining accurate information about 
axillary nodes. Clinical staging is of no value (Borup Christensen and Lundgren: 1989; Fisher 
et al: 1981), and radiological methods remain experimental (Bruneton et al: 1986). Limited 
axillary staging using a node sample (Steele et al: 1985) requires a general anaesthetic, 
involves a significant surgical insult and does not provide information about the number of 
lymph nodes. 
Initial axillary surgery will defeat much of the theoretical advantages of primary systemic 
treatment and cannot be used effectively as an entrance criterion for a trial. 
6.1.1.2.2 Tumour size 
Tumour size is an easily measurable parameter which can provide information on prognosis 
on two counts. Firstly, tumour size is an independent predictor of prognosis as indicated by 
multivariate analysis of risk factors, and analysis of outcome in patients with no axillary 
lymph node involvement (Nemoto et al: 1980; Koscielny et al: 1984; Fisher et a!: 1980; 
O'Reilly et al: 1990; Adair et al: 1974). Secondly, size correlates directly with the presence 
and extent of axillary lymph node involvement (Carter et al: 1989; Paterson et a!: 1982; 
Nemoto et al: 1980; Rosen et al: 1989; Fisher et al: 1969). 
6.1.1.2.3 The choice of tumour size 
Size has been found by some studies to relate to prognosis in a linear fashion throughout a 
range (Carter el al: 1989; Koscielny et al: 1984), while others have suggested that above a 
threshold value further increases in size are less significant determinants of prognosis. The 
threshold has most frequently been placed at 3 -4 cm (Hartveit et al: 1984; Fisher et al: 1980; 
Duncan and Kerr: 1976; Fisher et al: 1969). The cut off level of 4 cm was originally chosen 
in order to avoid conflicts with breast conservation trials (section 2.3.5). The bulk of the 
evidence however suggests that there is little difference in prognosis between patients with 
tumours of 3 -4 cm, and those who have tumours of larger than 4 cm. The protocol was later 
modified to allow inclusion of this additional group of patients. 
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6.1.2 Choice of locoregional therapy 
Modified radical mastectomy is regarded as the gold standard for local control of breast 
cancer and was the surgical option chosen (section 1.2.2.3). 
6.1.2.1 Modified radical mastectomy after response 
Breast conservation after successful primary systemic treatment is the subject of a number of 
PST trials. These have universally shown increased local recurrence rates (Zurrida et al: 
1994; Veronesi et al: 1995; Schwartz et al: 1994; Singletary et al: 1992). Since the principle 
aim of this trial was to compare the results of the systemic component of the treatment, 
locoregional therapy was standardised between the two treatment groups in order to avoid 
uncertainties introduced by variations in the quality of locoregional control. This 
standardisation has been maintained following the modification of the protocol in 1992. 
6.1.3 Choice of systemic treatment 
6.1.3.1 Conventional therapy 
6.1.3.1.1 Postmenopausal women and node -positive premenopausal women 
The choices of CMF chemotherapy as standard treatment for node- positive premenopausal 
women and of tamoxifen for all postmenopausal women are based on the results of large 
numbers of clinical trials and arc well established (section 1.3.2.4). 
6.1.3.1.2 Premenopausal node -negative women 
The best treatment for premenopausal node -negative women is not clear. The absolute benefits 
derived from systemic therapy by node -negative women are relatively small because of their 
smaller absolute risks. The women in this trial had large cancers and were at increased risk 
regardless of their nodal status. It was therefore reasonable to offer them systemic therapy. 
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The choice of systemic therapy is more difficult. Although younger women do benefit from 
adjuvant tamoxifen, the size of the benefit is much smaller than that achieved with cytotoxic 
chemotherapy, with a proportional reduction in the odds of recurrence of 22% compared with 
36% for chemotherapy (Early Breast Cancer Trialists' Collaborative Group. 1992). Since the 
proportional reduction in the odds of death achieved with chemotherapy is independent of 
nodal involvement, it may be argued that if node- negative premenopausal women require 
systemic therapy at all they should be offered the most effective treatment. 
The choice of tamoxifen for this group of patients is a compromise between avoiding the side 
effects of chemotherapy and deriving smaller, but nonetheless significant benefits from 
tamoxifen. 
6.1.3.2 Primary systemic treatment 
Systemic treatment was offered as a "package" in the PST arm of the trial. Individual 
components of the package are nevertheless all of proven value as adjuvant treatments for 
breast cancer. 
6.1.3.2.1 Ovarian ablation 
In premenopausal women, ovarian ablation produces proportional reductions in the odds of 
death which are comparable in size to those achieved with cytotoxic chemotherapy (section 
1.3.2.3). The treatment was confined to oestrogen receptor positive patients primarily because 
in the Edinburgh consecutive series, patients with ER <20U did not respond or progressed with 
ovarian ablation (Anderson et al: 1989). This decision is further supported by the findings 
from adjuvant trials, and studies in patients with advanced breast cancer as follows: 
In the Scottish /Guys Hospital trial of chemotherapy versus ovarian ablation, patients with 
ER >19U derived the maximum survival advantage from oophorectomy (Scottish Cancer 
Trials Breast Group and ICRF Breast Unit, London: 1993). In the International Breast Cancer 
Study Group's (1990) trial of chemotherapy versus chemotherapy and ovarian ablation, 
addition of oophorectomy benefited the ER positive patients most. 
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In metastatic breast cancer, patients with high ER tumours experience the greatest response 
rates from ovarian ablation (Conte et al: 1989; Oriana et al: 1989; Chen et al: 1989; 
Kaufmann et al: 1989). 
6.1.3.2.2 Mode of ovarian ablation 
Ovarian ablation was initially achieved using the LHRH1 analogue goserelin. The supra 
physiological, non -pulsatile levels of LHRH produced in the scrum result in suppression of 
pituitary LH2 and FSH3 production and arrest in ovarian function (Furr: 1989; Williamson et 
al: 1988; Furr and Milsted: 1987). Administration of goserelin achieves postmenopausal 
oestrogen levels within 4 weeks of starting therapy (Bajetta et al: 1994a; Brambilla el al: 
1991a; Kaufmann et al: 1989a; Nicholson et al: 1987a; Robertson et al: 1989a). In 
metastatic breast cancer LHRH analogues produce response rates similar to those achieved 
with other forms of ovarian ablation ( Bajetta et al: 1994b; Brambilla et al: 1991b; Robertson 
et al: 1989b; Harvey et al: 1985b; Kaufmann et al: 1989b). 
Goscrclin was used as a reversible method of achieving ovarian ablation. The long term 
effects of medical ovarian ablation are not clear. In at least one study, direct comparison 
between goserelin and surgical oophorectomy suggested a survival trend in favour of the latter 
method (Boccardo et al: 1994). The trials showing a benefit in favour of adjuvant treatment 
with ovarian ablation are based on surgical or radiation ablation (Early Breast Cancer 
Trialists' Collaborative Group. 1992). It was therefore decided that once the responsiveness of 
the tumour to ovarian ablation had been established the patients receive conventional ovarian 
ablation by surgical oophorectomy. 
6.1.3.2.3 Choice of chemotherapy regime 
Doxorubicin is highly active against breast cancer, producing 40 -50% remission rates in 
previously untreated metastatic breast cancer (Mouridsen: 1992; Jones et al: 1975; 
Bonadonna et al: 1975). Doxorubicin containing regimes produce greater overall remission 
1LIIRH: Luteinizing Hormone Releasing Hormone (also gonadotropin releasing hormone) 
2L11: Luteinizing Ilormone 
3FSH: Follicle Stimulating Hormone 
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rates and longer duration of response when compared with regimes not containing an 
anthracycline (Tormcy et al: 1984; Aisner et al: 1987; Smalley et al: 1977; Muss et al: 1978; 
Bull et al: 1978). 
Because of its high level of activity in metastatic breast cancer, doxorubicin has frequently 
been the first choice fòr the primary systemic treatment of locally advanced disease (section 
2.2), and its use has been extended to the treatment of large operable breast cancers. 
In the Edinburgh sequential series of primary systemic treatment the chemotherapy regime 
used consisted of cyclophosphamide, doxorubicin, vincristine and prednisolone. In that study a 
number of patients experienced significant neurotoxicity attributable to vincristine (Anderson 
et al: 1991). Since other direct comparisons have suggested equivalence between CMF and a 
regime of cyclophosphamide and doxorubicin (Fisher et al: 1989e; Fisher et al: 1990e), it was 
decided to drop vincristine from the regime. 
6.1.3.2.4 Chemotherapy in postmenopausal patients 
The use of chemotherapy in postmenopausal patients who fail to respond to tamoxifen is 
justifiable on the basis of evidence from adjuvant chemotherapy trials. Cytotoxic 
chemotherapy in women over the age of 50 produces reductions in the odds of recurrence and 
death which, although smaller than that seen for younger women, are still substantial (Early 
Breast Cancer Trialists' Collaborative Group: 1992). 
It may be argued that high risk postmenopausal patients should receive tamoxifen and 
chemotherapy together as the benefits of chemotherapy appear to be in addition to the benefits 
of tamoxifen (Early Breast Cancer Trialists' Collaborative Group. 1992; Falkson et al: 1990; 
Fisher et al: 1990). Studies of the additive effects of the two modalities were however 
performed on patients who were at best selected for tamoxifen responsiveness by oestrogen 
receptor status. In the present trial patients receiving tamoxifen alone were known to be 
tamoxifen responsive. Combining chemotherapy with tamoxifen in known tamoxifen 
responsive patients is likely to be of little additional benefit. The toxicity of chemotherapy has 
significant adverse effects on quality of life which are particularly pronounced in older 
women. My benefits are therefore 
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likely to be outweighed by the toxicity of chemotherapy 
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(Gelber et al: 1996). It was therefore justified to use tamoxifen alone in those patients who 
proved responsive to it. 
Postmenopausal women with oestrogen receptor poor tumours derive benefit from adjuvant 
tamoxifen which, in indirect comparisons, is similar in magnitude to the benefits seen with 7 0 
cytotoxic chemotherapy (Early Breast Cancer Trialists' Collaborative Group. 1992). It may `rsr 
therefore be argued that all postmenopausal patients should have received adjuvant tamoxifen. 
The combination of tamoxifen with melphalan and 5- fluorouracil had an adverse effect on 
survival in several of the subgroups of patients in the NSABP trial (Fisher et a/: 1983c). In 
cell culture systems tamoxifen reduces cytotoxicity of melphalan and 5- fluorouracil (Osborne 
et al: 1989). It was therefore argued that continuing tamoxifen could interfere with the 
efficacy of chemotherapy. 
Tamoxifen however potentiates the actions of cyclophosphamide and doxorubicin in culture 
systems (Osborne et al: 1989). Furthermore, in a study of primary chemotherapy for operable 
and locally advanced breast cancers the combination of tamoxifen and chemotherapy produced 
the greatest rate of regression (Jacyuillat et al: 1989a). 
Even if there were persistent worries about adverse interaction between tamoxifen and 
chemotherapy, tamoxifen could still have been started following completion of chemotherapy. 
Tamoxifen treatment was not restarted however on the rationale that in non -responding 
postmenopausal patients further benefits from tamoxifen were unlikely. 
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6.2 EQUIVALENCE OF TREATMENT COMPONENTS 
The hypothesis under test in this trial was that it is th nd the sklcctive nature nl the 
new treatment package which has an influence on the outcome. Substantial differences in the 
actual treatment modalities received by the two groups would make it impossible to draw any 
conclusions in relation to the hypothesis under test. 
There were three major differences in treatment modalities received by the patients in the two 
arms of the trial, as follows: 
1. Choice of chemotherapy: six cycles of CAP versus six cycles of CMF 
2. Greater use of chemotherapy for postmenopausal women in the PST arm 
3. Oophorectomy versus tamoxifen for premenopausal women 
These will be discussed in turn. 
6.2.1 The choice of chemotherapy 
The PST patients in this trial received a two drug regime with cyclophosphamide and 
doxorubicin. There were differences in the drug used and the way the treatments were 
administered. The equivalence of these regimes is discussed below. 
6.2.1.1 Comparisons between regimes with and without an anthracycline 
As discussed earlier, patients with metastatic disease given doxorubicin containing regimes 
have greater remission rates and longer times to progression than patients given the same 
regimes but with another drug (usually methotrexate) substituted for doxorubicin (Tormey et 
al: 1984; Aisner el a!: 1987; Smalley et a!: 1977; Muss et al: 1978). 
In the adjuvant setting a number of trials have compared doxorubicin containing regimes with 
non anthracycline regimes. The largest of these were the NSABP trials B -11 and B -12. These 
compared a combination of melphalan and 5- fluorouracil against the same combination with 
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doxorubicin added. At seven years follow -up patients with oestrogen receptor poor tumours 
given doxorubicin had a disease free advantage, and a marginal overall survival advantage. 
There was however no difference when tamoxifen was added to the two trcatmcnt arms for 
patients with oestrogen receptor rich tumours (Fisher et al: 1989e). 
The study by Misset and colleagues compared a CMF regime with CAF plus vincristine and 
found a survival advantage for the doxorubicin arm (Misset et al: 1992). An advantage for the 
anthracycline regime was also found by Beuzeboc and colleagues who compared 
methotrexate, mitomycin, 5- fluorouracil and cyclophosphamide with the same regime except 
for doxorubicin in place of fluorouracil ( Bcuzeboc et al: 1992) . 
In these studies doxorubicin is either used as an extra drug or along with additional drugs. In 
some studies the anthracyclinc regimes are administered intravenously, thus guaranteeing 
compliance, where as at least one drug in the non -anthracycline regimes is administered by 
mouth. For these reasons none of these studies provide convincing evidence for the superiority 
of anthracyclinc regimes (Namer: 1993). 
The most direct comparison between an anthracycline regime and an equivalent non 
anthracycline regime comes from the study by the International Collaborative Cancer Group 
(Coombes et al: 1996; Wils el al: 1993). In this study CMF (oral cyclophosphamide) was 
compared with a regime consisting of intravenous cyclophosphamide, the anthracyclinc 
epirubicin and 5- fluorouracil in 759 patients. Overall there was no advantage for the 
anthracyclinc containing regime, although a subset of patients given more intensive treatment 
seemed to benefit (Coombes et al: 1996). 
The active components of the CAP regime used in the present study were intravenous 
cyclophosphamide and doxorubicin (AC). This type of regime has been directly compared 
with CMF in another large NSABP trial: B -15 (Fisher et al: 1990a). Treatment with 4 cycles 
of AC produced identical results to 6 cycles of CMF. The trial was interpreted as showing 
that AC was more acceptable to administer, although other commentators have suggested that 
equivalent lengths of treatment may have led to superior results for AC (Hortobagyi and 
Buzdar: 1993). 
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6.2.1.2 Differences in chemotherapy administration in this trial 
The dose of cyclophosphamide was greater in the PST arm (1g/m2 versus 600 mg/m2). 
Furthermore patients given CAP experienced less marrow toxicity, which resulted in them 
receiving their treatment at a greater dose intensity than the CMF patients. Both the greater 
dose of cyclophosphamide (llryniuk: 1988), and the greater dose intensity of treatment 
(Henderson et al: 1988) may have favoured the CAP regime. 
6.2.1.3 Overall differences between chemotherapy regimes 
The differences in outcome between anthracycline and non- anthracyclinc regimes arc at best 
minor, and the choice of the drugs in the CAP regime is unlikely to have conferred an 
advantage to the PST patients as such, although the possible additional advantages of the 
more prolonged use of CAP are unknown. Furthermore CAP was better tolerated than CMF 
and was given at a greater dose intensity. 
Although any advantages conferred by these factors are likely to be minor, the possibility that 
at least part of any observed differences in outcome are attributable to differences in 
chemotherapy, and not to the hypothesis under test cannot be excluded. 
6.2.2 Frequency of use of chemotherapy 
Compared with conventional treatment, a significantly larger number of PST patients received 
cytotoxic chemotherapy. The excess was entirely due to the treatment of postmenopausal 
patients. 
The reduction in the odds of death reported by the EBCTCG (1992) in unselected women over 
the age of 50 was of the same order of magnitude for tamoxifen and chemotherapy. The 
treatment of more postmenopausal women with chemotherapy in itself therefore does not 
indicate more aggressive therapy for the PST patients. 
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It is possible that the more targeted use of chemotherapy in postmenopausal patients would 
produce differences in outcome which are greater than that seen in unselected patients. This 
possibility is consistent with the hypothesis being tested by this study. 
6.2.3 Choice of endocrine therapy in premenopausal patients 
Premenopausal patients with hormone responsive tumours received an oophorectomy after 
PST. Node -negative premenopausal patients were given tamoxifen in the conventional arm. 
Ovarian ablation is a highly effective mode of adjuvant treatment for premenopausal patients, 
leading to proportional reduction in the odds of death in unselected premenopausal women of 
the order of 25%. By contrastunsclected premenopausal patients derive limited benefit from 
tamoxifen with a reduction of 6% in the odds of death (EBCTCG: 1992). 
Conventionally treated patients were selected for adjuvant tamoxifen by their negative axillary 
nodal status. The EBCTCG meta -analysis suggested that in premenopausal women the 
maximum benefits of both ovarian ablation and tamoxifen were likely to be had by node - 
negative patients ( reductions of 42% and 19% respectively), although for both groups little 
statistical confidence could be placed in the actual size of the odds reduction ( EBCTCG: 
1992). 
There are few direct comparisons between tamoxifen and ovarian ablation in premenopausal 
patients. ln metastatic breast cancer the two modes of treatment produce similar response 
rates (Sunderland and Osborne: 1991; Rose and Mouridsen: 1988; Rose and Mouridsen: 
1989). In the adjuvant setting ovarian ablation by radiation has been compared in 373 
premenopausal women taking part in the Christie Hospital trial (Ribeiro and Swindell: 1988; 
Ribeiro and Swindell: 1985; Ribciro and Palmer: 1983). In the most recent update of the trial 
there is no advantage for ovarian ablation, the overall trend being in favour of tamoxifen 
(Ribeiro and Swindell: 1992). 
Overall any differences in the quality of endocrine treatment options offered to premenopausal 
patients in the two arms of the trial are probably minor and unlikely to influence the testing of 
the principal hypothesis of this trial. 
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6.3 DISCUSSION OF TRIAL RESULTS 
6.3.1 Recruitment 
Despite the complexity of the protocol, the trial was found acceptable by the majority of 
eligible patients, with over 90% of those approached during the first part of the trial agreeing 
to participate. One patient was excluded from analysis because of the presence of in sittt 
disease only. This underlines the importance of histological confirmation of invasive disease 
before embarking on potentially toxic systemic therapy. 
The recruitment rate was appreciably lower in the second part of the trial, with only 92 of 257 
potential patients taking part. The main reason for this was the increasing concern that the 
conventional arm of the study was under -treating patients with potentially high risk cancers. 
Thus patients likely to have high risk tumours such as those with clinically obvious axillary 
lymph node involvement were frequently not approached. These patients were either treated by 
modifications of the primary systemic treatment regime outside the trial, or by one of the high 
dose conventional chemotherapy regimes under investigation within the breast unit. This 
concern was also reflected in the growing numbers of clinician initiated protocol violations 
during the later part of the study, particularly within the conventional arm. 
6.3.1.1 Handling of protocol violations 
6.3.1.1.1 First part of the trial 
Protocol violations introduce bias into the trial, and to avoid this, analysis by intention to treat 
is customary (Pocock: 1983a). It was felt justifiable to exclude the patient with in situ disease 
only from survival analysis because she clearly did not have the disease the trial was designed 
to treat. Data from this patient were however used where questions of treatment morbidity 
were being addressed. The remaining four protocol violations consisted of patients swapping 
from one arm of the trial to the other. In order to maximise information about the efficacy and 
morbidity of the trial results were presented on the basis of actual treatments given. Survival 
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is the main outcome of the trial and data relating to it were therefore analysed by treatment 
intention and by actual treatments. 
6.3.1.1.2 Second part of the trial 
Protocol violations were more complex in the second part of the trial, and often occurred 
because patients were treated by regimes other than those stipulated in the trial protocol. The 
results of the whole study, including the second part were therefore analysed on the basis of 
treatment intention only. 
6.3.2 Patient and tumour characteristics 
The patients randomised to the two arms of the study were well balanced in terms of patient 
characteristics and tumour stage at diagnosis. 
6.3.2.1 Axillary lymph nodes 
Axillary nodal involvement is the most significant indicator of prognosis in breast cancer 
(Carter et al: 1989). There was no difference in the number of patients who were node - 
positive 00 histology between the two arms of the study. Most PST patients had their axillary 
lymph nodal status confirmed only after the completion of primary systemic treatment and the 
actual number of involved nodes was on average lower amongst the PST group of patients. 
In a previous study where axillary nodal status was determined before and after systemic 
treatment, 14 of the 33 patients who had axillary involvement on node sampling subsequently 
had clear axillac (Anderson el al: 1991). Although the node sampling procedure is liable to 
remove all involved nodes in some patients (Steele et al: 1985) much of the discrepancy can 
be attributed to down staging of the tumour. These findings raise the possibility that more of 
the PST patients were originally node -positive and were therefore in a poorer prognostic 
category. 
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6.3.3 Length of treatment 
6.3.3.1 Delay to start of treatment 
Data were available for the first part of the trial. The additional surgery and tumour 
assessment that was required for the PST patients did not delay the start of definitive 
treatment. This was largely achieved through the use of day case surgery under local 
anaesthesia. 
6.3.3.2 Duration of treatment 
Data were available for all patients. The initial cancer treatment was on average significantly 
more protracted in PST patients. Three factors contributed to this: 
1. Need for regular tumour monitoring during primary endocrine therapy. 
2. Greatly prolonged treatment for patients in whom endocrine therapy failed. 
3. The significantly larger number of patients who received cytotoxic chemotherapy. 
The implications of the length of treatment on quality of life are discussed in chapter 7. 
6.3.4 Treatment toxicity 
Toxicity data were analysed for patients in the first part of the study only. 
There was little toxicity amongst endocrine treated patients, the most significant being 
menopausal symptoms. 
The CAP regime was better tolerated as regards myelotoxicity, but caused significantly 
greater minor toxicity in terms of nausea and mucositis. 
Total alopecia in patients given CAP was expected, and patients were warned about it during 
the pre -recruitment counselling sessions. Alopecia was not a significant problem in the CMF 
treated patients. 
Discussion: trial results 6 -152 
6.3.5 Survival results 
6.3.5.1 Differences in survival 
All patients have been fully followed up, and there have been a large number of events, 
particularly amongst the patients in the first part of the study. At the present stage of follow - 
up no significant differences in disease free and overall survival have emerged. A trend in 
favour of the primary systemic treatment group became apparent early on during follow -up, 1 
and has been maintained. 
6.3.5.2 The power of the study 
The trial had a target of 326 patients, to be recruited at a rate of 60 per year. The trial was 
closed after 5 years and 9 months, having recruited 171 patients. The original survival 
estimate for the patients treated conventionally was 50% at 5 years. This projection appears to 
have been accurate for patients treated in the first part of the trial. This group have had a 
median recurrence free survival of 53 months by intention to treat, and it is likely that median 
overall survival will be around 5 years. The proportion of patients surviving within the PST 
arm at the present stage of follow -up are also consistent with the projected survival figures. 
The assumptions on which the trial's initial power calculations were based have therefore not 
been contradicted. 
An absolute survival difference of 15% between 65% and 50% at 5 years represents a 30% 
reduction in the odds of death. This is comparable in size to the best results of the trials of 
adjuvant versus no adjuvant therapy (EBCTCG: 1992), and it will be unrealistic to expect a 
difference which is much larger than this. 
If the projected survival of 65% at five years for primary systemic treatment is actually true, 
the first part of the trial on its own will have a 20% power of being able to detect this 
difference at the 5% level of statistical significance, and the power for the entire trial will be 
45 %. 
The odds of death for those who have survived up to five years are reduced over the 
subsequent years (survival curves become less steep), and even if the postulated 30% 
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reduction in the odds of death is maintained, the absolute survival difference will not change a 
great deal, thus the power is unlikely to improve appreciably with longer follow -up. 
The present report of the entire trial refers to a median follow -up of 37 months. A follow -up 
of at least five years is required before any conclusions can be drawn in relation to survival j 
outcome. 
6.3.5.3 The problem of inadequate recruitment 
The recruitment target for the study was 60 patients per year. Despite the fact that more than 
90% of eligible patients were recruited, the study had accrued only 70 patients by the end of 
the second year, well short of its projected target. 
In an attempt to increase the recruitment rate, a number of other centres were approached 
regarding participation in the trial, and the trial was widely publicised amongst other surgeons 
treating breast cancer within the Lothian Region and surrounding areas. Mainly because of the 
complexity of the protocol, no other centres joined the trial, and only one patient was recruited 
from outside the Edinburgh Breast Unit. 
The modification Of the protocol in order to allow recruitment of patients with tumours over 
30 mm, was also partly designed to improve recruitment rate. It was expected that this 
modification would have increased the number of patients potentially eligible for the trial to 80 
per year. During the subsequent 41 months 257 potentially eligible patients did present, and 
had the previous recruitment rate of 90% been maintained, the trial would have achieved 
adequate power. Unfortunately the overall recruitment rate during the second part of the trial 
was only 35% for reasons which were explained in section 6.3.1. In retrospect the projected 
recruitment period of 5 years may have been too long for a trial treating patients within the 
very rapidly moving field of high risk breast cancer, leading to a loss of interest in the trial, 
particularly in its later stages. Recruitment to the trial was closed after the completion of its 
projected accrual period. 
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6.3.6 Indicators of prognosis 
6.3.6.1 All patients 
Axillary lymph node involvement and oestrogen receptor status were found to be highly 
significant indicators of prognosis, while tumour size and tumour histological grade were 
found not to be important. 
6.3.6.1.1 Oestrogen receptor status 
High oestrogen receptor content has previously been reported to correlate with improved 
prognosis in breast cancer (Paterson et al: 1982; Kinne et al: 1981; Knight, III et al: 1977) 
although not all studies have found a significant independent relationship (Fisher et al: 1983c; 
Singh et al: 1988c). In the present study a very strong relationship was found between 
oestrogen receptor status and survival. The relationship was found to be independent of other 
prognostic indicators. 
6.3.6.1.1.1 The significance of the immuno -cytochemical assay 
Previous reports examining the relationship between ER and prognosis have examined ER in 
homogenised tissue. The immuno -cytochemical assay has the advantage of being able to be 
performed on samples obtained by fine needle aspiration. 
The characteristics of the subgroup of patients in whom ER was determined by the immuno- 
cytochemical assay were similar to those for the entire cohort of patients. ER determined on 
fine needle aspirates provides information about prognosis which is similar to that provided by 
examining homogenised tissues. 
A number of different cut off values were examined for ER as measured by ERICA. The 
difference in prognosis was not sensitive to the cut off level. The presence of even very small 
amounts of ER staining correlated with a more favourable prognosis. 
Discussion: trial results 6 -155 
6.3.6.1.2 Axillary lymph nodes 
The relationship between involvement of axillary lymph nodes, as assessed by primary 
surgery, and survival in breast cancer is well described (Carter et al: 1989; Fisher el al: 1981; 
Adair et al: 1974; Fisher and Slack: 1970). In the present study the relationship between nodal 
involvement and prognosis was confirmed. As in other studies the prognosis was related to the 
number of involved axillary lymph nodes (Fisher et al: 1983a) with patients with 10 or more 
tumours having the worst outlook. 
6.3.6.1.3 Tumour size 
Previous studies have indicated that while tumour size is an independent indicator of 
prognosis, the relationship is mainly true for smaller tumours. Once larger than 3 -4 cm, 
further increases in size have little further adverse effects on prognosis (Hartveit et a/: 1984; 
Fisher et a/: 1980; Fisher et a/: 1969; Carter et a/: 1989). In the present study all patients 
were selected to have tumours larger than 30 mm, and tumour size was not found to relate et6 
prognosis. 
6.3.6.1.4 Tumour histological grade 
While grade has been related to prognosis in other studies (Sunderland and McGuire: 1990; 
Meakin et a1: 1979; Singh et al: 1988), its assessment can be difficult and its value as a 
prognostic indicator is highly dependant on consistent observers (Gilchrist el al: 1985) 
Histological grade was not found to relate to prognosis, either in the entire group of patic or 
in those treated with primary systemic therapy. 
6.3.6.2 Patients given primary systemic treatment 
As with the entire group, axillary lymph nodes and oestrogen receptor status were found to be 
independent indicators of prognosis in PST patients. In addition the speed of tumour response 
emerged as an additional indicator of prognosis. 
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6.3.6.2.1 Oestrogen receptor status 
The relationship between ER and survival was strong amongst PST patients particularly when 
lymph node status was taken into account. 
Measurement of preoperative ER levels was necessary in order to decide treatment. Prognosis 
was determined according to initial ER values. Post treatment oestrogen receptor levels, when 
available, had shown significant change from their starting values. Furthermore 9 patients 
changed their ER status with treatment. 
Despite these changes, post treatment ER values retain their prognostic significance, with 
those patients with ER positive patients (ER>19) surviving significantly longer. 
6.3.6.2.2 Axillary lymph nodes 
Response to primary systemic treatment can potentially down stage the tumour such that some 
patients with originally involved axillac appear to become node- negative. There were strong 
indications Of this down staging effect in the present study (section 5.2). There is little known 
about the relationship between axillary nodal involvement in axillac down staged following 
primary systemic treatment. In a study of 56 patients with large operable breast cancers 
treated by primary high dose chemotherapy, Botti and colleagues (1995), reported that the 
number of involved nodes following chemotherapy does correlate with survival at three years. 
A surprising finding in that study was that amongst node -positive patients those who had 
failed to respond to chemotherapy had a better prognosis. Response was defined according to 
UICC criteria and oestrogen receptor status was not considered. 
In the present study patients who had uninvolved axillae following completion of primary 
systemic therapy had a better prognosis than those who had any residual involved lymph 
nodes. The size of the relationship was particularly strong when other prognostic indicators 
were taken into account, and was independent of tumour response. 
The number of involved axillary lymph nodes recovered following primary systemic treatment 
correlated with survival. Because of the small numbers in each nodal category, little 
confidence can be placed on the results of comparisons between nodal subgroups, 
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nevertheless, the pattern is similar to that seen for all the patients, and patients with 4 or inure 
residual nodes following systemic therapy have a grave prognosis. 
6.3.6.2.3 Speed of tumour response 
The relationship between overall tumour response to primary systemic therapy and long term 
survival has been observed previously by the Edinburgh group (Anderson et al: 1991), and 
has also been reported extensively by other investigators (Scholl et al: 1995; Sataloff et al: 
1995; Hortobagyi et al: 1988; Jacquillat et al: 1991). In these studies the patients were 
divided on the basis of clinical regression according to the UICC criteria (Hayward et al: 
1977). Clinical response defined in this way was reported not to relate to survival, whereas 
response determined by the histological examination of the tumour did (Scholl et al: 1995). 
Since detailed information about response was available in this study, it was possible to relate 
the pattern of response, and not simply the extent of final response to outcome. 
The actions of cytotoxic chemotherapy and endocrine therapy are essentially different in that 
chemotherapy produces regression by inducing cell death, whereas endocrine treatment 
reduces cell proliferation and relies on the natural process of cell loss for tumour regression 
(Knabbe et al: 1987; Cullen et al: 1989). The relatively slow rate of regression by endocrine 
therapy has been well described (Gazet et al: 1991; Anderson el al: 1991; Anderson el al: 
1989), and was again observed in the present study. In order to be able to relate tumour 
response to outcome it was necessary to define fast and slow response for each type of 
treatment separately. The dividing point between fast and slow responses was simply chosen 
to be the median response time, and the data were not explored for the "best" cut off point. 
Patients with the fastest responses in their own category had a significantly better prognosis 
compared with those with slower responding tumours. Once corrected for other important 
prognostic indicators such as axillary nodal involvement and ER status, the size of the 
difference between the two groups was greatly reduced, but remained significant. 
The present use of rate of response for determining prognosis is particularly important in 
attempting to quantify the prognosis of patients on endocrine therapy whose tumours respond 
relatively slowly and who may therefore have considerable residual tumour burden at the time 
of locoregional therapy. 
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6.3.6.2.4 Interactions between axillary lymph node status, ER and response 
Tumours with high oestrogen receptor content are known to respond relatively poorly to 
chemotherapy (Livingston and Mortimer: 1987; Rosner el al: 1989; Anderson el al: 1989). In 
the present study only patients with ER <20U were given cytotoxic chemotherapy. The cut off 
level of "20U" is much higher than used in many previous studies (Oriana et al: 1989; 
Cocconi el al: 1990; Fisher et al: 1983), and patients given chemotherapy had a wide range of 
ER values. The speed of response to cytotoxic chemotherapy in patients with tumour ER 
levels of <20U depended on the actual level of tumour ER. Thus patients with the lowest ER 
values had the fastest responses to cytotoxic chemotherapy and were more likely to have few 
residual involved axillary nodes. \ 
6.3.7 Assessment of prognosis following primary systemic treatment 
One of the potential disadvantages of using primary systemic treatment is the loss of potential 
prognostic indicators. The results presented here indicate that tumour characteristics 
determined after primary systemic treatment retain their value as prognostic indicators. 
Furthermore, supplementary prognostic information is provided by observations regarding 
tumour response. 
The tumour oestrogen receptor levels provide valuable information about the patient's 
prognosis, and may be used in making decisions regarding future systemic therapy. This 
information was available from the incisional biopsy taken prior to the start of primary 
systemic treatment. The current results indicate that oestrogen receptor values determined by 
the immuno- cytochemical assay, and oestrogen receptor levels determined from specimens 
obtained after systemic therapy, can provide similar information to the initial ER values, 
without the need for incisional biopsy. 
The current results have also confirmed that residual axillary lymph node involvement is an 
important indicator of prognosis following primary systemic treatment, particularly when the 
confounding effect of oestrogen receptor content is accounted for. The grouping of the number 
of nodes into different prognostic categories (Fisher et al: 1983a), appears to apply after 
primary systemic therapy. 
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CHAPTER 7 
7. Psychological Morbidity 
and 
Primary Systemic Treatment 
7.1 INTRODUCTION 
7.1.1 Psychological morbidity and cancer 
7.1.1.1 Prevalence of psychiatric disorders 
The experience of having cancer is a major stressful life event. The association between the 
diagnosis of malignancy and the presence of psychological disturbance was observed early in 
the history of the study of neoplasia (Goldfarb et al: 1967; Guy: 1759). It was however only 
recently that attempts have been made to formally observe and describe the psychological 
disturbances caused by cancer, and to distinguish them from simple "unhappiness" (Derogatis 
et al: 1983; Greer: 1985; Vachon and Lyall: 1976; Craig and Abeloff: 1974; Holland: 1977; 
Peck: 1972). Derogatis and his colleagues used structured interviews and applied strict 
diagnostic criteria to assess the state of mind of a sample of 215 randomly selected patients 
with a variety of malignancies. Nearly half the patients had formally identifiable psychiatric 
disease. The main symptoms were anxiety or depression in 85% of the patients, and the 
psychiatric problem was classed as an adjustment disorder in 68% (Derogatis et al: 1983). 
7.1.1.2 The influence of treatment 
The psychological blow of a cancer diagnosis is usually followed by the stress of having to 
cope with unpleasant treatment, be it major or mutilating surgery, cytotoxic chemotherapy or 
radiotherapy. Such treatment is in itself often accompanied by significant levels of anxiety and 
mood disturbance. 
Cytotoxic chemotherapy has been associated with significant psychological morbidity. This is 
often directly related to the toxicity experienced with the treatment (Cooper et al: 1980; 
Maguire et al: 1980). Patients undergoing cytotoxic chemotherapy express significant anxiety 
ill anticipation for each cycle of treatment (Nerenz et al: 1982). The anxiety has been linked to 
the severity of the expected acute side effects such as nausea , and may follow the classic 
patterns of a conditioned response (Jacobsen et al: 1993). Duration of treatment in itself 
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influences the severity of the psychological disturbances experienced by the patients, thus 
regimes lasting for a year are significantly more morbid compared with six month 
chemotherapy regimes (Hughson et al: 1986). Depression is another association with 
cytotoxic chemotherapy (Foltz et al: 1984), resulting more from chronic side effects such as 
generalised malaise or chronic fatigue. Depressive symptoms have also been observed in 
cancer patients undergoing radiotherapy (Berglund et al: 1991; Lasry el al: 1987). The 
prevalence of radiotherapy associated symptoms also appears to relate to the experience of 
physical side effects (Graydon: 1994). Studies which have examined the long term 
psychological sequelac of treatment suggest that the problems are most apparent at the time of 
treatment with most patients returning to normal after the completion of treatment (Berglund 
et al: 1991). 
7.1.2 Psychiatric morbidity in breast cancer 
Anxiety, depression and impairment of daily function particularly in relation to body image 
and sexual function, have been well documented following a diagnosis of breast cancer 
(Maguire et al: 1978; Renneker and Cutler: 1952; Bard and Sutherland: 1955; Morris et al: 
1977). Much emphasis has been placed on the influence of breast loss on subsequent levels of 
psychological morbidity (Bartelink et al: 1985; Fallowfield et al: 1986; Maunsell et al: 1989; 
Fallowficld and Hall: 1991; Lasry et a/: 1987; Roberts et a!: 1972; Morris et al: 1977). 
Comparisons between mastectomy and breast conserving treatments have however made it 
clear that the type of surgery has little influence on the more serious psychological problems 
following breast cancer (Goldberg et al: 1992; Fallowfield et al: 1990; Fallowfield and Hall: 
1991; van Heeringen el al: 1989; Wilson el a!: 1988), and that these problems can largely be 
explained in terms of the diagnosis of malignancy and the effects of subsequent treatment ,J I G t? 
(Scnescuc: 1963; Maunsell et a/: 1992; Alagaratnam and Kung: 1986; Deadman et al: 1989). 
7.1.3 Primary systemic treatment and psychiatric morbidity 
Patients undergoing primary systemic therapy for cancer are likely to share the experience of 
all cancer sufferers in relation to the diagnosis of malignancy and subsequent treatment. There 
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is however little known about any additional psychological morbidity which may be associated 
with delaying the removal of the primary tumour. 
7.1.3.1 Primary systemic treatment and breast cancer 
Historically, removal of the breast tumour has been seen as the most important component of 
treatment for breast cancer (see section 1.2). It may be speculated that patients also perceive 
ablative surgery as the most important part of the treatment for their cancer. This contention is 
supported by the fact that many women continue to choose mastectomy over breast 
conservation when the choice is offered them (Wilson el al: 1988: Morris and Roylc: 1987). If 
this is the case, surgical delay introduced by primary systemic treatment may be seen as a 
potential additional source of psychological stress. 
There is little actual information available abou atients' perceptions of what treatment is 
most appropriate for their cancer. It is however apparent that patients often overestimate their 
chances of survival with conventional therapy, and that they are much more receptive to new 
treatments when given accurate information about their prognosis (Siminoff el al: 1989; 
Felting el al: 1990). 
The present randomised trial has provided an opportunity for the study of psychiatric 
morbidity in relation to primary systemic treatment. 
7.1.4 Measurement of psychological morbidity 
7.1.4.1 The structured interview 
The structured interview is the gold standard for assessment of psychological morbidity. Such 
interviews have the advantage of being able to address issues specific to a particular 
treatment, and to explore and identify new areas of concern. An interview is however a time \./ consuming process, requiring trained staff, and may be open to different interpretations, 
depending on the diagnostic criteria in use (Spitzer el al: 1978; Wing el al: 1978). 
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7.1.4.2 Self rating questionnaires 
Specific aspects of psychological morbidity can be explored in similar groups of patients 
using questionnaires which are completed by patients. The items in the questionnaires arc 
usually derived from the detailed assessment of large numbers of structured interviews, but 
once validated, questionnaires provide a relatively simple way of assessing morbidity. 
A number of such validated questionnaires have been developed which allow assessment of 
mood, psychological adjustment and general well -being of patients receiving hospital 
treatment, and in particular treatment for cancer. 
Anxiety, depression and adjustment disorders are the most frequently observed psychological 
problems experienced by cancer patients (Derogatis et al: 1983). Two well validated 
questionnaires were selected to address these specific problems. 
7.1.4.2.1 The Hospital Anxiety and Depression (HAD) scale 
The 1 IAD scale, developed in 1983 by Zigmond and Snaith (Zigmond and Snaith: 1983), lias 
been designed specifically for the assessment of mood disorders in non -psychiatric hospital 
patients. It takes into account the effects of physical illness on mood and is designed to assess 
the states of anxiety and depression separately. The scale has been used extensively for the 
assessment of psychological morbidity in cancer patients (Morris and Royle: 1987; 
Fallowficld et al: 1990; Rosengvist et al: 1993; Bulman: 1992; Hopwood el al: 1991; 
Hopwood et al: 1991). The results compare well with other methods of measuring anxiety and 
depression (Miller et al: 1995; Fallowfield el al: 1990). 
7.1.4.2.2 The Mental Adjustment to Cancer (MAC) scale 
The MAC scale described by Watson and her colleagues (Watson et al: 1988), was developed 
from analysing the outcome of structured interviews with breast cancer patients (Greer et al: 
1979) and was later extended to include responses from patients with other forms of cancer. 
The five sub scales of the MAC scale are specifically designed to assess the various facets of 
the patients' style of adjustment to a cancer diagnosis. The MAC scale is of particular interest 
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in that the response to its different items have been linked to survival outcome from breast 
cancer (Greer ei al: 1990; Greer ei al: 1979). 
The MAC and the IiAi) scales were used to assess psychological morbidity in patients 
entering this trial of selective primary systemic treatment in breast cancer. 
7.1.5 Overall quality of life 
Quality of life issues are assuming increasing importance in the assessment of the results of 
clinical trials, particularly where new treatments result in modest gains (Gelber and Gelber: 
1995; Schipper: 1990). The present study of psychological morbidity addresses only one of 
the measures of quality of life. Some of the other aspects are covered by findings regarding 
length of treatment, treatment related toxicity and surgical morbidity. 
7.1.5.1 Quality adjusted survival analysis 
Quality adjusted survival analysis provides a way in which the impact of adverse effects of 
treatment on the patient's overall quality of life can be taken into consideration when 
interpreting the significance of small survival gains from treatment (Gelber and Gelber: 1995). 
7.1.5.1.1 The TWiST method 
In 1986 Gelber and colleagues described a method of dividing the patients survival following 
the diagnosis of cancer into three separate phases. The first is the diagnosis and treatment 
phase. The final phase is the time following the diagnosis of recurrence until death. The phase 
between these is termed "time without symptoms of disease and subjective toxic effects of 
treatment" and abbreviated as TWiST. Gelber and colleagues showed that the chemotherapy 
for node- positive premenopausal women, not only resulted in prolonged survival, but also 
produced gains in TWiST (Gelber and Goldhirsch: 1986). 
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7.1.5.1.2 The Q -TWiST method 
7.1.5.1.2.1 Inadequacies of the TWiST technique 
There arc two problems with the TWiST method. The first problem is that it assigns no value 
to life during treatment, or after recurrence. The second problem is related to the treatment of 
censored data. The most common reason for censoring is that the patient is alive and 
recurrence free at the time of assessment. In the traditional TWiST methodology, the results 
assessed at a time point before the death of all patients are biased in favour of the treatment 
with the shortest duration since patients who may have undergone prolonged treatment, and 
are censored at the time of assessment may not have had enough time to derive the maximum 
benefit from their treatment (Gelber et al: 1989). 
7.1.5.1.2.2 The Q -TWiST methodology 
The problems inherent in the TWiST methodology have been overcome by using Quality 
adjusted TWiST or Q- 'l'WiST (Gelber et al: 1995; Glasziou et al: 1990; Goldhirsch et al: 
1989). 
In this method the average time spent by the group of patients in each of the three health 
phases following diagnosis of cancer is calculated as the area under the survival curve for that 
health phase. The relative worth of each health phase is then assigned a numerical value 
between `zero', representing a state comparable to being dead, and `one' representing a state 
of "perfect health ". This value is termed the "utility coefficient ". The utility coefficient 
applicable to each health phase is multiplied by the area under the survival curve to calculated 
the quality adjusted mean time spent in that phase. The Q -TWiST is the sum of the quality of 
adjusted values for each of the three survival phases as follows: 
Q-TWIST=(u ,ox x TOX)+TWiST+(uR, x REL) 
Where TOX= mean time in treatment phase, REL= mean time in recurrence phase, u= utility 
coefficient, TWiST= time without symptoms of disease and toxicity of treatment. 
The utility coefficients are the components of the equation which can be assigned using quality 
of life data. 
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7.1.5.1.2.3 Comparing Q -TWiST for different treatments 
The most practical way to compare the Q -TWiST for two treatment groups is to estimate the 
variance using a "bootstrap" technique (Efron: 1980). In this technique the data are sampled 
with replacement from the original data to derive a new sample equal in size to the original. 
The analysis is then repeated on the new data set a large number of times to generate a set of 
results. The standard deviation of this "bootstrap sample" can then be used as the variance for 
the Q- TWiST. 
The basic techniques have been developed to allow inclusion of covariates using proportional 
hazard models (Cole et al: 1993), and quality adjusted meta -analysis (Gelber et al: 1996; 
Cole et al: 1995). 
7.1.5.1 .2.4 The application of Q -TWiST 
The technique has been used to show that chemotherapy increases quality adjusted survival in 
premenopausal women (Cole et al: 1995; Hurny et al: 1996), but has little impact in 
postmenopausal women (Gelber et al: 1996). It has also been used in assessing the impact of 
Zidovudinc treatment for acquired immunodeficiency syndrome (Gelber et al: 1992), and the 
outcome of clinical intervention on the quality of life with epilepsy (Schwartz et al: 1995). 
The method was used in this trial to assess the quality adjusted survival difference between 
patients treated by primary systemic treatment and those treated conventionally. 
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7.2 PATIENTS AND METHODS 
7.2.1 Patients 
All patients were those taking part in the main trial of primary systemic treatment. The 
psychological study was confined to the first 69 patients recruited to the trial. Patients were 
independently asked to participate in the psychological study. Patients with known previous 
psychiatric illness and those who required psychiatric intervention during the study were 
excluded. Patients who developed recurrence within 8 weeks of completing treatment as 
defined in section 3.5.1.1 were also excluded. 
7.2.1.1 Psychological support 
All patients were seen by a specialist breast care nurse at the time of first presentation, at the 
time of confirmation of diagnosis and prior to making any final decisions regarding any 
subsequent treatment. Furthermore, the patients had unrestricted access to the breast care 
nursing team at all other times, and were seen at regular intervals during prolonged treatments. 
Before entry into the trial each patient had two full consultations on consecutive days with the 
surgeon in charge of conducting the trial. The patient was seen along with a close friend or a 
relative, and a breast care nurse was also present. During these consultations the rationale for 
the trial and all possible treatments were fully discussed with the patient. Written information 
was provided following the first consultation, and patients were asked to choose a treatment 
option following the second consultation. Following completion of all treatment, patients were 
given further verbal information regarding their specific type of tumour, lymph node status 
and oestrogen receptor status. Specific information in relation to prognosis was only given if 
directly asked for by the patient. 
Patients who displayed significant difficulty in coping with their diagnosis or treatment were 
referred for a formal psychiatric consultation. 
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7.2.1.2 Baseline patient data 
Data were available for patients' general characteristics and tumour characteristics, as 
described in section 4.1.2. Baseline social parameters were established by obtaining data 
regarding patients social class, marital status and employment status as follows: 
7.2.1.2.1 Social class 
Occupational social class, according to the Registrar General's Classification of occupations 
(O.P.C.S.: 1980), was recorded. Patients were classified according to their own occupation if 
single and according to husband's occupation if married. 
The following categories of social class were recorded: 
1. I. Professional 
2. II. Managerial 
3. Ill non manual 
4. III. manual 
5. IV. Skilled manual 
6. V. Unskilled manual 
For the purposes pf statistical analysis social classes I, 11 and Ill non manual were categorised 
as "NON- MANUAL ", while social classes III manual, IV and V were classed as "Manual ". 
7.2.1.2.2 Marital status 
This was recorded as follows: 
1. Married or living with partner 
2. Single, widowed or divorced living with another adult 
3. Single, widowed or divorced living with children 
4. Single, widowed or divorced living alone 
Psychological morbidity: methods 7 -169 
For the purposes of analysis, patients in category 1 were designated "WITH PARTNER" 
while those in categories 2, 3 and 4 were classed as "WITHOUT PARTNER" 
7.2.1.2.3 Employment status 
The patients' own employment status was recorded as described by the patient, and classed as 
follows: 
1. Currently in work 
2. Previously in work, retired 
3. Previously in work, Unemployed 
4. Ilousewife 
For the purposes of analysis patients in category 1 were classed as "IN PAID WORK" while 
those in categories 2, 3 and 4 were allocated to the single category of "NOT IN PAID 
WORK ". 
7.2.2 Psychological questionnaires 
7.2.2.1 The questionnaires 
The Hospital Anxiety and Depression Scale (HAD scale) and the Mental Adjustment to 
Cancer Scale were used. The questionnaires are presented and described in detail in the 
appendix (section 14.2.). 
Patients were given the questionnaires and asked to complete and return them on their next 
visit or to post them back. Those who failed to return their questionnaires were reminded once. 
If patients still failed to return a questionnaire after being reminded, they were categorised as 
having declined to take part in the study of psychological morbidity. 
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7.2.2.1.1 The HAD scale 
This is a general questionnaire designed for assessment of reaction to illness. It assess 2 
factors: anxiety and depression. Each factor is assessed by seven questions. 
In addition to assessing the degree with which the patient's mood is affected by anxiety or 
depression, the HAD scale is designed to detect pathological levels of either trait. The cut off 
can be set anywhere between 8 and 10, depending on the desired level of sensitivity and 
specificity (Zigmond and Snaith: 1983). For this study a score of 1 to 9 was regarded as 
within normal limits. Scores of 10 and over were regarded as pathological. 
7.2.2.1.2 The MAC scale 
This questionnaire is specifically designed to assess the patient's attitude to a diagnosis of 
cancer. It has 40 items which address 5 factors. The factors and their possible range of scores 
are as follows: 
1. Fighting spirit 16 -64 
2. Hopelessness and helplessness 6 -24 
3. Anxious preoccupation 9 -36 
4. Fatalism 8 -32 
5. Avoidance 1 -4 
7.2.2.2 Timing 
Patients undergoing primary systemic treatment were requested to complete questionnaires 
early and late during the period of systemic therapy, but before undergoing mastectomy. All 
patients were requested to complete the same questionnaires after the completion of their 
hospital based treatment, as defined in section 3.5.1.1. 
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7.2.3 Quality adjusted survival analysis 
The Q -TWiST method, as introduced in section 7.1.5.1.2 was used for quality adjusted 
survival analysis. 
7.2.3.1 Phases of survival 
The three phases of survival were defined as follows: 
7.2.3.1.1 The treatment phase 
This phase lasted from the time of entry into the trial until the date of discharge to long term 
follow -up. Hospital visits for breast reconstruction were not regarded as cancer treatment. 
Time of discharge to long term follow -up was defined as follows: 
7.2.3.1.1.1 Cytotoxic chemotherapy 
Three weeks after the final cycle of chemotherapy, or the date the patient had fully recovered 
from any immediate side effects of their final cycle of chemotherapy, whichever was later. 
7.2.3.1.1.2 Endocrine treatment 
The time when the patient was first started on long term tamoxifen, or when the patient had 
fully recovered from any complications of surgery, whichever was later. 
7.2.3.1.1.3 Radiotherapy 
If radiotherapy was the last adjuvant treatment given, the patient was discharged to long term 
follow -up three weeks after the final dose of radiotherapy, or the date the patient had fully 
recovered from any immediate side effects of radiotherapy, whichever was later. 
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7.2.3.1.2 The recurrence phase 
7.2.3.1.2.1 Local recurrence 
Local recurrence, without systemic recurrence, can be regarded as a condition which can be 
treated within a definable period of time, leaving the patient to continue to enjoy good health 
thereafter. For the purpose of calculating Q- TWiST, The duration of treatment for local 
recurrence was measured and added to the total time with systemic recurrence. 
Treatment for local recurrence was defined as starting on the day of diagnosis, and continued 
until the patient had again been discharged to long term follow -up. The criteria for discharge 
were as defined for the treatment of primary disease. 
7.2.3.1.2.2 Systemic recurrence 
The recurrence phase was defined as starting on the day when diagnosis of systemic 
recurrence was confirmed, and continued until the time of death. 
For patients with local recurrence prior to systemic recurrence, the date of diagnosis of 
systemic recurrence was brought forward by the duration of treatment for local recurrence. 
Patients with treated local recurrence who at the time of diagnosis had not developed systemic 
recurrence, were defined as having had a date of recurrence equal to the date of analysis minus 
the duration of treatment for local recurrence. 
7.2.3.1.3 TWiST phase 
Survival time which was not allocated to treatment or recurrence was defined as TWiST. 
7.2.3.2 Utility coefficients 
The utility coefficient for TWiST was designated as "one" (7.1.5.1.2.2). Analyses were then 
performed to cover all possible extreme situations. No further analysis was performed once it 
was established that no difference in quality adjusted survival could be detected even in the 
extreme situations. 
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7.2.3.2.1 Comparison of overall survival 
Treatment and recurrence phase are designated as having a utility of one. This represents the 
extreme situation where treatment and recurrence are assumed to have no impact on quality of 
life. The analysis simply compares overall survival between the two groups. 
7.2.3.2.2 Comparison of disease free survival 
Life after recurrence is given a utility of zero. and life with treatment a utility of one. The 
analysis compares recurrence free survival. 
7.2.3.2.3 Comparison of treatment free survival 
Treatment phase was given a utility coefficient of zero. The results represent overall survival 
after completion of all treatments. 
7.2.3.2.4 Comparison of TWiST survival 
Treatment and recurrence phase are designated as having no utility. This represents the 
extreme, where the quality of life during treatment and recurrence is comparable to being 
dead. The analysis compares only the TWIST. 
7.2.4 Analytical methods 
All statistical analyses were performed using the statistical software package Stata 4.0 for 
Windows, Stata Corporation, 702 University Drive East, College Station, Texas 77840 USA. 
The results were analysed on the basis of actual treatments received. 
7.2.4.1 Direct comparisons 
Actual scores were treated as ordered categorical data and compared using non parametric 
techniques. Paired data were compared using Wilcoxon signed -rank test and unpaired data 
using the Mann -Whitney U test. Proportions were compared using Fisher's exact test. Where 
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a "mean" value is reported (e.g.: mean age) comparisons were made using Student's t -test. 
Other tests are specified within the results section. 
7.2.4.2 Patient and tumour factors and psychological outcomes 
The relationships between patient and tumour characteristics (explanatory variables) and 
psychological outcomes (outcome variables) were assessed using univariate and multivariate 
techniques. 
7.2.4.2.1 Univariate techniques 
Where the explanatory variables were dichotomous the differences in the outcomes for each 
category were compared using the Mann -Whitney U test. The relationships between 
continuous explanatory variables and the outcome variables were examined using the 
Spearman Rank correlation coefficient. 
The following categorical explanatory variables were examined: 
1. Treatment option: 
2. Adjuvant treatment: 
3. Axillary lymph node status: 
4. Oestrogen receptor status: 
5. Breast reconstruction: 
6. Social class: 
7. Partnership: 
8. Employment: 
Conventional or primary systemic treatment 
Cytotoxic chemotherapy or endocrine treatment 
Nodes involved or not involved 
Negative ( <20U) or positive ( >19U) 
Performed and not performed 
Manual or Non -manual 
With partner or not with partner 
Working or Not in work 
The following continuous explanatory variables were examined: 
1. Age 
2. Tumour diameter at diagnosis 
Tumour response was examined in relation to psychological scores late during primary 
systemic treatment. 
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7.2.4.2.2 Multivariate techniques 
Because of the relatively small number of cases involved, clinically important degrees of 
confounding may have gone unnoticed in univariate analysis. The relationship between 
explanatory and outcome variables was therefore further examined using multivariate 
techniques. 
Since psychological outcome variables are categorical, an ordered logistic regression model 
(McCullagh: 1977) was used. The frequency distributions of scores for each outcome variable 
were examined and an appropriate number of ordered categories, each including 
approximately equal number of cases were derived. The number of categories were as follows: 
Anxiety: 8, Depression: 6, Fighting spirit: 9, Hopelessness/ helplessness: 4, Anxious 
preoccupation: 7, Fatalism: 8 and Avoidance: 3. The re -coded outcome variables were used to 
build multiple regression models. 
All 10 explanatory variables were tested starting with variables with the greatest degree of 
significance on univariate analysis. Those variables which contributed to the model with 
p <0.15 were retained in the model. 
7.2.4.3 Analysis of survival 
To assess the relationship between each psychological outcome variable and distant disease 
free survival and overall survival, each outcome variable was re -coded into a dichotomous 
variable by coding values lower than the median score to zero and those greater than the 
median to one. The outcomes for the categories were compared using a log -rank test. Where a 
difference was found, the relationship was further examined in a multivariate model using 
Cox's proportional hazard model (Cox: 1972). Axillary lymph node status and the natural 
logarithm of the actual oestrogen receptor measurements were entered into the model as well 
as any other patient or tumour factors which were found to relate to psychological outcome. 
7.2.4.4 Quality adjusted survival analysis 
The principles of Q-TWiST analysis are summarised in section 7.1.5.1.2. 
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The area under the survival curves was calculated from life tables. This is equal to the sum of 
the product of the probability of survival at the beginning of each time band and the length of 
that time band, and represents "mean" survival. The standard error of mean survival was 
estimated using the "bootstrap" procedure, by re- sampling the data 2500 times. The standard 
deviation of the bootstrap sample by definition represents the standard error of the mean. 
Q -TWiST analysis was performed using a computer programme module specially written to 
work with the statistical analysis package "Stata 4 ". The details of the programme are 
provided in the appendix (14.3). 




Of the 69 patients recruited for the psychiatric study, 34 (including 2 originally randomised to 
primary systemic treatment arm) received conventional therapy and 35 (including one patient 
originally randomised to conventional therapy) received primary systemic treatment. Thirty 
patients given primary systemic treatment and 27 patients treated conventionally returned 
completed psychological questionnaires. 
7.3.1.2 Reasons for not entering the study 
7.3.1.2.1 Primary systemic treatment arm 
Thirty of the 35 eligible patients participated in the psychological study. Four patients 
declined to take part. One patient who required treatment for an overt anxiety state was 
excluded. 
All patients completed two sets of questionnaires, one at the start and one following 
completion of treatment. Twenty -eight patients also completed a third questionnaire late 
during primary systemic treatment. 
7.3.1.2.2 Conventional arm 
Of the 34 patients treated by conventional therapy, 27 patients took part in this study. Three 
patients declined to take part. Two patients developed recurrence during or immediately after 
the completion of treatment and were excluded. Two further patients who required psychiatric 
intervention, one for an overt anxiety state and the second for depression, were also excluded. 
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7.3.1.3 Patient characteristics 
Distribution of various patient and tumour characteristics for patients taking part in the study 
and those patients remaining outside the study are summarised in Table 7 -1. The general 
characteristics of participants and non -participants were similar, although a greater proportion 
of the non -participants (7/ 12 vs. 13/ 57), also chose not to undergo breast reconstruction. 
Five of the 7 patients declining to take part had also declined breast reconstruction. 
Number of patients 
In the study Not in the study 
Stat P= 57 12 
Age (mean ±SEM) 50.0 ±1.3 54.6 ±3.2 1 =1.41 0.16 
Treatment (PST / CONV) 30 / 27 5 / 7 Exact 0.540 
Social Class (man /nonman) 20 / 37 6 / 6 Exact 0.347 
Partner (with /without) 31 / 26 7 / 5 Exact 1.000 
Employment (working /not) 31 / 26 4 / 8 Exact 0.218 
Tumour size (median, range) 45 (41 -80) 45 (41 -85) z =0.06 0.956 
ER (median, range) 19 (0 -472) 17.5 (0 -552) z = -1.01 0.331 
Axillary nodes (pN 1 / pNO) 33 / 24 7 / 5 Exact 1.000 
Adjuvant therapy (endo /chemo) 26 / 31 7 / 5 Exact 0.540 
Breast reconstruction (yes /no) 44 / 13 5 / 7 Exact 0.031 
Unless otherwise specified, number of patients in each category are reported. MAN: manual , NON 
MAN: non manual, ER: Oestrogen receptor levels, pNl: involved nodes, pNO: uninvolved nodes, 
ENDO: endocrine therapy, CHEMO: cytotoxic chemotherapy. 
Table 7 -1: Characteristics of patients in the study of psychological morbidity 
The distributions of basic social profiles of the patients in the primary systemic treatment arm 
and those in the conventional arm of the study are presented in Table 7 -2. The profiles are 
confined to those patients taking part in the study of psychological morbidity. There were no 
differences between the two groups. 
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Number of patients 
PST CONV 
P= 30 27 Stat 
Age (mean ±SEM) 49.7 ±1.9 50.2 ±2.0 1 =0.22 0.827 
Breast reconstruction (yes /no) 25 / 5 19 / 8 Exact 0.345 
Social Class (man /nonman) 19 / 11 18 / 9 Exact 1.000 
Partner (with /without) 17 / 13 14 / 13 Exact 0.793 
Employment (working /not) 17 / 13 14 / 13 Exact 0.793 
Number of patients in each category are reported. 
Table 7 -2: Social characteristics of patients in the study of psychological 
morbidity 
7.3.1.4 Timing of questionnaires 
Of the 30 patients in the primary systemic treatment arm of the study all returned 
questionnaires in the initial stages and 28 in the late stages of preoperative systemic treatment. 
Following completion of treatment, 30 further questionnaires were completed by patients 
undergoing primary systemic treatment and 27 by patients in the conventional arm of the 
study. 
7.3.1.5 Relationship between questionnaire items 
A total of 115 questionnaires were completed. The HAD and the MAC scale together covered 
7 items. To assess whether the items were related to each other all 115 questionnaires were 
considered together. The correlation coefficients between each of the seven items were 
calculated using linear regression. The correlation matrix is presented in Table 7 -3. Although 
significant relationships were detected between a number of the items, these were generally 
weak with the values for the correlation coefficients ranging between 0.05 and 0.55. The 
largest relationship was between the two items of the HAD scale (p =0.66, p= 0.0001). 
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ANX. 
DEP 0.66 0.001 DEP. 
F.S. -0.40 0.001 -0.46 0.001 F.S. 
H.H. 0.51 0.001 0.42 0.001 -0.55 0.001 H.H. 
A. P. 0.42 0.001 0.33 0.001 -0.05 0.628 0.28 0.003 A. P. 
FAT. 0.18 0.060 0.05 0.629 -0.1 0.268 0.26 0.007 0.15 0.101 FAT. 
AVO 0.28 0.002 0.31 0.001 -0.15 0.100 0.19 0.040 0.53 0.001 0.17 0.066 
p= P< P= p< p= P< P= P< P= p< p= P< 
ANX.: anxiety, DEP. Depression, F.S.: Fighting spirit, H.H.: Hopelessness/ helplessness, A.P.: 
Anxious preoccupation, FAT.: Fatalism, AVO.: Avoidance. Adjusted Spearman Rank correlation 
coefficient and the significance of the correlation are presented. 
Table 7 -3: Correlation matrix, demonstrating the relationship between the 
seven items covered by the HAD and the MAC scales 
In the studies leading to the design of the MAC scale, "fighting spirit" and "avoidance" 
behaved as desirable mechanisms of psychological adjustment, while other factors indicated 
poor adjustment (Watson et al: 1988; Watson et al: 1984). In the present study avoidance 
scores directly correlated with all other scores except for fighting spirit where the relationship 
was an inverse one. It therefore appears that in this group of patients avoidance behaved as a 
negative psychological trait. 
Each of the seven items were analysed independently. 
7.3.2 Psychological score and primary systemic treatment 
7.3.2.1 Early versus late during primary systemic treatment 
Twenty -eight patients completed questionnaires during early and the later stages of primary 
systemic treatment. 
7.3.2.1.1 Abnormal levels of anxiety and depression 
Anxiety and depression scores of 10 and over using the HAD scale were classed as 
pathological. The number of patients with a pathological score during the early and late parts 
of treatment are presented in Table 7 -4. Abnormal levels of anxiety were common, affecting 
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one in five patients. Depression was rare. There were no significant differences in the number 
of patients with pathological anxiety and depression scores at different stages of preoperative 
treatment. 
Early during PST Late during PST Stat p= 
Total 30 28 
Anxiety seore010 6 (20.0%) 6 (21.4%) Exact 1.000 
Depression score 10 0 1 (3.6%) Exact 0.483 
Numbers of patients in each category are reported 
Table 7 -4: Patients with pathological levels of anxiety and depression early 
and late during primary systemic treatment 
7.3.2.1.2 Changes in scores with treatment 
The actual scores for the early and late stages of treatment for the 2 items of the HAD scale 
and the 5 items of the MAC scale were compared using the Wilcoxon signed -rank test. The 
median and range of scores for each item are presented in Table 7 -5. Overall, there was no 
significant change in the scores for any of the questionnaire items. There was however a 
tendency for patients to have increased levels of depression (p= 0.068) and to be more 
anxiously pre- occupied with their cancer (p= 0.052). 
Factor (range) Early during PST Late during PST Change z= p= 
Total 28 28 inc dec nc 
ANX. (0 -21) 7.5 (2-15) 7 (0-18) 8 14 6 -1.22 0.224 
DEP. (0 -21) 2 (0-9) 2.5 (0-10) 13 5 10 -1.82 0.068 
F.S. (16 -64) 53 (46-62) 51.5 (42-63) 12 14 2 -0.63 0.532 
H.H. (6 -24) 8 (6-18) 8 (5-18) 11 8 9 -1.11 0.267 
A.P. (9 -36) 21 (9-28) 22.5 (12-28) 15 10 3 -1.94 0.052 
FAT. (8 -32) 19 (9-24) 19 (8-27) 11 8 9 -1.07 0.283 
AVO. (1 -4) 2 (1-4) 2 (1-4) 1 3 24 -1.00 0.317 
ANX: anxiety, DEP: Depression, F.S.: fighting spirit, H.H.: Hopelessness/ Helplessness, A.P.: 
anxious preoccupation, FAT.: Fatalism, AVO.: Avoidance. The possible range of scores for each 
item are presented. The "change" column refers to the number of patients whose scores increased 
(inc), decreased ((icc) or did not change (ne). Scores were compared using Wilcoxon signed -rank test 
Table 7 -5: Responses to the elements of the HAD and MAC scales during 
the early and late part of primary systemic treatment 
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7.3.2.2 Change in score before start and following completion of treatment 
Thirty patients completed questionnaires at the start of primary systemic trcatmcnt and 
following the completion of all treatments. 
7.3.2.2.1 Abnormal levels of anxiety and depression 
Following completion of treatment none of the patients maintained a pathological level of 
anxiety or depression, significantly fewer than the 6 patients who had abnormal anxiety levels 
during treatment (p= 0.012, Fisher's exact test). 
7.3.2.2.2 Changes in scores for individual questionnaire items 
The points scored for the 2 items of the HAD scale and the 5 items of the MAC scale during 
primary systemic treatment and following completion of treatment were compared using the 
Wilcoxon signed -rank test. The median and range of scores for each item are presented in 
Table 7 -6. 
Factor (range) During treatment After treatment Change z= P2 
Number of patients 30 30 inc dec nc 
ANX. (0-21) 7.5 (2 -15) 3.5 (0-9) 3 26 1 -4.42 0.001 
DEP. (0-21) 2 (0 -9) 2 (0-9) 8 14 8 -1.47 0.142 
F.S. (16 -64) 53 (46 -62) 53 (42 -62) 14 12 4 -0.17 0.868 
H.H. (6-24) 8 (6 -18) 7.5 (6 -15) 7 18 5 -1.89 0.059 
A.P. (9 -36) 21 (9 -28) 20 (10 -26) 10 18 2 -2.24 0.025 f 
FAT. (8 -32) 19 (9 -24) 17.5 (8 -23) 12 12 6 -0.80 0.425 
AVO. (1-4) 2 (1 -4) 1.5 (1 -4) 2 13 15 -2.84 0.005 ` 
The possible range of scores for each item are presented. The "change" column refers to the number 
of patients whose scores increased (inc), decreased (dec) or did not change (nc). Scores were 
compared using the Wilcoxon signed -rank test. ANX: anxiety, DEP: Depression, F.S.: fighting 
spirit, H.H.: Hopelessness/ Helplessness, A.P.: anxious preoccupation, FAT.: Fatalism, AVO.: 
Avoidance 
Table 7 -6: Responses to the HAD and MAC scales during primary systemic 
treatment and following completion of all treatment. 
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There was a highly significant decrease in anxiety levels following completion of treatment, 26 
patients showing a reduction in their score (median score of 3.5 vs. 7.5, p= 0.0001, Wilcoxon 
signed -rank test, Figure 7 -1). There were also significant reductions in the levels of anxious 
preoccupation (median of 20 vs. 21, p= 0.025, Wilcoxon signed -rank test) and avoidance 
(median of 1.5 vs. 2, p= 0.005, Wilcoxon signed -rank test). Furthermore, there was a reduction 
in the levels of hopelessness/ helplessness which approached significance (median 7.5 vs. 8, 






During Rx After Rx 
Figure 7 -1: Change in the anxiety score as assessed by the HAD scale with 
completion of primary systemic treatment 
7.3.2.3 Response to primary systemic therapy and psychological scores 
Three of the 28 patients who returned a second questionnaire had failed to respond to primary 
systemic treatment. Four further patients who eventually responded to cytotoxic clteniotherapy 
had failed to respond to initial endocrine therapy. The psychological scores in this group of 
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seven patients were analysed separately from the scores for the 21 patients who responded to 
treatment. Median and range of scores and the number of patients who showed a change in 
their score and the direction of the change are presented in Table 7 -7. There was no significant 
change in any of the scores for responding patients. The scores for hopelessness/ helplessness, 
anxious preoccupation and fatalism all showed a tendency to increase for non -responding 
patients although an increase in anxious preoccupation was the only score to achieve 
statistical significance. 
Factor 
Responding patients (n =21) Non responding patients (n =7) 






inc dec nc 
0.142 8(2 -9) 
7(1 -10) 
inc dec nc 






9 4 8 0.244 2(0 -9) 
3(1 -8) 






9 IO 2 0.935 56(46 -61) 
51(47 -63) 






6 8 7 0.580 8(6 -9) 
9(6 -13) 






9 9 3 0.350 20(9 -23) 
22(12 -28) 






6 7 8 0.887 19(16 -24) 
21(18 -27) 






0 2 19 0.157 2(1 -4) 
2(1 -4) 
1 1 5 1.000 
Median (range ) of scores and the number of patients whose scores increased (inc), decreased (dec) 
or did not change (nc) are presented. Early and late values were compared using the Wilcoxon 
signed -rank test 
Table 7 -7: Median and range of psychological scores during primary 
systemic treatment according to response 
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To further assess the effects of response on psychological well -being the scores for responders 
and non responders were compared using the Mann -Whitney U test. The median and range of 
scores are presented in Table 7 -8. 
Early during PST Late during PST 
Factor R. (n=23) N.R. (n=7) P= R. (n=21) N.R. (n=7) P= 
ANX. 7 (3-15) 8 (2-9) 0.621 7 (0 -18) 7 (1 -10) 0.632 
DEP. 2 (0-7) 2 (0-9) 0.766 2 (0 -10) 3 (1 -8) 0.727 
F.S. 53 (46-62) 56 (46-61) 0.538 52 (42 -63) 51 (47 -63) 0.811 
H.H. 9 (6-18) 8 (6-9) 0.158 8 (5 -18) 9 (6 -13) 0.627 
A.P. 22 (15-28) 20 (9-23) 0.094 23 (16 -27) 22 (12 -28) 0.540 
FAT. 19 (9-24) 19 (16-24) 0.225 19 (8 -23) 21(18 -27) 0.029 
AVO. 2 ( l-4) 2 (1-4) 0.578 2 (1 -4) 2 (1 -4) 0.328 
Median and range of scores for each category are reported. R: 
from the start. NR: No response. Scores were compared using 
response to primary systemic treatment 
the Mann -Whitney U test. 
Table 7 -8: Difference in psychological scores between responding and non 
responding patients 
On univariate analysis patients who had failed to respond to treatment appeared to be 
significantly more fatalistic in their attitude compared with those patients who did respond 
(z =2.18 p= 0.029, Mann -Whitney U test). However when adjusted for the effects of age using 
multivariate analysis, response no longer appeared to be of any significance (Table 7 -9). 
y= Fatalistic attitude Coefficient 95% C.I. z= p= 
Age 0.08 0.01 to 0.16 2.13 0.033 
Tumour size 0.90 -0.20 to 2.00 1.60 0.110 
Response -1.13 -2.89 to 0.63 1.26 0.209 
Log likelihood: -48.3 y2=11.79 0.0081 
Ordered logistic regression model 
Table 7 -9: Contribution of "response" to the level of "Fatalistic attitude" late 
during primary systemic therapy. 
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7.3.2.4 Mode of primary systemic therapy and psychological scores 
Of the 28 patients who returned a second questionnaire 8 were given endocrine treatment only, 
and 20 had received cytotoxic chemotherapy. Psychological scores for the two groups were 
analysed separately. Median and range of scores and the number of patients who showed a 
change in their score and the direction of the change are presented in Table 7 -10. 
Factor 
Cytotoxic chemotherapy (n =20) Endocrine treatment (n =8) 






inc dec nc 
0.756 8 (4 -12) 
6 (2 -12) 
inc dec nc 






12 3 5 0.014 2(0 -7) 
2 (0 -8) 






7 11 2 0.126 52(46 -58) 
51(47 -63) 






9 4 7 0.060 11(6 -12) 
9(6 -12) 






13 6 1 0.022 21(15 -26) 
21(16 -24) 






8 8 4 0.405 19(12 -21) 
20(12 -21) 






1 3 16 0.317 1.5 (1 -3) 
1.5 (1 -3) 
0 0 8 1.000 
Median and range of scores. The number of patients whose scores increased (inc), decreased (dec) or 
did not change (nc) are presented. Early and late values were compared using the Wilcoxon signed - 
rank test. 
Table 7 -10: Psychological scores during primary systemic treatment 
according to the mode of adjuvant therapy 
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Patients given cytotoxic chemotherapy became significantly more depressed and anxiously 
preoccupied towards the end of primary systemic treatment. They also had a tendency to feel 
more hopeless. Psychological score for patients given endocrine therapy did not significantly 
change except in the case of anxiety, where patients were less anxious towards the completion 
of primary systemic therapy. 
The effects of the mode of primary systemic treatment on psychological well -being was 
further studied by comparing the late scores of patients on endocrine and cytotoxic therapy 
using the Mann -Whitney U test. The median and range of scores are presented in Table 7 -11. 
There were no significant differences in psychological scores between the two groups. 
Factor 
Early during PST Late during PST 
CY. (n=20) EN. (n=10) P= CY. (n=20) EN. (n=8) P= 
ANX. 7.5 (2-15) 7.5 (4-12) 0.740 7 (0-18) 6 (2-12) 0.878 
DEP. 3 (t)-9) 2 (0-7) 0.476 2 (1-10) 2 (0-8) 0.237 
F.S. 54 (46-62) 52 (46-68) 0.353 52 (42-63) 51 (47-63) 0.818 
H.H. 8 (6-17) 10.5 (6-12) 0.411 8 (5-18) 9 (6-12) 0.756 
A.P. 22 (9-28) 21 (15-27) 0.808 23 (12-28) 21 (16-24) 0.092 
FAT. 19 (9-24) 19.5 (12-21) 0.706 19 (8-27) 20(12-21) 0.878 
AVO. 2 (1-4) 2 (1-3) 0.405 2(1-4) 1.5 (1-3) 0.321 
Median and range of scores. CY: primary cytotoxic therapy. 
were compared using the Mann -Whitney U test. 
EN: primary endocrine therapy. Scores 
Table 7 -11: Psychological scores for patients treated by primary cytotoxic 
and primary endocrine therapy 
7.3.3 Differences in psychological scores by treatment option 
Following the completion of all treatment, 30 patients given primary systemic treatment and 
27 patients treated conventionally returned completed questionnaires. To assess whether there 
were differences in psychological adjustment between the two groups, the scores for each of 
the seven psychological factors were compared. 
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7.3.3.1 Abnormal levels of anxiety and depression 
'Iherc was a single patient in the conventional arm of the study who had a pathologically 
raised level of anxiety. The same patient also had a depression score that was pathological. No 
patient given primary systemic treatment had a pathological level of depression or anxiety 
following the completion of all treatment. The difference between the two groups was not 
significant (p= 1.000, Fisher's exact test). 
7.3.3.2 Differences in scores between the two groups 
The mean, median and range of scores for each of the seven factors are presented in Table 7- 
12. Patients treated conventionally had a greater score for fighting spirit compared with those 
treated by primary systemic therapy (z =2.06, p= 0.038, Mann -Whitney U test), but they also 
had a tendency to be more anxiously preoccupied with cancer (z =1.91, p= 0.055, Mann - 
Whitney U test). Overall there were no differences between the two groups. 
CONV PST 
Factor (range) mean med range mean med range z= p= 
ANX. (0 -21) 5.0 4 0 -16 4.2 3 0 -9 -0.66 0.511 
DEP. (0 -21) 2.5 2 0 -11 2.1 2 0 -9 -0.65 0.516 
F.S. (16 -64) 55.7 56 47 -64 52.9 53 42 -62 -2.07 0.038 
H.H. (6 -24) 7.6 7 6 -12 8.3 7.5 6 -15 -0.49 0.626 
A.P. (9 -36) 22.0 23 14 -28 20.0 20 10 -26 -1.92 0.055 
FAT. (8 -32) 17.7 17 10 -30 17.4 17.5 8 -23 -0.05 0.962 
AVO. (1 -4) 2.0 2 1 -4 1.7 1.5 1 -4 -1.29 0.199 
Scores were compared using the Mann -Whitney U test. ANX: anxiety, DEP: Depression, F.S.: 
fighting spirit, 11.11.: Hopelessness/ Helplessness, A.P.: anxious preoccupation, FAT.: Fatalism, 
AVO.: Avoidance 
Table 7 -12: Psychological scores after the completion of all treatment for 
patients treated conventionally and by PST 
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7.3.4 Patient and tumour characteristics and psychological outcomes 
Ten patient and tumour characteristics (explanatory variables, section 7.2.4.2) were tested for 
their contribution to psychological outcome following the completion of all treatments. 711e 
results of univariale analysis are presented in Table 7 -13. 


















p= 0.09 0.03 -0.09 0.20 0.10 0.22 0.22 
P= 0.572 0.950 0.471 0.210 0.474 0.112 0.205 
Treatment option 
PST (n =30) 3 (0 -9) 2 (0 -9) 53(42 -46) 7.5(6 -15) 20(10 -26) 17(8 -23) 1.5 (1 -4) 
CONV (n =27) 4 (0 -16) 2 (0 -11) 56(47 -64) 7 (6 -12) 23(14 -28) 17(10 -30) 2(1 -4) 
P= 0.511 0.516 0.038 0.626 0.055 0.962 (1.199 
Mode of adjuvant treatment 
Chemo (n =30) 
Endo (n =27) 
P= 
3.5 (0 -9) 
4 (0 -16) 
0.703 
2 (0 -9) 

















Axillary lymph node status 
Pos (n =33) 3 (0 -9) 
Neg (n =24) 5 (2 -16) 
P= 0.372 
2 (0 -5) 

















Oestrogen receptor status 
Neg (n =29) 5 (0 -16) 2 (0-11) 53(42 -62) 8(6 -15) 22(10 -28) 17(8 -30) 2 (1 -4) 
Pos (n =28) 3 (0 -9) 1 (0 -5) 56(47 -64) 7(6 -10) 20(14 -28) 18(11 -24) 1.5 (I -4)' 
p= 0.071 0.342 0.051 0.284 0.532 0.516 0.035 
Breast reconstruction 
Done (n =13) 4 (0-9) 1 (0 -4) 53(47 -64) 8(6 -12) 22(10 -26) 18(14 -24) 2(1-3) 
None (n =44) 4 (1 -16) 2(0 -11) 56(42 -63) 7(6 -15) 21(14 -28) 17(8 -30) 2(1 -4) 
p= 0.817 0.250 0.276 0.623 0.647 0.032 0.960 
Social class 
Non -man (n =37) 5 (0 -16) 2 (0 -11) 53(47 -64) 7.5(6 -15) 22(10 -28) 18(8 -24) 2(I-4) 
Manual (n =20) 3 (1 -9) 2 (0 -9) 56(42 -63) 7 (6 -14) 21(14 -28) 17(10 -30) I (1-4) 
P= 0.519 0.683 0.239 0.523 0.687 0.250 0.063 
Partnership 
With (n =31) 3(0 -9) 1 (0 -5) 56(42 -64) 6 (6 -13) 22(10 -28) 16(10 -24) I (1-4) 
Not with (n =26) 5 (1 -16) 2 (0 -11) 52(47 -60) 8 (6 -15) 21(14 -28) 19(8 -30) 2 (1-4) 
p= 0.283 0.316 0.101 0.009 0.879 0.162 0.118 
Employment 
In work (n =26) 3 (0 -9) 2 (0-9) 56(48-62) 7(6 -14) 21(15 -28) 17(10 -30) 2(1 -4) 
Not (n =31) 4 (0 -16) 2 (0-1I) 53(42-64) 7 (6 -15) 22(10 -28) 19(8 -24) 1.5 (1 -3) 
p= 0.858 0794 0.221 0.503 0.541 0.096 0.448 
Age and tumour size were compared using Spearman Rank correlation coefficient. The remaining factors were 
compared using the Mann -Whitney U test. 
Table 7 -13: Relationship between patient and tumour factors and 
psychological outcomes 
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These findings and the results of multivariate analysis for each outcome arc detailed below. 
7.3.4.1 The HAD scale: Anxiety 
Patients with oestrogen receptor rich tumours had a tendency to report lower levels of anxiety 
compared with patients with oestrogen receptor poor tumours (z= -1.81, p= 0.071, Mann - 
Whitney U test), but there was no significant relationship between any of the explanatory 
variables and anxiety. No further significant contributors to anxiety were identified on 
multivariate analysis. 
7.3.4.2 The HAD scale: Depression 
There was no relationship between any of the explanatory variables considered and 
depression. 
7.3.4.3 The MAC scale: Fighting Spirit 
Patients treated conventionally reported significantly higher levels of fighting spirit compared 
with patients given primary systemic treatment (z= -2.07, p= 0.038, Mann -Whitney U test). 
There was also a greater degree of fighting spirit amongst oestrogen receptor positive patients 
(z= -1.95, p= 0.051, Mann -Whitney U test). 
Multivariate analysis confirmed that treatment option and oestrogen receptor status were 
highly significant independent predictors for the level of fighting spirit. In addition the choice 
to undergo breast reconstruction appeared to relate to higher levels of fighting spirit 
(p= 0.051). The best model was derived by including "partnership" as one of the explanatory 
variables. The details of the model are presented in Table 7 -14. 
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y= Fighting spirit Coefficient 95% C.I. z= 
Treatment option -1.32 -2.31 to -0.33 -2.61 
ER status 1.07 0.11 to 2.02 2.19 
Reconstruction 1.25 0.00 to 2.50 1.95 
Partnership 0.71 -0.22 to 1.65 1.50 







Ordered logistic multivariate regression model 
Table 7 -14: Contribution of patient and tumour factors to the level of 
"Fighting spirit ". 
7.3.4.4 The MAC scale: Hopelessness/ Helplessness 
Patients who were living with a partner displayed a significantly smaller level of hopelessness/ 
helplessness compared with patients not living with another adult (z= -2.61, p= 0.009, Mann - 
Whitney U test). On multivariate analysis, not having a partner remained the only significant 
independent factor associated with hopelessness/ helplessness. 
7.3.4.5 The MAC scale: Anxious Preoccupation 
There was a suggestion that conventionally treated patients may be more anxiously pre - 
occupied with their cancer compared with those patients treated by primary systemic therapy 
(z= -1.92, p= 0.055, Mann -Whitney U test). On multivariate analysis this relationship was 
maintained, but no new factors emerged as significant. va' 
7.3.4.6 The MAC scale: Fatalistic attitude 
There was a highly significant relationship between increasing age and increasingly fatalistic 
attitude (p=0.54, p= 0.0001, Spearman Rank correlation coefficient). Patients with the lowest 
levels of fatalism (less than the median), had a mean ±SEM age of 45.5 ±1.64, ten years 
younger than patients with the highest levels: 54.9 ±1.72 (t = -3.92 d.f. =55, p= 0.0002, Student's 
t- test). Furthermore, not opting for breast reconstruction appeared to be associated with 
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greater fatalism (z= -2.15, p =0.032, Mann -Whitney U test). There was also a suggestion that 
patients who were not working had a more fatalistic outlook. 
On multivariate analysis it became clear that breast reconstruction and employment were 
confounded by age, neither remaining significantly related to a fatalistic attitude. It however 
also emerged that once controlled for the effect of age, increasing tumour size was associated 
with an increasingly fatalistic attitude. The regression model is presented in Table 7 -15. 
y= Fatalistic attitude Coefficient 95% C.I. z= p= 
Age 0.12 0.07 to 0.18 4.37 <0.0001 
Tumour size 0.64 0.08 to 1.20 2.23 0.026 
Log likelihood = -105.6 y2= 24.57 <0.0001 
Ordered logistic multivariate regression model 
Table 7 -15: Contribution of patient and tumour factors to the level of 
"Fatalistic attitude" 
7.3.4.7 The MAC scale: Avoidance 
Oestrogen receptor positive patients were significantly less likely to respond by avoidance 
than were oestrogen receptor negative patients (z= -2.11, p= 0.035, Mann -Whitney U test). 
There was also a tendency for patients in the non -manual social class to show less avoidance 
behaviour. 
On multivariate analysis, oestrogen receptor status remained significantly associated with 
avoidance, and social class remained in the model. The best model in addition contained 
treatment option. The final model is presented in Table 7 -16. 
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y= Avoidance Coefficient 95% C.I. z= 
ER status -1.13 -2.16 to -0.09 -2.13 
Social class -0.918 -1.97 to 0.13 -1.72 
Treatment option -0.823 -1.84 to 0.20 -1.58 






Ordered logistic multivariate regression model 
Table 7 -16: Contribution of patient and tumour factors to the degree of 
"Avoidance" 
7.3.5 Relationship between psychological outcome and survival 
Each psychological outcome was dichotomised as described in section 7.2.4.3. Cox's 
regression was used to assess the contribution of each outcome measure to event free survival, 
distant disease free survival and overall survival. The results for event free survival are 
presented in Table 7-17. I Iigh levels of anxious preoccupation were associated with poorer 
event free survival. 
Univariate analysis of recurrence free survival 
Hazard ratio 95% C.I. z= P= 
ANX. 1.23 0.55- 2.73 0.50 0.616 
DEP. 1.24 0.55- 2.80 0.53 0.597 
F.S. 0.95 0.43 -2.12 -0.13 0.901 
H.H. 1.39 0.62 -3.10 0.80 0.424 
A.P. 2.38 1.02 -5.57 2.00 0.039 
FAT. 0.86 0.39 -1.92 -0.37 0.714 
AVO. 1.14 0.50 -2.56 0.31 0.757 
Table 7 -17: Event free survival by psychological scores 
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The results for distant disease free survival and overall breast cancer survival are presented in 
tables Table 7 -18 and Table 7 -19 respectively. 
Univariate analysis of distant disease free survival 











F.S. 1.04 0.46 -2.37 0.10 0.917 
H.H. 1.26 0.56 -2.87 0.56 0.574 
A.P. 2.19 0.92 -5.17 1.79 0.066 
FAT. 0.94 0.42 -2.14 -0.14 0.888 
AVO. 1.29 0.56 -2.98 0.60 0.548 
Table 7 -18: Distant disease free survival by psychological scores 
Univariate analysis of overall survival 











F.S. 1.22 0.52 -2.87 0.45 0.653 
H.H. 1.05 0.45 -2.48 0.91 0.911 
A.P. 2.23 0.90 -5.54 1.74 0.073 
FAT. 0.77 0.32 -1.84 -0.59 0.557 
AVO. 1.13 0.47 -2.69 0.27 0.789 
Table 7 -19: Overall survival by psychological scores 
Patients with high levels of anxious preoccupation were diagnosed with a breast cancer event 
(either local or distant recurrence) significantly earlier than patients with low levels of anxious 
preoccupation. The difference persisted for distant disease free and overall survival, although 
it did not reach significance at the 95% level. The Kaplan -Meier event free survival curves arc 
shown in Figure 7 -2 (Table 14 -22). Overall survival curves are shown in and Figure 7 -3 
(Table 14 -23). 
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Figure 7 -3: Overall survival by the level of anxious preoccupation 
Treatment option was the only factor which related to the level of anxious preoccupation. 
Anxious preoccupation was entered into a multivariate Cox's proportional hazard model, 
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along with treatment option, axillary nodal status and the natural logarithm of oestrogen 
receptor levels. "Anxious preoccupation" remained a significant predictor of event free 
survival even when corrected for other important prognostic indicators (Table 7 -20). 
Multivariate Cox's proportional hazard model 
Hazard ratio 95% C.I. z= p= 
Anxious preoccupation 2.37 1.00 -5.60 1.97 0.049 
In initial ER 0.60 0.42 -0.85 -2.87 0.004 
Axillary nodal status 7.90 2.57 -24.26 3.61 0.000 
Trial option 0.85 0.37 -1.95 -0.38 0.707 
Log likelihood = -78.7 X2 =22.68 0.0001 
Table 7 -20: Contribution of the level of anxious preoccupation in 
conjunction with relevant patient and tumour factors to event free survival 
The event free survival advantage of low anxious preoccupation when adjusted for other 
prognostic indicators was marginal. The Kaplan -Meier survival curves, adjusted as appears in 
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Figure 7 -4: Adjusted event free survival by level of anxious preoccupation 
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7.3.6 Quality adjusted survival analysis 
The duration of treatment for each arm of the study and details of disease free and recurrence 
free survival arc reported in chapter 4. 
The extreme measures of quality adjusted survival are reported for all patients taking part in 
the trial. Mean survival and 95% confidence intervals are summarised in Table 7 -21. There 
were no significant differences for phases of survival between patients treated by primary 
systemic and conventional therapy. 
All patients Conventional PST 
z= p= n=171 n=86 n=85 
mean 95% C.I. mean 95% C.I. mean 95% C.I. 
Overall survival 60 56 -64 58 52 -64 62 56 -68 -0.84 0.402 
Disease free survival 56 52 -60 55 48 -61 57 50 -63 -0.45 0.651 
Treatment free survival 55 51 -59 54 48 -60 55 50 -61 -0.22 0.823 
TWiST 51 46 -55 51 44 -57 50 44 -57 0.12 0.907 
Means compared using the "normal" test 
Table 7 -21: Quality adjusted survival analysis for all patients within the trial 
Two further extreme situations were also examined. The first was the situation in which 
primary systemic treatment was assumed to be so intolerable as to be comparable to death 
(utility coefficient of zero), while conventional therapy was assumed to have no impact on 
quality of life (utility coefficient of 1). Life after recurrence was assumed to have no impact 
on quality of life. This is equivalent to comparing treatment free survival for PST patients 
with overall survival for conventionally treated patients. Although the mean survival is smaller 
(55 vs. 60 months) this difference is not significant (z =0.73, p= 0.468). 
Since no significant difference could be demonstrated even in the extreme situations, no other 
utility coefficients were tested. 
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7.4 CONCLUSIONS AND DISCUSSION 
7.4.1 The conduct of the study 
This study employed two validated questionnaires for the semi -quantitative measurement of a 
limited number of factors relevant to overall psychological adjustment to cancer. Little is 
known abouttiatients' perceptions of primary systemic treatment as well as how such 
treatment influences the patients' daily activities, and these may form the basis for further 
study. The main area of concern for this study was major psychological morbidity and 
psychological adjustment; it did not aim to provide a comprehensive assessment of the 
patients' psychological well -being. Within these constraints, the study was able to uncover a 
number of findings which will be discussed below. 
7.4.1.1 The effects of patient non -participation 
Twelve of the 69 patients potentially eligible for the study did not participate. Five were 
excluded by design, but seven patients (10%), declined to take part. It is possible that this 
group of seven patients may have psychological reactions which were different from the 
cohort as a whole, as suggested by the fact they were also less likely to have opted for breast 
reconstruction. However their relatively small number, and the fact that they were equally 
distributed between the two treatment groups makes it unlikely that their exclusion would have 
introduced significant bias into the overall findings of the study. 
7.4.1.2 The significance of an "avoidance" response 
In the present study, an "avoidance" response directly correlated with other indicators of poor 
psychological adjustment. During the development of the MAC scale, denial was secn as a 
positive coping strategy (Watson et al: 1988; Nerenz et al: 1982) and, along with "fighting 
spirit ", was found to predict a positive survival outcome for patients with breast cancer (Greer 
el a!: 1990; Greer el al: 1979). Avoidance has in the past been regarded as one of the most 
common reactions to cancer (Shands et al: 1951; Peck: 1972), but there are conflicting 
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opinions on its role in psychological adjustment (Klein: 1971; Watson et al: 1984) . During its 
construction, the MAC scale retained only one item addressing the "avoidance" response. The 
reasons and possible significance of this were discussed in the original description of the scale 
(Watson et al: 1988). It was suggested then that the relative importance of "avoidance" as a 
response may be changing with changes in medical practice. 
Patients taking part in the present study were repeatedly reminded of their diagnosis and its 
implications. It is therefore possible that an avoidance response reflects general lack of 
psychological adjustment. Alternatively, this anomalous result may simply be the result of the 
inherent instability of using a single item to assess the avoidance response. 
7.4.2 Primary systemic treatment and psychological response 
7.4.2.1 Adjustment during and after primary systemic treatment 
Patients undergoing primary systemic treatment reported high levels of anxiety during therapy. 
High levels of anxiety have been reported for patients about to undergo surgery or awaiting 
other treatment (Miller et al: 1995). It was noteworthy that these levels appeared to remain 
relatively high throughout what was frequently a lengthy period of primary systemic therapy. 
Other psychological scores also remained at best unchanged. Indeed there was a suggestion 
that patients may become more anxiously preoccupied and more depressed as primary 
systemic treatment progressed. Levels of anxiety, anxious preoccupation, hopelessness and 
avoidance decreased following the completion of all treatment. The biggest reduction was in 
anxiety levels. This supports the contention that patients experienced poor psychological 
adjustment during primary systemic therapy. It is however likely that much of this is related to 
the fact that a significant proportion of these patients were actively receiving cytotoxic 
chemotherapy at the time of the second psychological assessment. Cytotoxic chemotherapy 
has been found to independently influence psychological adjustment (Hughson el al: 1986; 
Cooper et al: 1980; McArdlc et al: 1981; Maguire et al: 1980; Nerenz et al: 1982). In the 
present study, patients receiving primary cytotoxic chemotherapy became psychologically less 
well adjusted during primary systemic therapy as evidenced by increasing levels of depression, 
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anxious preoccupation and hopelessness/ helplessness. No such deterioration was observed 
amongst endocrine treated patients. 
Psychological adjustment for conventionally treated patients during adjuvant cytotoxic 
chemotherapy was not assessed in this study. It is therefore not possible to separate the 
contribution of the timing of treatment and the mode of treatment to the psychological 
maladjustment experienced by patients undergoing primary systemic therapy. 
7.4.2.2 The psychological effects of failure to respond 
The number of patients who failed to respond to primary systemic therapy was small, making 
it difficult to draw any firm conclusions about the influence of response on psychological well- 
being. There were however strong indications that lack of response was associated with 
worsening psychological scores. Most of the non -responding patients had increases in 
hopelessness, anxious preoccupation and fatalism, and had a significantly more fatalistic 
outlook compared with responding patients. 
7.4.2.3 Residual psychological morbidity following completion of all treatment 
Following the completion of all treatment, the relationship between treatment option and 
psychological outcome was examined using multivariate techniques. Even when corrected for 
other factors, patients given primary systemic treatment displayed less fighting spirit 
compared with conventionally treated patients although they were also less anxiously 
preoccupied. There were no other differences in psychological adjustment according to the 
treatment given. 
Although the main purpose of this part of the study was to assess differences in psychological 
morbidity between patients treated conventionally and those treated by primary systemic 
treatment, the multivariate techniques used revealed other factors which can influence 
psychological outcome. These arc discussed below. 
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7.4.3 Factors influencing psychological outcome 
Psychological outcome was found to be influenced by a number of patient and tumour factors. 
7.4.3.1 Patient factors 
From amongst the patient factors, having a partner was associated with less hopelessness/ 
helplessness and greater fighting spirit, while increasing patient age strongly related to a 
fatalistic attitude. 
7.4.3.2 The influence of oestrogen receptor status 
Patients with oestrogen receptor positive tumours were found to be psychologically better 
adjusted compared with patients who had oestrogen receptor poor tumours. Thus they were 
less anxious, had greater fighting spirit and less avoidance. 
While it is possible to explain the relationship between patient factors and psychological 
outcome on an intuitive basis, it is more difficult to find reasons for the connection between 
tumour oestrogen receptor level and psychological well -being. Such a relationship has been 
observed in one other study (Razavi et al: 1990), however other groups have failed to show 
any correlation between oestrogen receptor levels and psychological adjustment (Rosenyvist et 
al: 1993; Hislop and Kan: 1990; Maunsell et al: 1990). 
In the present study the information given to patients regarding the trial and its various options 
placed a great deal of emphasis on oestrogen receptor levels as a prognostic indicator, and as 
an important factor in deciding final treatment. During the post -mastectomy consultation, 
there was a tendency to present indicators of a good prognosis such as lack of axillary nodal 
involvement or higher oestrogen receptor levels enthusiastically as a piece of good news, while 
indicators of a poorer prognosis such as lack of oestrogen receptors were generally put 
forward as neutral news (neither good nor bad). The combination of preoperative emphasis on 
oestrogen receptors and postoperative presentation of results could have disproportionately 
influenced the patients' perception of their prognosis, and hence their overall degree of 
psychological adjustment. 
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7.4.4 Psychological adjustment and survival 
Disease free survival was longest for patients with the lowest levels of anxious preoccupation. 
This effect was independent of other important prognostic indicators such as oestrogen 
receptor status, tumour size or axillary nodes. Relationships between high levels of fighting 
spirit and avoidance and longer survival in early breast cancer have previously been reported 
(Greer et al: 1990; Greer el al: 1979). The levels of fighting spirit and avoidance had been 
determined using interviews which eventually formed the basis for the development of the 
MAC scale (Watson et al: 1988). Longer survival has also been reported for better adjusted 
patients with good social support in metastatic breast (Derogatis el a!: 1979) and lung cancer 
(Ganz el al: 1991). While it is possible that psychological adjustment may have a direct effect 
on outcome through various psychosomatic routes (Levy et al: 1987; Southam: 1969), the 
present result may be explained in at least two further possible ways: 
Firstly, psychological adjustment may be influenced by the information the patient has been 
given regarding prognosis. Thus poor psychological adjustment may simply reflect patients' 
awareness of their poor prognosis. 
Secondly, anxiously preoccupied patients may report symptoms of recurrence earlier than 
others, creating the impression of shorter disease free survival, without influencing the overall 
survival. 
Although the relationship between psychological adjustment, oestrogen receptors and survival 
is not directly relevant to the study of psychological morbidity in primary systemic treatment, 
it illustrates the importance of the way information exchange with the patient may influence 
final psychological outcome. This factor should be more directly taken into account in a 
future studies. 
7.4.5 Overall quality of life issues 
The present trial was aimed at comparing two treatment packages which are very different in 
ternis of the demands they palace on patients' time, requirements for attending hospital and the 
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types of treatment related toxicity expected. It is therefore essential that small differences in 
treatment outcome are carefully balanced against the possibility of poorer quality of life. 
The appraisal of quality of life comprises many issues of which psychiatric and emotional 
well -being are only one aspect. Quality of life assessment should also include measures of the 
patients level of physical capacity, the ability to maintain social and sexual functioning, and 
overall measures of well -being (Moinpour el al: 1989). Other measures relate to specific ways 
in which treatment interferes with quality of life such as treatment related toxicity, and the 
impact of treatment on patients' daily living (Cella and Tulsky: 1993; Love et al: 1989). 
A number of instruments have been developed specifically aimed at addressing overall quality 
of life issues in cancer patients (Ganz et al: 1992; Cella et al: 1993; Moinpour: 1994; Cella 
and Tulsky: 1990), and in particular in patients with breast cancer (Winer: 1994; Levine et al: 
1988). The proper application of these measures can often be difficult, and results depend 
very much on the participation of clinicians involved in all aspects of assessment, treatment 
and follow -up (Cella and Tulsky: 1990; Schipper: 1990; Hayden el al: 1993). It is 
nevertheless important that an integrated approach to measurement of quality of life is adopted 
in future trials of different forms of systemic therapy. 
7.4.6 Quality adjusted survival analysis 
Throughout the quality adjusted analysis, it was assumed that the time after completion of 
treatment and before development of recurrence has a utility value of "1 ". Significant 
psychological morbidity related to the diagnosis of malignancy may become apparent during 
this "TWiST" phase. This study did not find a difference in psychological adjustment 
following completion of all treatment. and the assumption that TWiST time can be assigned a 
relative utility of "1" for both arms of the trial can be upheld. 
There was no difference in quality adjusted measures of survival between the two arms of the 
study, even when the most extreme situations were examined. A difference against PST may 
have been expected because of the more prolonged treatment phase when primary systemic 
treatment was used. It is however possible that losses from more prolonged treatment are 
offset by minor gains in survival. 
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7.4.7 Overall conclusion 
Primary systemic treatment is acceptable as a mode of systemic therapy, and is not associated 
with lasting excess psychological morbidity. The greater length of the treatment phase does 
not adversely effect quality adjusted survival. 
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CHAPTER 8 
8. Surgical Morbidity 
and 
Primary Systemic Treatment 
8.1 INTRODUCTION 
Surgery forms an important part of many of the protocols for primary systemic treatment of 
breast cancer (Mauriac et al: 1991; Jacquillat et al: 1990; Forouhi and Chetty: 1991; Fisher 
and Wickerham: 1991; DeVita, Jr. 1990). The outcome of surgery following systemic therapy 
is examined in this chapter. 
8.1.1 Surgical morbidity associated with mastectomy 
8.1.1.1 Frequency of complications 
Modified radical mastectomy (Patey and Dyson: 1948) is the operation of choice for local 
treatment of larger breast cancers (Osborne and Borgen: 1990). Mastectomy is associated 
with significant surgical morbidity. While complications ranging from nerve injuries to air 
embolism are well recognised following mastectomy (Aitken and Minton: 1983), it is the local 
complications which are most frequent and result in the greatest morbidity ( Feigenberg et al: 
1977; Say and Donegan: 1974; Hayes and Bryan: 1984; Budd et al: 1978). The late 
complications of lymphoedema and shoulder dysfunction (Pollard et al: 1976; Dawson et al: 
1989; Petrek et al: 1990; Aitken and Minton: 1983) can often follow problems in the early 
postoperative period. Persistent seroma formation is the most frequently reported complication 
of the axillary component of the operation, being reported in 10 -50% of patients (Hayes and 
Bryan: 1984; Budd et al: 1978; Bryant and Baum: 1987; Tadych and Donegan: 1987). 
Although not a serious complication as such, seroma formation predisposes to infection 
(Hayes and Bryan: 1984), other flap complications (Aitken and Minton: 1983), and late 
lymphoedema ( Tadych and Donegan: 1987). The more serious complication of wound 
infection is reported in 8 -18% of patients (Aitken and Minton: 1983; Say and Donegan: 1974; 
Chen et al: 1991; Beatty et al: 1983; Budd et al: 1978), while flap necrosis happens in 3- 
10% of cases (Feigenberg et al: 1977; Say and Donegan: 1974; Hayes and Bryan: 1984; 
Budd et al: 1978). 
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8.1.1.2 Known risk factors for complications 
A number of patient factors can influence the rate of complications following surgery. Age is 
an important risk factor for seroma formation and wound infection (Tejler and Aspegren: 
1985; Say and Donegan: 1974; Vinton et al: 1990; Borup Christensen and Lundgren: 1989; 
Chen et al: 1991; Miller and Falcone: 1991). Obesity also predisposes to infections and skin 
necrosis (Tejler and Aspegren: 1985; Say and Donegan: 1974; Vinton et al: 1991; Hoefer, Jr. 
et al: 1990; Miller and Falcone: 1991), and the risks of skin necrosis is significantly increased 
in smokers (Miller et al: 1980; Craig and Rees: 1985; Rees et al: 1984). Number of involved 
lymph nodes appears to be the most important tumour factor in predisposing to complications 
(Say and Donegan: 1974; 1- loefer, Jr. et al: 1990; Bryant and Baum: 1987; Petrek ci al: 
1990). 
8.1.1.3 The effects of breast reconstruction 
Primary breast reconstruction following mastectomy helps with postoperative psychological 
adjustment and may be offered as an option to patients undergoing mastectomy (Dean el al: 
1983; Bostwick, III: 1990). Complications following primary reconstruction using implants, 
either with the tissue expansion technique (Radovan: 1984; Argenta: 1984; De Mey et al: 
1991) or with the latissimus dorsi myocutancous flap reconstruction technique (Biggs and 
Cronin: 1981; Schneider el a!: 1977), appear to be related to the mastectomy rather than to 
the reconstructive procedure as such (Vinton el al: 1990; Miller and Falcone: 1991). Risk 
factors for complications following mastectomy with primary breast reconstruction appear to 
be the same as for mastectomy alone (Vinton et al: 1991; Miller and Falcone: 1991). 
Prosthetic breast reconstruction however may be associated with a small excess of cases of 
complication, particularly in the 3 -6% of cases which result in implant loss (Miller and 
Falcone: 1991), and may therefore act as an additional risk factor for complications following 
mastectomy (Vinton et a!: 1991). 
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8.1.2 Systemic treatment and surgery 
8.1.2.1 Theoretical background 
During normal wound healing, the wound passes through the three phases of inflammation, 
proliferation and maturation (Thomas et al: 1995; Springfield: 1993; Hunt: 1990; Waldorf 
and Fewkcs: 1995). Systemic treatment particularly with cytotoxic agents can cause 
neutropcnia (Dionigi et al: 1980), interfere with cell proliferation and impair collagen 
synthesis (Ferguson: 1982) and can therefore potentially interfere with all three phases of 
wound healing (Springfield: 1993; Ehrlichman et al: 1991; Drake and Oishi: 1995). 
Experimental studies in animal models suggest that cytotoxic agents, given before or after 
surgery, have their maximum effect on the proliferative and the maturation phase of the 
healing process (Lawrence et al: 1986; Ferguson: 1982; Devereux et al: 1979), although 
increased susceptibility to infection is also an important factor (Dionigi et al: 1980; Drake and 
Oishi: 1995; Waldorf and Fcwkcs: 1995). 
8.1.2.2 Clinical effects in non -breast malignancy 
A number of studies have reported increased surgical complication rates in relation to cancer 
chemotherapy. Postoperative complications such as wound dehiscence and wound infections 
amongst a group of children receiving cytotoxic chemotherapy for a variety of cancers were 
three times more common if the children had been given initial systemic treatment 
(Angcrpointncr el al: 1989). In patients undergoing prosthetic reconstruction following limb 
salvage surgery for malignant or benign bone tumours, the risk of prosthetic infection and 
limb loss was greatest if surgery followed systemic therapy. Postoperative chemotherapy also 
increased the risk of surgical complications, although it did so to a much smaller extent 
(McDonald et al: 1990). Pneumonectomy following aggressive preoperative chemotherapy 
and radiotherapy is associated with very high levels of morbidity and mortality in lung cancer 
patients (Fowler et al: 1993). 
Not all studies have found primary systemic therapy to be detrimental. Early postoperative 
chemotherapy had no adverse effects on the surgical outcome following surgery for epithelial 
ovarian cancer. The down staging achieved with preoperative treatment improves the outcome 
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of operations for such tumours as oesophageal cancer (Le Prise et a!: 1994; Girvin et a!: 
1995; Schlag: 1991), hcpatocellular cancer (Lygidakis et al: 1995) and pancreatic carcinoma 
(Weese et al: 1990). In a series of patients with a variety of advanced malignancies, including 
breast cancer, major surgery within three weeks of cytotoxic chemotherapy was associated 
with relatively low rates of morbidity and mortality (Finn et al: 1980). 
8.1.2.3 Effects on operations for breast cancer 
Mastectomy in combination with peri- operative chemotherapy for operable breast cancer has 
been associated with increased surgical morbidity, and unexpected mortality in one study 
(Ludwig Breast Cancer Study Group: 1983), although most other studies addressing this 
question have not found any such increase. In a retrospective analysis of patients treated by 
mastectomy, pre or postoperative radiotherapy was found to be associated with a greatly 
increased incidence of wound complications, but no increase was detected with the use of 
perioperative thiotepa (Say and Donegan: 1974). In another randomised trial of perioperative 
versus postoperative chemotherapy, surgical morbidity was similar in the two arms (Sertoli et 
al: 1995). 
High rates of surgical complications have been reported with mastectomy following intensive 
primary chemotherapy for locally advanced breast cancer (Sauter et al: 1993), although 
wound infection or flap necrosis rates have been reported to be comparable with rates found in 
historical controls (Luboinski et al: 1991; Broadwatcr et al: 1991; Danforth, Jr. et al: 1990). 
Surgery following primary chemotherapy in these series was often less extensive than that 
performed in the historical control groups, and should therefore have been expected to be 
associated with lower rates of morbidity (Frank: 1992). 
8.1.3 Study objectives 
'Ihe objectives of this study were to investigate in a prospective randomised trial whether 
primary systemic treatment increased the morbidity associated with modified radical 
mastectomy, and to identify patient and tumour factors other than the mode of systemic 
therapy which may contribute to mastectomy related morbidity. 
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8.2 PATIENTS AND METHODS 
8.2.1 Patients 
All patients taking part in the main trial of primary systemic treatment versus conventional 
therapy were included in the study. Briefly these were women aged under 70 with operable, 
localised breast cancers more than 4 cm in maximum diameter. The criteria for inclusion in 
the study and randomisation procedures are detailed in section 3.2. 
8.2.2 Study design 
Patients were randomly allocated to one of the study options by the Scottish Cancer Trials 
Office and data were recorded prospectively, with prior knowledge of treatment options. 
8.2.2.1 Systemic treatment 
All patients were treated in accordance with the protocol detailed in section 3.3.1.2 and 
3.3.2.2. 
8.2.3 Surgical details 
8.2.3.1 The operation 
All patients underwent surgery in accordance with the trial protocol (sections 3.3.1.5 and 
3.3.2.1). General anaesthesia was used in all cases. Mastectomy with level III axillary 
clearance, with the division of the pectoralis minor muscle was carried out removing a 3 cm 
skin margin around the tumour. Where a tumour had regressed with therapy, its Fe-treatment 
size was used to plan skin margins. For larger tumours skin closure was achieved using a 
latissimus dorsi myocutancous flap (LD flap). Skin flaps where raised with the minimum use 
of diathermy. All wounds were irrigated with Ticept' (Scion Healthcare, Oldham, U.K.) 
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solution for 2 minutes prior to closure. Two closed suction drains were used for mastectomies 
and 4 for LD flaps. Skin closure was achieved using a continuous subcuticular technique, with 
an absorbable suture material. 
8.2.3.2 Breast reconstruction 
8.2.3.2.1 Latissimus dorsi myocutaneous flaps 
This procedure was selected if it was required for adequate skin closure. Where additional 
bulk was required to match the other breast, a silicone gel filled prosthesis (Nagor Ltd., P.O. 
Box 21, Douglas, Isle of Man, U.K.) was placed under the flap, superficial to the pectoralis 
major muscle. In practice all patients required a prosthesis and the majority of prosthesis were 
of the smooth type. 
8.2.3.2.2 Subpectoral tissue expansion technique 
This technique was used for all other patients who requested immediate breast reconstruction. 
A subpectoral pocket was created and a silicone tissue expansion device (Dow Corning 
Wright, 5677 Airline Road, Arlington, TN 38002) was placed in position. The injection port 
was located in an accessible position in the axillary space. 
8.2.3.3 Peri -operative precautions and postoperative care 
8.2.3.3.1 Antibiotic prophylaxis 
No antibiotics were used in patients undergoing mastectomy alone. Patients with breast 
implants were given prophylactic flucloxacillin and benzylpenicillin. Penicillin allergic 
patients were given erythromycin. Antibiotics were started at induction of anaesthesia and 
given intravenously for 48 hours postoperatively. Oral antibiotics were continued thereafter 
for a further 5 days, or until removal of all surgical drains, whichever was later. 
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8.2.3.3.2 Prophylaxis against deep venous thrombosis 
All patients wore anti -embolism stockings throughout the perioperative period. Subcutaneous 
heparin was started an hour before surgery and continued at a dose of 5000 units twice daily 
until the patient was fully mobile. 
8.2.3.4 Postoperative care 
Each suction drainage tube was removed when it drained less than 30 mis of fluid in a 24 
hour period. Patients were mobilised on the first postoperative day. Shoulder physiotherapy 
was started on the second postoperative day and maintained until discharge. Patients who 
made an uncomplicated recovery were discharged one day after the removal of their last 
surgical drain. The timing of discharge in other patients was dictated by the severity of their 
complications. 
8.2.3.5 Surgical follow -up 
Inpatients were examined daily and were reviewed one week after discharge. Patients with 
complications requiring outpatient treatment were seen weekly until recovery. Thereafter 
patients were discharged to long term follow -up, where they were seen within six weeks. 
8.2.4 The recording of surgical complications 
8.2.4.1 Wound complications 
Wound complications were divided into minor and major categories. A further category of 
any complication was created by combining the minor and major categories. Each 
complication was recorded as either "absent" or "present'. Complications were defined as 
follows: 
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8.2.4.1.1 Minor complications 
8.2.4.1.1.1 Minor seroma 
Any wound collection requiring drainage to relieve discomfort. 
8.2.4.1.1.2 Minor infection 
Wound erythema in the absence of an implant, associated with pyrexia less than 38 °C and 
treated by oral antibiotics only, whether or not positive on culture. 
8.2.4.1.1.3 Minor wound edge necrosis 
Superficial sloughing of edges of the mastectomy or LD flaps, or full thickness necrosis 
involving an arca no greater than 1 cm in diameter, and requiring outpatient dressings only. 
8.2.4.1.2 Major complications 
8.2.4.1.2.1 Major wound collection 
Any wound collection requiring open drainage. 
8.2.4.1.2.2 Major infection 
Any wound infection with positive bacteriology on culture and requiring intravenous 
antibiotics, or open surgical drainage or removal of an implant. 
8.2.4.1.2.3 Major flap necrosis 
Any area of full thickness necrosis of mastectomy or LD flap requiring surgical excision or 
removal of an implant. 
8.2.4.2 Systemic complications 
Any deep venous thrombosis or pulmonary embolism proven radiologically, and any chest 
infection proven on positive sputum culture were recorded. 
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8.2.4.3 Delayed complications 
Since the aim of the study was to assess immediate operative complications, the late 
complications of mastectomy including lymphocdema and shoulder immobility were not 
included in the assessment. Any late complications relating to a tissue expander device or its 
subsequent replacement with a permanent prosthesis were also omitted. 
8.2.5 Analytical methods 
All statistical analyses were performed using the statistical software package Stata 4.0 for 
Windows, Stata Corporation, 702 University Drive East, College Station, Texas 77840 USA. 
The results were analysed on the basis of actual treatments received. Primary systemic 
treatment was treated as the "treatment" group and conventional therapy as the "control" 
group. 
8.2.5.1 Direct comparisons 
The odds ratio. 95% confidence intervals, and the significance for the difference in the 
proportion of patients in each treatment category with or without a complication were 
calculated for each complication category using exact statistical methods. 
8.2.5.2 Relationship between patient and tumour factors and complications 
The relationships between patient and tumour characteristics (explanatory variables) and 
complications (outcome variables) wereissessed using univariate and multivariate techniques. 
For the first analysis all patients werrre considered together and "mode of treatment" was 
regarded as an explanatory variable. An additional analysis was performed only on the 
"study" patients when the variable "adjuvant therapy: cytotoxic or endocrine" was substituted 
for the variable "mode of treatment ". 
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8.2.5.2.1 Variables examined 
8.2.5.2.1.1 Explanatory variables 
The following categorical explanatory variables were examined: 
I a. Mode of treatment: conventional or primary systemic treatment 
lb. Adjuvant therapy: Cytotoxic or endocrine (study patients only) 
2. Breast reconstruction: Performed and not performed 
3. Smoking habit: Smoker or non -smoker 
Patients were defined as non -smokers if they had not smoked for 3 months or more before 
entering the study. 
The following continuous explanatory variables were examined: 
1. Age 
2. Tumour diameter at diagnosis 
3. The number of involved 
4. Body mass index (weight in kilos / the square of height in meters) 
8.2.5.2.1.2 Outcome variables 
Three outcome variables were independently examined as follows: 
1. Any seroma 
2. Any infection 
3. Any necrosis 
8.2.5.2.2 Statistical methods 
8.2.5.2.2.1 Univariate techniques 
Where the explanatory variables were dichotomous the proportions of patients with or without 
complications were compared using exact statistical methods. Where the explanatory variable 
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was continuous (e.g.: age), the difference between the explanatory variable for the group with 
or without complications was examined using the Mann -Whitney U test. 
8.2.5.2.2.2 Multivariate techniques 
Because of the relatively small number of cases involved, clinically important degrees of 
confounding may have gone unnoticed in univariate analysis. The relationship between 
explanatory and outcome variables was therefore further examined using logistic regression. 
All 8 explanatory variables were tested starting with variables with the greatest degree of 
significance on univariate analysis. Those variables which contributed to the regression model 
with a probability of <0.15 were retained. 
8.2.5.3 Hospital stay and outpatient treatment 
The date of admission, discharge and final discharge from outpatient follow -up were recorded 
for all patients. Total inpatient stay was calculated from the dates of admission and discharge. 
Total duration of surgical treatment was calculated from the date of first admission to hospital 
to the date of final surgical discharge. 
Inpatient hospital stay and the duration of treatment were compared between the primary 
systemic treatment group and the conventionally treated group using the log -rank test. 




Seventy nine eligible patients were randomised into the study. The details of the patients are 
presented in section 4.1.2.1. Thirty nine patients were randomised to conventional therapy and 
40 to primary systemic treatment. There were four protocol violations. One patient from the 
conventional arm was treated by primary systemic therapy, and 3 patients randomised to the 
study arm received conventional therapy. None of these four patients suffered any surgical 
complications. Thirty eight patients were treated by primary systemic treatment and 41 
patients by conventional therapy. 
Conventional P.S.T. Statistic p value 
Number of patients 41 38 
Adjuvant Treatment 
Cytotoxic therapy 24 
Endocrine therapy 14 
Breast reconstruction 
Tissue expander 11 16 
LD Flap 15 11 Exact 0.485 
None 15 11 
Smoking habit 
Smokers 16 12 
Non -smokers 25 26 Exact 0.638 
Age [mean (range)] 52 (31 -69) 51 (33 -69) t =0.48 0.633 
Tumour diameter [Median (range)] 4.6 (3.9 -8.5) 4.5 (4.1 -7.9) z=- 0.77 0.444 
Nodes involved [median (range)] 1 (0 -23) 1 (0 -13) z = -1.2 0.231 
Body mass index [median (range)] 25.0 (19.6 -42.5) 26.1 (19.6 -41.4) z =1.05 0.294 
Unless otherwise stated, number of patients in each category are reported 
Table 8 -1: Patient and tumour characteristics. 
8.3.1.2 Patient characteristics 
The full details of the patients and their treatments are summarised in sections 4.1.2.1 and 
4.1.3.4. 
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The distribution of patient and tumour characteristics relevant to this part of the study are 
summarised in Table 8 -1. There were no significant differences between the two groups. 
8.3.2 Complications and mode of treatment 
8.3.2.1 Wound complications 
Seventeen conventionally treated patients developed a total of 14 minor and 6 major 
complications. Fourteen patients given primary systemic treatment developed 11 minor and 6 
major complications (Table 8 -2). There were no significant differences between the number of 
complications in patients treated by primary systemic treatment and those treated 
conventionally. Seroma was the most frequent minor complication, affecting 11 patients 
treated conventionally and 7 patients treated by primary systemic treatment. The most 
frequent major complication was wound infection, affecting 3 conventional and 4 primary 
systemic therapy patients. 
Complication Conventional P.S.T. Odds ratio 95% CI Exact p= 
Total number 41 38 
Seroma 
minor 11 7 0.62 0.21 -1.80 0.429 
major 2 1 0.53 0.05 -6.06 1.000 
all 13 8 0.57 0.21- 1.59 0.318 
Infection 
minor 1 4 4.71 0.50 -44.1 0.19 
major 3 4 1.49 0.31 -7.14 0.705 
all 4 8 2.47 0.68 -8.90 0.215 
Necrosis 
minor 3 1 0.34 0.03 -3.44 0.616 
major 2 2 1.08 0.14 -8.10 1.000 
all 5 3 0.62 014 -2.78 0.713 
All minors 14 11 0.79 0.30 -2.04 0.638 
All majors 6 6 1.09 0.32 -3.74 1.000 
All complications 17 14 0.82 0.33 -2.04 0.818 
Numbers of patients in each category are reported 
Table 8 -2: Number of complications according to the mode of treatment 
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8.3.2.2 Hospital stay and outpatient treatment 
The duration of hospital stay and the total length of surgical treatments are summarised in 
Table 8 -3. There were no significant differences between conventionally treated patients and 
those given primary systemic treatment. 
Median (range) 
Days of hospital stay 
Days of surgical treatment 
Conventional 










Table 8 -3: Hospital stay and duration of surgical treatment 
8.3.3 Patient and tumour factors and complications 




The relationship between the patient and tumour factors and each of the outcome variables is 
presented in Table 8 -4. These are further discussed below. 
Total Number Number Number 
number given of with 











Statistic Exact Exact Exact t -test M -W U M -W U M -W U 
Seroma 
present 21 8 7 10 55 4.5 1 25.5 
Absent 58 30 21 43 48 4.5 0.5 25.8 
p value 0.32 1.00 0.03 0.05 0.79 0.64 0.71 
Infection 
present 12 8 3 7 52.5 4.9 1.5 27.8 
Absent 67 30 25 46 50 4.5 1 25.4 
p value 0.22 0.52 0.52 0.71 0.37 0.45 0.03 
Necrosis 
present 8 3 2 4 50 4.9 0 32.8 
Absent 71 35 26 49 50 4.5 1 25.4 
p value 0.71 0.71 0.43 0.87 0.28 0.24 0.0003 
Number in each category are reported. recon: reconstruction. 13M1: Body Mass Index. Exact: Fisher's 
exact test. M -W U: Mann -Whitney U test. 
Table 8 -4: The association between patient and tumour factors and 
development of complications for the entire group of patients 
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8.3.3.1.1 Seroma 
On univariate analysis, seroma formation appeared to be more common with older age (odds 
ratio 1.05, 95% CI: 1.00 -1.10) and in the absence of a breast reconstruction (odds ratio 0.32, 
95% CI: 0.11- 0.90). 
A logistic regression model containing these two variables was of borderline significance, with 
neither variable achieving statistical significance on their own (Table 8 -5). 
y= Seroma Odds ratio 95% Cl z= p value 
Age 1.02 
Reconstruction 0.42 
0.96 to 1.08 





Log likelihood= -43.1 x2 =5.23 0.073 
Mullivariale logistic regression model 
Table 8 -5: The relationship between seroma formation and age and breast 
reconstruction. 
8.3.3.1.2 Infection 
On univariate analysis, patients with larger body mass indices were at greater risk of 
developing wound infection (odds ratio: 1.15, 95% C.I.: 1.03 to 1.30). The association with 
body mass index was maintained on multivariate analysis, and no other significant factors 
emerged. 
8.3.3.1.3 Necrosis 
On univariate analysis, patients with larger body mass indices were at greater risk of 
developing skin edge necrosis. This association was highly significant (odds ratio: 1.32, 95% 
C.i.: 1.13 to 1.55). The strong association with body mass index was maintained on 
multivariate analysis, and no other significant factors emerged. 
8.3.3.2 Primary systemic treatment only 
The relationship between the patient and tumour factors and each of the outcome variables is 
presented in Table 8 -6. The mode of adjuvant treatment was not significantly associated with 
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any of the complications. The pattern of association between complications and patient and 























Statistic Exact Exact Exact t -test M -W U M -W U M -W U 
Seroma 
present 8 4 2 4 57.5 4.5 1.5 26.3 
Absent 30 10 10 23 47 4.5 0 26.1 
p value 0.43 1.00 0.20 0.01 0.87 0.57 0.28 
Infection 
present 8 4 2 4 54 4.7 1 30.6 
Absent 30 10 10 23 48 4.5 0.5 25.6 
p value 0.43 1.00 0.20 0.51 0.82 0.84 0.003 
Necrosis 
present 3 2 1 1 50 5.1 0 37.1 
Absent 35 12 11 26 48 4.4 1 25.9 
p value 0.54 1.00 0.20 0.45 0.18 0.67 0.017 
Number in each category are reported. recon: reconstruction, BMI: Body Mass Index. Exact: Fisher's 
exact test. M -W U: Mann -Whitney U test. 
Table 8 -6: The association between patient and tumour factors and 
development of complications for patients given primary systemic treatment 
8.3.3.2.1 Seroma 
Older age was associated with seroma formation in the PST group (odds ratio: 1.12, 95% 
C.I.: 1.02 to 1.24). In this subset the effect of age was independent of breast reconstruction, 
and age remained the only significant predictor of seroma formation on multivariate analysis. 
8.3.3.2.2 Infection 
Larger BMI was the only significant risk factor for wound infections (odds ratio: 1.30, 95% 
C.I.: 1.07 to 1.56). 
8.3.3.2.3 Necrosis 
Large BMI was a risk factor for wound age necrosis (odds ratio: 1.31, 95% C.1.: 1.04 to 
1.65). There were no other significant associations on uni- or multivariate analysis. 
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8.4 CONCLUSIONS AND DISCUSSION 
8.4.1 Complication rates 
The overall incidence of surgical complications in this group of patients was 39 %. Most 
complications were minor and self limiting. Clinically important complications occurred in 
15% of patients, a finding similar to other observations (Feigenberg et al: 1977; Vinton et al: 
1991; Say and Donegan: 1974; Hocfer, Jr. et al: 1990; Budd et al: 1978). 
8.4.2 Differences between study and control arms 
This randomised trial found no difference in the rate of complications following mastectomy 
whether this was performed as initial treatment or followed a period of systemic therapy. 
These results are consistent with those from previous uncontrolled series. No excess 
complications were found in 54 patients undergoing mastectomy following aggressive 
chemotherapy for locally advanced breast cancer (Danforth, Jr. et al: 1990). Complication 
rates Billowing chemotherapy for large operable breast tumours in a further 106 patients were 
similar to those for a group of 95 matched controls (Broadwater et al: 1991). Wound healing 
following biopsy in the irradiated breast was not found to be adversely influenced by cytotoxic 
chemotherapy prior to surgery (Pezner et al: 1992). Primary chemotherapy did not influence 
prosthetic infection rates in 17 patients following breast reconstruction (Hoffman et al: 1991), 
nor did it influence complication rates or cosmetic outcome in 207 patients being treated by 
breast conservation (Engel et al: 1991). 
8.4.3 The influence of patient and tumour factors 
Whether patients treated by primary systemic therapy had received cytotoxic treatment or 
endocrine treatment only did not influence their surgical outcome. 
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Older patients had a greater risk of forming a seroma, particularly following primary systemic 
therapy. The influence of breast reconstruction on seroma formation rates is not clear. 
Younger patients more frequently had breast reconstruction (section 8.3.1.2), and this may 
partly be responsible for the apparent fewer seromas seen in the presence of reconstruction. 
The most striking finding was the strong influence of obesity on the risk of post -mastectomy 
wound complications, and in particular wound infection and wound necrosis. This is 
consistent with the findings from other studies (Aitken and Minton: 1983; Vinton et al: 1991; 
Vinton et al: 1990) and may be related to larger breast size (Pezner et al: 1992). 
8.4.4 Overall conclusion 
This study adds to the overall weight of evidence that primary systemic therapy does not 
adversely influence the outcome of surgery for breast cancer. 






9. Tumour Markers and 
Tumour Monitoring 
9.1 INTRODUCTION 
Cancer cells, by reason of their abnormal differentiation can produce and secrete molecules 
normally not found in significant quantities in the body. When these molecules arc detectable 
in the circulation they have the potential to be used as serological tumour markers (Jacobs and 
Haskell: 1991). Monitoring serum levels of such markers can potentially complement tumour 
size measurement in monitoring response to primary systemic treatment. 
9.1.1 Tumour markers in breast cancer 
Onco -foetal proteins, cytokeratins and acute phase proteins are released in a number of 
malignancies, and have all been used as markers of breast cancer (Rustin and Bagshawc: 
1987; Tjandra and McKenzie: 1988). By their nature however they are non -specific , and have 
the added disadvantage of being expressed in a relatively small proportion of cancers (van 
Dalen: 1989). 
Monoclonal antibodies raised against normal and neoplastic tissue components have been 
extensively investigated as the basis for various assays for breast cancer specific tumour 
markers ( Tjandra and McKenzie: 1988). While marker assays aimed at oncogene products 
and other cancer specific molecules are in the early stages of development (Mayes: 1993), one 
antigen, the Polymorphic Epithelial Mucin (PEM) antigen (Gendler et al: 1990) or Episialin 
(Ligtenbcrg et al: 1990), has formed the basis for some of the most extensively studied marker 
assays in breast cancer. 
9.1.2 The Polymorphic Epithelial Mucin antigen 
9.1.2.1 Suitability as a tumour marker 
Normal and malignant breast epithelial cells express a high molecular weight glycoprotein on 
the luminal side of their apical surface, which is also released on human milk fat globule 
membranes (Taylor -Papadimitriou et al: 1981; Arklie et al: 1981; Ceriani el al: 1977; 
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Hilkens et al: 1981; Ceriani et al: 1982; Peterson et al: 1978). Although the molecule can 
also be detected on non -mammary epithelium, transplanted breast tumours release high 
quantities of this molecule into the circulation (Ceriani et al: 1977), much more than other 
epithelial malignancies investigated in the same way (Sasaki et al: 1981). 
The glycoprotein is a differentiation antigen (Lundy et al: 1985), present on both normal and 
malignant cells. The protein core of the molecule contains a region coded for by a tandem 
repeated DNA sequence. (Swallow et al: 1987; Siddiqui el al: 1988). This sequence codes for 
a 20 amino acid region, and the molecule's polymorphism is attributable to the different 
number of repeats of this sequence which can range anywhere between 21 and 125 times 
( Gendler et al: 1990). The glycoprotein produced by cancer cells shows an aberrant pattern of 
glycosylation (Burchell et al: 1987). The carbohydrate side chains in the aberrantly 
glycosylated molecule are shorter than normal, allowing the highly immunogenic core protein 
chain to become available for antibody action (Burchell et al: 1989). This combination of 
factors has made this molecule a target for the development of monoclonal antibody based 
tumour marker assays. 
Human milk fat globulins, and membrane preparations from cultured human breast carcinoma 
cells or human metastatic carcinoma deposits have been used by different groups to produce a 
number of monoclonal antibodies against different epitopes of the glycoprotein antigen, 
(Ashall et al: 1982; Cordell et al: 1985; Kcnemans et al: 1988; Burchell et al: 1984; Taylor - 
Papadimitriou et al: 1981; Kufe et al: 1984; Hilkens et al: 1984; Hilkens et al: 1981; Xing et 
al: 1989; Tjandra et al: 1988; Stacker et al: 1985). The cloning of the DNA sequence for the 
core protein by different groups (Gendler et al: 1990; Ligtenberg et al: 1990), has now 
confirmed that these antibodies do indeed act on different epitopes of the same antigen. 
Nevertheless many of the assays developed to detect the antigen have been traditionally 
investigated as though they detect distinct molecules, and depending on the antibody they use, 
have been designated as distinct "tumour markers ". 
Two tumour marker, CA 15 -3, and an IIMFG2 (human Milk Fat Globule antigen) were 
selected for use in this study. 
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9.1.3 The CA 15 -3 tumour marker 
9.1.3.1 Characteristics 
CA 15 -3 is recognised in a sandwich type immunoradiometric assay, using two different 
monoclonal antibodies,DF3 and 115D8, for its primary and tracer molecules. The DF3 
antibody was generated against the membrane enriched fraction of a human metastatic 
carcinoma (Scholm et al: 1984; Kufe et al: 1984), and the 115D8 antibody was raised against 
human milk fat globules (Hilkens et al: 1984a; Hilkens et a/: 1981a). Both antibodies can be 
used to independently demonstrate their target antigen in the sera of breast cancer patients 
(Hilkens et al: 1984b; Hayes et a/: 1985b). The combined assay (Tobias et al: 1985) has 
been commercially available in kit forni (CIS International, Paris) since the mid 1980's and 
has been extensively investigated in the diagnosis and follow -up of breast cancer patients. 
9.1.3.1.1 Expression in the normal population and patients with benign disease 
As with any biochemical assay, the baseline expression of CA 15 -3 is likely to vary between 
different populations, and ideally each laboratory will establish its own reference values. In 
practice however, the baseline values obtained in European populations are fairly similar. 
A number of groups have reported CA 15 -3 value for healthy blood donors, and patients with 
benign disease. Although the distribution of CA 15 -3 is skewed (Colomer et al: 1989a), most 
reports present the data as mean and standard deviation (S.D.) for the population studied. The 
normal values from different reports are summarised in Table 9 -1. The largest study of 
normal values was a Spanish study (Colomer et al: 1989a), which reported normal values for 
275 healthy blood donors and 1220 patients with a variety of non -malignant, non -breast 
related conditions. Based on this study 95% of normal individuals or patients with benign 
disease will have a CA 15 -3 value less than 37 U /ml (mean + 2S.D.). The next largest study, a 
Japanese study of 462 normal individuals found a much lower 95% cut -off level of 19 U /ml 
(Fujino et al: 1986). Because of the difference in patterns of breast disease amongst the 
Japanese, this cut -off may not however be applicable to European populations. Three further 
major studies from Italy, France and Ireland, looking at healthy individuals, reported 95% cut- 
off levels of 25 (Gion el al: 1991), 24, (Pons- Anicet et al: 1987) and 27 U /ml (O'Hanlon et 
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al: 1995a) respectively, while a variety of other values ranging from 15 to 44 U /ml were 
reported by other smaller studies in Caucasian women (Table 9 -1). A number of other studies 
have reported normal values based on median CA 15 -3 levels (Kallioniemi et al: 1988; Hayes 
et al: 1986; Safi et al: 1991). The largest of these contained 1050 patients and recommended 
a cut off of 30 U /ml (Hayes et al: 1986). 
Reference Country Sample type n= mean S.D. Mean 
of origin +2S.D. 
(Colomer et al: 1989a) Spain Benign 
disease 
1220 16 10.5 37 
Normal 275 16.5 9.4 35 
(Fujino et al: 1986) Japan Normal 462 10.3 4.3 19 
(Gion et al: 1991) Italy Normal 193 14.0 5.6 25 
(Pons-Anicet et al: 1987) France Normal 100 13.7 5.2 24 
(O'Hanlon et al: 1995a) Ireland Benign 
disease 
73 16,8 5.1 27 
(Eskelinen et al: 1988) Finland Benign 
disease 
52 13.7 7.2 28 
(Sacks et al: 1987) Australia Normal 30 18.0 4.9 28 
Benign 
disease 
13 12.0 1.4 15 
(Barak et a/: 1988) Israel Normal 22 16.6 6.5 40 




10 21.0 11.5 44 
Table 9 -1: Studies stating mean and standard deviations (S.D.) for CA 15 -3 
levels measured in normal individuals, or patients with non -malignant 
conditions. 
9.1.3.2 CA 15 -3 in patients with breast cancer 
9.1.3.2.1 Metastatic disease 
The levels of CA 15 -3 generally appear to reflect tumour burden in breast cancer. The highest 
values arc reported amongst patient with distant metastatic disease (Colomer et al: 1986; 
Tumour markers: introduction 9 -230 
Colomer et al: 1989; Fujino el al: 1986; Barak el al: 1988; Kcrin et al: 1989; Zanco et al: 
1989; Steger et al: 1989). In one study total body tumour burden was estimated by defining 
the sites of tumour metastases, and CA 15 -3 values were shown to correlate with the 
estimated tumour burden (Colomer et al: 1989b). CA 15 -3 has been used, often in conjunction 
with other markers, for follow -up of disease free breast cancer patients and has been shown to 
be successful in the detection of metastatic disease before it is clinically apparent (Geraghty et 
al: 1992; Viscera et al: 1994; Colomer et al: 1989; Martoni et al: 1988; Zanco et al: 1989). 
9.1.3.2.2 Localised breast cancer 
Elevated marker levels have been reported for all stages of disease in patients with non - 
metastatic breast cancer. In these patients CA 15 -3 values correlate with tumour diameter 
(Gion et al: 1991; Pons -Anicet et al: 1987; O'Hanlon et al: 1995) and extent of nodal 
involvement (O'1 'anion et al: 1995a; Pons -Anicet et al: 1987a; Gion et al: 1991a) and 
average marker levels increase with increasing stage of the disease ( O'Hanlon et al: 1995b; 
O'Hanlon et al: 1995b; Horobin et al: 1991b; Gion et al: 1991b). 
Most patients with early cancers [stage I and II (Beahrs et al: 1988)], have CA 15 -3 levels 
which arc comparable to the normal population, but even in earliest stages of the disease 10- 
20 %, of patients show marker levels above the normal range (O'Hanlon et al: 1995a; Horobin 
et al: 1991a; Kallioniemi et al: 1988a; Gion et al: 1991a). Furthermore, even when marker 
levels are within the normal range, drops in marker levels can be detected following removal 
of the primary cancer (O'l Ianlon et al: 1995a; Omar et al: 1989a; Eskelinen et al: 1989a). 
9.1.3.2.3 Response assessment 
Several studies have evaluated the role of CA 15 -3 in the assessment of response following 
systemic therapy for metastatic cancer. It is clear that the changes in marker levels correlate 
with tumour response (Colomer et al: 1986; Barak et al: 1988). Paradoxical responses 
however can be seen in individual patients with rises in marker level following successful 
initial induction, and rapid initial falls in patients who fail to respond (Kiang et al: 1990). 
CA 15 -3 has not been previously evaluated for the assessment of response to primary systemic 
treatment in either locally advanced, or operable breast cancer. 
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superior, although in some cases the combined assay enhances the overall sensitivity 
(Biegimayer ei al: 1988; Rasoul -Rockenschaub ei al: 1989). 
In the present study CA 15 -3 and HMFG2 were studied simultaneously. 
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9.2 PATIENTS AND METHODS 
9.2.1 Patients 
9.2.1.1 Samples during primary systemic treatment 
Sequential samples were obtained from two groups of patients. The first group were a subset 
of patients from those undergoing primary systemic therapy. Serum samples were obtained 
before the start of treatment, at three weekly intervals during the period of primary systemic 
treatment, immediately prior to mastectomy and at least 4 weeks after the date of the 
mastectomy. Tumour volume was measured clinically and by ultrasound (section 10.2.1.2.3) 
each time a scrum samples were obtained. 
The second group included patients undergoing primary cytotoxic chemotherapy for locally 
advanced non -metastatic breast cancer (T4, N0 -2, Mo). Samples were obtained before the start 
of chemotherapy and at completion of chemotherapy prior to start of locoregional treatment. 
9.2.1.2 Pre and postoperative samples 
These were available for patients undergoing primary systemic treatment within the trial, and 
additionally in a subgroup of patients treated in the conventional treatment arm of the trial. 
Further pre and postoperative samples were obtained from patients who were suitable for 
entry to the trial, but had declined to be randomised. 
9.2.2 Assay techniques 
Serum samples were separated from 10 mis of clotted blood and stored at -70 °C until 
analysis. All samples were analysed simultaneously. 
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9.2.2.1 The CA 15 -3 Assay 
9.2.2.1.1 Description 
The CA 15 -3 antigen was measured using the commercially available kit by CIS bio 
international, France (ref: ELSA -CA 15 -3). 
The assay is a solid phase two site immunoradiometric assay. The CA 15 -3 antigen is 
"sandwiched" between two monoclonal antibodies raised against sterically remote sites on the 
antigen molecule. 
'The monoclonal antibody 115 Dfi, raised against human milk fat globule membranes (JJilkens 
et al: I981) is used as the primary antibody. The tracer antibody is the monoclonal antibody 
DF3 (Kure ('i al: 1984), labelled with 125I. 
9.2.2.1.2 Kit components 
I . plastic assay tubes pre- coated on their base with an excess amount of 1 1 5 1)8 monoclonal 
antibody. 
2. Tracer reagent containing 1251 labelled DF3 monoclonal antibody in buffer with protein 
and preservative. 
3. Standard solutions of cell culture derived CA 15 -3 in buffer, protein and preservative 
provided in ready -to -use dilutions of zero, 15, 40, 80, 140 and 240 arbitrary units per 
millilitre (U /ml). 
4. Control solution at a concentration of 30 U /ml in protein matrix with preservative. 
5. Diluent containing buffer, protein and preservative for use with patient sera. 
9.2.2.1.3 Assay procedure 
All materials were handled using no -touch techniques and standard rules of radiation safety 
were observed throughout. 
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Standard sample and control were assayed in triplicate, while patient samples were assayed in 
duplicates. All patient samples were assayed at the same time. 
20p1 of patient sera or control serum were added to l ml of diluent in a disposable polystyrene 
tube (Falcon U.K.) and mixed over a vortex mixer. 300,e1 of diluted samples, and 300,/el of 
pre- diluted standard sera were added to appropriately labelled assay tubes coated with the 
primary antibody and mixed over a vortex mixer. Tubes were incubated for 1 hour at room 
temperature in a shaking incubator (Dynatcch). At the end of the incubation period, the 
contents of the tube were aspirated to dryness and the tubes washed three times by adding 3 
mis of distilled water to the tube on each occasion mixing and then discarding the water. 
300íe1 of the solution containing tracer antibody was next added to each tube and the tubes 
incubated for a further hour at room temperature in a shaking incubator. On completion of the 
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Figure 9 -1: Standard curve used to calculate CA 15 -3 concentrations 
(mean ±2SE) 
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The tubes were placed in a gamma scintillation counter and activity counted for 60 seconds. 
Background gamma activity was subtracted to obtain the gamma activity for each tube. A 
standard curve was constructed using the values obtained from the standard dilutions (Figure 
9 -1), and the CA 15 -3 concentration for each sample calculated from the standard curve. 
9.2.2.2 The HMFG2 Assay 
9.2.2.2.1 Description 
The asay, developed by J. Fisken (Fisken el al: 1993; Fisken: 1991) is a solid phase enzyme 
linked immunosorbent assay. The monoclonal antibody 1.10.F3 (Taylor -Papadimitriou el al: 
MI). adsorbed on to assay plates is used as the primary antibody. The same antibody, 
conjugated to li i'cradish peroxidase is used as the tracer. 
9.2.2.2.2 Assay procedure 
9.2.2.2.2.1 Preparation of assay standards 
i i M FG 2 standards were prepared by J. Fisken using methods described previously ('I'aylor- 
l'apadimitriou ei al: 1981, 13urchell el al: 1987). Human breast milk was centrifuged at 
1O(HH)g for 3(I minutes to isolate the skimmed milk fraction. The 1 -IMFG antigen was prepared 
from human skimmed milk by affinity chromatography on a sepharose column prepared by 
coupling of the purified MFG! monoclonal antibody to cyanogen bromide activated 
sepharose (Pharmacia). Hunan skimmed milk was passed in batches of 100 ml through the 
column and the column washed with phosphate buffered saline pH 7.4 (PBS). Bound antigen 
was eluted using 0.1 M glycine pl 12.5, and the fractions pooled and dialysed against 0.25M 
acetic acid. Purified IIMFG was partially deglycosylated by hydrolysis with anhydrous 
hydrogen fluoride for I h at 4 °C (Mort and Lamport: 1977). Purified samples were freeze 
dried and stored at -20 °C. 
IIMFG concentrations were set by reference to an original preparation isolated by 
Dr. S. Mather (St. Bartholomew's Hospital, London). 1 mg of the freeze dried powder was 
arbitrarily equal to 106 units. Standard solutions were prepared in PBS, containing 7% bovine 
serum albumin and 0.01% w/v Thimerosal as preservative, and calibrated against a 
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preparation obtained from Dr. J. Taylor- Papadimitriou (I.C.R.F., Lincoln's Inn Fields, 
London). Aliquoted standards were stable for at least 2 weeks at 4 °C. 
9.2.2.2.2.2 Preparation of assay plates 
96 -well microtitre plates (M12913, Dynatech, Billingshurst, Kent, UK.) were used. HMFG2 
monoclonal antibody was prepared at a concentration of 5 pg /ml in 0.05M carbonate buffer 
p11 9.6. The plates were coated with primary antibody by adding 50p1 of the antibody solution 
to each well and allowing to stand overnight at 4 °C. At the end of the incubation period the 
plates were washed three times with 100p1 of PBS containing 0.05% polyoxycthylene sorbitan 
monolaurate (Tween 20), ready for use. 
9.2.2.2.2.3 Preparation of HMFG2- horseradish peroxidase conjugate 
horseradish pcn xidase (IIRP) enzyme was conjugated to IIMFG2 monoclonal antibody in a 
1: I ratio. Five mg I IRP (Sigma Type VI) was dissolved in 1 ml of distilled water, and oxidised 
by the addition of 11.4 ml freshly prepared 0.1M sodium mctaperiodate for 20 minutes at room 
temperature in the dark, while gently stirring occasionally. Oxidised HRP was dialysed 
overnight at 4 °C with I litre of I mM acetate buffer pH 4.4, stirring continuously. The pH 
was brought to p1I 9.0 with 0.2M carbonate buffer pH 9.5. Five mg HMFG2 antibody in 1 ml 
carbonate buffer was added and stirred gently for 2 hours at room temperature in the dark. 
Next. 1).1 ml of freshly prepared sodium borohydride (5 mg/ml in distilled water) was added 
and incubated at 4 °C for 2 hours. The conjugate was finally dialysed with phosphate buffered 
saline containing 0.01% w/v Thimerosal, and was stored in this buffer at 4 °C in the dark. 
The peroxidase substrate consisted of 0.04% w/v 0- phenylenediaminc and 0.02% v/v 
hydrogen peroxide in 0.15M citrate phosphate buffer pH 5.0. 
9.2.2.2.2.4 The assay protocol 
No -touch technique was used throughout. Patient samples were assayed in duplicate, and 
standards and controls in triplicate. 
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25p1 of neat patient serum, standard, or control were added to appropriately labelled wells 
along with 25,u1 of PBS /Tween. the plates were incubated for 30 minutes at 37 °C in a 
shaking incubator, and washed three times with PBS/Tween. 
The plate wells were next covered with 50 ,td of HMFG2 antibody -HRP conjugate at a 
dilution of 1:1000 in PBS/Tween, and incubated for a further 30 minutes at 37 °C. After three 
final washes, 100/1 of peroxidase substrate was added to the wells. The reaction was stopped 
after 31) minutes incubation at 37 °C with the addition of 50f1 of 2.5M sulphuric acid. 
The plates were placed in a densitometer (Titertek Multiscan), and their optical density 
determined at 492 nm. 
'Ihe standard curve was prepared using the following concentrations of HMFGZ: 0.0, 50.0, 
11H), 200, 400 and 600 arbitrary units per ml (Figure 9 -2), and the HMFG2 concentration in 





100 201 0 30I 0 500 600 
HMFG2Concentration (U/ml) 
Figure 9 -2: standard curve used to calculate HMFG2 concentrations 
(meant-2SE) 
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9.2.3 Analysis of results 
All statistical analyses were performed using the statistical software package Stata 4.0 for 
Windows, Stata Corporation, 702 University Drive East, College Station, Texas 77840 USA. 
9.2.3.1 Definition of response 
Response to primary systemic therapy was assessed by weekly measurement of tumour 
volume as explained previously (section 3.3.1.3). A similar technique was used to assess 
response in the group of patients with locally advanced breast cancer. 
9.2.3.2 Sequential measurements 
The marker values for patients treated within the trial were plotted against time, and using the 
method of least squares the rate of change of marker levels was calculated as the slope of the 
regression line. Where failed endocrine treatment was followed by chemotherapy, separate 
regression slopes were calculated for each phase of the treatment. Changes in sequential 
marker measurements were correlated with actual tumour response. 
9.2.3.3 Measurements before and after treatment 
9.2.3.3.1 Before and after primary systemic treatment 
In the group of patients who received a single mode of primary systemic treatment, including 
the subgroup of patients with locally advanced carcinomas, marker levels recorded before the 
start of treatment were compared with marker levels obtained at the time of the start of 
locoregional therapy. 
In those patients who failed to respond to endocrine therapy and went on to receive cytotoxic 
chemotherapy, each phase of treatment was treated as a separate treatment episode. Thus, 
marker levels obtained at the time of change in treatment were compared with levels obtained 
before the start of treatment and at the time of mastectomy. 
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9.2.3.3.2 Before and after mastectomy 
When a patient was treated by primary mastectomy, pre mastectomy marker levels were 
compared with those obtained immediately following mastectomy. For patients treated by 
primary systemic treatment, post -mastectomy marker levels were compared with marker levels 
obtained before any treatment had been given. 




9.3.1.1 Samples during primary systemic treatment 
Sequential samples were obtained for 30 treatment episodes from 26 patients undergoing 
primary systemic treatment within the trial. An average of 5 samples were collected for each 
patient (range 2 to K). In total 124 preoperative samples and 26 post -mastectomy samples 
were obtained. In addition pre and post treatment samples were obtained from 10 patients with 
locally advanced breast cancer. 
9.3.1.2 Pre and postoperative samples 
Pre and postoperative samples were available in a total of 42 patients: 26 from those given 
primary systemic treatment. 10 from patients treated conventionally within the trial and G 
samples from patients treated outside the trial. 
9.3.2 Marker characteristics 
All samples were assayed in duplicate. Marker values are recorded as the mean of two 
measurements and the standard error of the mean. A total of 202 corresponding measurements 
of CA 15 -3 and I1MFG2 were available. The distribution of marker values was examined 
using a probit plot, and found to be markedly skewed, but approximated to normal on 
logarithmic transformation. 
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9.3.2.1 Assay characteristics 
9.3.2.1.1 Intra -assay variability 
The intra -assay variability was assessed by calculating the overall coefficient of variation 
from the differences in values obtained from duplicate samples (Bland: 1987). All 202 
samples were used in the calculation. The coefficient of variation for CA 15 -3 was 
8.32 ±0.08 %. The coefficient of variation for HMFG2 was 12.74 ±0.37 %, somewhat higher 
than that seen for CA 15 -3. 
9.3.2.1.2 Sampling variability 
Since all samples were assayed simultaneously the question of inter -assay variability does not 
arise. It is however still possible to experience spurious variability between samples obtained 
at different times from the same patient. 
Sequential samples obtained 3 weeks apart during primary systemic treatment are likely to be 
sufficiently similar in order to give a measure of sampling variability. The first and the second 
samples in the sequence were selected in 26 such patients undergoing primary systemic 
treatment. There was no significant difference between the first and second sets of samples for 
either CA 15 -3 (n =26, z= -1.31, p =0.191 Wilcoxon signed -rank test) or for HMFG2 (n =26, 
z= -1.22, p= 11.224, Wilcoxon signed -rank test). 
The coefficient of variation for CA 15 -3 samples obtained at different times was 22.2 - 0.63 %. 
l'he corresponding variability for HMFG2 was 22.6 -2.0 %. 
9.3.3 Analysis of marker values 
9.3.3.1 Pre -treatment marker levels 
Distribution of pre -treatment CA 15 -3 and HMFG2 levels in the 42 patients with operable 
breast cancer are shown in Figure 9 -3 and Figure 9 -4. Even at a conservative cut off level of 
25 U /ml only 7 of the 42 patients had raised CA 15 -3 values. HMFG2 levels were raised above 
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the cut off of 40U/m1 in a significantly greater proportion, with 26 of 42 patients having a 
raised level (p= 1).11111), Fisher's exact test). 
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Figure 9 -4: The distribution of initial HMFG2 values 
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9.3.3.2 Relationship between CA 15 -3 and HMFG2 
The relationship between the natural logarithm of the two markers was examined using the 
method of least squares There was a weak but significant correlation between CA 15 -3 levels 
and 11MFG2 levels (r2= 0.140, p= 0.0001, Figure 9 -5). 
, 
1 2 3 4 
In of CA 15-3 values (U/ml) 
Figure 9 -5: The relationship between CA 15 -3 and HMFG2 values 
9.3.4 Initial marker levels and patient characteristics 
9.3.4.1 Tumour volume 
5 
124 corresponding measurements of tumour volume as measured by ultrasound (10.2.1.2.3) 
and tumour marker levels were available in 26 patients undergoing primary systemic 
treatment. A further 10 measurements were available in patients about to undergo 
mastectomy. The correlation between tumour marker values and tumour volume was 
examined using Spearman Rank correlation coefficient. 
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There was no significant relationship between CA 1.5 -3 and tumour volume (p= 0.002, 
p= 0.99). 11MFG2 levels showed a weak but significant correlation to tumour volume 
(p= 0.193, p= 0.027). 
9.3.4.2 Age and tumour oestrogen receptor content 
The relationship between tumour marker levels and these characteristics was examined in 
relation to the 36 initial marker measurements. Using Spearman Rank correlation coefficient, 
there was no significant relationship between initial levels of either tumour marker and age or 
tumour oestrogen receptor content (Table 9 -2). 
Age Oestrogen receptors 
Coefficient (p) Probability Coefficient (p) Probability 










Spearman's rank correlation coefficient 
Table 9 -2: relationship between tumour marker levels and patient's age and 
tumour oestrogen receptor level 
9.3.4.3 Axillary lymph node involvement 
lucre was no significant difference in the initial levels of either tumour marker between 
patients with pathologically involved axillary lymph nodes and those with nodes free of 
tumour (Table 9 -3). 
Markers Node -negative (n =16) Node -positive (n =20) z= P= 
CA 15-3 [median (range)] 
HMFG2 [median (range)] 
20 (10.7 -40.9) 
47.1 (3.0- 119.9) 
16.9 (6.6 -37.6) 





Mann -Whitney U test. 
Table 9 -3: Tumour marker levels by axillary nodal status 
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9.3.4.4 Tumour differentiation 
Tumours were divided into well, moderate and poorly differentiated categories. The difference 
in marker levels was examined using Kruskal -Wallis one way analysis of variance. Marker 
levels were similar for the three levels of differentiation (Table 9 -4). 
Markers Well (n =3) Moderate Poor (n =8) H= p= 
CA 15 -3 [median (range)] 20.4 (17.4 -40.9) 16.9 (6.6 -37.6) 17.6 (12.8 -34.1) 2.62 0.27 
HMFG2 [median (range)] 95 (3.0- 105.0) 55.0 (5.0- 185.0) 43.3(96.7- 119.9) 0.56 0.76 
Kruskal- Wallis one way analysis of variance 
Table 9 -4: Tumour marker levels by tumour differentiation 
9.3.4.5 Tumour markers and survival 
Patients were divided into those still disease free at the time of analysis and those with 
recurrence. Marker values were compared between the two groups using the Mann -Whitney U 
lest. There was no difference in the initial marker values between the two groups of patients 
(Table 9 -5). 
Markers Disease free (n =18) Recurrence (n =18) z= P= 
CA 15-3 [median (range)] 









Mann -Whitney U test 
Table 9 -5: Tumour marker levels by recurrence free survival. There was no 
significant difference between the two groups 
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9.3.5 Changes in markers with systemic treatment 
9.3.5.1 Sequential measurements 
9.3.5.1.1 Significant sequential change 
Sequential measurements were available for 30 treatment episodes in 26 patients. A change in 
marker level in relation to time from the start of treatment which was significant at the 85% 
level was observed in 11 of the 30 Treatment episodes for CA 15 -3 and in 6 of the 30 treatment 
episodes for JIM FG2. Combining the results from the two markers such that a significant 
change in either marker is regarded as a positive result, 14 of 30 treatment episodes were 
associated with a significant change in marker levels. 
Twelve of these 14 treatment episodes resulted in tumour response and 2 produced no 
response. Marker levels showed a sequential reduction (negative slope of the regression line) 
in only 7 of the 12 responders. In the remaining 5, level of markers sequentially increased 
(positive slope). ()IR. non- responder had an increase in markers and one a decrease. 
9.3.5.1.2 Rate of change and rate of volume regression 
There was no significant correlation between the rate of change of marker levels and the rate 
ot tumour response for either CA 15 -3 or HMFG2 (p = 0.101, p = 0.608 for CA 15 -3: 
r= 0.274. p =(.173 for 11MFG,. Spearman Rank correlation coefficient). 
9.3.5.2 Pre and post treatment measurements 
Marker levels before and after systemic therapy were available for 40 treatment episodes, 30 
in 26 patients within the trial and 10 further episodes in 10 patients with locally advanced 
breast cancer. Thirty treatment episodes resulted in a tumour response, and 10 episodes 
produced no response. 
The median and range of marker values at the start and at the completion of primary systemic 
treatment were compared for the entire group of patients, and separately for responding and 
non -responding patients, using the Wilcoxon signed -rank test. 
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9.3.5.2.1 CA 15-3 
There was no difference in the overall median CA 15 -3 values before and after treatment. 
Patients who subsequently failed to respond to treatment had a median initial CA 15 -3 level of 
14.2 U /ml (range 6.6- 24.1), significantly lower than the median of 17.6 U /ml (range 7.6- 
142.3) for those patients who later showed a response (z= -2.11, p= 0.035, Mann -Whitney U 
test, Table 9 -6). 
CA 15 -3 values [median (range)] Pre -treatment Post -treatment z= P= 
Entire group (n =40) 16.7(6.6 -142.3) 18.5 (8.0 -37.8) -0.57 0.57 
Responders (n =30) 17.6 (7.6- 142.3)* 18.8 (8.0 -37.8) -0.79 0.43 
Non -responders (n =10) 14.2 (6.6- 24.1)* 15.0 (9.3 -33.1) -2.70 0.007 
* z = -2.I I, p= 1).1)35 Mann- Whitney U test 
Table 9 -6: Starting CA15 -3 values for responders and non -responders 
CA 15 -3 values decreased in 15 of the 30 responding patients and increased in the remaining 
15. Amongst the It) non- responders however, CA 15 -3 increased in 9 patients and decreased 
in only une. Overall there was a significant rise in CA 15 -3 values in non -responding patients 







Responders Non -responders 
Figure 9 -6: Changes in CA 15 -3 values with primary systemic treatment 
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9.3.5.2.2 HMFG2 
The overall levels of 1 I M FG2 showed a tendency to fall following treatment (p= 0.049). There 
was no significant diticrence in the initial HMFG2 values between the responding and non - 
responding patients (z= 0.81, p= 0.417, Mann- Whitney U test, Table 9 -7). 
HMFG2 values [median (range)] Pre -treatment Post -treatment z= P= 
Entire group (n =40) 70.4 (3.0- 245.0) 63.8 (3 -215) -1.97 0.049 
Responders (n =30) 77.9 (3.0- 245.0)* 62.5 (3.0- 215.0) -2.38 0.017 
Non -responders (n =10) 57.1 (7.5- 185.0)* 67.9 (3.0- 112.5) -0.59 (1.554 
'z= -(1.8 I, p= (1.417, Mann -Whitney U test 
Table 9 -7: Starting HMFG2 values for responders and non -responders 
11M FG: values increased in 11 of the 30 responding patients, stayed constant in 2 and 
decrcawd in the remaining 17. Amongst the non responders, IIMFG2 values increased in only 
four patients. stayed constant in one and decreased in the remaining 5. Overall there was a 










Responders Non -responders 
Figure 9 -7: Changes in HMFG2 values following completion of primary 
systemic treatment 
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9.3.6 Changes in marker levels with surgery 
Pre and post -mastectomy samples were obtained in 42 patients. 
9.3.6.1 CA 15 -3 
There was an increase in the levels of CA 15 -3 in 13 of 42 patients in whom pre and 
postoperative samples were available. Levels stayed constant in one patient. In the remaining 
28 patients, CA 15 -3 values fell following surgery. Overall there was a significant drop in 









Pre op Post op 
Pre -mastectomy Post -mastectomy z= P= 
CA 15 -3 values [median (range)] 16.9 (6.6-63.5) 15.4 (5.6-50.1) -3.03 0.0tt)24 
Wilcoxon signed-rank test 
9.3.6.2 Figure 9 -8: CA 15 -3 values before and after mastectomyHMFG2 
HMFG2 levels increased in 12 of the 42 patients and decreased in 27. There was no change in 
the remaining 3 patients. Overall HMFG2 values decreased significantly following surgery 
(Figure 9 -9). 
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Pre op Post op 
Pre -mastectomy Post -mastectomy z= P. 
HMFG, values [median (range)] 46.6 (3.0- 185.0) 33.8 (3.0- 115.0) -2.72 0.0065 
w ilcoxun signed-rank tesi 
Figure 9 -9: HMFG2 values before and after mastectomy 
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9.4 CONCLUSIONS AND DISCUSSION 
9.4.1 General remarks 
In this group of patients with operable breast cancers, marker levels were generally low. Few 
patients presented with levels greater than those seen in the normal population, and the 
elevation in those with initially raised markers was relatively modest. This results in a low 
"signal to noise ratio" in this particular patient population, thus limiting the value of CA 15 -3 
and IIMFG, as a means of monitoring the progress of individual patients. It was nevertheless 
possible to detect a number of trends by examining changes in marker levels amongst the 
entire patient population. 
9.4.1.1 CA 15 -3 vs. HMFG2 
.1.hc performance oI' the two markers appeared to be similar. There was a relatively high 
degree of variability both within the assay and between samples. The CA 15 -3 assay 
performance was similar to figures reported previously (Pons -Anicet et al: 1987; Eskelincn et 
a!: 1988). intra patient variability has also been reported for CA 15 -3, and has been found to 
be generally greater than the intra -assay variability (Gion et al: 1993; Gion et a!: 1994; 
Lskelinen et a!: 1988) The correlation between the levels of the two was a relatively weak one. 
'ihis is again likely to be due to the generally low marker levels, making the assays subject to 
non-tumour related fluctuations. 
9.4.2 Tumour volume 
I he serum levels of tumour associated antigens are assumed to reflect the total body tumour 
burden (see section 9.1.1). In this patient population, tumour burden can be determined by the 
direct measurement of tumour volume. Volume did not correlate with CA 15 -3 and only 
correlated weakly with I IMFG2. Errors in volume measurements introduced by such factors as 
the presence of unyuantified amounts of tumour in involved axillary nodes may be partly 
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responsible for this lack of correlation. More importantly, it is likely that the relatively small 
tumour burden barely produces a detectable increase in tumour marker levels, making any 
relationship difficult to detect. 
9.4.3 Changes in markers with treatment 
9.4.3.1 Initial marker levels and response 
Patients whose tumours failed to respond to treatment on average had lower initial CA 15 -3 
than those patients whose tumours did respond. There was however complete overlap between 
the range of m;ukcr values. and initial values could not be used to predict response. 
9.4.3.2 Sequential marker values 
The sequential measurements of markers during primary systemic treatment produced little 
useful information in relation to individual patients. This is likely to be due to a combination 
of generally low tumour marker levels and high inter -sample variability. 
Tumour response was accompanied by an overall fall in 1 -IMFG2 levels. No such fall was 
detected for CA 15 -3. The change in HMFG2 in response to treatment is likely to represent a 
true change accompanying a reduction in tumour burden with treatment. 
CA 15 -3 levels rose following treatment in non -responding patients. No patient actually 
progressed during primary systemic treatment and it is unlikely that the rise is a reflection of 
increasing tumour burden. Regression of a subpopulation of tumour cells, along with rapid 
growth of another population may produce the overall effect of a static tumour, but the 
resulting increase in cell turnover may be sufficient to lead to increasing release of marker 
antigens (Kiang ('I al: 1990). This scenario however is made less likely by the fact that there 
was no suggestion of a corresponding rise in HMFG2. It is likely that at least part of the 
observed rise is in fact a spurious finding, caused by the combination of unusually low initial 
marker levels and the tendency for CA 15 -3 values to regress towards the mean. 
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9.4.3.3 Changes with tumour removal 
Both markers showed a significant drop following mastectomy. This observation, previously 
reported in other studies (0'l lanlon et al: 1995a; Omar et al: 1989a; Eskelinen et al: 1989a), 
is likely to be a true reflection of the combination of reduced tumour burden, and a reduction 
in baseline antigen load caused by the removal of the breast. 
9.4.4 Overall conclusions 
The data presented here suggest that measurement of CA 15 -3 and 1 -IMFG2 levels in patients 
with operable breast cancer provides little useful information about the state of patients' 
disease. f 
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CHAPTER 10 
10. Ultrasound and Tumour 
Monitoring 
10.1 INTRODUCTION 
10.1.1 Measurement of tumour size 
10.1.1.1 The significance of tumour size 
Tumour size is an important independent indicator of overall prognosis (Carter et al: 1989; 
Koscielny et al: 1984; Fisher et al: 1969) and the risks of locoregional failure (Clarke and 
Martinez: 1992; Osteen et al: 1987; Locker et al: 1989) for patients suffering from carcinoma 
of the breast . It is required for accurate staging of breast tumours (Beahrs et al: 1988; UICC: 
19x7). and is an important criterion for deciding between mastectomy and breast conservation 
(Stewart et al: 1989: Fisher et al: 1989; Osteen and Smith: 1990). Repeated measurements of 
tumour size may he used to assess response to preoperative radiotherapy (Chung and 
Johnson: 1991a; 'lhomlinson: 1987a), and systemic treatment (Cheung and Johnson: 1991a; 
Forrest cat al: l 986a). 
10.1.1.2 Conventional measurement of tumour size 
10. 1.1.2.1 Clinical measurement 
Tumour size has conventionally been measured clinically using engineers' callipers to measure 
the tumour in two diameters (Hayward et al: 1977; Thomlinson: 1987; Thomlinson: 1982). 
Such measurements provide an indirect estimate of tumour size and are influenced the 
presence of associated oedema and obesity (Dixon et al: 1984). They are highly observer 
dependent ( Cheung and Johnson: 1991b). 
10. 1.1.2.2 Mammography 
Mammography is well established as an objective method of assessing breast tumours (Feig: 
1992). It has the potential disadvantage that the frequency with which it may be performed is 
limited by the radiation close to the breast. An additional problem is that in a significant 
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minority of patients, the mammographie tumour outline is so diffuse as to make it impossible 
to estimate small variations in tumour size (Hilleren et al: 1991; Smith: 1991). 
10.1.1.3 The place of ultrasound in measuring tumour size 
Breast ultrasonography is simple to perform, provides a permanent record of tumour size, and 
may be perlbrmed as frequently as required (Feig: 1992; Warwick et al: 1988; Leucht et al: 
1988; Vlaisavljevic: 1988). Ultrasound provides an alternative method of assessing response 
to primary systemic treatment, particularly in patients with dense breasts (Balu Maestro et al: 
). but its exact relationship to other methods of tumour monitoring has not been 
prrionil\ defined. 
10.1.2 Measurement of tumour response 
Measurement of tumour response to preoperative treatment can provide valuable information 
regarding the behaviour of tumours (Cheung and Johnson: 1991h; Thomlinson: 198211: 
'l hornlinson: 1987b). This information can be used to modify treatment in order to select the 
most effective treatment regime (Smith et al: 1993; Cheung and Johnson: 1991; Anderson el 
al: 1991; Forrest et al: 198t.í). Accurate assessment of final response may be used to allow 
breast conservation following primary systemic therapy (Singletary el al: 1992; Schwartz et 
al: 1994; Greer et al: 1979; Smith et al: 1993). The assessment of the degree of response can 
in itself be used as an important indicator of the patient's final prognosis (Jacquillat et al: 
1991b: Jacquillat et al: 1990b; Scholl et al: 1991b; Forrest and Anderson: 1991b; Hortobagyi 
et al: 1983b). 
Extensive information is available on monitoring tumour response by repeated measurements 




10.1.3 The conduct of the study 
The study was conducted in two parts. The first part of the study aimed to compare the 
accuracy of ultrasound as a method of measuring tumour size with other methods of tumour 
size measurement. The size of tumour in the resected specimen was used as the "gold 
standard ". This part of the study will be referred to as the "size study ". 
The second part of the study examined the efficacy monitoring changes in tumour size and 
assessing tumour response using ultrasound. This part of the study will be referred to as the 
"monitoring study ". 
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10.2 PATIENTS AND METHODS 
Two overlapping groups of patients were studied. 
10.2.1 The size study 
10.2.1.1 Patients 
Only patients with clinically palpable tumours were considered for this part of the study. All 
patients had clinical. mammographic and cytological confirmation of a diagnosis of breast 
cancer. and were about to undergo either a mastectomy or wide local excision of their breast 
tumour. There were no other restrictions in entering this part of the study. 
Mammography was performed as part of the routine preoperative assessment of all patients. 
All patients had agreed to undergo breast ultrasound and detailed clinical tumour 
measurements. and all measurements were completed in the week immediately preceding 
surgery. 
10.2.1.2 Methods 
Clinical. mamiimgraphic and sonographic measurements were performed by single designated 
observers. Pathological examination of resected specimens was performed, or directly 
supervised h\ one pathologist. 
10.2.1.2.1 Clinical measurement 
The tumour was measured in 4 diameters at 45 degrees to each other using engineers' 
callipers. Mean tumour diameter was recorded as the clinical tumour size. Tumour volume 
was calculated using the formula for the volume of a sphere: V= (U ?x3r) /6 (V= volume, 
D =mean diameter). 
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10.2.1.2.2 Mammographie measurement 
A single oblique view was used to measure tumour diameter. The largest tumour diameter and 
the diameter at 90° to this axis were measured. Mammographic size was recorded as the mean 
of the two measurements and tumour volume calculated using the formula for the volume of a 
sphere. Where mammographic tumour margins were indistinguishable from the surrounding 
breast tissue, tumour size was considered not assessable by mammography. 
10.2.1.2.3 Sonographic measurement 
A Siemens (Tokyo) SLI machine with a 7.5 MI lz linear array probe was used. The probe was 
held orthogonal to the skin and moved over the tumour until maximum diameter was 
demonstrated. The diameter and the thickness of the tumour were recorded using the 
machine's electronic callipers. Four measurements were made at 45° intervals, and mean 
diameter and mean thickness calculated. Tumour volume was calculated using the formula for 
the volume of an ellipsoid V =(l)'xdx7r)16 (V= volume, D =mean diameter, d =mean thickness). 
Where the sonographic image of a tumour could not be fitted in to a single screen (diameter 
over h cm). the tumour was considered not assessable by ultrasound. 
10.2.1.2.4 Measurements on the resected specimen 
Following surgery. fresh specimens were serially sectioned at 0.5 -1 cm intervals, and at right 
angles to the skin. The length, width and thickness of the tumour were recorded. Mean 
diameter was calculated from the length and the width and volume calculated using the 
formula for the volume of an ellipsoid. 
If the macroscopic margins of the tumour could not be determined with reasonable confidence 
on visual inspection of the sectioned tumour, that tumour was excluded from the study. 
10.2.1.2.5 Analysis of results 
All statistical analyses were performed using the statistical software package Stata 4.0 for 
Windows, Stata Corporation, 702 University Drive East, College Station, Texas 77840 USA. 
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Distribution of the data was assessed for normality using a probit plot and skewed data 
normalised using logarithmic transformation. Mean tumour diameter measured by the 
pathologist was designated "actual size ", and the relationship between this and diameters 
measured by other methods was established using linear regression by the method of least 
squares. To assess whether a method over- or underestimated tumour diameter, mean 
pathological, clinical, mammographie and ultrasonographic diameters were compared using 
Friedman two -way analysis of variance. 
10.2.2 The monitoring study 
10.2.2.1 Patients 
The patients were those receiving primary systemic treatment in the main clinical trial. The 
entry criteria are described in section 3.2. 
10.2.2.2 Methods 
10.2.2.2.1 Sequential assessment 
Patients were seen once a week and their tumour diameter measured by calliper and by 
ultrasound as described above. Single oblique mammography was performed once every 4 
weeks. Primary systemic treatment was continued for 12 weeks at the end of which time a 
mastectomy was performed. The natural logarithm of tumour volume was plotted against 
time, and response defined as a significant negative correlation between time from start 
of 
treatment and the natural logarithm of volume, as described in section 3.3.1.3. 
Tumours with diffuse mammographie margins or with initial diameters larger 
than one 
ultrasound screen were considered not assessable by these modalities. 
10.2.2.2.2 Definition of response 
Response to primary systemic treatment as assessed by sequential 
measurement of tumour 
volume was compared with "actual response ". This was 
determined by estimating the pre- 
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treatment tumour volume and standard error (SE) from the initial mammographic and 
ultrasonographic measurements, using data obtained from the "size study ". Following primary 
systemic treatment macroscopic size and microscopic extent of tumour were measured in the 
surgical specimen, and volume of residual tumour calculated. if this was equal to the 
estimated initial volume ± 2SE, the disease was classed as static. Residual volumes less or 




10.3.1 The size study 
10.3.1.1 Patients 
Sixty three tumours were measured in 62 patients. The sample included 42 patients treated by 
initial surgery, and 20 patients who had completed 12 weeks of primary systemic therapy. 
10.3.1.2 Tumour assessment 
Of the 63 surgical specimens examined, 5 contained no macroscopically detectable residual 
tumour and in a further 3 the tumour margins were too diffuse for accurate assessment. Fifty - 
five (87('; ) of the tumours wcrcasscssable. 
Two patients had clinically palpable lesions which did not correspond to tumours detected in 
resected specimens and two tumours presenting in one breast were clinically indistinguishable. 
Ten tumours had diffuse mammographie outlines and could not be measured by this method. 
Three tumours were larger than the maximum diameter of the ultrasound screen (6 cm), and 
were not assessable by sonography. Fifty one clinical, 45 mammographie and 52 sonographic 
measurements were available for analysis. 
10.3.1.3 The relationship between different methods of size measurement 
10.3.1.3.1 Measurements of tumour diameter 
Tie actual measurements obtained using different methods arc presented in the appendix 
(14.4). Diameter followed a positively skewed distribution curve and log -transformed data 
were used for linear regression. The following figures show the relationship between actual 
size and mean clinical, mammographie and sonographic tumour diameters. Diameter 
measured by calliper showed a moderate degree of correlation with actual size (r' =0.68, 
10 -264 
p<0.000 I, Figure 11) -1). Mammographic and ultrasonographic measurements correlated much 
more closely with actual size (r2 =0.84, p<0.0001, Figure 10 -2 and r2 =0.89, p <0.0001, Figure 
10 -3 respectively). 
Pathological size (cm) 
n =5 I. y= 1.55x" ",r2 =0.68, p <0.0001 
Figure 10 -1: Relationship between pathological and clinical mean tumour 
diameter 
1.0 
Pathological size (cm) 
n =45. y= 1.15x "x3, r2 =0.84, p<0.0001 
10.0 





Pathological size (cm) 
n=52, y=0.95x° y`', r2=0.89, p<0.0001 
100 
Figure 10 -3: Relationship between pathological and ultrasonographic mean 
tumour diameter 
10.3.1.3.2 Measurement of tumour volume 
Values for tumour volume also followed a positively skewed distribution curve, and 
logarithmic transformations of the data were used for linear regression. 
'tumour volume measurements followed the same pattern as tumour diameter. The correlation 
between pathological tumour volume and clinical volume remained moderate (r2 =0.63, 
p <0.000I , Figure 10 -4), and the close correlation between pathological tumour volume and 
mammographie and sonographic tumour volumes were maintained (r2 =0.85 and r2 =0.87, 
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Pathological volume (cm3) 
n =5I. }= 3.72x "7" r2 =0.63, p <0.0001 
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Figure 10 -4: Relationship between pathological and clinical tumour volume 
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Pathological volume (cm3) 
n =45. v= I.58x" 9 r =0.85, p <(I.0001 
Figure 10 -5: Relationship between pathological and mammographic tumour 
volume 
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Figure 10 -6: Relationship between pathological and ultrasonographic 
tumour volume 
10.3.1.3.3 Consistent bias in measurement 
For 45 in %% Bich measurements were available by all methods, Friedman analysis of 
variance found no significant difference between pathological (mean: 1.9 cm), mammographie 
(mean: I.O cm) and ultrasonographic (mean: 1.8 cm) diameters. Clinical diameter (mean: 
2.7 cm) was significantly larger than the others (p <0.0001). 
10.3.2 The monitoring study 
10.3.2.1 Patients 
Sequential measurements were performed over a period of 2 years on 38 patients (including 
20 cases included in the "size study "). 
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10.3.2.2 Tumour responses 
The details of tumour responses are presented in section 5.2.1.3.1. The tumours in 29 patients 
responded to treatment. 'There was no response in 4 patients. The remaining 5 patients had 
shown minimal response to treatment (a reduction of 25% or less in volume). Two of these 
patients were considered as non -responders according to the criteria used in the "monitoring 
study ", while the other three were designated responders. In all there were 32 responders and 6 
non responders. 
10.3.2.3 Assessment of response 
10.3.2.3.1 Clinical measurement 
Sequential clinical measurement was possible in all 38 patients. Clinical measurements 
correctly classified response in 30 responders and 4 non responders. Two non responders and 
2 responders were misclassifïed. 
10.3.2.3.2 Mammography 
Twenty si tumours wcreassessable by mammography. Mammography correctly detected 
response in 211 responders and three non -responders. Mammography suggested a response in 
one non -responding patient, and failed to detect response in 2 responders. 
10.3.2.3.3 Ultrasound 
Thirty six tumours wereasscssable by ultrasound, and response was correctly detected in 31 
responders and 3 non -responders. Of the 12 patients not assessable by mammography 10 were 
correctly assessed by ultrasound. The other two were not assessable by either ultrasound or 
mammography. Ultrasound failed to detect response in one responding patient and suggested a 
response in one non -responder. 
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10.3.2.3.4 Difficult to assess tumours 
TWO tumour s were incorrectly assessed by all three techniques. Two further tumours were not 
assessable by ultrasound and mammography, and were incorrectly assessed by clinical 
examination. Of these four tumours two were non -responders and two were responders. 
Histological examination revealed diffuse infiltration of the breast by two tumours which were 
incorrectly assessed as responders. The two patients who were incorrectly assessed as non - 
responders had discrete residual breast masses which were shown to consist of hyalinized 
stroma, with very few residual malignant cells. 
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10.4 CONCLUSIONS AND DISCUSSION 
10.4.1 The size study 
The correlation between tumour diameter measured by ultrasonography, and actual tumour 
diameter on excision, was greater in this study than in those previously reported (Pain et al: 
1992; Nishimura et al: 1988; Fornage et al: 1987). Ultrasonography was found to be the most 
accurate method of measuring tumour size in one study (Fornage el al: 1987), but a more 
recent study found all three methods to have the same degree of inaccuracy (Pain et al: 1992). 
These studies were retrospective and relied on sizes recorded in routine clinical notes. Actual 
size may often have been approximate, as evidenced by significant clustering of pathological 
sizes around whole numbers (Pain et al: 1992; Fornage et al: 1987). Pathological size was 
often reported in one plane only and, in one study, was measured on fixed specimens. Two 
studies had used a 5 MI Iz ultrasound probe which may have further contributed to the lower 
accuracy. 
Size was recorded prospectively in the present study. Tumours were measured in several 
planes. thu\ mini umi imig errors duc to irregularities in tumour shape. 
lrltra\onnigraphy was the best method of measuring tumour diameter but mammography can 
also estimate the pathological mean tumour diameter and tumour volume with a much higher 
dcelce of accuracy than clinical measurement. 
10.4.2 The monitoring study 
'llie aim of repeated measurements is to assess the overall pattern of response. To this end the 
present study confirms the accuracy of sequential calliper measurements performed by the 
WIC person in monitoring response to primary systemic treatment. Imaging techniques are 
nevertheless important in providing independent and objective verification of 
clinically 
observed responses. Mammography and ultrasonography were equally good 
in assessing 
response in mammographically discrete tumours, but ultrasonography could 
also be used to 
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assess the response of diffuse tumours, and was therefore successful in significantly more 
patients. Failure to correctly assess response appeared to be a function of the tumour 
architecture rather than the measurement technique. It is likely that such failures can only be 
avoided by nnmitnring parameters other than tumour dimensions. 
The assessment of the extent of pathological response requires full histological examination of 
resected breast tissue, and none of the currently available imaging techniques are sensitive 
enough to be used as a substitute for this (Helvie et al: 1996; Vinnicombe et al: 1996). 
10.4.3 Overall conclusion 
r 1 iììinugraphic or ultrasonographic tumour diameter, rather than clinical diameter, should be 
used in clinical staging of breast cancer and in planning future clinical trials. Ultrasonography 





11. Optimum Monitoring Frequency 
11.1 FREQUENCY OF TUMOUR MONITORING 
11.1.1 Rationale for weekly monitoring 
An important concern with regard to the use of primary systemic treatment is that the delay in 
surgery may result in local tumour progression. Partly for this reason, the current protocol 
requires the examination of the patient and measurement of tumour volume once a week. The 
requirement for weekly outpatient attendance is however burdensome to patients and costly in 
terms of the time of health service resources. 
Ile optimum interval for tumour monitoring is examined in this part of the study. 
11.1.2 Patients and methods 
Sequential clinical and sonographic weekly tumour measurements were available on patients 
who had received primary systemic treatment within the main trial. Tumour response was 
defined according to the criteria set out in section 3.3.1.3, using sonographic measurements. In 
two cases where ultrasound was deemed unreliable, clinical measurements were used. 
11.1.2.1 Re- sampling of measurements 
Sequential measurements were re- sampled as follows 
Weekly: (Actual response) 
Every 2 weeks : Weeks 0, 2, 4, 6, 8, 10 and 12 
Every 3 weeks: Weeks 0, 3, 6, 9 and 12 
Every 4 weeks: Weeks 0, 4, 8 and 12 
When a patient's treatment was changed because of lack of response, tumour 
sizes from each 
phase of treatment were treated as a distinct set of measurements. 
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11.1.2.2 Analysis of results 
For each simulated sample the slope of the regression line and its significance were calculated 
and tumour half life determined as explained in section 3.3.1.4.2. For sets of measurements 
obtained weekly or once every two weeks, a significance level of 95% or better was considered 
to indicate a clinically relevant change in tumour volume. For samples taken once every 3 or 4 
weeks, a significance level of 90 %, or better was considered acceptable. 
The simulated therapeutic decisions were compared with actual therapeutic decisions to assess 
whether a lower frequency of examination had any implications for treatment safety. 
11.1.3 Results 
11.1.3.1 Patients 
All 38 patients treated by primary systemic therapy in the first part of the trial were studied. 
I his sample included five patients who had received and failed to respond to endocrine 
therapy, and subsequently received chemotherapy. There were 43 sets of measurements 
available for re- analysis, covering 9 phases of non -response and 34 phases of tumour 
response. 
11.1.3.2 Decisions regarding response 
of responders and non -responders according to each simulated sample 
are 
presented in 'Table I l -l. The number of phases of treatment categorised 
as producing a 
response or not resulting in response did not change when tumours 
were measured once every 
two, or once every three weeks. Sampling once every 
4 weeks considerably reduced the 
sensitivity of detecting a response. With this frequency 
of monitoring, four phases of 
endocrine treatment and two phases of chemotherapy would 
have been erroneously categorised 
as resulting in no response. Furthermore, 9 treatment 
phases which were categorised as 
producing a response had regression lines which were 
significant at 90 to 95% level, further 
reducing the reliability of sampling once every 4 weeks. 
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Weekly Every 2 wks Every 3 wks Every 4 wks 
Response 34 34 34* 28b 
No response, Chemo 4 4 4 6 
No response, Endocrine 5 5 5 9 
Regression in 3 patients was significant at 93 to 95% level 
§: Regression in 9 patients was significant at 90 to 95% level. 
Table 11 -1: Tumour assessment using less frequent sampling than once a 
week 
11.1.3.3 Tumour half lives 
llalf líß fir the nine phases of treatment resulting in no response could not be calculated and 
they were excluded from further analysis. For the remaining 34 treatment phases, tumour half 
lives calculated from weekly measurements were not significantly different from half' lives 
obtained from less frequent monitoring. (Table 11 -2). Furthermore, the individual values 
obtained from weekly measurements closely correlated with values obtained by less frequent 
monitoring ('Table I I -2). 
Weekly Every 2 wks Every 3 wks Every 4 wks 
Half lives: median (range) 39 (5 -105) 38 (5 -117) 40 (5 -105) 42 (5 -113) 
Wilcoxon signed -rank test - z = -1.09 z = -0.13 z = -1.37 
(weekly vs. others) p =0.28 p =0.90 p =0.17 
Spearman Rank correlation p =0.98 p =0.98 p =0.95 
coefficient (weekly vs others) p <0.0001 p <0.0001 p<0.0001 
Table 11 -2: The relationship between tumour half lives calculated from 
weekly and less frequent monitoring 
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11.1.4 Conclusions 
It is clear that weekly tumour monitoring is unnecessarily intensive. Monitoring the tumour 
once every three weeks is as informative as more frequent regimes, and does not compromise 
treatment safety. Outpatient visits may be scheduled to coincide with hospital attendance for 
other purposes such as receiving cytotoxic chemotherapy, and will be much less disruptive to 
patients. 
It is recommended that a regime of monitoring the tumour once every three weeks be adopted 
for future studies. 
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11.2 MONITORING STUDIES: OVERALL CONCLUSIONS 
Accurate measurement of response is critical to the success of response based regimes of 
primary systemic treatment. The accessibility of primary tumours makes direct measurement 
of size a suitable method for monitoring tumour response. In the last three sections an attempt 
was made to improve the way tumours are monitored during primary systemic therapy 
The question of improving the accuracy of clinical size measurement for monitoring tumour 
response was addressed in chapter 9. 
In many patients, the primary tumour represents only part of the total body tumour burden. 
Tumour markers can reflect the total body burden of tumour. The utility of tumour markers in 
monitoring tumour burden during primary systemic treatment was examined in chapter 8. 
The present study used an intensive weekly tumour monitoring regime. The need for such an 
intensive regime was questioned in the current chapter . 
The three main conclusions of these studies are as follows: 
1. Ultrasound is the most effective method of monitoring tumours during primary systemic 
therapy, and should also be used for the initial measurement of tumour size. 
2. it is not necessary to monitor the tumour more than once every three weeks. 
3. 'Tumour markers CA 15 -3 and IiMFG, are not sufficiently sensitive to be used for tumour 
monitoring during primary systemic treatment. 
11.2.1 Other methods of tumour monitoring 
The techniques of monitoring examined in this part of the thesis concentrate in detecting 
changes in tumour bulk. An alternative approach will be invasive tumour 
monitoring. 
Attempts have been made to assess changes in tumour biology by sequential 
needle biopsies 
(Baildam c°! al: 1989), or fine needle aspirates (Forouhi et a!: 1992; Jordan 
et al: 1986; 
Zbicranowski et al: 1992; Spyratos et al: 1992; Briffod el al: 1989; Heyderman et 
al: 1989). 
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These techniques however involve considerable inconvenience to patients, and carry risks of 
potential morbidity. Colour Doppler ultrasound (Srivastava et al: 1988), and magnetic 
resonance imaging of tumour circulation (Knopp et al: 1994) are non invasive methods of 
assessing changes in tumour architecture which may reflect ultimate response,. and are worthy 






12.1 SUMMARY OF RESULTS 
The package of treatment which was investigated in this study evolved out of Sir Patrick 
Forrest's initial experiments with reversing the traditional order of breast cancer treatment in 
order to use the breast primary as a guide to best treatment in a "Human tumour model" 
(Forrest et al: I986). Over the past decade initial systemic treatment of operable breast cancer 
has become more widely used, but many questions remain to be answered. In this thesis, a 
group of patients randomised to receive either the new package or conventional treatment were 
studied in an attempt to answer some of these questions. 
12.1.1 Practical disadvantages of primary systemic therapy 
In section 1.6.2.2 three potential practical disadvantages of primary systemic therapy were 
pointed out. All three have been addressed as follows: 
12.1.1.1 Loss of potential prognostic indicators 
It was sImmn in section 5.2.1 that the characteristics of tumours which are of prognostic 
significance are substantially changed by primary systemic therapy. The tumours become 
smaller, the number of involved lymph nodes are fewer, more well differentiated tumours are 
recovered. and ER values tend to become lower. In some cases no evidence of tumour 
remains. 
Uespilc these changes the post treatment tumour characteristics bear the same 
relationship to 
prognosis as do their pre -treatment counterparts. Thus prognosis appears 
to relate to the 
number of post treatment involved lymph nodes in the same way 
as it relates to pre -treatment 
nodes. Patients with fewer than 4 involved nodes have a prognosis 
which is only marginally 
worse than those with no nodes involved. In the same way post 
treatment ER correlates with 
prognosis, with patients with ER rich tumours continuing to 
do substantially better than those 
with ER poor cancers. What is more, speed of response provides 
an additional marker of 
prognosis. 
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In a significant proportion cif patients not enough tissue was available for post treatment ER 
measurements, but this problem can be overcome by the use of a cytochemical assay, which 
was shown to provide the same quality of prognostic information as the traditional enzyme 
immuno- assay. 
The quality of prognostic indicators are not significantly affected by primary systemic 
therapy. 
12.1.1.2 Potential psychiatric morbidity 
The most significant aspects of cancer related psychological problems, mood and adjustment 
disorders. were examined using well validated instruments. Treatment was an anxious time for 
patients, but significant morbidity was low, and levels of anxiety returned to baseline after 
treatment was completed. Primary systemic treatment had no adverse psychological sequelae. 
Primary systemic treatment required protracted hospital attendance. Despite this, even at the 
short follow -up of 37 months. patients in the two arms of the study had almost identical mean 
TWIST times. Longer follow -up is needed to consolidate these results. 
An interesting coincidental finding was the relationship between being anxiously preoccupied 
with cancer and shorter event free survival. 
12.1.1.3 Potential surgical morbidity 
Although problems after mastectomy were not uncommon, there was no significant difference 
in the number of complications between the two arms of the trial, and any non -significant 
trends were in favour of PST. If PST can be used to allow breast conservation where 
mastectomy was required before, it may in fact reduce the overall surgical morbidity 
experienced by individual patients. 
Obese patients were particularly at risk of developing surgical complications. 
Thesis conclusions 
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12.1.2 Optimising the treatment 
An important advantage of primary systemic treatment is the ability to directly assess 
response to therapy. Ultrasound was shown to be a highly effective means of doing so. Weekly 
monitoring was shown to be unnecessary, with assessment once every three weeks providing 
the same amount of information, without putting patients at risk. Serological tumour markers 
were shown to be ineffective in monitoring response. 
12.1.3 Efficacy of primary systemic therapy 
The main outcome of this trial is survival. The 78 evaluable patients treated in the first part of 
the study have been followed up for 57 months. No significant difference in disease free or 
overall survival has emerged, although there has been a consistent trend in favour of primary 
systemic therapy. With this sample size the likelihood of detecting a significant difference of 
the size suggested by this trend is less than 20 %. 
The entire cohort of patients have been followed up for 37 months. No differences in survival 
have emerged at this stage. but it is unlikely that any differences will be detectable before 5 
years of follow -up. 
12.1.4 The power of the study 
An important shortcoming of comparative studies reported in this thesis is the relatively small 
number of patients who were studied, giving the negative results limited confidence. 
The trial was initiated with realistic objectives. When it failed to meet initial recruitment 
objectives. timely action was taken to increase recruitment rate. Unfortunately despite 
these 
efforts the trial failed to recruit the number of patients stipulated as necessary 
to provide it 
with reasonable power. Thus even on maturity, the power of the 
trial will not exceed 45 %, and 
is likely to be even lower because of protocol violations. 
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Thesis conclusions 
Not withstanding, the trial and associated studies remain of considerable value in an area 
where controlled studies are few. They have provided a considerable amount of new controlled 
data about important aspects of primary systemic treatment, thus expanding the total body of 
knowledge about this important potential advance in the treatment of breast cancer. 
Even if these data prove inadequate on their own, combined with data from other similar 
studies, they will help establish the definitive role for primary systemic therapy in the 
treatment of breast cancer. 
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12.2 DIRECTION FOR FUTURE RESEARCH 
Axillary lymph nodes remain the single most important indicator of prognosis in breast 
cancer, and continue to be used as the main criterion for selecting patients for aggressive 
chemotherapy (t3onadonna and Valagussa: 1995; Steward: 1995; Bonadonna: 1992). 
Although post treatment nodal status continues to indicate the patient's prognosis, it would be 
desirable to have a method of identifying high risk patients who may be candidates for 
aggressive chemotherapy before treatment is started. Developments in imaging technology 
such as colour Doppler (Walsh et a/: 1994), and positron emission tomography (Alder et al: 
1993; Niewcg et al: 1993) may be able to identify some patients, although false negatives 
relative to surgery however remain high. What may decide the ultimate usefulness of these ,,, 
non -invasive tests will be the relationship between "radiological nodal status" and prognosis. 
Single centre trials such as this one have the advantage of being able to successfully 
implement complex treatment regimes, and to carry out detailed studies of outcomes other 
than survival. such as the comparative studies of psychological and surgical morbidity 
presented in this thesis. Realistic comparisons of useful treatment gains however require much 
larger numbers of patients than a single centre is ever likely to recruit. For example, A 
reduction in the odds of death from 50% to 40% will provide substantial benefits to large 
numbers of women, but will require over 800 patients in order to have an 80 %, chance of 
being detected. 
Primary systemic treatment can be used to provide relatively rapid assessment of new 
treatment regimes relative to each other, by assessing the direct effect on the tumour. For 
example it will not he unreasonable to expect an improvement in response rate from 40% to 
70% with two different chemotherapy regimes. Such a difference will be detectable with 80% 
power in 100 patients. Of course such a trial may well be too small to detect a survival 
advantage, but provided that the design is kept simple, will point the way for larger 
collaborative trials, as well as adding to the pool of data for future meta -analyses. 
This thesis has concentrated on the clinical aspects of primary systemic 
treatment. One of the 
most attractive aspects of this treatment is the unique opportunity 
it offers for studying the 
biology of a tumour during systemic therapy. Through such 
studies it may ultimately be 
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possible to predict the behaviour of a tumour and to tailor -make treatment to specific tumours. 
Many questions must be answered before this vision can be realised. 
Any serious study of tumour biology however will require examination of tissue samples. For 
patients already worn down by the rigors of their breast cancer treatment even a minimally 
invasive test such as a fine needle aspirate represents a significant imposition. Establishing an 
adequate method of tumour sampling is the first priority if such studies are to be performed. 
Some work has been done on the cell yield of fine needle aspirates (Mullen and Miller: 1989; 
Hartley et al: 1988) and limited attempts have been made to study biological markers in 
breast aspirates. often in conjunction with flow cytometry (Forouhi et al: 1992; Zbicranowski 
el al: 1992; Fuhr et al: 1992; Spyratos el al: 1992; Palmer et al: 1988; Remvikos et al: 
1989; Fernando et al: 1995; Bozzetti et al: 1994). Much work is still needed to assess the 
efficacy of minimally invasive sampling methods and to develop techniques of biological study 
before meaningful numbers of patients can be approached to undergo repeated tumour 
sampling. 
At the time of starting this trial primary systemic therapy for operable breast cancer was 
regarded as a highly experimental technique. Although it is now more frequently used, much 
more data are needed before its role in the treatment of breast cancer is clarified. This should 
be forthcoming as this and other trials of primary systemic therapy mature. In the mean time it 
is important that the efficacy and morbidity of primary systemic therapy continues to be 
closely monitored. 
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14. 
APPENDIX 
14.1 LIFE TABLES 
The life tables relating to the survival curves displayed in the body of the thesis are presented 
in this section. The material included in each life table and the figure to which each life table 
refers is provided in the caption. 
"Ihe following notation is used for the life tables: 
Interval: time interval, in months, for which the risk is calculated 
No: Number of patients at risk at the starty of the interval 
Ev: Number of events (recurrence, death etc.) during the interval 
('e: Number of patients cencorcd during the interval 
PS: Probability of remaining free of events during the interval 
95'; ('I 1)5'; confidence intervals for "PS ". 
The life tables are presented in the following pages. 
Interval No Ev Ce PS 95°óCl 
1 to 2 78 1 0 0.99 0.91 - 1.00 
2 to 3 77 1 0 0.97 0.90 - 0.99 
8 to 9 76 1 0 0.96 0.89 - 0.99 
9 to 10 75 1 0 0.95 0.87 - 0.98 
10 to 11 74 2 0 0.92 0.84 - 0.96 
11 to 12 72 1 0 0.91 0.82 - 0.96 
12 to 13 71 1 0 0.90 0.81 - 0.95 
13 to 14 70 2 0 0.87 0.77 - 0.93 
14 to 15 68 1 0 0.86 0.76 - 0.92 
15 to 16 67 1 0 0.85 0.75 - 0.91 
16 to 17 66 1 0 0.83 0.73 - 0.90 
17 to 18 65 1 0 0.82 0.72 - 0.89 
18 to 19 64 1 0 0.81 0.70 - 0.88 
20 to 21 63 2 0 0.78 0.67 - 0.86 
21 to 22 61 1 0 0.77 0.66 - 0.85 
24 to 25 60 1 0 0.76 0.65 - 0.84 
26 to 27 59 1 0 0.74 0.63 - 0.83 
27 to 28 58 1 0 0.73 0.62 - 0.82 
28 to 29 57 2 0 0.71 0.59 - 0.79 
34 to 35 55 2 0 0.68 0.56 - 0.77 
43 to 44 53 2 0 0.65 0.54 - 0.75 
44 to 45 51 1 0 0.64 0.52 - 0.74 
47 to 48 50 1 0 0.63 0.51 - 0.72 
48 to 49 49 1 0 0.62 0.50 - 0.71 
49 to 50 48 1 0 0.60 0.49 - 0.70 
Interval No Ev Ce PS 95°óCl 
50 to 51 47 2 2 0.58 0.46 - 0.68 
51 to 52 43 0 1 0.58 0.46 - 0.68 
52 to 53 42 1 1 0.56 0.45 - 0.66 
53 to 54 40 0 1 0.56 0.45 - 0.66 
55 to 56 39 0 1 0.56 0.45 - 0.66 
56 to 57 38 0 5 0.56 0.45 - 0.66 
58 to 59 33 1 0 0.55 0.43 - 0.65 
59 to 60 32 0 1 0.55 0.43 - 0.65 
60 to 61 31 0 2 0.55 0.43 - 0.65 
61 to 62 29 0 1 0.55 0.43 - 0.65 
63 to 64 28 0 1 0.55 0.43 - 0.65 
64 to 65 27 0 4 0.55 0.43 - 0.65 
65 to 66 23 0 1 0.55 0.43 - 0.65 
66 to 67 22 0 1 0.55 0.43 - 0.65 
67 to 68 21 0 1 0.55 0.43 - 0.65 
68 to 69 20 1 3 0.52 0.39 - 0.63 
69 to 70 16 0 1 0.52 0.39 - 0.63 
70 to 71 15 0 3 0.52 0.39 - 0.63 
71 to 72 12 0 1 0.52 0.39 - 0.63 
72 to 73 11 0 3 0.52 0.39 - 0.63 
73 to 74 8 0 1 0.52 0.39 - 0.63 
75 to 76 7 0 3 0.52 0.39 - 0.63 
76 to 77 4 0 4 0.52 0.39 - 0.63 
Table 14 -1 Recurrence free survival for the cohort of patients in the first 
part of the trial 
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Interval No Ev Ce PS 95% CI 
5 to 6 78 1 0 0.99 0.91 - 1.00 
9 to 10 77 1 0 0.97 0.90 - 0.99 
10 to 11 76 3 0 0.94 0.85 - 0.97 
12 to 13 73 1 0 0.92 0.84 - 0.96 
16 to 17 72 1 0 0.91 0.82 - 0.96 
17 to 18 71 2 0 0.88 0.79 - 0.94 
19 to 20 69 1 0 0.87 0.77 - 0.93 
21 to 22 68 1 0 0.86 0.76 - 0.92 
22 to 23 67 1 0 0.85 0.75 - 0.91 
25 to 26 66 2 0 0.82 0.72 - 0.89 
27 to 28 64 1 0 0.81 0.70 - 0.88 
29 to 30 63 1 0 0.79 0.69 - 0.87 
30 to 31 62 1 0 0.78 0.67 - 0.86 
31 to 32 61 2 0 0.76 0.65 - 0.84 
36 to 37 59 1 0 0.74 0.63 - 0.83 
41 to 42 58 1 0 0.73 0.62 - 0.82 
45 to 46 57 1 0 0.72 0.60 - 0.80 
48 to 49 56 1 0 0.71 0.59 - 0.79 
49 to 50 55 1 0 0.69 0.58 - 0.78 
50 to 51 54 0 2 0.69 0.58 - 0.78 
51 to 52 52 2 1 0.67 0.55 - 0.76 
Interval No Ev Ce PS 95% CI 
52 to 53 49 0 2 0.67 0.55 - 0.76 
53 to 54 47 1 1 0.65 0.53 - 0.75 
55 to 56 45 1 1 0.64 0.52 - 0.73 
56 to 57 43 0 5 0.64 0.52 - 0.73 
59 to 60 38 1 1 0.62 0.50 - 0.72 
60 to 61 36 0 2 0.62 0.50 - 0.72 
61 to 62 34 0 1 0.62 0.50 - 0.72 
63 to 64 33 2 1 0.58 0.46 - 0.69 
64 to 65 30 0 4 0.58 0.46 - 0.69 
65 to 66 26 0 1 0.58 0.46 - 0.69 
66 to 67 25 0 1 0.58 0.46 - 0.69 
67 to 68 24 1 1 0.56 0.43 - 0.67 
68 to 69 22 0 4 0.56 0.43 - 0.67 
69 to 70 18 0 1 0.56 0.43 - 0.67 
70 to 71 17 0 3 0.56 0.43 - 0.67 
71 to 72 14 0 1 0.56 0.43 - 0.67 
72 to 73 13 0 5 0.56 0.43 - 0.67 
73 to 74 8 0 1 0.56 0.43 - 0.67 
75 to 76 7 1 3 0.46 0.25 - 0.64 
76 to 77 3 0 3 0.46 0.25 - 0.64 
Table 14 -2 Overall survival for patients in the first part of the trial 
Interval No Ev Ce PS 95% CI 
Conventional treatment 
1 to 2 38 1 0 0.97 0.83 - 1.00 
2 to 3 37 1 0 0.95 0.81 - 0.99 
8 to 9 36 1 0 0.92 0.77 - 0.97 
10 to 11 35 2 0 0.87 0.71 - 0.94 
11 to 12 33 1 0 0.84 0.68 - 0.93 
13 to 14 32 2 0 0.79 0.62 - 0.89 
16 to 17 30 1 0 0.76 0.59 - 0.87 
17 to 18 29 1 0 0.74 0.57 - 0.85 
24 to 25 28 1 0 0.71 0.54 - 0.83 
26 to 27 27 1 0 0.68 0.51 - 0.81 
34 to 35 26 2 0 0.63 0.46 - 0.76 
43 to 44 24 1 0 0.61 0.43 - 0.74 
47 to 48 23 1 0 0.58 0.41 - 0.72 
48 to 49 22 1 0 0.55 0.38 - 0.69 
49 to 50 21 1 0 0.53 0.36 - 0.67 
50 to 51 20 0 2 0.53 0.36 - 0.67 
52 to 53 18 1 0 0.50 0.33 - 0.64 
53 to 54 17 0 1 0.50 0.33 - 0.64 
56 to 57 16 0 1 0.50 0.33 - 0.64 
59 to 60 15 0 1 0.50 0.33 - 0.64 
60 to 61 14 0 1 0.50 0.33 - 0.64 
61 to 62 13 0 1 0.50 0.33 - 0.64 
64 to 65 12 0 2 0.50 0.33 - 0.64 
65 to 66 10 0 1 0.50 0.33 - 0.64 
67 to 68 9 0 1 0.50 0.33 - 0.64 
68 to 69 8 1 1 0.43 0.25 - 0.60 
69 to 70 6 0 1 0.43 0.25 - 0.60 
70 to 71 5 0 2 0.43 0.25 - 0.60 
72 to 73 3 0 1 0.43 0.25 - 0.60 
76 to 77 2 0 2 0.43 0.25 - 0.60 
Interval No Ev Ce PS 95% CI 
Primary systemic treatment 
9 to 10 40 1 0 0.98 0.84 - 1.00 
12 to 13 39 1 0 0.95 0.81 - 0.99 
14 to 15 38 1 0 0.93 0.79 - 0.98 
15 to 16 37 1 0 0.90 0.76 - 0.96 
18 to 19 36 1 0 0.88 0.73 - 0.95 
20 to 21 35 2 0 0.83 0.67 - 0.91 
21 to 22 33 1 0 0.80 0.64 - 0.89 
27 to 28 32 1 0 0.78 0.61 - 0.88 
28 to 29 31 2 0 0.73 0.56 - 0.84 
43 to 44 29 1 0 0.70 0.53 - 0.82 
44 to 45 28 1 0 0.68 0.51 - 0.80 
50 to 51 27 2 0 0.63 0.46 - 0.75 
51 to 52 25 0 1 0.63 0.46 - 0.75 
52 to 53 24 0 1 0.63 0.46 - 0.75 
55 to 56 23 0 1 0.63 0.46 - 0.75 
56 to 57 22 0 4 0.63 0.46 - 0.75 
58 to 59 18 1 0 0.59 0.42 - 0.73 
60 to 61 17 0 1 0.59 0.42 - 0.73 
63 to 64 16 0 1 0.59 0.42 - 0.73 
64 to 65 15 0 2 0.59 0.42 - 0.73 
66 to 67 13 0 1 0.59 0.42 - 0.73 
68 to 69 12 0 2 0.59 0.42 - 0.73 
70 to 71 10 0 1 0.59 0.42 - 0.73 
71 to 72 9 0 1 0.59 0.42 - 0.73 
72 to 73 8 0 2 0.59 0.42 - 0.73 
73 to 74 6 0 1 0.59 0.42 - 0.73 
75 to 76 5 0 3 0.59 0.42 - 0.73 
76 to 77 2 0 2 0.59 0.42 - 0.73 
Table 14 -3: Recurrence free survival by intention to treat for patients in the 
first part of the trial 
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Interval No Ev Ce PS 95% CI 
Conventional treatment 
1 to 2 40 1 0 0.98 0.84 - 1.00 
2 to 3 39 1 0 0.95 0.81 - 0.99 
8 to 9 38 1 0 0.93 0.79 - 0.98 
10 to 11 37 2 0 0.88 0.73 - 0.95 
11 to 12 35 1 0 0.85 0.70 - 0.93 
13 to 14 34 2 0 0.80 0.64 - 0.89 
16 to 17 32 1 0 0.78 0.61 - 0.88 
17 to 18 31 1 0 0.75 0.59 - 0.86 
24 to 25 30 1 0 0.73 0.56 - 0.84 
26 to 27 29 1 0 0.70 0.53 - 0.82 
34 to 35 28 1 0 0.68 0.51 - 0.80 
43 to 44 27 1 0 0.65 0.48 - 0.78 
44 to 45 26 1 0 0.63 0.46 - 0.75 
47 to 48 25 1 0 0.60 0.43 - 0.73 
48 to 49 24 1 0 0.58 0.41 - 0.71 
49 to 50 23 1 0 0.55 0.38 - 0.69 
50 to 51 22 0 2 0.55 0.38 - 0.69 
51 to 52 20 0 1 0.55 0.38 - 0.69 
52 to 53 19 1 0 0.52 0.36 - 0.66 
53 to 54 18 0 1 0.52 0.36 - 0.66 
56 to 57 17 0 1 0.52 0.36 - 0.66 
59 to 60 16 0 1 0.52 0.36 - 0.66 
60 to 61 15 0 1 0.52 0.36 - 0.66 
61 to 62 14 0 1 0.52 0.36 - 0.66 
64 to 65 13 0 3 0.52 0.36 - 0.66 
65 to 66 10 0 1 0.52 0.36 - 0.66 
67 to 68 9 0 1 0.52 0.36 - 0.66 
68 to 69 8 1 1 0.45 0.26 - 0.62 
69 to 70 6 0 1 0.45 0.26 - 0.62 
70 to 71 5 0 2 0.45 0.26 - 0.62 



















Primary systemic treatment 
9 to 10 38 1 0 0.97 0.83 - 1.00 
12 to 13 37 1 0 0.95 0.81 - 0.99 
14 to 15 36 1 0 0.92 0.77 - 0.97 
15 to 16 35 1 0 0.89 0.74 - 0.96 
18 to 19 34 1 0 0.87 0.71 - 0.94 
20 to 21 33 2 0 0.82 0.65 - 0.91 
21 to 22 31 1 0 0.79 0.62 - 0.89 
27 to 28 30 1 0 0.76 0.59 - 0.87 
28 to 29 29 2 0 0.71 0.54 - 0.83 
34 to 35 27 1 0 0.68 0.51 - 0.81 
43 to 44 26 1 0 0.66 0.48 - 0.78 
50 to 51 25 2 0 0.61 0.43 - 0.74 
52 to 53 23 0 1 0.61 0.43 - 0.74 
55 to 56 22 0 1 0.61 0.43 - 0.74 
56 to 57 21 0 4 0.61 0.43 - 0.74 
58 to 59 17 1 0 0.57 0.39 - 0.71 
60 to 61 16 0 1 0.57 0.39 - 0.71 
63 to 64 15 0 1 0.57 0.39 - 0.71 
64 to 65 14 0 1 0.57 0.39 - 0.71 
66 to 67 13 0 1 0.57 0.39 - 0.71 
68 to 69 12 0 2 0.57 0.39 - 0.71 
70 to 71 10 0 1 0.57 0.39 - 0.71 
71 to 72 9 0 1 0.57 0.39 - 0.71 
72 to 73 8 0 2 0.57 0.39 - 0.71 
73 to 74 6 0 1 0.57 0.39 - 0.71 
75 to 76 5 0 3 0.57 0.39 - 0.71 
76 to 77 2 0 2 0.57 0.39 - 0.71 
Table 14 -4: Recurrence free survival by actual treatments given for patients 
in the first part of the trial 
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Interval No Ev I Ce I PS I 95% CI 
Conventional treatment 
5 to 6 86 1 0 0.99 0.92 - 1.00 
9 to 10 85 2 0 0.97 0.90 - 0.99 
10 to 11 83 3 1 0.93 0.85 - 0.97 
11 to 12 79 0 5 0.93 0.85 - 0.97 
12 to 13 74 1 2 0.92 0.83 - 0.96 
13 to 14 71 0 1 0.92 0.83 - 0.96 
14 to 15 70 0 1 0.92 0.83 - 0.96 
16 to 17 69 1 0 0.90 0.82 - 0.95 
17 to 18 68 1 2 0.89 0.80 - 0.94 
18 to 19 65 0 1 0.89 0.80 - 0.94 
19 to 20 64 0 1 0.89 0.80 - 0.94 
20 to 21 63 0 2 0.89 0.80 - 0.94 
21 to 22 61 1 2 0.88 0.78 - 0.93 
22 to 23 58 2 0 0.85 0.74 - 0.91 
23 to 24 56 0 2 0.85 0.74 - 0.91 
24 to 25 54 2 1 0.81 0.70 - 0.89 
25 to 26 51 1 0 0.80 0.69 - 0.87 
27 to 28 50 0 3 0.80 0.69 - 0.87 
29 to 30 47 0 1 0.80 0.69 - 0.87 
31 to 32 46 0 1 0.80 0.69 - 0.87 
34 to 35 45 1 1 0.78 0.66 - 0.86 
35 to 36 43 0 1 0.78 0.66 - 0.86 
36 to 37 42 1 2 0.76 0.64 - 0.85 
37 to 38 39 0 1 0.76 0.64 - 0.85 
40 to 41 38 0 1 0.76 0.64 - 0.85 
41 to 42 37 0 1 0.76 0.64 - 0.85 
43 to 44 36 0 2 0.76 0.64 - 0.85 
44 to 45 34 0 2 0.76 0.64 - 0.85 
46 to 47 32 0 1 0.76 0.64 - 0.85 
47 to 48 31 0 2 0.76 0.64 - 0.85 
48 to 49 29 1 0 0.73 0.61 - 0.83 
49 to 50 28 1 1 0.71 0.57 - 0.81 
50 to 51 26 0 2 0.71 0.57 - 0.81 
52 to 53 24 0 1 0.71 0.57 - 0.81 
53 to 54 23 1 1 0.68 0.53 - 0.79 
55 to 56 21 1 1 0.64 0.49 - 0.76 
56 to 57 19 0 1 0.64 0.49 - 0.76 
59 to 60 18 1 1 0.61 0.44 - 0.74 
60 to 61 16 0 1 0.61 0.44 - 0.74 
61 to 62 15 0 1 0.61 0.44 - 0.74 
63 to 64 14 1 0 0.56 0.39 - 0.70 
64 to 65 13 0 2 0.56 0.39 - 0.70 
65 to 66 11 0 1 0.56 0.39 - 0.70 
67 to 68 10 1 1 0.50 0.32 - 0.67 
68 to 69 8 0 1 0.50 0.32 - 0.67 
69 to 70 7 0 1 0.50 0.32 - 0.67 
70 to 71 6 0 2 0.50 0.32 - 0.67 
72 to 73 4 0 2 0.50 0.32 - 0.67 
76 to 77 2 0 2 0.50 0.32 - 0.67 
Primary systemic treatment 
9 to 10 85 0 1 1.00 . - . 
Interval No Ev Ce PS 95% CI 
10 to 11 84 1 0 0.99 0.92 - 1.00 
11 to 12 83 1 0 0.98 0.91 - 0.99 
12 to 13 82 0 3 0.98 0.91 - 0.99 
14 to 15 79 0 3 0.98 0.91 - 0.99 
15 to 16 76 0 2 0.98 0.91 - 0.99 
16 to 17 74 0 1 0.98 0.91 - 0.99 
17 to 18 73 1 0 0.96 0.89 - 0.99 
18 to 19 72 0 3 0.96 0.89 - 0.99 
19 to 20 69 1 1 0.95 0.87 - 0.98 
20 to 21 67 0 1 0.95 0.87 - 0.98 
21 to 22 66 0 1 0.95 0.87 - 0.98 
22 to 23 65 0 1 0.95 0.87 - 0.98 
23 to 24 64 1 2 0.93 0.85 - 0.97 
24 to 25 61 0 1 0.93 0.85 - 0.97 
25 to 26 60 2 2 0.90 0.80 - 0.95 
26 to 27 56 0 1 0.90 0.80 - 0.95 
27 to 28 55 1 1 0.89 0.78 - 0.94 
29 to 30 53 1 0 0.87 0.76 - 0.93 
30 to 31 52 1 2 0.85 0.74 - 0.92 
31 to 32 49 3 0 0.80 0.68 - 0.88 
34 to 35 46 0 1 0.80 0.68 - 0.88 
35 to 36 45 0 1 0.80 0.68 - 0.88 
38 to 39 44 0 1 0.80 0.68 - 0.88 
39 to 40 43 1 0 0.78 0.66 - 0.87 
40 to 41 42 0 1 0.78 0.66 - 0.87 
41 to 42 41 1 1 0.76 0.63 - 0.85 
42 to 43 39 0 2 0.76 0.63 - 0.85 
43 to 44 37 0 3 0.76 0.63 - 0.85 
44 to 45 34 0 1 0.76 0.63 - 0.85 
45 to 46 33 1 0 0.74 0.61 - 0.83 
48 to 49 32 0 3 0.74 0.61 - 0.83 
51 to 52 29 2 1 0.69 0.54 - 0.79 
52 to 53 26 0 1 0.69 0.54 - 0.79 
55 to 56 25 0 1 0.69 0.54 - 0.79 
56 to 57 24 0 4 0.69 0.54 - 0.79 
60 to 61 20 0 1 0.69 0.54 - 0.79 
63 to 64 19 1 1 0.65 0.49 - 0.77 
64 to 65 17 0 2 0.65 0.49 - 0.77 
66 to 67 15 0 1 0.65 0.49 - 0.77 
68 to 69 14 0 3 0.65 0.49 - 0.77 
70 to 71 11 0 1 0.65 0.49 - 0.77 
71 to 72 10 0 1 0.65 0.49 - 0.77 
72 to 73 9 0 3 0.65 0.49 - 0.77 
73 to 74 6 0 1 0.65 0.49 - 0.77 
75 to 76 5 1 3 0.46 0.15 - 0.73 
76 to 77 1 0 1 0.46 0.15 - 0.73 
Table 14 -5: Overall survival by intention to treat for patients in the first part 
of the trial 
Appendix: life tables 14 -327 
Interval No Ev 
I 
Ce I PS 1 95% CI 
Conventional treatment 
5 to 6 91 1 0 0.99 0.92 - 1.00 
9 to 10 90 2 0 0.97 0.90 - 0.99 
10 to 11 88 3 1 0.93 0.86 - 0.97 
11 to 12 84 0 5 0.93 0.86 - 0.97 
12 to 13 79 1 3 0.92 0.84 - 0.96 
13 to 14 75 0 1 0.92 0.84 - 0.96 
14 to 15 74 0 1 0.92 0.84 - 0.96 
16 to 17 73 1 0 0.91 0.83 - 0.95 
17 to 18 72 1 2 0.90 0.81 - 0.94 
18 to 19 69 0 1 0.90 0.81 - 0.94 
19 to 20 68 0 1 0.90 0.81 - 0.94 
20 to 21 67 0 2 0.90 0.81 - 0.94 
21 to 22 65 1 2 0.88 0.79 - 0.94 
22 to 23 62 2 0 0.85 0.76 - 0.91 
23 to 24 60 0 3 0.85 0.76 - 0.91 
24 to 25 57 2 1 0.82 0.72 - 0.89 
25 to 26 54 1 0 0.81 0.70 - 0.88 
27 to 28 53 0 3 0.81 0.70 - 0.88 
29 to 30 50 0 1 0.81 0.70 - 0.88 
31 to 32 49 1 1 0.79 0.68 - 0.87 
34 to 35 47 1 1 0.77 0.66 - 0.85 
35 to 36 45 0 1 0.77 0.66 - 0.85 
36 to 37 44 1 2 0.76 0.64 - 0.84 
37 to 38 41 0 1 0.76 0.64 - 0.84 
40 to 41 40 0 1 0.76 0.64 - 0.84 
41 to 42 39 0 1 0.76 0.64 - 0.84 
43 to 44 38 0 2 0.76 0.64 - 0.84 
44 to 45 36 0 2 0.76 0.64 - 0.84 
45 to 46 34 1 0 0.73 0.61 - 0.82 
46 to 47 33 0 1 0.73 0.61 - 0.82 
47 to 48 32 0 2 0.73 0.61 - 0.82 
49 to 50 30 1 1 0.71 0.58 - 0.81 
50 to 51 28 0 2 0.71 0.58 - 0.81 
51 to 52 26 0 1 0.71 0.58 - 0.81 
52 to 53 25 0 1 0.71 0.58 - 0.81 
53 to 54 24 1 1 0.68 0.54 - 0.79 
55 to 56 22 1 1 0.65 0.50 - 0.76 
56 to 57 20 0 1 0.65 0.50 - 0.76 
59 to 60 19 1 1 0.61 0.46 - 0.74 
60 to 61 17 0 1 0.61 0.46 - 0.74 
61 to 62 16 0 1 0.61 0.46 - 0.74 
63 to 64 15 1 0 0.57 0.41 - 0.71 
64 to 65 14 0 3 0.57 0.41 - 0.71 
65 to 66 11 0 1 0.57 0.41 - 0.71 
67 to 68 10 1 1 0.51 0.33 - 0.67 
68 to 69 8 0 1 0.51 0.33 - 0.67 
69 to 70 7 0 1 0.51 0.33 - 0.67 
70 to 71 6 0 2 0.51 0.33 - 0.67 
72 to 73 4 0 2 0.51 0.33 - 0.67 
76 to 77 2 0 2 0.51 0.33 - 0.67 
primary systemic treatment 
Interval No Ev Ce PS 95% CI 
9 to 10 80 0 1 1.00 . - . 
10 to 11 79 1 0 0.99 0.91 - 1.00 
11 to 12 78 1 0 0.97 0.90 - 0.99 
12 to 13 77 0 2 0.97 0.90 - 0.99 
14 to 15 75 0 3 0.97 0.90 - 0.99 
15 to 16 72 0 2 0.97 0.90 - 0.99 
16 to 17 70 0 1 0.97 0.90 - 0.99 
17 to 18 69 1 0 0.96 0.88 - 0.99 
18 to 19 68 0 3 0.96 0.88 - 0.99 
19 to 20 65 1 1 0.95 0.86 - 0.98 
20 to 21 63 0 1 0.95 0.86 - 0.98 
21 to 22 62 0 1 0.95 0.86 - 0.98 
22 to 23 61 0 1 0.95 0.86 - 0.98 
23 to 24 60 1 1 0.93 0.84 - 0.97 
24 to 25 58 0 1 0.93 0.84 - 0.97 
25 to 26 57 2 2 0.90 0.79 - 0.95 
26 to 27 53 0 1 0.90 0.79 - 0.95 
27 to 28 52 1 1 0.88 0.77 - 0.94 
29 to 30 50 1 0 0.86 0.75 - 0.93 
30 to 31 49 1 2 0.84 0.73 - 0.91 
31 to 32 46 2 0 0.81 0.68 - 0.89 
34 to 35 44 0 1 0.81 0.68 - 0.89 
35 to 36 43 0 1 0.81 0.68 - 0.89 
38 to 39 42 0 1 0.81 0.68 - 0.89 
39 to 40 41 1 0 0.79 0.66 - 0.87 
40 to 41 40 0 1 0.79 0.66 - 0.87 
41 to 42 39 1 1 0.77 0.64 - 0.86 
42 to 43 37 0 2 0.77 0.64 - 0.86 
43 to 44 35 0 3 0.77 0.64 - 0.86 
44 to 45 32 0 1 0.77 0.64 - 0.86 
48 to 49 31 1 3 0.74 0.60 - 0.84 
51 to 52 27 2 0 0.69 0.54 - 0.80 
52 to 53 25 0 1 0.69 0.54 - 0.80 
55 to 56 24 0 1 0.69 0.54 - 0.80 
56 to 57 23 0 4 0.69 0.54 - 0.80 
60 to 61 19 0 1 0.69 0.54 - 0.80 
63 to 64 18 1 1 0.65 0.48 - 0.77 
64 to 65 16 0 1 0.65 0.48 - 0.77 
66 to 67 15 0 1 0.65 0.48 - 0.77 
68 to 69 14 0 3 0.65 0.48 - 0.77 
70 to 71 11 0 1 0.65 0.48 - 0.77 
71 to 72 10 0 1 0.65 0.48 - 0.77 
72 to 73 9 0 3 0.65 0.48 - 0.77 
73 to 74 6 0 1 0.65 0.48 - 0.77 
75 to 76 5 1 3 0.46 0.15 - 0.73 
76 to 77 1 0 1 0.46 0.15 - 0.73 
Table 14 -6: Overall survival by actual treatments given for patients in the 
first part of the trial 
Appendix: life tables 14 -328 
Interval No Ev Ce PS 95% Cl 
1 to 2 170 1 0 0.99 0.96 - 1.00 
2 to 3 169 2 0 0.98 0.95 - 0.99 
5 to 6 167 2 0 0.97 0.93 - 0.99 
8 to 9 165 2 0 0.96 0.92 - 0.98 
9 to 10 163 1 1 0.95 0.91 - 0.98 
10 to 11 161 3 1 0.94 0.89 - 0.96 
11 to 12 157 2 5 0.92 0.87 - 0.95 
12 to 13 150 2 5 0.91 0.86 - 0.95 
13 to 14 143 2 1 0.90 0.84 - 0.94 
14 to 15 140 2 4 0.88 0.83 - 0.92 
15 to 16 134 2 1 0.87 0.81 - 0.91 
16 to 17 131 1 1 0.86 0.80 - 0.91 
17 to 18 129 2 1 0.85 0.79 - 0.90 
18 to 19 126 1 4 0.84 0.78 - 0.89 
19 to 20 121 0 2 0.84 0.78 - 0.89 
20 to 21 119 2 3 0.83 0.76 - 0.88 
21 to 22 114 1 3 0.82 0.75 - 0.87 
22 to 23 110 0 1 0.82 0.75 - 0.87 
23 to 24 109 0 4 0.82 0.75 - 0.87 
24 to 25 105 3 3 0.80 0.73 - 0.85 
25 to 26 99 0 2 0.80 0.73 - 0.85 
26 to 27 97 1 1 0.79 0.72 - 0.85 
27 to 28 95 2 4 0.77 0.70 - 0.83 
28 to 29 89 2 0 0.76 0.68 - 0.82 
29 to 30 87 0 1 0.76 0.68 - 0.82 
30 to 31 86 0 1 0.76 0.68 - 0.82 
31 to 32 85 0 1 0.76 0.68 - 0.82 
34 to 35 84 2 2 0.74 0.66 - 0.80 
35 to 36 80 0 2 0.74 0.66 - 0.80 
36 to 37 78 0 2 0.74 0.66 - 0.80 
37 to 38 76 0 1 0.74 0.66 - 0.80 
38 to 39 75 0 1 0.74 0.66 - 0.80 
40 to 41 74 0 2 0.74 0.66 - 0.80 
41 to 42 72 0 2 0.74 0.66 - 0.80 
Interval No Ev Ce PS 95% CI 
42 to 43 70 0 2 0.74 0.66 - 0.80 
43 to 44 68 3 4 0.70 0.62 - 0.78 
44 to 45 61 1 3 0.69 0.60 - 0.77 
46 to 47 57 0 1 0.69 0.60 - 0.77 
47 to 48 56 1 1 0.68 0.59 - 0.76 
48 to 49 54 1 3 0.67 0.57 - 0.74 
49 to 50 50 2 1 0.64 0.54 - 0.72 
50 to 51 47 2 2 0.61 0.51 - 0.70 
51 to 52 43 0 1 0.61 0.51 - 0.70 
52 to 53 42 1 1 0.60 0.49 - 0.69 
53 to 54 40 0 1 0.60 0.49 - 0.69 
55 to 56 39 0 1 0.60 0.49 - 0.69 
56 to 57 38 0 5 0.60 0.49 - 0.69 
58 to 59 33 1 0 0.58 0.47 - 0.67 
59 to 60 32 0 1 0.58 0.47 - 0.67 
60 to 61 31 0 2 0.58 0.47 - 0.67 
61 to 62 29 0 1 0.58 0.47 - 0.67 
63 to 64 28 0 1 0.58 0.47 - 0.67 
64 to 65 27 0 4 0.58 0.47 - 0.67 
65 to 66 23 0 1 0.58 0.47 - 0.67 
66 to 67 22 0 1 0.58 0.47 - 0.67 
67 to 68 21 0 1 0.58 0.47 - 0.67 
68 to 69 20 1 3 0.55 0.43 - 0.65 
69 to 70 16 0 1 0.55 0.43 - 0.65 
70 to 71 15 0 3 0.55 0.43 - 0.65 
71 to 72 12 0 1 0.55 0.43 - 0.65 
72 to 73 11 0 3 0.55 0.43 - 0.65 
73 to 74 8 0 1 0.55 0.43 - 0.65 
75 to 76 7 0 3 0.55 0.43 - 0.65 
76 to 77 4 0 4 0.55 0.43 - 0.65 
Table 14 -7: Disease free survival for all patients in the trial 
Appendix: life tables 14 -329 
Interval No Ev Ce PS 95% CI 
5 to 6 170 1 0 0.99 0.96 - 1.00 
9 to 10 169 2 1 0.98 0.95 - 0.99 
10 to 11 166 4 1 0.96 0.92 - 0.98 
11 to 12 161 1 5 0.95 0.91 - 0.98 
12 to 13 155 1 5 0.95 0.90 - 0.97 
13 to 14 149 0 1 0.95 0.90 - 0.97 
14 to 15 148 0 4 0.95 0.90 - 0.97 
15 to 16 144 0 2 0.95 0.90 - 0.97 
16 to 17 142 1 1 0.94 0.89 - 0.97 
17 to 18 140 2 2 0.93 0.87 - 0.96 
18 to 19 136 0 4 0.93 0.87 - 0.96 
19 to 20 132 1 2 0.92 0.86 - 0.95 
20 to 21 129 0 3 0.92 0.86 - 0.95 
21 to 22 126 1 3 0.91 0.86 - 0.95 
22 to 23 122 2 1 0.90 0.84 - 0.94 
23 to 24 119 1 4 0.89 0.83 - 0.93 
24 to 25 114 2 2 0.87 0.81 - 0.92 
25 to 26 110 3 2 0.85 0.78 - 0.90 
26 to 27 105 0 1 0.85 0.78 - 0.90 
27 to 28 104 1 4 0.84 0.77 - 0.89 
29 to 30 99 1 1 0.83 0.76 - 0.89 
30 to 31 97 1 2 0.82 0.75 - 0.88 
31 to 32 94 3 1 0.80 0.72 - 0.86 
34 to 35 90 1 2 0.79 0.71 - 0.85 
35 to 36 87 0 2 0.79 0.71 - 0.85 
36 to 37 85 1 2 0.78 0.70 - 0.84 
37 to 38 82 0 1 0.78 0.70 - 0.84 
38 to 39 81 0 1 0.78 0.70 - 0.84 
39 to 40 80 1 0 0.77 0.69 - 0.83 
40 to 41 79 0 2 0.77 0.69 - 0.83 
41 to 42 77 1 2 0.76 0.67 - 0.82 
42 to 43 74 0 2 0.76 0.67 - 0.82 
Interval No Ev Ce PS 95% CI 
43 to 44 72 0 5 0.76 0.67 - 0.82 
44 to 45 67 0 3 0.76 0.67 - 0.82 
45 to 46 64 1 0 0.75 0.66 - 0.82 
46 to 47 63 0 1 0.75 0.66 - 0.82 
47 to 48 62 0 2 0.75 0.66 - 0.82 
48 to 49 60 1 3 0.73 0.64 - 0.80 
49 to 50 56 1 1 0.72 0.63 - 0.79 
50 to 51 54 0 2 0.72 0.63 - 0.79 
51 to 52 52 2 1 0.69 0.60 - 0.77 
52 to 53 49 0 2 0.69 0.60 - 0.77 
53 to 54 47 1 1 0.68 0.58 - 0.76 
55 to 56 45 1 1 0.66 0.56 - 0.75 
56 to 57 43 0 5 0.66 0.56 - 0.75 
59 to 60 38 1 1 0.65 0.54 - 0.73 
60 to 61 36 0 2 0.65 0.54 - 0.73 
61 to 62 34 0 1 0.65 0.54 - 0.73 
63 to 64 33 2 1 0.61 0.49 - 0.70 
64 to 65 30 0 4 0.61 0.49 - 0.70 
65 to 66 26 0 1 0.61 0.49 - 0.70 
66 to 67 25 0 1 0.61 0.49 - 0.70 
67 to 68 24 1 1 0.58 0.46 - 0.68 
68 to 69 22 0 4 0.58 0.46 - 0.68 
69 to 70 18 0 1 0.58 0.46 - 0.68 
70 to 71 17 0 3 0.58 0.46 - 0.68 
71 to 72 14 0 1 0.58 0.46 - 0.68 
72 to 73 13 0 5 0.58 0.46 - 0.68 
73 to 74 8 0 1 0.58 0.46 - 0.68 
75 to 76 7 1 3 0.47 0.26 - 0.66 
76 to 77 3 0 3 0.47 0.26 - 0.66 
Table 14 -8: Overall survival for all patients in the trial 
Appendix: life tables 14 -330 
Interval No Ev I Ce PS I 95% CI 
Conventionl treatment 
1 to 2 85 1 0 0.99 0.92 - 1.00 
2 to 3 84 1 0 0.98 0.91 - 0.99 
8 to 9 83 2 0 0.95 0.88 - 0.98 
10 to 11 81 3 1 0.92 0.83 - 0.96 
11 to 12 77 2 5 0.89 0.80 - 0.94 
12 to 13 70 1 2 0.88 0.79 - 0.93 
13 to 14 67 2 1 0.85 0.76 - 0.91 
14 to 15 64 0 1 0.85 0.76 - 0.91 
15 to 16 63 1 0 0.84 0.74 - 0.90 
16 to 17 62 1 0 0.83 0.72 - 0.89 
17 to 18 61 2 1 0.80 0.69 - 0.87 
18 to 19 58 0 1 0.80 0.69 - 0.87 
19 to 20 57 0 1 0.80 0.69 - 0.87 
20 to 21 56 0 2 0.80 0.69 - 0.87 
21 to 22 54 0 2 0.80 0.69 - 0.87 
23 to 24 52 0 2 0.80 0.69 - 0.87 
24 to 25 50 1 2 0.78 0.67 - 0.86 
26 to 27 47 1 0 0.77 0.65 - 0.85 
27 to 28 46 0 3 0.77 0.65 - 0.85 
29 to 30 43 0 1 0.77 0.65 - 0.85 
31 to 32 42 0 1 0.77 0.65 - 0.85 
34 to 35 41 2 1 0.73 0.61 - 0.82 
35 to 36 38 0 1 0.73 0.61 - 0.82 
36 to 37 37 0 2 0.73 0.61 - 0.82 
37 to 38 35 0 1 0.73 0.61 - 0.82 
40 to 41 34 0 1 0.73 0.61 - 0.82 
41 to 42 33 0 1 0.73 0.61 - 0.82 
43 to 44 32 2 2 0.68 0.55 - 0.78 
44 to 45 28 0 2 0.68 0.55 - 0.78 
46 to 47 26 0 1 0.68 0.55 - 0.78 
47 to 48 25 1 1 0.65 0.51 - 0.76 
48 to 49 23 1 0 0.63 0.48 - 0.74 
49 to 50 22 1 1 0.60 0.45 - 0.72 
50 to 51 20 0 2 0.60 0.45 - 0.72 
52 to 53 18 1 0 0.56 0.41 - 0.69 
53 to 54 17 0 1 0.56 0.41 - 0.69 
56 to 57 16 0 1 0.56 0.41 - 0.69 
59 to 60 15 0 1 0.56 0.41 - 0.69 
60 to 61 14 0 1 0.56 0.41 - 0.69 
61 to 62 13 0 1 0.56 0.41 - 0.69 
64 to 65 12 0 2 0.56 0.41 - 0.69 
65 to 66 10 0 1 0.56 0.41 - 0.69 
67 to 68 9 0 1 0.56 0.41 - 0.69 
68 to 69 8 1 1 0.49 0.30 - 0.65 
69 to 70 6 0 1 0.49 0.30 - 0.65 
70 to 71 5 0 2 0.49 0.30 - 0.65 
72 to 73 3 0 1 0.49 0.30 - 0.65 
76 to 77 2 0 2 0.49 0.30 - 0.65 
Primary systemic treatment 
2 to 3 85 1 0 0.99 0.92 - 1.00 
Interval No Ev Ce PS 95% CI 
5 to 6 84 2 0 0.96 0.89 - 0.99 
9 to 10 82 1 1 0.95 0.88 - 0.98 
12 to 13 80 1 3 0.94 0.86 - 0.97 
14 to 15 76 2 3 0.92 0.83 - 0.96 
15 to 16 71 1 1 0.90 0.81 - 0.95 
16 to 17 69 0 1 0.90 0.81 - 0.95 
18 to 19 68 1 3 0.89 0.80 - 0.94 
19 to 20 64 0 1 0.89 0.80 - 0.94 
20 to 21 63 2 1 0.86 0.76 - 0.92 
21 to 22 60 1 1 0.85 0.74 - 0.91 
22 to 23 58 0 1 0.85 0.74 - 0.91 
23 to 24 57 0 2 0.85 0.74 - 0.91 
24 to 25 55 2 1 0.82 0.71 - 0.89 
25 to 26 52 0 2 0.82 0.71 - 0.89 
26 to 27 50 0 1 0.82 0.71 - 0.89 
27 to 28 49 2 1 0.78 0.67 - 0.86 
28 to 29 46 2 0 0.75 0.63 - 0.83 
30 to 31 44 0 1 0.75 0.63 - 0.83 
34 to 35 43 0 1 0.75 0.63 - 0.83 
35 to 36 42 0 1 0.75 0.63 - 0.83 
38 to 39 41 0 1 0.75 0.63 - 0.83 
40 to 41 40 0 1 0.75 0.63 - 0.83 
41 to 42 39 0 1 0.75 0.63 - 0.83 
42 to 43 38 0 2 0.75 0.63 - 0.83 
43 to 44 36 1 2 0.73 0.60 - 0.82 
44 to 45 33 1 1 0.70 0.57 - 0.80 
48 to 49 31 0 3 0.70 0.57 - 0.80 
49 to 50 28 1 0 0.68 0.54 - 0.78 
50 to 51 27 2 0 0.63 0.48 - 0.74 
51 to 52 25 0 1 0.63 0.48 - 0.74 
52 to 53 24 0 1 0.63 0.48 - 0.74 
55 to 56 23 0 1 0.63 0.48 - 0.74 
56 to 57 22 0 4 0.63 0.48 - 0.74 
58 to 59 18 1 0 0.59 0.44 - 0.72 
60 to 61 17 0 1 0.59 0.44 - 0.72 
63 to 64 16 0 1 0.59 0.44 - 0.72 
64 to 65 15 0 2 0.59 0.44 - 0.72 
66 to 67 13 0 1 0.59 0.44 - 0.72 
68 to 69 12 0 2 0.59 0.44 - 0.72 
70 to 71 10 0 1 0.59 0.44 - 0.72 
71 to 72 9 0 1 0.59 0.44 - 0.72 
72 to 73 8 0 2 0.59 0.44 - 0.72 
73 to 74 6 0 1 0.59 0.44 - 0.72 
75 to 76 5 0 3 0.59 0.44 - 0.72 
76 to 77 2 0 2 0.59 0.44 - 0.72 
Table 14 -9: Recurrence free survival for all patients in the trial by intention 
to treat 
Appendix: life tables 14 -331 
Interval No Ev I Ce PS I 95% CI 
Conventional treatment 
5 to 6 85 1 0 0.99 0.92 - 1.00 
9 to 10 84 2 0 0.96 0.89 - 0.99 
10 to 11 82 3 1 0.93 0.85 - 0.97 
11 to 12 78 0 5 0.93 0.85 - 0.97 
12 to 13 73 1 2 0.92 0.83 - 0.96 
13 to 14 70 0 1 0.92 0.83 - 0.96 
14 to 15 69 0 1 0.92 0.83 - 0.96 
16 to 17 68 1 0 0.90 0.81 - 0.95 
17 to 18 67 1 2 0.89 0.80 - 0.94 
18 to 19 64 0 1 0.89 0.80 - 0.94 
19 to 20 63 0 1 0.89 0.80 - 0.94 
20 to 21 62 0 2 0.89 0.80 - 0.94 
21 to 22 60 1 2 0.87 0.78 - 0.93 
22 to 23 57 2 0 0.84 0.74 - 0.91 
23 to 24 55 0 2 0.84 0.74 - 0.91 
24 to 25 53 2 1 0.81 0.70 - 0.88 
25 to 26 50 1 0 0.80 0.68 - 0.87 
27 to 28 49 0 3 0.80 0.68 - 0.87 
29 to 30 46 0 1 0.80 0.68 - 0.87 
31 to 32 45 0 1 0.80 0.68 - 0.87 
34 to 35 44 1 1 0.78 0.66 - 0.86 
35 to 36 42 0 1 0.78 0.66 - 0.86 
36 to 37 41 1 2 0.76 0.64 - 0.84 
37 to 38 38 0 1 0.76 0.64 - 0.84 
40 to 41 37 0 1 0.76 0.64 - 0.84 
41 to 42 36 0 1 0.76 0.64 - 0.84 
43 to 44 35 0 2 0.76 0.64 - 0.84 
44 to 45 33 0 2 0.76 0.64 - 0.84 
46 to 47 31 0 1 0.76 0.64 - 0.84 
47 to 48 30 0 2 0.76 0.64 - 0.84 
48 to 49 28 1 0 0.73 0.60 - 0.82 
49 to 50 27 1 1 0.70 0.56 - 0.80 
50 to 51 25 0 2 0.70 0.56 - 0.80 
52 to 53 23 0 1 0.70 0.56 - 0.80 
53 to 54 22 1 1 0.67 0.52 - 0.78 
55 to 56 20 1 0 0.64 0.48 - 0.76 
56 to 57 19 0 1 0.64 0.48 - 0.76 
59 to 60 18 1 1 0.60 0.44 - 0.73 
60 to 61 16 0 1 0.60 0.44 - 0.73 
61 to 62 15 0 1 0.60 0.44 - 0.73 
63 to 64 14 1 0 0.56 0.38 - 0.70 
64 to 65 13 0 2 0.56 0.38 - 0.70 
65 to 66 11 0 1 0.56 0.38 - 0.70 
67 to 68 10 1 1 0.50 0.31 - 0.66 
68 to 69 8 0 1 0.50 0.31 - 0.66 
69 to 70 7 0 1 0.50 0.31 - 0.66 
70 to 71 6 0 2 0.50 0.31 - 0.66 
72 to 73 4 0 2 0.50 0.31 - 0.66 
76 to 77 2 0 2 0.50 0.31 - 0.66 
Primary systemic treatment 
9 to 10 85 0 1 1.00 
Interval No Ev Ce PS 95% CI 
10 to 11 84 1 0 0.99 0.92 - 1.00 
11 to 12 83 1 0 0.98 0.91 - 0.99 
12 to 13 82 0 3 0.98 0.91 - 0.99 
14 to 15 79 0 3 0.98 0.91 - 0.99 
15 to 16 76 0 2 0.98 0.91 - 0.99 
16 to 17 74 0 1 0.98 0.91 - 0.99 
17 to 18 73 1 0 0.96 0.89 - 0.99 
18 to 19 72 0 3 0.96 0.89 - 0.99 
19 to 20 69 1 1 0.95 0.87 - 0.98 
20 to 21 67 0 1 0.95 0.87 - 0.98 
21 to 22 66 0 1 0.95 0.87 - 0.98 
22 to 23 65 0 1 0.95 0.87 - 0.98 
23 to 24 64 1 2 0.93 0.85 - 0.97 
24 to 25 61 0 1 0.93 0.85 - 0.97 
25 to 26 60 2 2 0.90 0.80 - 0.95 
26 to 27 56 0 1 0.90 0.80 - 0.95 
27 to 28 55 1 1 0.89 0.78 - 0.94 
29 to 30 53 1 0 0.87 0.76 - 0.93 
30 to 31 52 1 2 0.85 0.74 - 0.92 
31 to 32 49 3 0 0.80 0.68 - 0.88 
34 to 35 46 0 1 0.80 0.68 - 0.88 
35 to 36 45 0 1 0.80 0.68 - 0.88 
38 to 39 44 0 1 0.80 0.68 - 0.88 
39 to 40 43 1 0 0.78 0.66 - 0.87 
40 to 41 42 0 1 0.78 0.66 - 0.87 
41 to 42 41 1 1 0.76 0.63 - 0.85 
42 to 43 39 0 2 0.76 0.63 - 0.85 
43 to 44 37 0 3 0.76 0.63 - 0.85 
44 to 45 34 0 1 0.76 0.63 - 0.85 
45 to 46 33 1 0 0.74 0.61 - 0.83 
48 to 49 32 0 3 0.74 0.61 - 0.83 
51 to 52 29 2 1 0.69 0.54 - 0.79 
52 to 53 26 0 1 0.69 0.54 - 0.79 
55 to 56 25 0 1 0.69 0.54 - 0.79 
56 to 57 24 0 4 0.69 0.54 - 0.79 
60 to 61 20 0 1 0.69 0.54 - 0.79 
63 to 64 19 1 1 0.65 0.49 - 0.77 
64 to 65 17 0 2 0.65 0.49 - 0.77 
66 to 67 15 0 1 0.65 0.49 - 0.77 
68 to 69 14 0 3 0.65 0.49 - 0.77 
70 to 71 11 0 1 0.65 0.49 - 0.77 
71 to 72 10 0 1 0.65 0.49 - 0.77 
72 to 73 9 0 3 0.65 0.49 - 0.77 
73 to 74 6 0 1 0.65 0.49 - 0.77 
75 to 76 5 1 3 0.46 0.15 - 0.73 
76 to 77 1 0 1 0.46 0.15 - 0.73 
Table 14 -10: Overall survival for all patients in the trial by intention to treat 
Appendix: life tables 14 -332 
Interval No Ev Ce PS I 95% CI 
ER negative patents 
5 to 6 75 1 0 0.99 0.91 - 1.00 
9 to 10 74 2 1 0.96 0.88 - 0.99 
10 to 11 71 4 1 0.91 0.81 - 0.95 
11 to 12 66 0 1 0.91 0.81 - 0.95 
12 to 13 65 0 2 0.91 0.81 - 0.95 
14 to 15 63 0 2 0.91 0.81 - 0.95 
15 to 16 61 0 1 0.91 0.81 - 0.95 
16 to 17 60 1 0 0.89 0.79 - 0.94 
17 to 18 59 2 2 0.86 0.75 - 0.92 
19 to 20 55 1 0 0.84 0.74 - 0.91 
20 to 21 54 0 1 0.84 0.74 - 0.91 
21 to 22 53 0 3 0.84 0.74 - 0.91 
22 to 23 50 1 1 0.83 0.71 - 0.90 
23 to 24 48 1 1 0.81 0.69 - 0.89 
24 to 25 46 2 0 0.77 0.65 - 0.86 
25 to 26 44 1 1 0.76 0.63 - 0.84 
27 to 28 42 1 0 0.74 0.61 - 0.83 
29 to 30 41 1 0 0.72 0.59 - 0.82 
30 to 31 40 1 0 0.70 0.57 - 0.80 
31 to 32 39 3 0 0.65 0.51 - 0.75 
34 to 35 36 1 0 0.63 0.50 - 0.74 
35 to 36 35 0 1 0.63 0.50 - 0.74 
36 to 37 34 1 1 0.61 0.48 - 0.72 
38 to 39 32 0 1 0.61 0.48 - 0.72 
39 to 40 31 1 0 0.59 0.46 - 0.71 
41 to 42 30 1 1 0.57 0.43 - 0.69 
42 to 43 28 0 2 0.57 0.43 - 0.69 
43 to 44 26 0 2 0.57 0.43 - 0.69 
44 to 45 24 0 1 0.57 0.43 - 0.69 
45 to 46 23 1 0 0.55 0.41 - 0.67 
47 to 48 22 0 1 0.55 0.41 - 0.67 
48 to 49 21 1 1 0.52 0.38 - 0.64 
50 to 51 19 0 1 0.52 0.38 - 0.64 
53 to 54 18 0 1 0.52 0.38 - 0.64 
55 to 56 17 1 0 0.49 0.35 - 0.62 
59 to 60 16 0 1 0.49 0.35 - 0.62 
63 to 64 15 0 1 0.49 0.35 - 0.62 
64 to 65 14 0 1 0.49 0.35 - 0.62 
66 to 67 13 0 1 0.49 0.35 - 0.62 
67 to 68 12 0 1 0.49 0.35 - 0.62 
70 to 71 11 0 2 0.49 0.35 - 0.62 
71 to 72 9 0 1 0.49 0.35 - 0.62 
72 to 73 8 0 2 0.49 0.35 - 0.62 
73 to 74 6 0 1 0.49 0.35 - 0.62 
75 to 76 5 1 2 0.37 0.15 - 0.59 
76 to 77 2 0 2 0.37 0.15 - 0.59 
ER positive patients 
11 to 12 93 1 4 0.99 0.92 - 1.00 
12 to 13 88 1 3 0.98 0.91 - 0.99 
13 to 14 84 0 1 0.98 0.91 - 0.99 
Interval No Ev Ce PS 95% CI 
14 to 15 83 0 2 0.98 0.91 - 0.99 
16 to 17 81 0 1 0.98 0.91 - 0.99 
18 to 19 80 0 3 0.98 0.91 - 0.99 
19 to 20 77 0 2 0.98 0.91 - 0.99 
20 to 21 75 0 2 0.98 0.91 - 0.99 
21 to 22 73 1 0 0.96 0.89 - 0.99 
22 to 23 72 0 1 0.96 0.89 - 0.99 
23 to 24 71 0 3 0.96 0.89 - 0.99 
24 to 25 68 0 2 0.96 0.89 - 0.99 
25 to 26 66 2 1 0.93 0.85 - 0.97 
26 to 27 63 0 1 0.93 0.85 - 0.97 
27 to 28 62 0 4 0.93 0.85 - 0.97 
29 to 30 58 0 1 0.93 0.85 - 0.97 
30 to 31 57 0 2 0.93 0.85 - 0.97 
31 to 32 55 0 1 0.93 0.85 - 0.97 
34 to 35 54 0 2 0.93 0.85 - 0.97 
35 to 36 52 0 1 0.93 0.85 - 0.97 
36 to 37 51 0 1 0.93 0.85 - 0.97 
37 to 38 50 0 1 0.93 0.85 - 0.97 
40 to 41 49 0 2 0.93 0.85 - 0.97 
41 to 42 47 0 1 0.93 0.85 - 0.97 
43 to 44 46 0 3 0.93 0.85 - 0.97 
44 to 45 43 0 2 0.93 0.85 - 0.97 
46 to 47 41 0 1 0.93 0.85 - 0.97 
47 to 48 40 0 1 0.93 0.85 - 0.97 
48 to 49 39 0 2 0.93 0.85 - 0.97 
49 to 50 37 1 1 0.91 0.80 - 0.96 
50 to 51 35 0 1 0.91 0.80 - 0.96 
51 to 52 34 2 1 0.85 0.72 - 0.93 
52 to 53 31 0 2 0.85 0.72 - 0.93 
53 to 54 29 0 1 0.85 0.72 - 0.93 
55 to 56 28 0 1 0.85 0.72 - 0.93 
56 to 57 27 0 5 0.85 0.72 - 0.93 
59 to 60 22 1 0 0.82 0.66 - 0.91 
60 to 61 21 0 2 0.82 0.66 - 0.91 
61 to 62 19 0 1 0.82 0.66 - 0.91 
63 to 64 18 1 1 0.77 0.58 - 0.88 
64 to 65 16 0 3 0.77 0.58 - 0.88 
65 to 66 13 0 1 0.77 0.58 - 0.88 
67 to 68 12 1 0 0.71 0.49 - 0.84 
68 to 69 11 0 4 0.71 0.49 - 0.84 
69 to 70 7 0 1 0.71 0.49 - 0.84 
70 to 71 6 0 1 0.71 0.49 - 0.84 
72 to 73 5 0 3 0.71 0.49 - 0.84 
75 to 76 2 0 1 0.71 0.49 - 0.84 
76 to 77 1 0 1 0.71 0.49 - 0.84 
Table 14 -11: Overall survival by oestrogen receptor status 
Appendix: life tables 14 -333 
Interval No Ev j Ce PS I 95% CI 
ERICA ER negative 
5 to 6 35 1 0 0.97 0.81 - 1.00 
10 to 11 34 2 1 0.91 0.76 - 0.97 
11 to 12 31 1 1 0.88 0.72 - 0.95 
12 to 13 29 0 1 0.88 0.72 - 0.95 
14 to 15 28 0 1 0.88 0.72 - 0.95 
15 to 16 27 0 1 0.88 0.72 - 0.95 
17 to 18 26 2 0 0.82 0.63 - 0.91 
19 to 20 24 1 0 0.78 0.59 - 0.89 
21 to 22 23 1 1 0.75 0.55 - 0.87 
22 to 23 21 1 1 0.71 0.51 - 0.84 
23 to 24 19 0 1 0.71 0.51 - 0.84 
24 to 25 18 1 0 0.67 0.47 - 0.81 
25 to 26 17 1 0 0.63 0.43 - 0.78 
30 to 31 16 0 1 0.63 0.43 - 0.78 
39 to 40 15 1 0 0.59 0.39 - 0.75 
41 to 42 14 1 0 0.55 0.34 - 0.71 
42 to 43 13 0 1 0.55 0.34 - 0.71 
43 to 44 12 0 1 0.55 0.34 - 0.71 
44 to 45 11 0 1 0.55 0.34 - 0.71 
45 to 46 10 1 0 0.49 0.29 - 0.67 
47 to 48 9 0 1 0.49 0.29 - 0.67 
52 to 53 8 0 1 0.49 0.29 - 0.67 
53 to 54 7 0 1 0.49 0.29 - 0.67 
63 to 64 6 0 1 0.49 0.29 - 0.67 
70 to 71 5 0 1 0.49 0.29 - 0.67 
72 to 73 4 0 1 0.49 0.29 - 0.67 
75 to 76 3 0 2 0.49 0.29 - 0.67 
76 to 77 1 0 1 0.49 0.29 - 0.67 
ERICA ER pos live 
9 to 10 61 1 0 0.98 0.89 - 1.00 
11 to 12 60 0 1 0.98 0.89 - 1.00 
12 to 13 59 0 3 0.98 0.89 - 1.00 
14 to 15 56 0 2 0.98 0.89 - 1.00 
15 to 16 54 0 1 0.98 0.89 - 1.00 
16 to 17 53 1 0 0.97 0.87 - 0.99 
Interval No Ev Ce PS 95% CI 
18 to 19 52 0 4 0.97 0.87 - 0.99 
19 to 20 48 0 1 0.97 0.87 - 0.99 
20 to 21 47 0 1 0.97 0.87 - 0.99 
23 to 24 46 0 1 0.97 0.87 - 0.99 
24 to 25 45 0 2 0.97 0.87 - 0.99 
25 to 26 43 1 1 0.94 0.83 - 0.98 
26 to 27 41 0 1 0.94 0.83 - 0.98 
27 to 28 40 0 2 0.94 0.83 - 0.98 
31 to 32 38 0 1 0.94 0.83 - 0.98 
34 to 35 37 0 2 0.94 0.83 - 0.98 
35 to 36 35 0 1 0.94 0.83 - 0.98 
36 to 37 34 1 1 0.91 0.78 - 0.97 
37 to 38 32 0 1 0.91 0.78 - 0.97 
43 to 44 31 0 2 0.91 0.78 - 0.97 
44 to 45 29 0 1 0.91 0.78 - 0.97 
48 to 49 28 1 1 0.88 0.73 - 0.95 
49 to 50 26 1 0 0.85 0.68 - 0.93 
50 to 51 25 0 1 0.85 0.68 - 0.93 
51 to 52 24 1 1 0.81 0.63 - 0.91 
52 to 53 22 0 1 0.81 0.63 - 0.91 
53 to 54 21 0 1 0.81 0.63 - 0.91 
55 to 56 20 1 1 0.77 0.58 - 0.88 
56 to 57 18 0 5 0.77 0.58 - 0.88 
59 to 60 13 1 0 0.71 0.49 - 0.85 
60 to 61 12 0 1 0.71 0.49 - 0.85 
61 to 62 11 0 1 0.71 0.49 - 0.85 
64 to 65 10 0 1 0.71 0.49 - 0.85 
66 to 67 9 0 1 0.71 0.49 - 0.85 
67 to 68 8 1 1 0.62 0.35 - 0.80 
68 to 69 6 0 2 0.62 0.35 - 0.80 
70 to 71 4 0 1 0.62 0.35 - 0.80 
72 to 73 3 0 3 0.62 0.35 - 0.80 
Table 14 -12: Overall survival by oestrogen receptor status defined by the 
ERICA assay as ER negative (0-1% of cells staining), and ER positive (2% 
or more cells staining) 
Appendix: life tables 14 -334 
Interval No Ev Ce I PS 95% CI 
Node negative patients 
10 to 11 79 1 0 0.99 0.91 - 1.00 
11 to 12 78 0 3 0.99 0.91 - 1.00 
12 to 13 75 0 1 0.99 0.91 - 1.00 
14 to 15 74 0 2 0.99 0.91 - 1.00 
17 to 18 72 0 2 0.99 0.91 - 1.00 
18 to 19 70 0 4 0.99 0.91 - 1.00 
19 to 20 66 1 2 0.97 0.89 - 0.99 
20 to 21 63 0 2 0.97 0.89 - 0.99 
21 to 22 61 0 1 0.97 0.89 - 0.99 
22 to 23 60 0 1 0.97 0.89 - 0.99 
23 to 24 59 0 2 0.97 0.89 - 0.99 
25 to 26 57 1 1 0.95 0.87 - 0.99 
26 to 27 55 0 1 0.95 0.87 - 0.99 
27 to 28 54 0 3 0.95 0.87 - 0.99 
30 to 31 51 1 0 0.94 0.84 - 0.98 
34 to 35 50 0 2 0.94 0.84 - 0.98 
35 to 36 48 0 1 0.94 0.84 - 0.98 
36 to 37 47 1 2 0.92 0.81 - 0.96 
38 to 39 44 0 1 0.92 0.81 - 0.96 
39 to 40 43 1 0 0.89 0.78 - 0.95 
40 to 41 42 0 2 0.89 0.78 - 0.95 
41 to 42 40 0 2 0.89 0.78 - 0.95 
42 to 43 38 0 2 0.89 0.78 - 0.95 
43 to 44 36 0 3 0.89 0.78 - 0.95 
44 to 45 33 0 2 0.89 0.78 - 0.95 
48 to 49 31 0 2 0.89 0.78 - 0.95 
50 to 51 29 0 2 0.89 0.78 - 0.95 
51 to 52 27 0 1 0.89 0.78 - 0.95 
52 to 53 26 0 2 0.89 0.78 - 0.95 
53 to 54 0 1 
56 to 57 23 0 1 0.89 0.78 - 0.95 
59 to 60 22 1 1 0.85 0.70 - 0.93 
60 to 61 20 0 1 0.85 0.70 - 0.93 
63 to 64 19 1 1 0.81 0.62 - 0.91 
64 to 65 17 0 4 0.81 0.62 - 0.91 
65 to 66 13 0 1 0.81 0.62 - 0.91 
66 to 67 12 0 1 0.81 0.62 - 0.91 
70 to 71 11 0 1 0.81 0.62 - 0.91 
71 to 72 10 0 1 0.81 0.62 - 0.91 
72 to 73 9 0 3 0.81 0.62 - 0.91 
73 to 74 6 0 1 0.81 0.62 - 0.91 
75 to 76 5 1 2 0.61 0.20 - 0.86 
76 to 77 2 0 2 0.61 0.20 - 0.86 
Node ositive patients 
5 to 6 89 1 0 0.99 0.92 - 1.00 
9 to 10 88 2 1 0.97 0.90 - 0.99 
Interval No Ev Ce PS 95% CI 
10 to 11 85 3 1 0.93 0.85 - 0.97 
11 to 12 81 0 2 0.93 0.85 - 0.97 
12 to 13 79 1 4 0.92 0.84 - 0.96 
13 to 14 74 0 1 0.92 0.84 - 0.96 
14 to 15 73 0 2 0.92 0.84 - 0.96 
15 to 16 71 0 2 0.92 0.84 - 0.96 
16 to 17 69 1 1 0.91 0.82 - 0.95 
17 to 18 67 2 0 0.88 0.79 - 0.93 
20 to 21 65 0 1 0.88 0.79 - 0.93 
21 to 22 64 1 2 0.87 0.77 - 0.92 
22 to 23 61 1 1 0.85 0.75 - 0.91 
23 to 24 59 1 2 0.84 0.73 - 0.90 
24 to 25 56 2 2 0.81 0.70 - 0.88 
25 to 26 52 1 1 0.79 0.68 - 0.87 
27 to 28 50 1 1 0.77 0.66 - 0.85 
29 to 30 48 1 1 0.76 0.64 - 0.84 
30 to 31 46 0 2 0.76 0.64 - 0.84 
31 to 32 44 3 1 0.71 0.58 - 0.80 
34 to 35 40 1 0 0.69 0.56 - 0.78 
35 to 36 39 0 1 0.69 0.56 - 0.78 
37 to 38 38 0 1 0.69 0.56 - 0.78 
41 to 42 37 1 0 0.67 0.54 - 0.77 
43 to 44 36 0 2 0.67 0.54 - 0.77 
44 to 45 34 0 1 0.67 0.54 - 0.77 
45 to 46 33 1 0 0.65 0.52 - 0.75 
46 to 47 32 0 1 0.65 0.52 - 0.75 
47 to 48 31 0 2 0.65 0.52 - 0.75 
48 to 49 29 1 1 0.63 0.49 - 0.73 
49 to 50 27 1 1 0.60 0.47 - 0.71 
51 to 52 25 2 0 0.55 0.41 - 0.67 
53 to 54 23 0 1 0.55 0.41 - 0.67 
55 to 56 22 1 1 0.53 0.39 - 0.65 
56 to 57 20 0 4 0.53 0.39 - 0.65 
60 to 61 16 0 1 0.53 0.39 - 0.65 
61 to 62 15 0 1 0.53 0.39 - 0.65 
63 to 64 14 0 1 0.53 0.39 - 0.65 
67 to 68 13 1 1 0.49 0.33 - 0.62 
68 to 69 11 0 4 0.49 0.33 - 0.62 
69 to 70 7 0 1 0.49 0.33 - 0.62 
70 to 71 6 0 2 0.49 0.33 - 0.62 
72 to 73 4 0 2 0.49 0.33 - 0.62 
75 to 76 2 0 1 0.49 0.33 - 0.62 
76 to 77 1 0 1 0.49 0.33 - 0.62 
Table 14 -13: Overall survival for patients with and without axillary nodal 
involvement 
Interval I No I EvI Ce I PS 
No involved nodes 
95% CI 
10 to 11 76 1 0 0.99 0.91 - 1.00 
11 to 12 75 0 3 0.99 0.91 - 1.00 
Appendix: life tables 
Interval No Ev Ce PS 95% CI 
14 to 15 72 0 2 0.99 0.91 - 1.00 
17 to 18 70 0 2 0.99 0.91 - 1.00 
18 to 19 68 0 4 0.99 0.91 - 1.00 
14 -335 
Interval No Ev Ce PS 95% CI 
19 to 20 64 1 2 0.97 0.89 - 0.99 
20 to 21 61 0 2 0.97 0.89 - 0.99 
21 to 22 59 0 1 0.97 0.89 - 0.99 
22 to 23 58 0 1 0.97 0.89 - 0.99 
23 to 24 57 0 2 0.97 0.89 - 0.99 
25 to 26 55 1 1 0.95 0.86 - 0.98 
26 to 27 53 0 1 0.95 0.86 - 0.98 
27 to 28 52 0 3 0.95 0.86 - 0.98 
30 to 31 49 1 0 0.93 0.83 - 0.98 
34 to 35 48 0 2 0.93 0.83 - 0.98 
35 to 36 46 0 1 0.93 0.83 - 0.98 
36 to 37 45 1 2 0.91 0.80 - 0.96 
38 to 39 42 0 1 0.91 0.80 - 0.96 
39 to 40 41 1 0 0.89 0.77 - 0.95 
40 to 41 40 0 2 0.89 0.77 - 0.95 
41 to 42 38 0 2 0.89 0.77 - 0.95 
42 to 43 36 0 2 0.89 0.77 - 0.95 
43 to 44 34 0 3 0.89 0.77 - 0.95 
44 to 45 31 0 2 0.89 0.77 - 0.95 
48 to 49 29 0 2 0.89 0.77 - 0.95 
50 to 51 27 0 2 0.89 0.77 - 0.95 
51 to 52 25 0 1 0.89 0.77 - 0.95 
52 to 53 24 0 2 0.89 0.77 - 0.95 
53 to 54 22 0 1 0.89 0.77 - 0.95 
56 to 57 21 0 1 0.89 0.77 - 0.95 
59 to 60 20 1 1 0.84 0.68 - 0.93 
60 to 61 18 0 1 0.84 0.68 - 0.93 
63 to 64 17 1 1 0.79 0.60 - 0.90 
64 to 65 15 0 4 0.79 0.60 - 0.90 
65 to 66 11 0 1 0.79 0.60 - 0.90 
66 to 67 10 0 1 0.79 0.60 - 0.90 
70 to 71 9 0 1 0.79 0.60 - 0.90 
71 to 72 8 0 1 0.79 0.60 - 0.90 
72 to 73 7 0 2 0.79 0.60 - 0.90 
73 to 74 5 0 1 0.79 0.60 - 0.90 
75 to 76 4 1 2 0.53 0.10 - 0.84 
76 to 77 1 0 1 0.53 0.10 - 0.84 
1-3 involved nodes 
11 to 12 43 0 1 1.00 . - . 
12 to 13 42 1 3 0.98 0.84 - 1.00 
13 to 14 38 0 1 0.98 0.84 - 1.00 
14 to 15 37 0 2 0.98 0.84 - 1.00 
16 to 17 35 0 1 0.98 0.84 - 1.00 
22 to 23 34 1 1 0.95 0.80 - 0.99 
23 to 24 32 0 1 0.95 0.80 - 0.99 
24 to 25 31 1 2 0.91 0.76 - 0.97 
25 to 26 28 1 0 0.88 0.71 - 0.95 
27 to 28 27 0 1 0.88 0.71 - 0.95 
29 to 30 26 1 1 0.85 0.67 - 0.93 
30 to 31 24 0 1 0.85 0.67 - 0.93 
31 to 32 23 1 1 0.81 0.62 - 0.91 
43 to 44 21 0 1 0.81 0.62 - 0.91 
44 to 45 20 0 1 0.81 0.62 - 0.91 
47 to 48 19 0 1 0.81 0.62 - 0.91 
48 to 49 18 0 1 0.81 0.62 - 0.91 
51 to 52 17 1 0 0.76 0.56 - 0.88 
53 to 54 16 0 1 0.76 0.56 - 0.88 
55 to 56 15 1 0 0.71 0.49 - 0.85 
Interval 
56 to 57 
60 to 61 
67 to 68 
68 to 69 
70 to 71 
72 to 73 
75 to 76 






































0.49 - 0.85 
0.49 - 0.85 
0.49 - 0.85 
0.49 - 0.85 
0.49 - 0.85 
0.49 - 0.85 
0.49 - 0.85 
0.49 - 0.85 
4-9 involved nodes 
9 to 10 29 1 0 0.97 0.78 - 1.00 
10 to 11 28 1 1 0.93 0.75 - 0.98 
12 to 13 26 0 2 0.93 0.75 - 0.98 
15 to 16 24 0 1 0.93 0.75 - 0.98 
16 to 17 23 1 0 0.89 0.70 - 0.96 
17 to 18 22 1 0 0.85 0.65 - 0.94 
21 to 22 21 1 1 0.81 0.60 - 0.92 
23 to 24 19 0 1 0.81 0.60 - 0.92 
24 to 25 18 1 0 0.76 0.54 - 0.89 
25 to 26 17 0 1 0.76 0.54 - 0.89 
30 to 31 16 0 1 0.76 0.54 - 0.89 
35 to 36 15 0 1 0.76 0.54 - 0.89 
37 to 38 14 0 1 0.76 0.54 - 0.89 
41 to 42 13 1 0 0.70 0.47 - 0.85 
43 to 44 12 0 1 0.70 0.47 - 0.85 
45 to 46 11 1 0 0.64 0.39 - 0.81 
46 to 47 10 0 1 0.64 0.39 - 0.81 
47 to 48 9 0 1 0.64 0.39 - 0.81 
48 to 49 8 1 0 0.56 0.30 - 0.76 
51 to 52 7 1 0 0.48 0.23 - 0.70 
55 to 56 6 0 1 0.48 0.23 - 0.70 
56 to 57 5 0 2 0.48 0.23 - 0.70 
61 to 62 3 0 1 0.48 0.23 - 0.70 
63 to 64 2 0 1 0.48 0.23 - 0.70 
69 to 70 1 0 1 0.48 0.23 - 0.70 
Ten or more involved nodes 
5 to 6 20 1 0 0.95 0.69 - 0.99 
9 to 10 19 1 1 0.90 0.65 - 0.97 
10 to 11 17 2 0 0.79 0.54 - 0.92 
11 to 12 15 0 1 0.79 0.54 - 0.92 
15 to 16 14 0 1 0.79 0.54 - 0.92 
17 to 18 13 1 0 0.73 0.47 - 0.88 
20 to 21 12 0 1 0.73 0.47 - 0.88 
21 to 22 11 0 1 0.73 0.47 - 0.88 
23 to 24 10 1 0 0.66 0.38 - 0.83 
27 to 28 9 1 0 0.59 0.31 - 0.78 
31 to 32 8 2 0 0.44 0.19 - 0.66 
34 to 35 6 1 0 0.37 0.14 - 0.60 
49 to 50 5 1 1 0.28 0.09 - 0.53 
67 to 68 3 1 0 0.19 0.04 - 0.44 
72 to 73 2 0 1 0.19 0.04 - 0.44 
76 to 77 1 0 1 0.19 0.04 - 0.44 
Table 14 -14: Overall survival by the number of involved axillary nodes 
Appendix: life tables 14 -336 
Interval No Ev I Ce I PS I 95% CI 
ER negative patients 
10 to 11 19 1 0 0.95 0.68 - 0.99 
14 to 15 18 0 1 0.95 0.68 - 0.99 
15 to 16 17 0 2 0.95 0.68 - 0.99 
19 to 20 15 1 0 0.88 0.61 - 0.97 
21 to 22 14 0 1 0.88 0.61 - 0.97 
27 to 28 13 1 0 0.82 0.53 - 0.94 
29 to 30 12 1 0 0.75 0.46 - 0.90 
30 to 31 11 1 2 0.67 0.38 - 0.85 
31 to 32 8 1 0 0.59 0.30 - 0.79 
38 to 39 7 0 1 0.59 0.30 - 0.79 
41 to 42 6 1 1 0.48 0.19 - 0.72 
42 to 43 4 0 1 0.48 0.19 - 0.72 
60 to 61 3 0 1 0.48 0.19 - 0.72 
63 to 64 2 0 1 0.48 0.19 - 0.72 
75 to 76 1 0 1 0.48 0.19 - 0.72 
ER positive patients 
9 to 10 30 0 1 1.00 . - . 
12 to 13 29 0 1 1.00 . - . 
Interval No Ev Ce PS 95% CI 
14 to 15 28 0 1 1.00 . - . 
18 to 19 27 0 2 1.00 . - . 
20 to 21 25 0 1 1.00 . - . 
25 to 26 24 0 1 1.00 . - . 
26 to 27 23 0 1 1.00 . - . 
31 to 32 22 1 0 0.95 0.72 - 0.99 
34 to 35 21 0 1 0.95 0.72 - 0.99 
43 to 44 20 0 2 0.95 0.72 - 0.99 
48 to 49 18 1 1 0.90 0.65 - 0.97 
51 to 52 16 2 0 0.79 0.53 - 0.92 
52 to 53 14 0 1 0.79 0.53 - 0.92 
55 to 56 13 0 1 0.79 0.53 - 0.92 
56 to 57 12 0 4 0.79 0.53 - 0.92 
66 to 67 8 0 1 0.79 0.53 - 0.92 
68 to 69 7 0 3 0.79 0.53 - 0.92 
70 to 71 4 0 1 0.79 0.53 - 0.92 
72 to 73 3 0 2 0.79 0.53 - 0.92 
75 to 76 1 0 1 0.79 0.53 - 0.92 
Table 14 -15: Overall survival by post treatment oestrogen receptor status 
Interval No Ev Ce PS I 95% CI 
Node negat ve patients 
10 to 11 41 1 0 0.98 0.84 - 1.00 
12 to 13 40 0 1 0.98 0.84 - 1.00 
14 to 15 39 0 2 0.98 0.84 - 1.00 
18 to 19 37 0 3 0.98 0.84 - 1.00 
19 to 20 34 1 1 0.95 0.80 - 0.99 
20 to 21 32 0 1 0.95 0.80 - 0.99 
21 to 22 31 0 1 0.95 0.80 - 0.99 
23 to 24 30 0 1 0.95 0.80 - 0.99 
25 to 26 29 0 1 0.95 0.80 - 0.99 
26 to 27 28 0 1 0.95 0.80 - 0.99 
30 to 31 27 1 0 0.91 0.75 - 0.97 
34 to 35 26 0 1 0.91 0.75 - 0.97 
35 to 36 25 0 1 0.91 0.75 - 0.97 
38 to 39 24 0 1 0.91 0.75 - 0.97 
39 to 40 23 1 0 0.87 0.69 - 0.95 
40 to 41 22 0 1 0.87 0.69 - 0.95 
41 to 42 21 0 1 0.87 0.69 - 0.95 
42 to 43 20 0 2 0.87 0.69 - 0.95 
43 to 44 18 0 1 0.87 0.69 - 0.95 
44 to 45 17 0 1 0.87 0.69 - 0.95 
48 to 49 16 0 2 0.87 0.69 - 0.95 
52 to 53 14 0 1 0.87 0.69 - 0.95 
56 to 57 13 0 1 0.87 0.69 - 0.95 
60 to 61 12 0 1 0.87 0.69 - 0.95 
63 to 64 11 0 1 0.87 0.69 - 0.95 
64 to 65 10 0 1 0.87 0.69 - 0.95 
66 to 67 9 0 1 0.87 0.69 - 0.95 
71 to 72 8 0 1 0.87 0.69 - 0.95 
72 to 73 7 0 2 0.87 0.69 - 0.95 
73 to 74 5 0 1 0.87 0.69 - 0.95 
Interval 
75 to 76 














0.09 - 0.89 
0.09 - 0.89 
Node positive patients 
9 to 10 37 0 1 1.00 . - . 
12 to 13 36 0 1 1.00 . - . 
14 to 15 35 0 1 1.00 . - . 
15 to 16 34 0 2 1.00 . - . 
16 to 17 32 0 1 1.00 . - . 
17 to 18 31 1 0 0.97 0.79 - 1.00 
22 to 23 30 0 1 0.97 0.79 - 1.00 
23 to 24 29 1 0 0.93 0.76 - 0.98 
24 to 25 28 0 1 0.93 0.76 - 0.98 
25 to 26 27 1 1 0.90 0.72 - 0.97 
27 to 28 25 1 1 0.86 0.67 - 0.95 
29 to 30 23 1 0 0.82 0.63 - 0.92 
30 to 31 22 0 2 0.82 0.63 - 0.92 
31 to 32 20 2 0 0.74 0.53 - 0.87 
41 to 42 18 1 0 0.70 0.49 - 0.84 
43 to 44 17 0 2 0.70 0.49 - 0.84 
48 to 49 15 1 1 0.65 0.43 - 0.80 
51 to 52 13 2 0 0.55 0.33 - 0.73 
55 to 56 11 0 1 0.55 0.33 - 0.73 
56 to 57 10 0 3 0.55 0.33 - 0.73 
63 to 64 7 0 1 0.55 0.33 - 0.73 
68 to 69 6 0 3 0.55 0.33 - 0.73 
70 to 71 3 0 1 0.55 0.33 - 0.73 
72 to 73 2 0 1 0.55 0.33 - 0.73 
75 to 76 1 0 1 0.55 0.33 - 0.73 
Table 14 -16: Overall survival by post- treatment lymph node status 
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Interval No I Ev Ce I PS I 95% CI 
No involved nodes 
10 to 11 79 1 0 0.99 0.91 - 1.00 
11 to 12 78 0 3 0.99 0.91 - 1.00 
12 to 13 75 0 1 0.99 0.91 - 1.00 
14 to 15 74 0 2 0.99 0.91 - 1.00 
17 to 18 72 0 2 0.99 0.91 - 1.00 
18 to 19 70 0 4 0.99 0.91 - 1.00 
19 to 20 66 1 2 0.97 0.89 - 0.99 
20 to 21 63 0 2 0.97 0.89 - 0.99 
21 to 22 61 0 1 0.97 0.89 - 0.99 
22 to 23 60 0 1 0.97 0.89 - 0.99 
23 to 24 59 0 2 0.97 0.89 - 0.99 
25 to 26 57 1 1 0.95 0.87 - 0.99 
26 to 27 55 0 1 0.95 0.87 - 0.99 
27 to 28 54 0 3 0.95 0.87 - 0.99 
30 to 31 51 1 0 0.94 0.84 - 0.98 
34 to 35 50 0 2 0.94 0.84 - 0.98 
35 to 36 48 0 1 0.94 0.84 - 0.98 
36 to 37 47 1 2 0.92 0.81 - 0.96 
38 to 39 44 0 1 0.92 0.81 - 0.96 
39 to 40 43 1 0 0.89 0.78 - 0.95 
40 to 41 42 0 2 0.89 0.78 - 0.95 
41 to 42 40 0 2 0.89 0.78 - 0.95 
42 to 43 38 0 2 0.89 0.78 - 0.95 
43 to 44 36 0 3 0.89 0.78 - 0.95 
44 to 45 33 0 2 0.89 0.78 - 0.95 
48 to 49 31 0 2 0.89 0.78 - 0.95 
50 to 51 29 0 2 0.89 0.78 - 0.95 
51 to 52 27 0 1 0.89 0.78 - 0.95 
52 to 53 26 0 2 0.89 0.78 - 0.95 
53 to 54 24 0 1 0.89 0.78 - 0.95 
56 to 57 23 0 1 0.89 0.78 - 0.95 
59 to 60 22 1 1 0.85 0.70 - 0.93 
60 to 61 20 0 1 0.85 0.70 - 0.93 
63 to 64 19 1 1 0.81 0.62 - 0.91 
64 to 65 17 0 4 0.81 0.62 - 0.91 
65 to 66 13 0 1 0.81 0.62 - 0.91 
66 to 67 12 0 1 0.81 0.62 - 0.91 
70 to 71 11 0 1 0.81 0.62 - 0.91 
71 to 72 10 0 1 0.81 0.62 - 0.91 
72 to 73 9 0 3 0.81 0.62 - 0.91 
73 to 74 6 0 1 0.81 0.62 - 0.91 
75 to 76 5 1 2 0.61 0.20 - 0.86 
76 to 77 2 0 2 0.61 0.20 - 0.86 
1-3 involved nodes 
11 to 12 40 0 1 1.00 . - . 
12 to 13 39 1 2 0.97 0.83 - 1.00 
13 to 14 36 0 1 0.97 0.83 - 1.00 
14 to 15 35 0 2 0.97 0.83 - 1.00 
16 to 17 33 0 1 0.97 0.83 - 1.00 
22 to 23 32 1 1 0.94 0.79 - 0.99 
23 to 24 30 0 1 0.94 0.79 - 0.99 
24 to 25 29 1 2 0.91 0.74 - 0.97 
25 to 26 26 1 0 0.87 0.70 - 0.95 
27 to 28 25 0 1 0.87 0.70 - 0.95 
29 to 30 24 1 1 0.84 0.65 - 0.93 
30 to 31 22 0 1 0.84 0.65 - 0.93 
31 to 32 21 1 1 0.80 0.60 - 0.90 
43 to 44 19 0 1 0.80 0.60 - 0.90 
44 to 45 18 0 1 0.80 0.60 - 0.90 
47 to 48 17 0 1 0.80 0.60 - 0.90 
48 to 49 16 0 1 0.80 0.60 - 0.90 
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Interval No Ev Ce PS 95% CI 
51 to 52 15 1 0 0.74 0.53 - 0.87 
53 to 54 14 0 1 0.74 0.53 - 0.87 
55 to 56 13 1 0 0.69 0.45 - 0.84 
56 to 57 12 0 2 0.69 0.45 - 0.84 
60 to 61 10 0 1 0.69 0.45 - 0.84 
67 to 68 9 0 1 0.69 0.45 - 0.84 
68 to 69 8 0 4 0.69 0.45 - 0.84 
70 to 71 4 0 2 0.69 0.45 - 0.84 
72 to 73 2 0 1 0.69 0.45 - 0.84 
75 to 76 1 0 1 0.69 0.45 - 0.84 
4-9 involved nodes 
9 to 10 29 1 0 0.97 0.78 - 1.00 
10 to 11 28 1 1 0.93 0.75 - 0.98 
12 to 13 26 0 2 0.93 0.75 - 0.98 
15 to 16 24 0 1 0.93 0.75 - 0.98 
16 to 17 23 1 0 0.89 0.70 - 0.96 
17 to 18 22 1 0 0.85 0.65 - 0.94 
21 to 22 21 1 1 0.81 0.60 - 0.92 
23 to 24 19 0 1 0.81 0.60 - 0.92 
24 to 25 18 1 0 0.76 0.54 - 0.89 
25 to 26 17 0 1 0.76 0.54 - 0.89 
30 to 31 16 0 1 0.76 0.54 - 0.89 
35 to 36 15 0 1 0.76 0.54 - 0.89 
37 to 38 14 0 1 0.76 0.54 - 0.89 
41 to 42 13 1 0 0.70 0.47 - 0.85 
43 to 44 12 0 1 0.70 0.47 - 0.85 
45 to 46 11 1 0 0.64 0.39 - 0.81 
46 to 47 10 0 1 0.64 0.39 - 0.81 
47 to 48 9 0 1 0.64 0.39 - 0.81 
48 to 49 8 1 0 0.56 0.30 - 0.76 
51 to 52 7 1 0 0.48 0.23 - 0.70 
55 to 56 6 0 1 0.48 0.23 - 0.70 
56 to 57 5 0 2 0.48 0.23 - 0.70 
61 to 62 3 0 1 0.48 0.23 - 0.70 
63 to 64 2 0 1 0.48 0.23 - 0.70 
69 to 70 1 0 1 0.48 0.23 - 0.70 
10 or more involved nodes 
5 to 6 20 1 0 0.95 0.69 - 0.99 
9 to 10 19 1 1 0.90 0.65 - 0.97 
10 to 11 17 2 0 0.79 0.54 - 0.92 
11 to 12 15 0 1 0.79 0.54 - 0.92 
15 to 16 14 0 1 0.79 0.54 - 0.92 
17 to 18 13 1 0 0.73 0.47 - 0.88 
20 to 21 12 0 1 0.73 0.47 - 0.88 
21 to 22 11 0 1 0.73 0.47 - 0.88 
23 to 24 10 1 0 0.66 0.38 - 0.83 
27 to 28 9 1 0 0.59 0.31 - 0.78 
31 to 32 8 2 0 0.44 0.19 - 0.66 
34 to 35 6 1 0 0.37 0.14 - 0.60 
49 to 50 5 1 1 0.28 0.09 - 0.53 
67 to 68 3 1 0 0.19 0.04 - 0.44 
72 to 73 2 0 1 0.19 0.04 - 0.44 
76 to 77 1 0 1 0.19 0.04 - 0.44 
Table 14 -17: Overall surviva by post- 
treatment nodal category 
14 -338 
Interval No Ev Ce I PS I 95% CI 
Fast response 
21 to 22 19 1 0 0.95 0.68 - 0.99 
43 to 44 18 1 0 0.89 0.64 - 0.97 
50 to 51 17 1 0 0.84 0.59 - 0.95 
52 to 53 16 0 1 0.84 0.59 - 0.95 
55 to 56 15 0 1 0.84 0.59 - 0.95 
56 to 57 14 0 2 0.84 0.59 - 0.95 
63 to 64 12 0 1 0.84 0.59 - 0.95 
64 to 65 11 0 1 0.84 0.59 - 0.95 
68 to 69 10 0 2 0.84 0.59 - 0.95 
71 to 72 8 0 1 0.84 0.59 - 0.95 
72 to 73 7 0 2 0.84 0.59 - 0.95 
73 to 74 5 0 1 0.84 0.59 - 0.95 
75 to 76 4 0 2 0.84 0.59 - 0.95 
76 to 77 2 0 2 0.84 0.59 - 0.95 
Slow response 
Interval No Ev Ce PS 95% CI 
9 to 10 19 1 0 0.95 0.68 - 0.99 
12 to 13 18 1 0 0.89 0.64 - 0.97 
14 to 15 17 1 0 0.84 0.59 - 0.95 
15 to 16 16 1 0 0.79 0.53 - 0.92 
18 to 19 15 1 0 0.74 0.48 - 0.88 
20 to 21 14 2 0 0.63 0.38 - 0.80 
27 to 28 12 1 0 0.58 0.33 - 0.76 
28 to 29 11 2 0 0.47 0.24 - 0.67 
34 to 35 9 1 0 0.42 0.20 - 0.62 
50 to 51 8 1 0 0.37 0.17 - 0.57 
56 to 57 7 0 2 0.37 0.17 - 0.57 
58 to 59 5 1 0 0.29 0.11 - 0.51 
60 to 61 4 0 1 0.29 0.11 - 0.51 
66 to 67 3 0 1 0.29 0.11 - 0.51 
70 to 71 2 0 1 0.29 0.11 - 0.51 
75 to 76 1 0 1 0.29 0.11 - 0.51 
Table 14 -18: Distant disease free survival acording to the speed of 
response to primary systemic treatment 
Interval No Ev I Ce I PS 95% CI 
Fast res.onse 
21 to 22 19 1 0 0.95 0.68 - 0.99 
43 to 44 18 1 0 0.89 0.64 - 0.97 
50 to 51 17 1 0 0.84 0.59 - 0.95 
52 to 53 16 0 1 0.84 0.59 - 0.95 
55 to 56 15 0 1 0.84 0.59 - 0.95 
56 to 57 14 0 2 0.84 0.59 - 0.95 
63 to 64 12 0 1 0.84 0.59 - 0.95 
64 to 65 11 0 1 0.84 0.59 - 0.95 
68 to 69 10 0 2 0.84 0.59 - 0.95 
71 to 72 8 0 1 0.84 0.59 - 0.95 
72 to 73 7 0 2 0.84 0.59 - 0.95 
73 to 74 5 0 1 0.84 0.59 - 0.95 
75 to 76 4 0 2 0.84 0.59 - 0.95 
76 to 77 2 0 2 0.84 0.59 - 0.95 
Slow response 
Interval No Ev Ce PS 95% CI 
9 to 10 19 1 0 0.95 0.68 - 0.99 
12 to 13 18 1 0 0.89 0.64 - 0.97 
14 to 15 17 1 0 0.84 0.59 - 0.95 
15 to 16 16 1 0 0.79 0.53 - 0.92 
18 to 19 15 1 0 0.74 0.48 - 0.88 
20 to 21 14 2 0 0.63 0.38 - 0.80 
27 to 28 12 1 0 0.58 0.33 - 0.76 
28 to 29 11 2 0 0.47 0.24 - 0.67 
34 to 35 9 1 0 0.42 0.20 - 0.62 
50 to 51 8 1 0 0.370.17-0.57 
56 to 57 7 0 2 0.37 0.17 - 0.57 
58 to 59 5 1 0 0.29 0.11 - 0.51 
60 to 61 4 0 1 0.29 0.11 - 0.51 
66 to 67 3 0 1 0.29 0.11 - 0.51 
70 to 71 2 0 1 0.29 0.11 - 0.51 
75 to 76 1 0 1 0.29 0.11 - 0.51 
Table 14 -19: Distant disease free survival acording to the speed of 
response to primary systemic treatment, adjusted for age, tumour size, 
initial ER status, axillary lymph node status and tumour differentiation 
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Interval No Ev I Ce PS I 95% Cl 
Fast response 
31 to 32 19 1 0 0.95 0.68 - 0.99 
52 to 53 18 0 1 0.95 0.68 - 0.99 
55 to 56 17 0 1 0.95 0.68 - 0.99 
56 to 57 16 0 2 0.95 0.68 - 0.99 
63 to 64 14 0 2 0.95 0.68 - 0.99 
64 to 65 12 0 1 0.95 0.68 - 0.99 
68 to 69 11 0 3 0.95 0.68 - 0.99 
71 to 72 8 0 1 0.95 0.68 - 0.99 
72 to 73 7 0 2 0.95 0.68 - 0.99 
73 to 74 5 0 1 0.95 0.68 - 0.99 
75 to 76 4 1 2 0.63 0.07 - 0.92 
76 to 77 1 0 1 0.63 0.07 - 0.92 
Slow response 
10 to 11 19 1 0 0.95 0.68 - 0.99 
17 to 18 18 1 0 0.89 0.64 - 0.97 
Interval No Ev Ce PS 95% CI 
19 to 20 17 1 0 0.84 0.59 - 0.95 
25 to 26 16 1 0 0.79 0.53 - 0.92 
27 to 28 15 1 0 0.74 0.48 - 0.88 
29 to 30 14 1 0 0.68 0.43 - 0.84 
30 to 31 13 1 0 0.63 0.38 - 0.80 
31 to 32 12 1 0 0.58 0.33 - 0.76 
41 to 42 11 1 0 0.53 0.29 - 0.72 
48 to 49 10 1 0 0.47 0.24 - 0.67 
51 to 52 9 2 0 0.37 0.17 - 0.57 
56 to 57 7 0 2 0.37 0.17 - 0.57 
60 to 61 5 0 1 0.37 0.17 - 0.57 
66 to 67 4 0 1 0.37 0.17 - 0.57 
70 to 71 3 0 1 0.37 0.17 - 0.57 
72 to 73 2 0 1 0.37 0.17 - 0.57 
75 to 76 1 0 1 0.37 0.17 - 0.57 
Table 14 -20: Overall survival acording to the speed of response to primary 
systemic treatment 
Interval No Ev I Ce PS I 95% CI 
Fast response 
31 to 32 18 1 0 0.94 0.67 - 0.99 
52 to 53 17 0 1 0.94 0.67 - 0.99 
55 to 56 16 0 1 0.94 0.67 - 0.99 
56 to 57 15 0 2 0.94 0.67 - 0.99 
63 to 64 13 0 1 0.94 0.67 - 0.99 
64 to 65 12 0 1 0.94 0.67 - 0.99 
68 to 69 11 0 3 0.94 0.67 - 0.99 
71 to 72 8 0 1 0.94 0.67 - 0.99 
72 to 73 7 0 2 0.94 0.67 - 0.99 
73 to 74 5 0 1 0.94 0.67 - 0.99 
75 to 76 4 1 2 0.63 0.07 - 0.92 
76 to 77 1 0 1 0.63 0.07 - 0.92 
Slow response 
10 to 11 19 1 0 0.95 0.68 - 0.99 
17 to 18 18 1 0 0.89 0.64 - 0.97 
Interval No Ev Ce PS 95% CI 
19 to 20 17 1 0 0.84 0.59 - 0.95 
25 to 26 16 1 0 0.79 0.53 - 0.92 
27 to 28 15 1 0 0.74 0.48 - 0.88 
29 to 30 14 1 0 0.68 0.43 - 0.84 
30 to 31 13 1 0 0.63 0.38 - 0.80 
31 to 32 12 1 0 0.58 0.33 - 0.76 
41 to 42 11 1 0 0.53 0.29 - 0.72 
48 to 49 10 1 0 0.47 0.24 - 0.67 
51 to 52 9 2 0 0.37 0.17 - 0.57 
56 to 57 7 0 2 0.37 0.17 - 0.57 
60 to 61 5 0 1 0.37 0.17 - 0.57 
66 to 67 4 0 1 0.37 0.17 - 0.57 
70 to 71 3 0 1 0.37 0.17 - 0.57 
72 to 73 2 0 1 0.37 0.17 - 0.57 
75 to 76 1 0 1 0.37 0.17 - 0.57 
Table 14 -21: Overall survival acording to the speed of response to primary 
systemic treatment, adjusted for age, tumour size, initial ER status, axillary 
lymph node status and tumour differentiation 
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Interval No ' Ev Ce PS 95% CI 
Low levels of anxious preoccupation 
13 to 14 28 1 0 0.96 0.77 - 0.99 
17 to 18 27 1 0 0.93 0.74 - 0.98 
20 to 21 26 1 0 0.89 0.70 - 0.96 
27 to 28 25 1 0 0.86 0.66 - 0.94 
28 to 29 24 1 0 0.82 0.62 - 0.92 
34 to 35 23 1 0 0.79 0.58 - 0.90 
50 to 51 22 1 0 0.75 0.55 - 0.87 
53 to 54 21 0 1 0.75 0.55 - 0.87 
56 to 57 20 0 4 0.75 0.55 - 0.87 
58 to 59 16 1 0 0.70 0.49 - 0.84 
59 to 60 15 0 1 0.70 0.49 - 0.84 
64 to 65 14 0 1 0.70 0.49 - 0.84 
65 to 66 13 0 1 0.70 0.49 - 0.84 
68 to 69 12 0 2 0.70 0.49 - 0.84 
70 to 71 10 0 2 0.70 0.49 - 0.84 
71 to 72 8 0 1 0.70 0.49 - 0.84 
72 to 73 7 0 2 0.70 0.49 - 0.84 
73 to 74 5 0 1 0.70 0.49 - 0.84 
75 to 76 4 0 2 0.70 0.49 - 0.84 
76 to 77 2 0 2 0.70 0.49 - 0.84 
High levels of anxious preoccupation 
10 to 11 29 1 0 0.97 0.78 - 1.00 
Interval No Ev Ce PS 95% CI 
11 to 12 28 1 0 0.93 0.75 - 0.98 
13 to 14 27 1 0 0.90 0.71 - 0.97 
15 to 16 26 1 0 0.86 0.67 - 0.95 
16 to 17 25 1 0 0.83 0.63 - 0.92 
18 to 19 24 1 0 0.79 0.60 - 0.90 
21 to 22 23 1 0 0.76 0.56 - 0.88 
24 to 25 22 1 0 0.72 0.52 - 0.85 
26 to 27 21 1 0 0.69 0.49 - 0.82 
28 to 29 20 1 0 0.66 0.45 - 0.80 
34 to 35 19 1 0 0.62 0.42 - 0.77 
41 to 42 18 1 0 0.59 0.39 - 0.74 
43 to 44 17 3 0 0.48 0.29 - 0.65 
50 to 51 14 1 0 0.45 0.27 - 0.62 
60 to 61 13 0 1 0.45 0.27 - 0.62 
63 to 64 12 0 1 0.45 0.27 - 0.62 
64 to 65 11 0 3 0.45 0.27 - 0.62 
66 to 67 8 0 1 0.45 0.27 - 0.62 
67 to 68 7 0 1 0.45 0.27 - 0.62 
68 to 69 6 0 1 0.45 0.27 - 0.62 
69 to 70 5 0 1 0.45 0.27 - 0.62 
72 to 73 4 0 1 0.45 0.27 - 0.62 
75 to 76 3 0 1 0.45 0.27 - 0.62 
76 to 77 2 0 2 0.45 0.27 - 0.62 
Table 14 -22: Event free survival by the levels of anxious preoccupation 
Interval No Ev I Ce I PS I 95% CI 
Low levels of anxious preoccupation 
21 to 22 28 1 0 0.96 0.77 - 0.99 
22 to 23 27 1 0 0.93 0.74 - 0.98 
30 to 31 26 1 0 0.89 0.70 - 0.96 
31 to 32 25 1 0 0.86 0.66 - 0.94 
51 to 52 24 2 0 0.79 0.58 - 0.90 
53 to 54 22 0 1 0.79 0.58 - 0.90 
55 to 56 21 1 0 0.75 0.54 - 0.87 
56 to 57 20 0 4 0.75 0.54 - 0.87 
59 to 60 16 0 1 0.75 0.54 - 0.87 
63 to 64 15 1 0 0.70 0.48 - 0.84 
64 to 65 14 0 1 0.70 0.48 - 0.84 
65 to 66 13 0 1 0.70 0.48 - 0.84 
68 to 69 12 0 2 0.70 0.48 - 0.84 
70 to 71 10 0 2 0.70 0.48 - 0.84 
71 to 72 8 0 1 0.70 0.48 - 0.84 
72 to 73 7 0 3 0.70 0.48 - 0.84 
73 to 74 4 0 1 0.70 0.48 - 0.84 
75 to 76 3 0 2 0.70 0.48 - 0.84 
76 to 77 1 0 1 0.70 0.48 - 0.84 
High levels of anxious preoccupation 
10 to 11 29 1 0 0.97 0.78 - 1.00 
Interval No Ev Ce PS 95% CI 
12 to 13 28 1 0 0.93 0.75 - 0.98 
16 to 17 27 1 0 0.90 0.71 - 0.97 
17 to 18 26 1 0 0.86 0.67 - 0.95 
25 to 26 25 1 0 0.83 0.63 - 0.92 
27 to 28 24 1 0 0.79 0.60 - 0.90 
29 to 30 23 1 0 0.76 0.56 - 0.88 
31 to 32 22 1 0 0.72 0.52 - 0.85 
36 to 37 21 1 0 0.69 0.49 - 0.82 
41 to 42 20 1 0 0.66 0.45 - 0.80 
48 to 49 19 1 0 0.62 0.42 - 0.77 
60 to 61 18 0 1 0.62 0.42 - 0.77 
61 to 62 17 0 1 0.62 0.42 - 0.77 
63 to 64 16 1 1 0.58 0.38 - 0.74 
64 to 65 14 0 3 0.58 0.38 - 0.74 
66 to 67 11 0 1 0.58 0.38 - 0.74 
67 to 68 10 1 1 0.52 0.31 - 0.69 
68 to 69 8 0 2 0.52 0.31 - 0.69 
69 to 70 6 0 1 0.52 0.31 - 0.69 
72 to 73 5 0 1 0.52 0.31 - 0.69 
75 to 76 4 1 1 0.37 0.12 - 0.63 
76 to 77 2 0 2 0.37 0.12 - 0.63 
Table 14 -23: Overall survival by levels of anxious preoccupation 
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Interval No Ev J Ce PS I 95% CI 
Low levels of anxious preoccupation 
13 to 14 25 1 0 0.96 0.75 - 0.99 
20 to 21 24 1 0 0.92 0.72 - 0.98 
27 to 28 23 1 0 0.88 0.67 - 0.96 
28 to 29 22 1 0 0.84 0.63 - 0.94 
34 to 35 21 1 0 0.80 0.58 - 0.91 
50 to 51 20 1 0 0.76 0.54 - 0.88 
53 to 54 19 0 1 0.76 0.54 - 0.88 
56 to 57 18 0 4 0.76 0.54 - 0.88 
58 to 59 14 1 0 0.71 0.48 - 0.85 
59 to 60 13 0 1 0.71 0.48 - 0.85 
64 to 65 12 0 1 0.71 0.48 - 0.85 
65 to 66 11 0 1 0.71 0.48 - 0.85 
68 to 69 10 0 2 0.71 0.48 - 0.85 
70 to 71 8 0 2 0.71 0.48 - 0.85 
72 to 73 6 0 2 0.71 0.48 - 0.85 
73 to 74 4 0 1 0.71 0.48 - 0.85 
75 to 76 3 0 1 0.71 0.48 - 0.85 
76 to 77 2 0 2 0.71 0.48 - 0.85 
High levels of anxious preoccupation 
Interval No Ev Ce PS 95% CI 
10 to 11 24 1 0 0.96 0.74 - 0.99 
11 to 12 23 1 0 0.92 0.71 - 0.98 
13 to 14 22 1 0 0.88 0.66 - 0.96 
18 to 19 21 1 0 0.83 0.61 - 0.93 
21 to 22 20 1 0 0.79 0.57 - 0.91 
26 to 27 19 1 0 0.75 0.53 - 0.88 
28 to 29 18 1 0 0.71 0.48 - 0.85 
34 to 35 17 1 0 0.67 0.44 - 0.82 
41 to 42 16 1 0 0.63 0.40 - 0.78 
43 to 44 15 3 0 0.50 0.29 - 0.68 
60 to 61 12 0 1 0.50 0.29 - 0.68 
64 to 65 11 0 3 0.50 0.29 - 0.68 
66 to 67 8 0 1 0.50 0.29 - 0.68 
67 to 68 7 0 1 0.50 0.29 - 0.68 
68 to 69 6 0 1 0.50 0.29 - 0.68 
69 to 70 5 0 1 0.50 0.29 - 0.68 
72 to 73 4 0 1 0.50 0.29 - 0.68 
75 to 76 3 0 1 0.50 0.29 - 0.68 
76 to 77 2 0 2 0.50 0.29 - 0.68 
Table 14 -24: Event free survival by anxious preoccupation, adjusted for trial 
option, axillary nodal status and In of initial ER 
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14.2 PSYCHOLOGICAL QUESTINNAIRES 
14.2.1 The Hospital Anxiety and Depression (HAD) Scale 
The HAD scale consists of an explanatory statement followed by 14 questionnaire items. Each 
item is followed by a choice of 4 remarks indicating strong agreement, mild agreement, mild 
disagreement and strong disagreement with the item Seven items are designed to assess 
anxiety. These alternate with the remaining seven which are aimed at evaluating depression. 
Scoring is from zero to 3, with directly scored questions alternating with reversed score 
questions. 
The details of the questionnaire arc as follows: 
14.2.1.1 Explanatory statement 
Doctors are aware that emotions play an important part in most illnesses. If your doctor 
knows about these feelings he will be able to help you more. 
This questionnaire is designed to help your doctor to know how you feel. Read each item and 
place a firm tick in the box opposite the reply which comes closest to how you have been 
feeling in the past week. 
Don't take too long over your replies: your immediate reaction to each item will probably be 
more accurate than a long thought -out response. 
14.2.1.2 Questionnaire items 
Type refers to whether the item addresses anxiety (Anx) or depression (Dep). The "score" 
does not appear on the questionnaire given to patients. The items are detailed in the next two 
pages. 
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The HAD Scale 
Type Questionnaire item Replies Score 
1. Anx I feel tense or 'wound up': Most of the time 3 
A lot of the time 2 
Time to time, Occasionally 1 
Not at all 0 
2. Dep I still enjoy the things I Definitely as much 0 
used to enjoy: Not quite so much 1 
Only a little 2 
Hardly at all 3 
3. Anx I get a sort of frightened Very definitely and quite badly 3 
feeling as if something Yes, but not too badly 2 
awful is about to happen: A little, but it doesn't worry me 1 
Not at all. 0 
4. Dep I can laugh and see the As much as I always could 0 
funny side of things: Not quite so much now 1 
Definitely not so much now 2 
Not at all 3 
5. Anx Worrying thoughts go A great deal of the time 3 
through my mind: A lot of the time 2 
From time to time but not too often 1 
Only occasionally 0 
6. Dep I feel cheerful: Not at all 3 
Not often 2 
Sometimes 1 
Most of the time 0 
7. Anx I can sit at ease and feel Definitely 0 
relaxed: Usually 1 
Not often 2 
Not at all 3 
8. Dep I feel as if I am slowed Nearly all the time 3 
down: Very often 2 
Sometimes 1 
Not at all 0 
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The HAD Scale 
Type Questionnaire item Replies Score 
9. Anx I get a sort of frightened Not at all 0 
feeling like butterflies' in Occasionally 1 
the stomach: Quite often 2 
Very often 3 
10. Dep I have lost interest in my Definitely 3 
appearance: I don't take so much care as I should 2 
I may not take quite as much care 1 
I take just as much care as ever 0 
11. Anx I feel restless as if I have Very much indeed 3 
to be on the move: Quite a lot 2 
Not very much 1 
Not at all 0 
12. Dep I look forward with As much as ever I did 0 
enjoyment to things: Rather less than I used to 1 
Definitely less than I used to 2 
Hardly at all 3 
13. Anx I get sudden feelings of Very often indeed 3 
panic: Quite often 2 
Not very often 1 
Not at all 0 
14. Dep I can enjoy a good book or Often 0 
radio or TV programme: Sometimes 1 
Not often 2 
Very seldom 3 
14.2.2 The Mental Adjustment to Cancer (MAC) Scale 
The MAC scale consists of an explanatory statement followed by 40 questionnaire items. 
Each item may he scored from l to 4, with no reverse scored items as follows: 
1. Definitely does not apply to me 
2. Does not apply to me 
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3. Applies to me 
4. Definitely applies to me 
The items fall into one of five categories appearing in random order: 
1. Fighting spirit: 16 items 
2. Helplessness / I lopclessness 6 items 
3. Anxious Preoccupation 9 items 
4. Fatalistic 8 items 
5. Avoidance one item 
The details of the questionnaire arc as follows: 
14.2.2.1 Explanatory statement 
A number of statements are given below which describe people's reactions to having cancer. 
Please circle the appropriate number to the right of each statement, indicating how far it 
applies to you al present For example, if the statement definitely does not apply to you then 
you should circle 1 in the first column. 
14.2.2.2 Questionnaire items 
"Type" refers to the aspect of mental adjustment addressed by the question, as follows: 
FS: Fighting spirit, l -l: Hopelessness /Helplessness, AP: Anxious preoccupation, F: Fatalistic, 
A: Avoidance 
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I have been doing things that I believe will improve my health e.g. changed my diet 
I feel I can't do anything to cheer myself up 
I feel that problems with my health prevent me from planning ahead 
I believe that my positive attitude will benefit my health 
I don't dwell on my illness 
I firmly believe that I will get better 
I feel that nothing I can do will make any difference 
I've left it all to my doctors 
I feel that life is hopeless 
I have been doing things that I believe will improve my health, e.g. exercised 
Since my cancer diagnosis I now realise how precious life is and I'm making th 
most of it 
I've put myself in the hands of God 
I have plans for the future, e.g. holiday, jobs, housing 
I worry about the cancer returning or getting worse 
I've had a good life what's left is a bonus 
I think my state of mind can make a lot of difference to my health 
I feel that there is nothing I can do to help myself 
I try to carry on my life as I've always done 
I would like to make contact with others in the same boat 
I am determined to put it all behind me 
I have difficulty in believing that this happened to me 
I suffer great anxiety about it 
I am not very hopeful about the future 
e 
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The MAC Scale 
Type Item 
24. F At the moment I take one day at a time 
25. H I feel like giving up 
26. FS I try to keep a sense of humour about it 
27. FS Other people worry about me more than I do 
28. FS I think of other people who are worse off 
29. AP I am trying to get as much information as I can about cancer 
30. F I feel that I can't control what is happening 
31. FS I try to have a very positive attitude 
32. FS I keep quite busy, so I don't have time to think about it 
33. F I avoid finding out more about it 
34. FS I see my illness as a challenge 
35. F I feel fatalistic about it 
36. H I feel completely at a loss about what to do 
37. AP I feel very angry about what has happened to me 
38. A I don't really believe I had cancer 
39. FS I count my blessings 
40. FS I try to fight the illness 
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14.3 THE Q -TWIST PROGRAM 
The Q- 'l'WiSI' analysis was performed using a routine (called an ado file) written for the 
statistical software package Stata 4, Stata Corporation, 702 University Drive East, College 
Station, 'Texas 77840 USA. 
"twist" is the name of the routine which contains the Q -TWiST programme. Its details are 
given below. All are "Stata" commands and should be placed in a text file named twist.ado 
exactly as written. twist.ado should be placed either in the drire:lpad, \ado \t directory, or in 
the same directory as the dataset being analysed. 
program define twist 
if -1'"=="?" { 




survcurv trex rex 
gen varl =trex[_n -l] 
recode vari . =0 
gen var2 =trex -varl 
gen var3 = var2 *_surv 
gen var4 =sum(var3) 
gen arl =var4 in 1 
recode arl . =max 
drop vari var2 var3 var4 
sort trec 
survcurv trec rec 
gen varl =trec[_n -1] 
recode vari . =0 
gen var2 =trec -vari 
gen var3 =var2 *_surv 
gen var4 =sum(var3) 
gen ar2 =var4 in 1 
recode ar2 .=max 
drop vari var2 var3 var4 
sort tdead 
survcurv tdead dead 
gen varl =tdead[_n -1] 
recode vari . =0 
gen var2 =tdead -varl 
gen var3= var2 *_surv 
gen var4= sum(var3) 
gen ar3 =var4 in 1 
recode ar3 . =max 
drop vari var2 var3 var4 
gen arrec =ar3 -ar2 
gen artwist =ar2 -arl 
gen final =(arl *urex) +artwist +(arrec *urec) 
sum final 
post '1' _result(3) 
end 
14 -349 
Once the twist.ado file is available the following commands need to be entered for the 
calculation of Q- TWIST. Stata commands appear in bold, while characters which appear in 
italics indicate variables to be entered by the user. 
gen t rec= name of variable indicating tinie to recurrence in days 
gen t d e a d= name of variable indicating tine to death in days 
gen trex= name of variable indicating duration of treatment in days 
gen rec= name of censoring variable for recurrence, coded 1 for an event 0 for censoring 
gen dead= name of censoring variable for death, coded 1 for an event 0 for censoring 
gen rex= name of censoring variable for treatment, coded 1 for an event O for censoring 
gen urec= number between 0 and 1, indicating the utility coefficient for recurrence 
gen urex= number between O and 1, indicating the utility coefficient for treatment 
keep tree tdead trex rec dead rex urec urex 
b s t rap twist , reps (number of bootstrap replications) d 
The results returns the mean Q- TWiST, and bootstrap standard deviation which is by 
definition the standard error of the mean. 
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14.4 TUMOUR SIZE MEASUREMENTS 
Actual tumour size measurements by different modalities. Path: diameter measured by the 
pathologist. Clin: clinical tumour size. Mann: Mammographie tumour size. US: Ultrasound 
tumour size. 
No Path Clin Mam US No Path Clin Mam US 
1 0.7 - - 0.7 29 2.1 2.6 2.4 1.8 
2 0.9 - 0.8 1.0 30 2.2 2.4 2.0 1.7 
3 1.0 1.6 1.1 0.9 31 2.3 2.8 2.4 2.3 
4 1.1 1.0 1.2 0.9 32 2.4 3.0 2.3 2.1 
5 1.1 1.2 1.5 1.1 33 2.5 4.1 - 2.7 
6 1.2 1.7 1.3 1.6 34 2.7 2.3 - 2.6 
7 1.3 2.0 2.2 1.3 35 2.8 4.2 3.2 2.8 
8 1.3 1.2 1.5 1.4 36 2.8 3.4 - 2.8 
9 1.3 1.1 - 0.9 37 2.9 4.3 2.4 2.7 
10 1.4 2.6 1.3 1.4 38 3.0 3.8 3.1 2.7 
11 1.5 - 1.8 1.3 39 3.0 3.8 - 2.6 
12 1.5 2.5 1.5 1.1 40 3.0 4.1 3.0 2.9 
13 1.5 2.6 1.1 1.1 41 3.0 3.7 3.0 3.2 
14 1.5 1.7 1.7 1.5 42 3.2 4.0 2.9 3.2 
15 1.7 3.3 1.9 1.5 43 3.3 4.4 2.7 3.0 
16 1.7 1.8 1.5 1.9 44 3.5 4.0 - 3.1 
17 1.7 1.7 1.6 1.4 45 3.5 3.3 5.0 3.7 
18 1.8 2.4 2.1 2.0 46 3.5 2.2 - 3.5 
19 1.8 3.5 2.3 1.9 47 3.5 4.0 2.9 3.7 
20 1.8 2.1 1.5 1.1 48 3.5 4.0 4.0 2.9 
21 1.9 2.6 1.2 1.1 49 4.2 4.1 3.8 4.4 
22 1.9 1.9 1.9 1.6 50 4.3 4.9 4.3 4.1 
23 1.9 - 2.0 1.6 51 5.9 4.0 3.5 4.6 
24 2.0 4.0 3.1 2.2 52 6.0 7.5 4.5 5.5 
25 2.0 5.4 1.7 2.1 53 7.5 5.5 5.0 - 
26 2.0 3.0 2.7 1.9 54 8.0 5.4 - - 
27 2.0 2.5 - 2.8 55 10.0 7.5 8.2 - 
28 2.0 2.2 2.2 1.9 
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14.5 PUBLISHED PAPERS 
Reprints of papers published from the work presented in this thesis are appended. 
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Ultrasonography as a method of measuring breast tumour size and 
monitoring response to primary systemic treatment 
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Accurate measurement of change in tumour size is a 
prerequisite for the use of response -based regimens of 
primary systemic therapy for breast cancer. This study 
evaluated the accuracy of clinical assessment, mammography 
and ultrasonography in measuring tumour size and in 
monitoring response to treatment. Size was determined 
during the week preceding surgery and actual size measured 
from resected specimens. Sequential measurements were 
performed in 35 patients undergoing primary systemic 
treatment. There was moderate correlation between 
pathological and clinical size (n =51, r2 =0.68, P <0.0001). 
Close correlation with pathological tumour size was 
observed for mammographic (n =45, r2 =0.84, P <0.0001) 
and ultrasonographic (n= 52, 12 =0.89, P <0.0001) tumour 
size. Response was correctly evaluated by clinical 
assessment in 31 of 35 patients, by mammography in 20 of 
35 and by ultrasonography in 31 of 35. Actual tumour size 
can be measured accurately by available imaging techniques 
but ultrasonography is the most practical and accurate 
method for monitoring response. 
Tumour size is an important independent indicator of prognosis 
for patients with carcinoma of the breast1-3. Repeated size 
measurements during primary systemic therapy produce 
detailed information about response' that can be used to select 
the most effective treatment regimens'6 and to estimate better 
a patient's prognosis'-' ̀  
Tumour size can be measured clinically using engineers' 
callipers4.1213; the estimate, however, is indirect, influenced by 
associated oedema and obesity ', and observer dependent's 
Mammography is well established as an objective technique 
of assessing breast tumours16 but the frequency with which it 
may be performed is limited by the radiation dose. In some 
patients the mammographic tumour outline is so diffuse as to 
preclude estimation of small variations in size "'s 
Ultrasonography is simple to perform, provides a permanent 
record of tumour size and may be carried out frequently16.19 -21 
This technique provides an alternative method of assessing 
response to primary systemic treatment, particularly in patients 
with dense breasts22. 
The aims of this study were to establish the degree with 
which estimates of tumour diameter determined by clinical, 
mammographic and ultrasonographic methods correlate with 
actual tumour size, and to compare the efficacy of the methods, 
used sequentially, to assess response to primary systemic 
treatment. 
Patients and methods 
A total of 77 patients with palpable operable tumours undergoing wide 
local excision or mastectomy were studied. Diagnosis of malignancy 
had been established by cytology and mammography. The study was 
conducted in two parts with two overlapping subsets of patients. 
For the first part of the study, single measurements were obtained 
on 63 tumours in 62 patients, including 42 patients treated by initial 
surgery and 20 who had completed 12 weeks of primary systemic 
therapy. Tumours were measured clinically, mammographically and 
ultrasonographically in the week preceding surgery. 
Presented to the Surgical Research Society in London, UK, January 
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For the second part of the study, sequential measurements were 
performed over a period of 2 years on 35 patients (including 20 from 
the first part) undergoing primary systemic treatment. Patients were 
seen once a week and lesions measured by calliper and ultrasonography. 
Single oblique mammography was performed once every 4 weeks. 
Primary systemic treatment was continued for 12 weeks when 
mastectomy was performed. The logarithm of tumour volume was 
plotted against time, and response defined as a significant negative 
correlation between time from the start of treatment and log [volume], 
as described previously5'23 
Clinical, mammographic and ultrasonographic measurements were 
performed by single designated observers. Examination of resected 
specimens was performed, or directly supervised, by one pathologist. 
The following techniques were used. 
Clinical assessment. Tumours were measured across four diameters 
at 45° to each other using engineers' callipers. Mean tumour diameter 
was recorded as the clinical tumour size. Tumour volume was calculated 
using the formula for the volume of a sphere. 
Mammography. Single oblique views were used to measure 
tumour diameter. The largest diameter and that at 90° to this axis were 
measured. Mammographic size was recorded as the mean of the two 
measurements and tumour volume calculated using the formula for the 
volume of a sphere. 
Ultrasonography. A Siemens SL1 machine (Siemens, Tokyo, 
Japan) with a 7.5 -MHz linear -array probe was used. The probe was 
held orthogonal to the skin and moved over the tumour until maximum 
diameter was demonstrated. Four measurements were made at 45° 
intervals, and the mean diameter and thickness of the lesion recorded 
using the machine's electronic callipers. Tumour volume (V) was 




where D is the mean diameter and d the mean thickness. 
Fresh resected specimens were serially sectioned at 0.5 -1-cm 
intervals and at right angles to the skin. Length, width and thickness 
of the tumour were recorded, and volume calculated using the formula 
for the volume of an ellipsoid. 
Distribution of the data was assessed for normality with a probit 
plot and skewed measurements normalized by logarithmic transform- 
ation. Mean tumour diameter measured by the pathologist was 
designated `actual size', and the relationship between this and size 
223 
224 P. FOROUHI, J. S. WALSH, T. J. ANDERSON and U. CHETTY 
assessed by other techniques was established using linear regression by 
the method of least squares. Mean pathological, clinical, mammographic 
and ultrasonographic diameters were compared using Friedman's 
two -way analysis of variance to determine overestimation and 
underestimation. 
Response to primary systemic treatment assessed by sequential 
measurement of tumour volume was compared with 'actual response'. 
This was determined by estimating the pretreatment tumour volume 
and standard error (s.e.) from the initial mammographic and 
ultrasonographic measurements, using graphs presented in the results 
section. After primary systemic treatment, macroscopic size and 
microscopic extent of tumour were measured in the surgical specimen, 
and volume of residual tumour calculated. The disease was classified 
as static if this was within 2 s.e. of the estimated initial volume. Residual 
volumes less or greater than this were classified as indicating regression 
and progression respectively. 
Results 
Of the 63 surgical specimens examined on excision, five 
contained no macroscopically detectable residual tumour and 
in a further three the margins were too diffuse for accurate 
assessment. Fifty -five lesions (87 per cent) were assessable. 
Two patients had clinically palpable lesions that did not 




Pathological size (cm) 
Fig. 1 Relationship between pathological and clinical tumour 





Pathological size (cm) 
Fig. 2 Relationship between pathological and mammographic 




Pathological size (cm) 
Fig. 3 Relationship between pathological and ultrasonographic 
tumour diameter (n= 52). y= 0-95x °'99; r2 =0.89, P<0.0001 
Table 1 Assessment of response to primary systemic treatment 
10.0 
Not Incorrectly Correctly 
Method assessable assessed assessed 
Clinical 0 4 31 
Mammography 12 3 20 
Ultrasonography 2 2 31 
Response was measured clinically, mammographically and ultra - 
sonographically, and compared with 'actual response' as defined in the 
text. Ultrasonography was able to detect response correctly in 
significantly higher numbers of patients compared with those identified 
using mammography (P= 0.005, McNemar's y2 test) 
tumours presenting in one breast were clinically indistinguish- 
able. Ten tumours had diffuse mammographic outlines and 
could not be measured by this method. Three lesions were larger 
than the maximum diameter of the ultrasonographic probe 
(6 cm) and were not assessable by ultrasonography. Fifty -one 
clinical, 45 mammographic and 52 ultrasonographic measure- 
ments were available for analysis. 
Diameter and volume values followed a positively skewed 
distribution curve and log -transformed data were used for linear 
regression. The relationship between actual size and mean 
clinical, mammographic and ultrasonographic tumour diameters 
is shown in Figs 1 -3. Correlation was moderate for 
measurements using calipers (Fig. I), but much closer for those 
assessed with mammography and ultrasonography (Figs 2 and 
3). 
For 45 cases in which measurements were available by all 
methods, Friedman's analysis of variance revealed no significant 
difference between pathological (mean 1.9 cm), mammographic 
(mean 1.9 cm) and ultrasonographic (mean 1.8 cm) diameters. 
Clinical diameter (mean 2.7 cm) was significantly larger than 
the others (P = 0.0001). 
Tumour volume was used for sequential assessment of 
response. Correlation between pathological and clinical tumour 
volumes was moderate (r2 =0.63, P<0.0001) and those 
between pathological tumour volume and mammographic and 
ultrasonographic volumes were close (r2 = 0.85 and r2 = 0.87 
respectively, P <0.0001). 
The results of sequential measurements of volume for 
assessment of response are presented in Table 1. Ultra - 
sonography correctly evaluated ten of the 12 patients who could 
not be assessed using mammography. Four tumours were either 
not assessable or incorrectly assessed by all three techniques. 
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Histological examination revealed diffuse infiltration of the 
breast in two patients who were erroneously evaluated as 
responders. The two patients who were inaccurately assessed 
as non -responders had discrete residual breast masses 
consisting of hyalinized stroma, with only a small rim of residual 
malignant cells. 
Discussion 
Ultrasonography and mammography estimate actual tumour 
diameter and volume with greater accuracy than clinical 
measurement. The correlation between tumour diameter 
measured by ultrasonography or mammography and actual 
tumour diameter on excision was greater in the present study 
than in others'''. In one series24, ultrasonography was the 
most accurate technique of measuring tumour size but a recent 
report26 described all three methods as having the same degree 
of inaccuracy. Pathological size is the standard against which 
other measurements are evaluated and the authors paid 
particular attention to its accurate assessment. Previous studies 
recorded this retrospectively, sometimes on fixed tissues. This 
may have been relatively inaccurate, as evidenced by the 
significant clustering of sizes around whole numbers'''. 
Sequential calliper measurements performed by the same 
person were confirmed as an accurate method of monitoring 
response to primary systemic treatment. Imaging techniques 
are nevertheless important in providing independent and 
objective verification of clinically observed responses. Mammo- 
graphy and ultrasonography were equally good in assessing 
response in mammographically discrete tumours, but ultra - 
sonography could also be used in diffuse lesions, and was 
therefore successful in significantly more patients. Failure to 
assess response correctly appeared to be a function of the 
tumour architecture rather than the technique. It is likely that 
this can be avoided only by monitoring parameters other than 
tumour dimensions. 
Mammographic or ultrasonographic tumour diameter, 
rather than clinical size, should be used in clinical staging of 
breast cancer and in planning future clinical trials. Ultra - 
sonography is the method of choice for monitoring the response 
of breast tumours to primary systemic treatment. 
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Risk factors for recurrent laryngeal nerve (RLN) lesions 
after thyroid gland surgery were evaluated retrospectively 
in 1026 patients. RLN palsy occurred in 5.9 per cent; 
the incidence of permanent palsy was 2.4 per cent as 
59 per cent of paralyses were transient. For euthyroid 
nodular goitre, Graves' disease, chronic lymphocytic 
thryoiditis, recurrent goitre and thyroid carcinoma, 
permanent nerve damage occurred in 1.7, 4, 5, 3.8 and 
8 per cent of patients respectively. In relation to the number 
of nerves at risk, the incidence of permanent RLN palsy 
was 1.1 per cent for subtotal lobectomy and 4.0 per cent 
for total lobectomy. The overall incidence of permanent 
RLN palsy was 1.8 per cent of nerves at risk. There was 
no statistically significant difference between the number 
of RLN paralyses occurring after nerve exposure and that 
occurring after non -exposure in subtotal lobectomy, but in 
total lobectomy the permanent palsy rate increased from 
3.8 to 7 per cent when the nerve was not exposed or 
identified (P<0.01). Underlying thyroid disease, the extent 
of resection and exposure of the nerve in total lobectomy 
are risk factors for both transient and permanent RLN 
palsy. 
The major concern in modern thyroid gland surgery is 
morbidity' 5. Besides haemorrhage and hypoparathyroidism, 
damage to the recurrent laryngeal nerve (RLN) is the 
complication most feared by both patient and surgeon". There 
is an expected risk of nerve damage during surgery for Graves' 
disease, thyroid carcinoma and recurrent goitre4.6-9, despite 
anatomical variations of the RLN'o -'4 and appropriate 
techniques for performing safe thyroid gland resection being 
well documented'S-'s Whether or not the RLN should be 
exposed during every thyroid operation is still debated, 
although recent publications favour exposure'5.'6.19 -zz 
To define the risk factors for RLN injury in thyroid gland 
surgery, 1026 patients who had 1474 nerves at risk were 
evaluated retrospectively. 
Patients and methods 
Between January 1983 and December 1991, 1026 patients underwent 
thyroid surgery at this institution. They comprised 770 women 
(75.0 per cent) and 256 men (25.0 per cent) of age 16-84 (mean 54) 
years. Details of operative procedures, histopathological reports and 
postoperative course obtained from patients' records were evaluated 
retrospectively. All patients underwent preoperative and postoperative 
laryngoscopy by an otorhinolaryngologist to examine vocal cord 
function. Those with RLN paralysis after operation received voice 
therapy until recovery of the nerve or voice. Of the 1026 patients, 896 
underwent primary and 130 secondary neck exploration, and 52 had 
pre -existing RLN palsy from either the underlying disease or previous 
operation. Two patients had nerve involvement at operation requiring 
resection. Therefore, 54 nerves were excluded from the study, which 
left 1474 at risk. 
Clinically, 820 patients (79.9 per cent) were euthyroid, 21 
(2.0 per cent) hypothyroid and 185 (18.0 per cent) hyperthyroid (which 
was the indication for operation). Other indications included 
symptomatic multinodular goitre (35.1 per cent) and cold nodules 
(20.0 per cent). A group of 205 patients (20.0 per cent) had findings 
suggesting malignancy on fine -needle aspiration cytology. Chronic 
lymphocytic thyroiditis with cold or enlarging nodules (2.0 per cent) and 
recurrent thyroid cancer (4.9 per cent) completed the case distribution. 
Surgical technique 
The procedure used for thyroid gland resection was similar to that 
described previously'S -'s.zo The neck was explored through a 
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transverse cervical incision and the thyroid gland exposed. The superior 
thyroid vessels and the lateral and lower pole veins were ligated and 
divided. After dissecting out the inferior thyroid artery, the RLN was 
usually identified and completely visualized in total but not subtotal 
resection. At least one parathyroid gland was preserved on each side. 
Parathyroid autografting was rarely performed. In bilateral subtotal 
resection the inferior thyroid artery was not routinely ligated, to prevent 
ischaemic damage to the parathyroid glands. The isthmus and 
pyramidal lobe were always resected. Subtotal lobectomy corresponded 
to resection leaving a remnant of about 4 x 1 x 1 cm. Overall, 606 
patients in this study (59.1 per cent) underwent unilateral and 420 
(40.9 per cent) bilateral resection. 
RLN palsy rates were calculated in relation to the number of patients 
and nerves at risk, the underlying disease, and extent of resection and 
exposure (versus non -exposure) of the nerve. Permanent RLN palsy 
was defined as persisting paralysis of the vocal cord 1 year after surgery. 
Differences were assessed using the x2 test with Yates' correction2324 
Results 
Pathological findings are shown in Table 1. Euthyroid, 
uninodular or multinodular goitre, hyperthyroid goitre, 
follicular adenoma, thyroid carcinoma and recurrent goitre 
were found in 51.0, 18.0, 7.2, 9.1 and 12.7 per cent of patients 
respectively. There were no deaths. Three patients suffering 
postoperative haemorrhage required re- exploration. Five 
patients had symptoms of hypocalcaemia after total thyroid - 
ectomy, one of which progressed to permanent hypopara- 
thyroidism. The duration of hospital stay ranged from 3 to 5 
(mean 3.5) days. 
RLN injury occurred in 61 patients (5.9 per cent); it was 
transient in 36 and permanent in 25 (Tables 1 and 2). One 
patient with pre -existing palsy needed a tracheostomy for 
contralateral transient paralysis. 
Patients with Graves' disease or chronic lymphocytic 
thryoiditis had a permanent RLN palsy rate of 4 and 5 per cent 
respectively; in euthyroid nodular goitre, hyperthyroid goitre, 
thyroid carcinoma and recurrent goitre, permanent nerve 
damage occurred in 1.7, 1.6, 8 and 3.8 per cent respectively. No 
permanent paralysis was seen after lobectomy for follicular 
adenoma (Table 1). 
Table 2 shows results according to the extent of resection 
and related to the number of nerves at risk. Postoperative nerve 
injury affected 4.1 per cent of nerves at risk and 1.8 per cent 
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Prospective randomized study of surgical morbidity following primary 
systemic therapy for breast cancer 
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The influence of primary systemic therapy in treating 
operable breast cancer on postmastectomy morbidity rates 
was investigated. The contribution of other risk factors was 
assessed by multiple logistic regression. Seventy-nine 
eligible patients were randomly allocated, 39 to undergo 
immediate modified radical mastectomy, and 40 to receive 
initial cytotoxic or endocrine treatment followed by 
mastectomy. Postoperative wound seroma, infection and 
necrosis were recorded prospectively. Fourteen minor and 
six major complications occurred in 17 patients treated 
conventionally, while 14 patients developed 11 minor and 
six major complications after systemic therapy (P >0.4). 
Median hospital stay was 8 days for both groups. Age, 
smoking, immediate breast reconstruction and the type of 
primary systemic treatment given were not independent 
predictors of complication risk. Obesity emerged as a 
significant risk factor for postmastectomy complications 
(P = 0.015). Primary systemic therapy does not increase the 
rate of morbidity after mastectomy. 
Systemic treatment, when used as an adjunct to surgery, 
increases the length of survival for patients with operable 
breast cancer'. Investigations examining systemic therapy as 
primary treatment are currently in progress2 -5, but surgery 
continues to form an important component of many 
protocols46 -9 
There is justifiable anxiety regarding the use of drugs 
before surgery. Cytotoxic agents compromise immune 
function and interfere with the normal healing of surgical 
wounds in animal modelst0 -12. Initial systemic treatment has 
been associated with more wound infections and wound 
dehiscence following surgical excision of childhood 
abdominal tumours13, greater risk of prosthetic infection and 
limb loss after surgical reconstruction for bone malignancy14, 
and increased mortality from pneumonectomy for lung 
cancer' 5. 
Modified radical mastectomy16 is the operation of choice 
for local treatment of larger breast cancers ". Increased 
surgical morbidity and unexpected mortality have been 
reported following mastectomy with perioperative chemo- 
therapy". Limited uncontrolled data on the effect of 
preoperative chemotherapy have failed to show an 
increase19.20. 
This study investigated in a prospective randomized trial 
whether primary systemic treatment increased the rate of 
morbidity associated with modified radical mastectomy. The 
contribution of other patient and tumour factors was 
coincidentally examined. 
Patients and methods 
Patients 
Women aged less than 70 years with operable breast cancer larger 
than 4 cm in maximum diameter, diagnosed by fine needle 
aspiration cytology and mammography, were eligible for the study. 
Inoperability was defined according to the criteria of Haagensen21, 
and patients with metastatic disease were excluded by applying 
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guidelines issued from the Union Internacional Contra la 
Cancrum22. Informed written consent was required from each 
patient before entry into the study. 
Study design 
Patients were randomly allocated to one of the study options by the 
Scottish Cancer Trials Office and data were recorded prospectively, 
with foreknowledge of the patient's treatment option. 
Surgery 
Mastectomy with level III axillary clearance was carried out, 
removing a 3 -cm skin margin around the tumour. Where a tumour 
had regressed with therapy, its pretreatment size was used to plan 
skin margins. For larger tumours skin closure was achieved using a 
latissimus dorsi myocutaneous flap (LD flap)23.24. Other patients 
were offered primary breast reconstruction with a subpectoral tissue 
expander25.26. Closed suction drainage of the axilla was maintained 
until less than 30 ml of fluid was drained in 24 h. Shoulder 
physiotherapy was started on the second day after operation. 
Patients with breast implants were given prophylactic flucloxacillin 
and penicillin (or erythromycin in cases of penicillin allergy) for 7 
days, or until removal of all surgical drains, whichever was later. All 
patients received subcutaneous heparin until fully mobile. 
Primary .systemic treatment 
Primary systemic (`preop') treatment was administered according to 
a modification of the protocol reported previously27. An incisional 
tumour biopsy was performed to determine oestrogen receptor 
(ER) levels and treatment was started within 10 days of the biopsy. 
Patients with ER less than 20 fmol /mg cytosol protein were defined 
as ER- negative28 and treated with four cycles of cyclophosphamide 
1 g/m2, doxorubicin 50 mg /m2 and prednisolone 40 mg for 5 days 
(CAP), administered at 3- weekly intervals. Surgery took place 3 
weeks after the final cycle of chemotherapy or, in neutropenic 
patients, was delayed until the white cell count was greater than 
3 x 109 /litre. Two further cycles of CAP were administered after 
operation. 
ER- positive patients received tamoxifen 20 mg daily if post- 
menopausal and goserelin, one injection every 4 weeks, if 
premenopausal. Endocrine treatment was continued for 12 weeks. 
Patients responding to goserelin treatment underwent surgical 
oöphorectomy at the same time as mastectomy. Patients with a 
preoperative response to tamoxifen continued with this therapy. 
Tumour response was assessed weekly by ultrasonography as 
described previously29. Patients failing to respond to endocrine 
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therapy were switched to chemotherapy and if tumour progression 
occurred on chemotherapy mastectomy was performed early. 
Conventional treatment 
Mastectomy was performed within 3 weeks of entry and 
appropriate adjuvant therapy' was started a minimum of 3 weeks 
after surgery. 
Stogie alfollow-up 
Inpatients were examined daily and were reviewed at 1 week and 6 
weeks after discharge. Patients with complications requiring 
outpatient treatment were seen weekly until recovery. 
Complications 
The incidence of early mastectomy- related wound complications 
has previously been reported as 10 -50 per cent, with seroma, 
wound infection and wound necrosis being the most frequent30 -33 
Complications were defined as shown in Table 1. 
Analysis of risk factors 
The risk of complications after mastectomy may be influenced by 
patient- related factors such as age, obesity and smoking32.34.35, and 
by the use of breast reconstruction32. These four risk factors were 
chosen for analysis. Obesity was defined in terms of body mass 
index (weight in kilograms divided by the square of height in 
metres). Those who had smoked in the year preceding surgery were 
considered to be smokers. LD flaps and tissue expanders were 
considered in a single 'breast reconstruction' category. The trial 
option was treated as an additional, fifth risk factor. 
To assess whether the choice of preoperative endocrine or 
cytotoxic therapy influenced complications, a further analysis was 
performed for patients in the primary systemic treatment arm of the 
study, but in this case 'trial option' was replaced with 'adjuvant 
therapy', categorized as any cytotoxic therapy or no cytotoxic 
therapy. 
Statistical analysis 
Results were analysed on the basis of intention to treat. The 
numbers of events in each arm of the trial were compared using a 
two -tailed Fisher's exact probability test, and duration of treatments 
compared using the log rank test. 
The technique of multiple logistic regression was used to assess 
the relative contribution of each risk factor to the probability of a 
patient developing complications. Five risk factors were entered 
into the regression equation as independent variables. Major and 
minor complications were combined to yield four dependent 
variables: seroma, infection, necrosis and any complications. 
Results 
Seventy -nine patients were randomized over a period of 2 
years, 39 received conventional treatment and 40 underwent 
primary systemic therapy. There were four major protocol 
violations: three patients in the primary systemic treatment 
arm were treated conventionally and one patient randomized 
to conventional treatment was given primary systemic 
therapy. None of these four patients developed any 
complication. Patient characteristics, including type of breast 
reconstruction, are detailed in Table 2. 
Recorded complications are detailed in Table 3. Patients 
who developed complications required an additional 3 -4 
weeks of treatment. 
Analysis of risk factors 
Body mass index was the only significant independent 
predictor of developing a complication (P= 0.015), and, 









Fluid collection requiring outpatient 
aspiration 
Clinically diagnosed, requiring oral 
antibiotics 
Superficial sloughing or edge necrosis 
under 1 cm in diameter 
Fluid collection requiring surgical 
drainage 
Culture proven, requiring intravenous 
antibiotics or surgery 
Full thickness, requiring surgery 
Table 2 Patient and tumour characteristics (no significant 
differences) 
Conventional Preoperative 
Total number 39 40 
Mean age (years) 51 51 
Mean BMI (kg /m2) 25.8 26.6 
Mean initial tumour diameter (mm) 50 48 
No. of pN, patients 23 20 
No. of ER + patients 19 20 
Immediate breast reconstruction 25 27 
LD flaps 15 11 
Tissue expanders 10 16 
BMI, body mass index (normal range: 18.7 -23.8 kg /m-); pN,, 
histologically proven involved axillary nodes; ER + , oestrogen 
receptor levels >20 fmol /mg cytosol protein 
Table 3 Details of all complications 
Conventional Preoperative P 
Total number 39 40 
Any complications 17 14 0.45* 
Total minor complications 14 11 0.43* 
Minor seroma 11 7 0.27* 
Minor infection 4 0.36* 
Minor necrosis 3 1 0.36* 
Total major complications 6 6 0.88* 
Major seroma 2 1 0.62* 
Major infection 3 4 0.67* 
Major necrosis 2 2 0.94* 
Median (range) hospital 
stay (days) 
8 (3 -27) 8(4 -23) <0.6t 
Median (range) outpatient 
treatment for complications 
(days) 
25 (4 -91) 20 (6 -92) <0.5t 
*Fisher's exact test. fLog rank test, X2 =0.03. *Log rank test, 
X2 =0.42 
when each complication was considered independently, was 
a highly significant predictor of wound necrosis (P= 0.006). 
Of the 40 patients in the primary systemic treatment arm, 
23 had received cytotoxic chemotherapy, 18 from the start 
and five after failing to respond to endocrine treatment. 
Fourteen patients received endocrine treatment only, and 
three had no systemic therapy. Six minor and four major 
complications occurred in eight endocrine- treated patients 
compared with five minor and two major complications in six 
patients given chemotherapy. In the multivariate analysis, 
adjuvant therapy was not a significant independent predictor 
of complications following mastectomy. 
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Discussion 
This randomized trial found no increase in morbidity rate 
following mastectomy when this follows a period of systemic 
treatment. These results are consistent with those from 
previous uncontrolled series, which found no excess in 
complications following chemotherapy for locally 
advanced'9 or large operable20 breast tumours. The same 
observations have been made following breast conservation 
where primary chemotherapy does not appear to be an 
independent predictor of wound complications36 or cosmetic 
outcome37. 
The overall incidence of surgical complications in this 
group of patients was 39 per cent. Most complications were 
minor and self -limiting. Clinically important complications 
occurred in 15 per cent of patients, a finding similar to other 
observations3°- 3 3s 
Obese patients were at significantly increased risk of 
postmastectomy wound complications, and in particular 
wound necrosis. This should be taken into consideration 
when making a choice between mastectomy and breast 
conservation. 
Breast cancer surgery can be performed after primary 
systemic treatment without an adverse effect on surgical 
outcome. 
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Scintigraphic detection of biliary fistula after 
removal of a T tube 
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After removal of a T tube there is always a temporary bilio- 
cutaneous fistula, which normally closes within 48 -72 h'. 
The irritant properties of the T tube stimulate a reactive 
granulation track2 over 7 -10 days. 
In this study technetium -99m dimethyliminodiacetic acid 
(99mTc -HIDA) scintigraphy was used to diagnose biliary 
fistulas and leaks after T tube removal. 
Patients and methods 
Between October 1990 and April 1993, 46 patients underwent 
surgery for benign common bile duct (CBD) pathology (lithiasis, 
eholangitis). After CBD exploration a latex and silicone T tube of 
size 14 -18 was left in the duct. 
T tube cholangiography was performed after operation to 
confirm patency and the absence of bile duct pathology. 
Scintigraphy was performed 24 h after T tube removal. A dose of 
4 mCi 99mTc linked to trimethyl -HIDA was given intravenously. The 
patient was placed under a y camera detection field and one image 
was obtained every 10 min for 1 h, using computer -based acquisi- 
tion every minute starting 10 min after injection. 
Results 
The mean age of patients was 70.4 (range 42 -91) years; 74 
per cent were women. 
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The T tube was in place for a mean of 13.9 (range 
6 -24) days. In some cases the T tube was used for a longer 
period as a result of cholangiographic findings (fistula, 
stenosis, residual lithiasis) or postoperative pancreatitis. The 
cholangiogram was normal in 74 per cent of cases. 
Scintigraphy provided normal findings in 35 of the 46 
patients. Clinically significant findings were asymptomatic 
stenosis in five patients, asymptomatic abdominal fistula in 
three, cutaneous fistula in two and symptomatic intra- 
abdominal leakage in one. 
Discussion 
Intraperitoneal biliary leakage after removal of a T tube is 
not a common problem (0.5 -0.8 per cent) but is a potentially 
fatal complication'-3. In the present series this complication 
occurred in one patient, fortunately without grave 
consequences although reoperation was necessary. 
When such leakage occurs ultrasonography and computed 
tomography cannot determine accurately whether the fluid 
collection represents a biliary fistula or blood, or whether 
there is good biliary flow to the duodenum'. 
The importance of HIDA scintigraphy following T tube 
removal lies in the possibility of evaluating the presence and 
amount of peritoneal bile leakage. Correlation of these data 
with clinical findings helps to determine whether surgical 
treatment is necessary. 
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